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It is well established that malignancies rely on anaerobic glycolysis for a major part 
of their energy consumption. However, as compared to aerobic glycolysis, anaerobic 
glycolysis is a relatively inefficient process, since it generates only a limited amount of 
energy (ATP) per molecule of glucose. This results in a strongly increased demand for 
glucose in cancer cells. The most frequently used tracer, 18F-fluorodeoxyglucose (FDG), 
in the oncological application of Positron Emission Tomography (PET), capitalizes on 
this characteristic feature of tumor cells. FDG-PET localizes tumors by accumulating 
in cells in the body that have increased glucose uptake and metabolism. Analogous 
to glucose, FDG is transported into cells via GLUT-transporters (mainly of type 1) and 
is converted to FDG-6-phosphate by hexokinase. This metabolite however, is unlike 
glucose-6-phosphate, trapped in the cell, as it will not be processed in the glycolytic 
pathway. Hence, FDG-6-phosphate will preferentially accumulate in those cells with 
high glucose uptake, such as tumor cells. This feature is primarily responsible for the 
clinical success of PET imaging. For several years, FDG-PET has become part of the 
standard of care in presurgical staging of a variety of malignant diseases, focusing on 
the detection of malignant lesions at early stages and early detection of recurrence and 
metastatic spread. FDG-PET has shown to be successful in distinguishing fibrosis and 
scar from viable tumor in residual masses after therapy and in localization of recurrence 
in patients with an unexplained rise of serum tumormarkers. As a whole, FDG-PET has 
proved to have a positive impact on overall staging and patient management with a 
wide variety of malignancies.
However, there is more beyond staging. The molecular metabolic information provided 
by FDG-PET, makes FDG-PET a promising imaging modality for tumor characterization, 
or in other words a promising imaging biomarker. Biomarkers in medical practice have 
been defined as indicators of normal biological processes, pathologic processes, or 
response to a therapeutic intervention. They are intended to substitute for a clinical 
endpoint and can be expected to suggest a diagnosis, characterize a disease, predict 
responsiveness to treatment, or suggest outcome. Thus, by definition, many specimen 
features can be considered biomarkers. However, the strength of FDG-PET is that it 
permits whole-body imaging in a non-invasive way. It is therefore not limited to the 
characterization of one or a few target lesions, but can be used to evaluate multiple 
tumor sites. Furthermore, FDG-PET allows serial studies, which allows to measure and 
monitor functional changes over time during therapeutic interventions. Intratumoral 
heterogeneity may therefore significantly confound the analysis of biomarkers derived 
from biopsy material of tumor samples. This is of particular concern when evaluating 
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changes in a biomarker during treatment, because it is difficult to ascertain that different 
parts of the tumor demonstrated the same expression of the biomarker before therapy. 
Furthermore FDG-PET cannot only visualize but can also quantify FDG uptake and is 
able to provide several highly reproducible quantitative parameters of tumor glucose 
metabolism. Finally, the ability to image a biochemical process in a living organism is 
probably the major strength of PET when compared with nonimaging biomarkers.
As individualized treatment strategies become more relevant and the choice of antitumor 
agents has been considerably expanded, there is a growing need to identify novel 
pretreatment factors that potentially predict outcome and to find molecular response-
monitoring tools. Some new therapies may be cytostatic instead of cytoreductive, in 
which case successful treatment may not lead to a decrease in tumor size, and thus 
poses new demands on imaging modalities. There are numerous patient management 
issues that would undoubtedly benefit from more accurate lesion characterization. 
Four diagnostic challenges in tumor diagnostics were addressed in the present thesis. 
These four topics include: the understanding of the underlying mechanisms of FDG 
accumulation, characterization of lesions with FDG-PET, definition of high-risk 
populations and prediction of treatment outcome. These four issues were studied in 
three types of cancer: non-small-cell lung cancer, colorectal cancer and cancer of the 
head- and neck area. 
Chapter 1
Predictive and prognostic value of 
18F-FDG-PET in non-small-cell lung cancer: 
a systematic review
Lioe-Fee de Geus-Oei
Henricus F.M. van der Heijden
Frans H.M. Corstens
Wim J.G. Oyen
Cancer, in press
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Abstract
For several years, molecular imaging with 18F-fluorodeoxyglucose positron emission 
tomography (FDG-PET) has become part of the standard of care in presurgical staging 
of patients with non-small-cell lung cancer (NSCLC), focusing on the detection of 
malignant lesions at early stages, early detection of recurrence and metastatic spread. 
Currently, there is an increasing interest in the role of FDG-PET beyond staging, such 
as the evaluation of biological characteristics of the tumor and prediction of prognosis 
in the context of treatment stratification and the early assessment of tumor response 
to therapy. In this systematic review, the literature on the value of the evolving 
applications of FDG-PET as a marker for prediction (i.e. therapy response monitoring) 
and prognosis in NSCLC is addressed, divided in sections on the predictive value of 
FDG-PET in locally advanced and advanced disease, the prognostic value of FDG-PET 
at diagnosis, after induction treatment and in recurrent disease. Furthermore, the 
background and recommendations for the application of FDG-PET for these indications 
will be discussed.
Introduction
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer related death in both 
men and women 1. Surgery with curative intent represents the best chance for cure, but 
is only an option in patients with stages I, II, and selected cases of stage III. However, 
only 30% of NSCLC cases present at early stages 2. Even if a complete curative resection 
can be performed, about 50% of patients will relapse without adjuvant chemotherapy 
treatment 3. The majority of these relapses occur at distant sites. Hence, each pathological 
stage consists of a heterogeneous population containing individuals at much higher risk 
of recurrence and death than others. Therefore, there is a need for noninvasive functional 
imaging modalities that could play a role in further characterization of NSCLCs.
Another major clinical problem in the treatment of NSCLC is therapy response monitoring, 
since the morphologic information provided by chest radiographs and computed 
tomography (CT) cannot reliably distinguish necrotic tumor or fibrotic scar from residual 
tumor tissue 4. Response evaluation with these morphological imaging methods do 
not correlate well with pathological response, nor with changes at the cellular level or 
with tumor viability 5. Indeed, final treatment outcome will be determined more by the 
biological aggressiveness of residual tumor than by its volume 5. Examination of biopsy 
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material also has its limitations, since it can be inconclusive due to sampling difficulties, 
it provides information at a single time-point only and is not suitable for sequential 
assessment 6.
A potential noninvasive molecular imaging tool that could be helpful in solving these 
problems is positron emission tomography (PET). The most frequently used tracer in 
PET is 18F-fluorodeoxyglucose (FDG). FDG-PET localizes tumors by identifying cells 
in the body that have increased glucose uptake and metabolism. FDG is transported 
into cells analogous to glucose and is converted to FDG-6-phosphate. This metabolite 
is trapped in the cell, as it will not be processed in the glycolytic pathway and hence 
will accumulate preferentially in those cells with high glucose uptake, such as tumor 
cells 7. The introduction of the combined use of FDG-PET and CT has had a major 
impact on the diagnosis and staging of lung cancer. FDG-PET has been employed to 
evaluate unclassified pulmonary nodules for malignancy 8,9. Furthermore, it provides 
noninvasive mediastinal staging and reduces the number of futile thoracotomies 
and mediastinoscopies 10-12. This imaging modality detects unsuspected extrathoracic 
metastases in 14-17% of patients otherwise considered potentially resectable 13. Recently, 
FDG-PET has also demonstrated its value in radiation treatment planning and detection 
of recurrent disease 14-17.
Since FDG-PET relies on the detection of metabolic alterations of cancer cells, this 
examination yields data independently of associated structural characteristics, and 
therefore allows the detection or monitoring of specific metabolic changes which are 
not associated with or precede the anatomical changes 18. One of the great advantages 
of this technique is that it cannot only visualize but can also quantify FDG uptake to 
distinguish metabolically highly active from less active tumor tissues and therefore offers 
an opportunity for noninvasive, in vivo tissue characterization. Hence, the number of 
clinical applications for FDG-PET in NSCLC continues to increase. This comprehensive 
review aims to discuss the potential future applications in the management of patients 
with NSCLC. The literature is reviewed on the value of FDG-PET in identifying tumor 
response to anticancer therapies at an early phase of treatment and in identifying 
subsets of patients with poor outcome.
Search strategy and selection criteria of literature
Data for this review were identified by searches of PubMed and SilverPlatter MEDLINE up 
to July 2006 using the search terms for identifying clinical FDG-PET studies as reported 
by Mijnhout et al. 19 plus the search terms “lung neoplasm or lung cancer or NSCLC” and 
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“prediction or prognosis or therapy monitoring or response monitoring”. Only papers 
that make use of the exact defintion for the terms “predictive” and “prognostic” were 
included. These exact definitions are as follows: 1) FDG-PET is considered an in vivo 
marker for prognosis if it is able to identify patients that are at a different risk of a specific 
outcome, such as tumor progression or death, irrespective of a specific therapy. 2) FDG-
PET is considered a predictive in vivo marker if it is able to define patient populations 
that (will) benefit from a specific form of treatment 20. Search results were checked for 
adequacy. Only papers published in English were included. Articles only dealing with 
staging and detection of relapses of NSCLC with FDG-PET, with other malignancies 
than NSCLC, and with radiopharmaceuticals other than FDG were omitted. References 
from adequate articles were checked for studies not retrieved by the search strategy. 
Abstracts, (extended) case reports, reports from meetings, editorial comments and 
letters-to-the-editor were not included.
Background and technical aspects of (semi)quantitative FDG-PET
For the application of FDG-PET in the detection, staging and surveillance of primary 
and recurrent tumors, a qualitative image interpretation has been found sufficient 
in most cases. In contrast, for the application of FDG-PET in chemotherapy response 
monitoring and prognostic stratification, quantification of FDG uptake will be required, 
in order to accurately determine tumor metabolism and changes in tumor metabolism 
over time. Glucose metabolism can be measured mathematically using the glucose flux 
constants (as used to determine the metabolic rate of glucose or MRglu) or, clinically 
more feasible, using the standardized uptake value (SUV), a semi-quantitative measure 
of FDG uptake 21.
A variety of techniques and analytical methods are currently used, which complicates 
the comparison of different studies on this subject. It is still unclear whether more 
advanced kinetic techniques are superior to more basic methods like calculation of the 
SUV. For calculation of SUVs, only the amount of injected radioactivity and the body 
weight of the patient are required 21. Many factors may influence FDG uptake, such as 
plasma glucose, insulin levels, the interval between FDG injection and image acquisition 
and a significant loss of body weight during anticancer therapy could affect the use of 
serial measurements of the SUV. Correction of SUV by body surface area (SUVBSM) or 
lean body mass (SUVLBM) reduces this dependency on body weight 
22,23. More advanced 
kinetic techniques and analytical methods, like the Patlak analysis 24, take into account 
differences in the whole-body distribution of FDG at the time of scanning. Therefore, 
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MRGlu is in principle a more reliable measure than SUV 
25. However, kinetic techniques 
require dynamic data acquisition and the clearance of FDG from the blood has to be 
determined. The different methods are not only of interest from a methodological 
point of view, but they also determine how readily PET imaging can be implemented 
as a routine clinical tool for response monitoring. Multiple follow-up scans encourage a 
simplified approach to improve patient compliance, an important feature of successful 
clinical trials. Furthermore, during the dynamic data acquisition only an axial field of 
view of 15-20 cm can be studied, whereas SUVs can also be calculated from whole-body 
PET studies. As metastatic lesions in different parts of the body may respond differently 
to chemotherapy, this represents a principal advantage of SUV 25.
SUV quantification depends on acquisition, reconstruction and region of interest 
parameters and differs between different scanners and different data analysis software 
26. Therefore, in treatment response monitoring, it is important to perform sequential 
scans of the same patient on the same scanner and under identical scanning, image 
reconstruction and data analysis conditions. Optimal timing of PET scans at some point 
during the treatment schedule or soon after the completion of treatment depends on 
different chemosensitivities of tumors, tumor heterogeneity and modes of drug action 
27. Assessments performed too early might overestimate FDG uptake, since glucose 
metabolism can still be present in cells that have received lethal damage, and due to 
inflammatory reactions in responding tissues. Assessments that are performed too 
late can also be less suitable, due to the risk of tumor repopulation 5. Especially after 
radiotherapy it has been frequently recommended 6,28-30 to carefully select the optimal 
interval from completion of radiotherapy to FDG-PET imaging. At present, there are 
no systematic data available on patients with NSCLC to determine the optimal time 
to perform FDG-PET after radiotherapy. However, the influence of radiation induced 
inflammatory reactions does not seem a major issue since all mentioned reports in a 
post-radiotherapy setting did not show major confounding results 4,31-39.
Predictive value of FDG-PET and assessment of histopathologic 
response in locally advanced disease
Nine studies indicated a possible role for PET in assessment of response during or after 
radiotherapy 31, induction chemotherapy 33,40 or a combination thereof 4,32,36,37,41,42. The 
earliest study, performed in 1996 by Ichiya et al. 31 reported on 20 patients prior and after 
radiation therapy. Patients with a higher FDG uptake on their baseline PET showed a 
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better response to treatment. The relapse rate was higher in lesions with higher uptake 
prior, as well as after treatment. A more prominent decrease in the FDG uptake was 
noted in patients with a response on CT compared with those with no change on CT. 
In the pilot study of Vansteenkiste et al. 40, who studied 15 patients before and after 
induction chemotherapy, a reduction in FDG uptake of at least 50% in the primary tumor 
or mediastinal clearance proved to be a better predictor of long-term survival compared 
to the standard used WHO criteria 43,44 for response assessment on CT. Another study 
that evaluated response monitoring of induction chemotherapy 33 showed that FDG-PET 
identified prognostically different strata in patients considered responsive according to 
CT. In this prospective multicenter study FDG-PET was performed before, after one and 
three cycles of induction chemotherapy. This was the only study that evaluates FDG-
PET at an earlier and perhaps clinically more relevant stage of treatment. The residual 
metabolic rate of glucose after one cycle selected patients with different outcomes. 
The residual metabolic rate of glucose after completion of induction chemotherapy 
proved to be the best prognostic factor. The other six studies 4,32,36,37,41,42 showed that 
FDG-PET was also predictive with respect to therapy outcome of combined modality 
therapy. Metabolic response proved to be associated with pathological response (table 
1) 32,37,41,42. The accuracy of a dynamic FDG-PET scan in the prediction of pathological 
tumor response was 83%-96% 32,37,41. There was a near linear relationship between the 
change in SUV and the percent of nonviable tumor cells in the resected tumors 41 and 
the percentage decrease in SUV in the primary tumor during induction therapy was 
significantly larger in patients with <10% than in patients with >10% residual tumor cells 
42. The SUV in the mediastinal lymph nodes after completion of chemoradiotherapy 
predicted the histopathologic lymph node status after radiochemotherapy (ypN0 status) 
with a sensitivity and specificity of 73% and 89% 42. Cerfolio showed that metabolic 
response correlated better to pathology than the change in size on CT scan 41. In a 
study performed by MacManus et al. 4 there was poor agreement between PET and 
CT responses, which were identical in only 40% of patients. There were significantly 
more complete responders on PET than CT, whereas fewer patients were judged to be 
nonresponders or nonassessable, which implies that chemoradiation may be a more 
effective therapy than previous CT-based assessments have suggested. On multifactor 
analysis (including the known prognostic factors of CT response, performance status, 
weight loss, and stage), only the PET response was significantly associated with the 
duration of survival. Another study performed by MacManus et al. 36, showed a 
significantly longer median survival for patients with complete metabolic response than 
for patients with non-complete metabolic response (31 versus 11 months). Non-complete 
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Table 1. Sensitivity and specificity of FDG-PET for assessing histopathologic response
Ref. Sens. Spec. Definition of metabolic response Definition of histopathologic response
32 86% 81% Classified as metabolic responder if 
predicted probability >0.5.
Post-hoc definition:
No complete pathologic response: 
residual MRglu ≥0.13 µmol/min/g.
Complete pathologic response: residual 
MRglu ≤0.05 µmol/min/g. 
No pathologic response: positive 
resection margins or gross residual 
tumor in the resected specimen.
Pathologic response: microscopic residual 
disease only or a pathologically complete 
response.
37 88% 89% Post-hoc definition for metabolic 
response: SUV ≤4.5 on the PET after 
therapy
No pathologic response: residual 
macroscopic disease.
Pathological response: no tumour 
(complete response) or residual 
microscopic disease only. 
41 90% 100% Post-hoc definition for metabolic 
response: >80% reduction of the 
maximum SUV
Complete pathologic response: ≤ 1% of 
viable tumor cells
42 80% 80% Post-hoc definition for metabolic 
response: SUV ≤3.3 after therapy
Grade 1, no or only spontaneous tumor 
regression; 
Grade 2a, evidence of therapy-induced 
tumor regression with >10% residual 
tumor cells; 
Grade 2b, evidence of therapy-induced 
tumor regression with <10% residual 
tumor cells; 
Grade 3, no evidence of vital tumor
38 88% 67% Post-hoc definition for metabolic 
response: SUV ≤3.0 after therapy
Residual cancer: resection specimen 
positive for malignant cells.
Pathologic complete response: resection 
specimen negative for malignant cells.
68 81% 64% Post-hoc definition for metabolic 
response: SUV ≤2.5 after therapy
Residual cancer: resection specimen 
positive for malignant cells.
Pathologic complete response: resection 
specimen negative for malignant cells.
73 97% 67% Visual analysis:
Residual cancer: residual FDG-uptake 
in the primary tumor
Metabolic complete response: no 
residual FDG-uptake in the primary 
tumor 
Residual cancer: resection specimen 
positive for malignant cells.
Pathologic complete response: resection 
specimen negative for malignant cells.
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metabolic response patients had higher rates of local failure and distant metastasis than 
patients with complete metabolic response. Significantly more patients with a larger 
percentage decrease in SUV in the primary tumor during induction therapy stayed free 
from extracerebral relapse compared to patients with a lesser response (83% versus 
43% at 16 months) 42.
Despite the fact that these nine studies were very heterogeneous with respect to the 
applied methods of PET quantification, the primary targets of PET evaluation (primary 
tumor and/or lymph nodes), and the clinical end points (histology, survival), all studies 
showed that FDG-PET is a significant predictor of therapy outcome and provides results 
of great prognostic significance. It seems that FDG-PET is able to predict pathological 
response more accurately and at earlier time points than conventional imaging 
methods.
Predictive value of FDG-PET in advanced disease
Early prediction of tumor response is of particular interest in patients with advanced 
stages of NSCLC. Tumor progression during first-line chemotherapy occurs in 
approximately 30% of patients 45. Thus a significant percentage of patients undergo 
toxic therapy during several weeks without benefit. As more options for second-line 
therapies and new-targeted therapies for advanced disease become available, there is 
a growing need to find a reliable response-monitoring tool. The experience with FDG-
PET in this field of NSCLC, however, is still limited. A recent study performed by Lee et 
al. 46, claimed that a sole pretreatment FDG-PET scan is sufficient to predict response 
and survival for platinum-based combination chemotherapy in chemonaïve patients 
with advanced NSCLC. They found that patients with a high SUV exhibited significantly 
higher response rates. Other factors, including sex, age, histology, performance status, 
number of involved organs, regimens used, and disease stage, did not affect response. 
Regrettably, high SUVs were related with a shorter response duration and shorter 
time to progression. The authors postulate that higher response rates in patients with 
hypermetabolic lesions can be explained in terms of the rapid proliferation of tumor 
cells 47,48 and the effectiveness of the chemotherapy against proliferating cells 49,50. At the 
same time these cells are more aggressive, which is reflected by the shorter response 
duration and the shorter time to progression. Lee et al. mentioned that response rates 
are often considered as a surrogate end point for survival 51, however, they are of the 
opinion that this is not a recommendable surrogate end-point, since there might be a 
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discordance 46. Weber et al. 25, however came to other conclusions. The only properly 
performed study on response assessment in advanced stages (stage IIIB or IV), using 
serial PET-scans was performed by them. Fifty-seven patients scheduled to undergo 
platinum-based chemotherapy were studied before and after the first cycle of therapy. 
A decrease in SUV of 20% or more after one cycle of chemotherapy was associated with 
a longer time to progression (163 days versus 54 days) and longer median overall survival 
time (252 days versus 151 days). The 1-year survival rate was also significantly higher in 
metabolic responders compared to nonresponders (44% versus 10%). This study showed 
that a reduction of metabolic activity already after one cycle of chemotherapy is closely 
correlated with final outcome of therapy. These results suggests that PET imaging may 
be used to personalize the use of chemotherapy  for individual patients and therapeutic 
regimens can be altered early in the course of therapy in order to deliver a more favorable 
outcome and reduce the morbidity and costs associated with prolonged, ineffective 
chemotherapy. Besides, using metabolic response as an end point may shorten the 
duration of phase II studies evaluating new cytotoxic drugs.
Prognostic value of FDG-PET at diagnosis
The tumor-node-metastasis (TNM) staging system is considered the most important tool to 
estimate prognosis and to date the most important guide in treatment decisions 52. However, 
the TNM staging system provides an incomplete biologic profile of NSCLC, does not always 
provide a satisfactory explanation for differences in relapse and survival and is thus far from 
perfect as a prognostic indicator 53. Quantitative measures of biological aggressiveness, like 
FDG uptake, could be better indicators for survival and risk of relapse, and thus for selection 
of patients for adjuvant treatment 54,55. For prognostic stratification the SUV can be calculated 
using a single whole body FDG-PET that is routinely performed in patients with NSCLC as 
part of their pretherapeutic staging procedure. A great advantage of measurement of FDG 
uptake is that this can be done before any treatment has been performed.
The prognostic value of FDG-PET at diagnosis has been evaluated in several studies 53,56-65. 
These studies have shown that the pretherapeutic FDG-PET not only improved patient 
staging, but also provided prognostic information (table 2). All eleven studies showed 
that patients with low FDG uptake values in their primary tumor have a significant 
longer overall- and progression-free survival than patients with high FDG uptake. 
Several studies 56,57,61 found that in patients patients with high FDG uptake prognosis 
was further reduced if the tumor also exceeded 3 cm in size. Higashi and Sasaki et 
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al. 53,62 found that FDG uptake in the primary tumor was a better prognostic variable 
than pathologic TNM system staging in predicting relapse of patients with NSCLC. 
Multivariate Cox analysis, including factors like disease stage, performance status, 
histology, tumor cell differentiation, tumor size, lymph node involvement, completeness 
of resection etc. identified in several studies 57,60,61,63-65 the SUV in the primary tumor as 
an independent prognostic factor. In contrast to FDG uptake in the primary tumor, the 
prognostic ability of the SUV for the regional lymph nodes remains uncertain. Sasaki et 
al. 62 observed that patients with high SUVs of their regional lymph nodes and low SUVs 
in their primary tumors did not experience any local or distant relapse. Therefore, it is at 
least speculated that the SUVs for the regional lymph nodes do not agree with and are 
not stronger prognostic factors than the SUVs for the primary tumor.
The univariate analyses performed to determine a cut-off point for the SUV in the 
primary tumor to discriminate between a more or less favorable prognosis has ranged 
widely from 5 to 20. Sasaki and Higashi et al. 53,62 reported that for the SUV a group 
dichotomy with a cut-off value of 5 had the best discriminative value for prognosis. Jeong 
as well as Vansteenkiste et al. 57,60 found a cut-off value of 7, Downey et al. 61 a cut-off of 9, 
Ahuja and Cerfolio et al. 56,63 a cut-off of ~ 10, Eschmann et al. 65 of 12 and Dhital et al. 59 a 
cut-off of 20 (table 2). Vansteenkiste and Higashi et al. 53,57 showed that dichotomization 
with a broad range of SUVs gave significantly discriminative log-rank probability values. 
Therefore, it implies that the relationship between SUV and prognosis could be a 
gradual one rather than based on a threshold. It seems reasonable to hypothesize that 
there is no true cut-off point but, rather, a transition zone, within which the prognosis 
gradually worsens. However, the wide range of SUV values seen in these studies can 
also be due to the heterogeneity of the analyzed patient cohorts and to variation in 
the PET-scanners and acquisition protocols used. Institutional-based technical factors 
can lead to variations in measurement of SUV and might hinder the integrated or 
comparative interpretation of the results from one centre to another 26,66. For example, 
in above-mentioned studies, there was considerable variability in the period between 
tracer administration and scanning, as well as in the serum glucose levels. There was 
also significant variation in reconstruction and interpretive criteria, such as the lack of 
correction for partial volume effects in certain studies. Most of the studies chose to use 
the maximum value of the SUV within the tumor (i.e. SUVmax) to avoid inadvertent bias. 
Therefore, standardisation of acquisition, reconstruction and ROI methods is preferred 
for SUV quantification in multi-centre trials 26. Agreement on methods of scanning, SUV 
measurement and the best cut-off values is needed before this technique can be fully 
exploited in clinical medicine to select patients for adjuvant treatments. In the most 
26 Chapter 1
Ta
bl
e 
2.
 P
ro
gn
os
ti
c 
va
lu
e 
of
 F
D
G
-P
ET
 a
t d
ia
gn
os
is
Ye
ar
n*
H
is
to
lo
gy
St
ag
e
Tr
ea
tm
en
t
Su
rv
iv
al
P
 v
al
ue
R
ef
.
19
98
15
5
Sq
ua
m
ou
s
A
de
no
La
rg
e 
ce
ll
U
nd
et
er
m
in
ed
37
%
34
%
7% 22
%
I o
r I
I
III IV
45
%
35
%
20
%
U
ns
pe
ci
fie
d
M
ed
ia
n 
su
rv
iv
al
 (m
o)
SU
V
>1
0
SU
V
≤1
0
11
.4
24
.6
0.
00
49
56
19
99
12
5
Sq
ua
m
ou
s
A
de
no
La
rg
e 
ce
ll
54
%
25
%
21
%
I II III
A
III
B
37
%
15
%
30
%
18
%
Re
se
ct
io
n
N
on
su
rg
ic
al
73
%
27
%
2-
ye
ar
 s
ur
vi
va
l
SU
V
>7
SU
V
≤7
43
%
83
%
0.
00
1
57
19
99
38
Sq
ua
m
ou
s
A
de
no
La
rg
e 
ce
ll
32
%
50
%
18
%
I II III
A
III
B
IV
19
%
13
%
50
%
5% 13
%
Re
se
ct
io
n
N
on
su
rg
ic
al
76
%
24
%
3-
ye
ar
 s
ur
vi
va
l
SU
V
>8
.7
2 
SU
V
≤8
.7
2 
40
%
70
%
0.
22
56
58
20
00
77
Sq
ua
m
ou
s
A
de
no
La
rg
e 
ce
ll
O
th
er
58
%
23
%
13
%
5%
A
ll 
st
ag
es
 II
IA
 o
r l
es
s
N
ot
 re
po
rt
ed
M
ed
ia
n 
su
rv
iv
al
 (m
o)
SU
V
>2
0
SU
V
≤2
0
6 33
0.
00
1
59
20
02
57
Sq
ua
m
ou
s
A
de
no
La
rg
e 
ce
ll
BA
C
A
de
no
sq
ua
m
ou
s
14
%
60
%
2% 23
%
2%
I    
IA
   
IB
II III
81
%
67
%
14
%
2% 17
%
Re
se
ct
io
n
10
0%
5-
ye
ar
 s
ur
vi
va
l
SU
V
>5
SU
V
≤5
5-
ye
ar
 d
is
ea
se
 fr
ee
 s
ur
vi
va
l 
(s
t I
)
SU
V
>5
SU
V
≤5
20
%
90
%
17
%
88
%
0.
00
02
<0
.0
00
1
53
 Predictive and prognostic value of 18F-FDG-PET in non-small-cell lung cancer 27
Ye
ar
n*
H
is
to
lo
gy
St
ag
e
Tr
ea
tm
en
t
Su
rv
iv
al
P
 v
al
ue
R
ef
.
20
02
73
Sq
ua
m
ou
s
A
de
no
La
rg
e 
ce
ll
BA
C
51
%
41
%
3% 5%
I II III
A
III
B
IV
44
%
23
%
7% 19
%
7%
Re
se
ct
io
n
N
on
su
rg
ic
al
92
%
8%
2-
ye
ar
 s
ur
vi
va
l
SU
V
≥7
SU
V
<7
56
%
96
%
0.
00
11
60
20
04
10
0
Sq
ua
m
ou
s
A
de
no
La
rg
e 
ce
ll
A
de
no
sq
ua
m
ou
s
C
ar
ci
no
id
24
%
67
%
3% 2% 4%
A
ll 
T1
-4
, N
0-
2,
 M
0
R0
 re
se
ct
io
n
10
0%
2-
ye
ar
 s
ur
vi
va
l
SU
V
>9
SU
V
<9
68
%
96
%
<0
.0
1
61
20
05
16
2
Sq
ua
m
ou
s
A
de
no
 o
r l
ar
ge
 c
el
l
O
th
er
43
%
46
%
10
%
I II III
A
III
B
40
%
16
%
20
%
24
%
Re
se
ct
io
n
Ra
di
ca
l r
ad
io
th
er
ap
y
57
%
43
%
2-
ye
ar
 s
ur
vi
va
l
SU
V
>5
SU
V
≤5
65
%
94
%
0.
02
62
20
05
31
5
Sq
ua
m
ou
s
A
de
no
O
th
er
54
%
33
%
13
%
IA IB II III
A
III
B
IV
19
%
26
%
18
%
23
%
5% 9%
Re
se
ct
io
n
N
on
su
rg
ic
al
71
%
29
%
M
ea
n 
su
rv
iv
al
 (y
rs
)
SU
V
≥1
0
SU
V
<1
0
1.6 3.
2
<0
.0
01
63
20
05
51
Sq
ua
m
ou
s
A
de
no
La
rg
e 
ce
ll
O
th
er
33
%
25
%
20
%
22
%
I II III
41
%
22
%
37
%
Ra
di
ca
l r
ad
io
th
er
ap
y
10
0%
2-
ye
ar
 s
ur
vi
va
l
SU
V
≥1
5
SU
V
<1
5
27
%
60
%
<0
.0
01
64
20
06
13
7
Sq
ua
m
ou
s
A
de
no
La
rg
e 
ce
ll
O
th
er
45
%
29
%
12
%
14
%
III
A
III
B
43
%
57
%
C
he
m
or
ad
ia
ti
on
10
0%
M
ed
ia
n 
su
rv
iv
al
 (m
o)
SU
V
>1
2
SU
V
<1
2
9 22
0.
05
65
28 Chapter 1
ideal situation it would be desirable to study a homogeneous patient cohort in which all 
patients have the same tumor stage, the same tumor histology and are treated by the 
same therapeutic protocol, in order to assess objectively the prognostic information 
provided by FDG uptake. Nevertheless, despite these variability and concerns, all 11 
studies arrived at the same conclusion and strongly confirmed that the degree of tumor 
glucose use on an FDG-PET scan provide independent prognostic information.
Prognostic value of FDG-PET after induction treatment
The prognostic value of FDG-PET after induction treatment has not been studied as 
thoroughly as at diagnosis. There is, however, increasing interest in determining the 
prognostic value of the post-therapy FDG-PET. Several studies (table 3) have shown 
promising results, indicating that the post-therapy FDG-PET also has an independent 
prognostic value and is superior to that of CT 4,33,67,68. The combination of platinum-
based chemotherapy and radiotherapy is a commonly recommended standard curative 
approach in unresectable locally advanced disease 69. Whether or not a pathologic 
complete response can be achieved is predictive for a more or less favorable outcome 
70,71. Therefore the pathologic complete response rate is an important endpoint for 
studies that evaluate new induction treatments. Especially when data of the resection 
specimen are lacking, accurate noninvasive assessment of pathologic complete response 
is important. Although pathologic complete response is mostly seen in patients who 
achieve major tumor shrinkage on CT, it is difficult to differentiate residual tumor from 
scar tissue in a residual mass on CT 72. Several studies showed that FDG-PET could be very 
helpful in this condition 38,73-75. PET response was correlated with pathologic response in 
five studies 38,40,68,74,75, and five studies also reported on the correlation of PET response 
and survival 4,33,40,67,68. Multivariate stepwise analysis in the multicenter trial of Hoekstra 
et al. 33 showed that PET identified prognostically different strata in patients considered 
responsive according to CT 33. Unanimously all studies on this subject (table 3) show that 
the degree of residual tumor FDG uptake after induction therapy is, like tumor FDG 
uptake at diagnosis, a strong prognostic factor. Patients in whom treatment results in 
complete resolution of prior FDG uptake have been shown to have a good prognosis as 
compared to those with residual FDG uptake after induction treatment.
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Prognostic value of FDG-PET in recurrent disease
The value of follow-up after primary treatment of NSCLC is a matter of debate 76,77. 
One may argue that relapsed NSCLC has a poor prognosis, but several studies have 
shown that re-treatment after surgery may increase survival in selected cases 77-79. After 
potentially curative therapy of NSCLC, masses or symptoms suggestive of relapse 
are common but may be difficult to characterize. The application of FDG-PET for the 
detection of relapsing lung cancer is increasingly being investigated 6,80-87. In two of 
these studies (table 4), FDG-PET has provided prognostic information in NSCLC 84,86. 
The study of Hellwig et al. 86 showed that FDG-PET helps in the selection of patients 
who will benefit from surgical re-treatment. In their study FDG-PET accurately detected 
recurrent lung cancer (sensitivity, specificity, accuracy: 93%, 89%, 92%) and the SUV in 
recurrent tumor tissue was an independent prognostic factor. SUV in recurrent tumor 
was significantly higher than in benign post-therapeutic changes (10.6+/-5.1 versus 2.1+/-
0.6) and median survival was significantly longer for patients with lower FDG uptake 
in recurrent tumor. In patients treated surgically, lower FDG uptake predicted longer 
median survival (SUV<11: 46 months, SUV≥11: 3 months). Hicks et al. 84 studied patients 
with suspected relapse >6 months after definitive treatment. PET had a sensitivity 
of 98%. No disease was evident during a minimum follow-up of 12 months in 14 of 15 
patients with clinically suspected relapse but negative PET findings (negative predictive 
value, 93%). Both the presence (p=0.01) and the extent (p<0.0001) of relapse on PET were 
highly significant prognostic factors. There was also significant prognostic stratification 
based on the treatment delivered after the PET study, but after adjustment for this 
treatment, PET status remained highly predictive of survival. The authors concluded that 
PET better assessed the status of disease and PET better stratified prognosis compared 
to conventional staging.
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Conclusions and recommendations
It has been shown that the degree of FDG uptake is of prognostic value at initial 
presentation, after induction treatment prior to resection and in case of relapse. At 
initial presentation, as well as posttreatment, FDG-PET is a better predictor of survival 
than TNM system staging or CT response. Agreement on methods of scanning, SUV 
measurement and the best cut-off values is needed before this technique can be fully 
exploited in clinical medicine to select patients for adjuvant treatments. In future 
multi-centre trials standardisation of acquisition, reconstruction and ROI methods is 
preferred for SUV quantification. Further research in this field is of great importance, 
since it may induce a change in the therapeutic concept of patients with NSCLC. FDG-
PET could separate patients with a good prognosis from those with a poor one, which 
may help in deciding on the most appropriate treatment and which may be of particular 
value in stratifying patients for clinical trials.
FDG-PET is also of value in predicting outcome of induction therapy and it probably also 
has a predictive value early in the course of first-line therapy in case of advanced disease. 
There are indications that FDG-PET can predict response and patient outcome as early 
as after one course of (induction) chemotherapy. However, monitoring tumor response 
with FDG-PET is still in its infancy. The methods of measurement of FDG uptake currently 
are diverse, timing with respect to anticancer therapy and used thresholds to define 
response are variable. Therefore, further study is required which has to deal with these 
major issues before it is possible to draw definite conclusions on FDG-PET as a tool for 
therapy response monitoring. If the results of the reviewed studies can be confirmed, 
FDG-PET could shorten the track of early clinical trials that assess new antineoplastic 
agents and could also improve patient management by reducing morbidity, efforts and 
costs of ineffective treatment in nonresponders.
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Abstract
A useful imaging tool in the evolving management of patients with colorectal carcinoma 
is 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), a technique that 
is able to measure and visualize metabolic changes in cancer cells. This feature results in 
the ability to distinguish viable tumor from scar tissue, in the detection of tumor foci at 
an earlier stage than possible by conventional anatomic imaging and in the measurement 
of alterations in tumor metabolism, indicative of tumor response to therapy. Nowadays, 
FDG-PET plays a pivotal role in staging patients before surgical resection of recurrence 
and metastases, in the localization of recurrence in patients with an unexplained rise of 
serum carcinoembryonic antigen and in assessment of residual masses after treatment. 
In the presurgical evaluation, FDG-PET may be best used in conjunction with anatomic 
imaging in order to combine the benefits of both anatomical (CT) and functional (PET) 
information, which leads to significant improvements in preoperative liver staging and 
preoperative judgement on the feasibility of resection. Integration of FDG-PET into the 
management algorithm of these catagories of patients alters and improves therapeutic 
management, reduces morbidity due to futile surgery, leads to substantial cost savings 
and probably also to a better patient outcome. FDG-PET also appears to have great 
potential in monitoring the success of local ablative therapies soon after intervention 
and in the prediction and evaluation of response to radiotherapy, systemic therapy, and 
combinations thereof. This review aims to outline the current and future role of FDG-
PET in the field of colorectal cancer.
Introduction
Colorectal cancer is the second leading cause of cancer-related deaths in the Western 
world and continues to be a major health problem worldwide. The cumulative lifetime 
risk is approximately 5%, the incident rate in the Western world 50/100000 and the 
5-year survival rate nowadays approximate 55% 1. The prognosis of this disease has 
improved substantially with the introduction of hepatic resection for treatment of 
isolated liver involvement and with the introduction of effective chemotherapeutic 
agents 2-4. A useful imaging tool in the evolving management of patients with colorectal 
cancer is 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET). FDG-PET 
localizes tumors by identifying cells in the body that have increased glucose uptake 
and metabolism. FDG is transported into cells analogous to glucose and is converted to 
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FDG-6-phosphate. This metabolite is trapped in the cell, as it will not be processed in 
the glycolytic pathway and hence will accumulate preferentially in those cells with high 
glucose uptake, such as tumor cells. Although the optimal use of FDG-PET in colorectal 
cancer continues to emerge, this comprehensive review aims to discuss its current and 
potential future applications in the management of patients with colorectal cancer. The 
literature will be reviewed on the established role of FDG-PET in distinguishing fibrosis 
and scar from viable tumor in residual masses of rectal cancer, localization of recurrence 
in patients with an unexplained rise of serum carcinoembryonic antigen (CEA), staging 
before surgical resection of recurrence and/or metastases, and on its emerging role in 
the prediction and evaluation of treatment response, such as monitoring of radiotherapy 
and multimodality treatment response in primary rectal cancer, monitoring response 
after local ablative therapy of liver metastases and monitoring chemotherapy response 
in advanced colorectal cancer. FDG-PET in the initial preoperative staging of newly 
diagnosed colorectal cancer will not be discussed, since there is no established role 
for the systematic use of PET in this part of the management proces, due to its poor 
sensitivity regarding detection of early tumor spread to regional lymph nodes 5.
Detection of recurrent disease
Recurrent rectal cancer in residual masses
Surgery is the key to cure for patients with rectal cancer. In the past, local recurrence rates 
after conventional surgery averaged 30% and varied considerably between institutions 
from 15% to 45% 6-8. Recently, total mesorectal excision with or without preoperative 
radiotherapy has played a major role in reducing the rates of local recurrence to 5-11% 9-11. 
One reason for this is the higher frequency of complete resection of the tumor together 
with its lymphatic and venous drainage that is achieved by complete removal of the 
mesorectum 12,13. During the past decades a broad spectrum of treatment modalities 
have been examined such as postoperative chemoradiotherapy with different 5-
fluorouracil (5FU) based schedules, short-term preoperative radiotherapy (5 Gray/day in 
5 days), prolonged preoperative radiotherapy (alone or in combination with 5FU based 
regimens or with new drugs), and intraoperative radiotherapy in primary disease, and 
combinations of drugs in patients with metastatic disease; all aiming at improvement 
in standards of care, ameliorating quality of life with better local control, fewer 
complications, and improved survival 14. 
After resection of the primary tumor most patients will develop a fibrotic mass in the 
presacral surgical bed, and external beam radiation therapy causes an inflammatory 
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reaction in the pelvic tissues which induces thickening of the perirectal fascia 15,16. These 
changes might complicate the detection of pelvic recurrence with ultrasound, CT or 
MRI, since these techniques have limited ability to distinguish scar from viable tumor. 
It appears that FDG-PET does not demonstrate this limitation. The first reports on 
the clinical application of FDG-PET in colorectal cancer addressed the differentiation 
between scar tissue and local recurrence in rectal cancer 17,18. There is evidence that FDG-
PET is superior to CT scanning for assessing disease activity. FDG-PET has been noted 
to have a sensitivity of 84% to 100% and a specificity of 80% to 100% in the detection 
of local recurrence and the accuracy ranges from 74% to 96% 16,19-29. The required interval 
for post-radiotherapy evaluation with FDG-PET has not been studied systematically. 
It is, however, generally accepted that FDG activity at 6 months after completion of 
radiation therapy most likely represents tumor recurrence. Increased FDG uptake 
immediately after radiotherapy may be due to inflammatory changes and is not always 
associated with residual tumor 19,30,31. Approximately 25% of FDG uptake can accumulate 
in non-tumor tissues such as macrophages, neutrophils, fibroblasts, and granulation 
tissue 32. Obviously, a true radiation-induced reduction in glucose utilization occurs due 
to tumor cell loss 33. However, a short-lived reversible decrease in glucose metabolism 
may also occur just after radiotherapy, due to the so-called stunning of tumor cells 34. 
This phenomenon can mimic actual cytotoxic therapy effects, although only temporarily. 
As early as 1991, Haberkorn et al. showed that it is not possible to distinguish between 
proliferation, repair, inflammation, and residual viable tumor cells shortly after 
radiotherapy. In this study, a significant decrease in FDG uptake was not observed in 
50% of patients despite good palliative effects 30. This was confirmed by another study 
performed in the same institute, and the authors postulated that FDG-PET evaluation 
is not reliable within 3 months after radiotherapy 31. This hypothesis was also supported 
by a retrospective case-controlled study performed by Moore et al. 19. They reviewed 
the records of 60 surgically resected rectal cancer patients who underwent FDG-PET at 
least 6 months after radiotherapy. A sensitivity of 84%, a specificity of 88%, an overall 
accuracy of 87%, a positive predictive value of 76% and a negative predictive value of 
92% were observed for the detection of local recurrence. The positive predictive value 
and accuracy improved in scans performed more than 12 months after radiotherapy. 
They postulated that the reliability of FDG-PET improves with time, probably due to 
resolution of early postradiation inflammation.
Accurate detection of locoregional recurrence may be hindered by a marked distortion 
of the normal pelvic anatomy 21,25. After abdominoperineal resection, the empty rectal 
fossa may result in displacement of other pelvic organs. For instance, the urinary bladder 
tends to move backwards to a presacral or precoccygeal location. Furthermore, the empty 
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fossa may be occupied by the seminal vesicles, uterus, or the small bowel. This altered 
pelvic anatomy may influence the interpretation of FDG-PET images, especially in the 
differentiation between tumoral and physiologic FDG uptake in the gastrointestinal or 
genitourinary tract. Even-Sapir et al. 25 reported that physiologic FDG uptake in displaced 
pelvic organs was the most common cause for false-positive interpretation of FDG-PET 
findings. Keogan et al. 21 suggested appropriate hydration and prescan voiding, bladder 
catheterization, and registration of anatomic and metabolic images as ways to overcome 
this problem. Therefore, there may be an important role for integrated PET/CT, which 
combines the benefits of the two imaging modalities and provides the clinician with 
simultaneous metabolic and anatomic imaging information 25. Even-Sapir et al. 25 studied 
62 patients and found presacral CT abnormalities in 30 patients (48%). Of these, seven 
(23%) abnormalities appeared to be malignant. For detection of malignancy in presacral 
residual masses with PET/CT, they reported a sensitivity, specificity, positive predictive 
value, and negative predictive value of 100%, 96%, 88%, and 100%, respectively. In 
this study PET/CT images also provided information concerning the involvement of 
pelvic structures, which was clinically relevant in selecting an appropriate surgically 
approach.
Unexplained carcinoembryonic antigen rise
Although the ideal postoperative follow-up regimen for asymptomatic patients 
after curative colorectal cancer resection remains undefined, clinicians often use a 
combination of history, physical examination, imaging, and laboratory tests including 
measurement of the serum tumor marker carcinoembryonic antigen (CEA) 15. Elevated 
serum CEA levels are detected in two-thirds of patients with recurrence of colorectal 
carcinoma and have been associated with a 3-9-month median lead-time in detection 
of recurrence over anatomic imaging modalities 5,35-39. Measurement of serum CEA every 
2-3 months for at least 2 years after surgery has been advocated 35,40-42. Such intensive 
follow-up after primary curative treatment may detect more cancer relapses that are 
amenable to curative resection. Two meta-analyses reported that intensive follow-up 
improves overall survival and reduces absolute mortality with 9-13% 43,44. Although 
serum CEA may detect recurrence, it does not identify the site of recurrence. Patients 
with rising serum CEA levels without detectable disease on morphological imaging 
pose a clinical challenge. Abnormal serum CEA levels are also observed in a variety of 
benign conditions, such as liver diseases, bowel diseases, smoking, and renal failure 35. 
The problem with false-positive serum CEA elevation is that it may lead to unnecessary 
imaging or even surgery with associated morbidity. Several studies have demonstrated 
 18F-FDG-PET in colorectal cancer 45
the value of FDG-PET in patients with rising serum CEA levels and no identifiable lesions 
on conventional imaging 23,27,45-53. Fletcher concluded that a serum CEA >10 ng/ml rarely 
was caused by benign conditions 54. Liu et al. 35 reported that the cumulative survival of 
patients with an unexplained serum CEA level >25 ng/ml was significantly worse than 
that of patients with levels <25 ng/ml. They suggested a serum CEA cutoff value of 10 
ng/ml as an indication for FDG-PET. An increase in CEA level is also strongly associated 
with tumor recurrence with a reported specificity of 70% to 84%. Its sensitivity is 
approximately 80%, but is not as high for locoregional recurrence and pulmonary 
metastases as it is for liver metastases 5. In asymptomatic patients with rising serum 
CEA levels without abnormal findings of conventional workup, the sensitivity for 
detection of recurrence with FDG-PET has been reported as 79% to 100%, specificity 
as 50% to 83%, and accuracy as 74% to 93% 22,35,45-49. Positive predictive values ranged 
from 89% to 95% and negative predictive values from 85% to 100% 22,45,47. In a study 
of 28 patients with a rising serum CEA, negative imaging and second look laparotomy, 
the results of FDG-PET and CEA scintigraphy scans (99mTc-labeled arcitumomab) were 
analysed as predictors of correct selection of patients for resection 48. Ninety four 
percent of patients had biopsy confirmation of recurrence. Disease was unresectable 
in 38% of these recurrences. PET correctly predicted unresectable disease in 90% of 
cases, whereas CEA scintigraphy scan failed to predict any. PET correctly predicted 
resectable disease in 81% and CEA scintigraphy in only 13%. The impact of FDG-PET on 
management of patients with a rising serum CEA after primary curative treatment has 
also been examined 47,55,56. In a series of 58 patients, 34 (59%) had a management change 
after FDG-PET, including 18 (31%) who underwent a curative resection and 16 (28%) who 
were treated with systemic chemotherapy 56. Similar findings have been reported by 
Flamen et al. 47. The impact on management in the study of Liu et al. 55, however, was 
even higher (68%). The positive impact of FDG-PET on management decision in this 
clinical scenario is evident. FDG-PET is recommended for patients with an otherwise 
unexplained increase of serum CEA level after primary curative treatment of colorectal 
carcinoma, provided they are fit to undergo salvage surgery.
Staging of recurrence irrespective of CEA or tumor site
Several studies have described the additional value of FDG-PET imaging over anatomical 
imaging in recurrent colorectal cancer 20,22,26-28,57-69. Metabolically active tumors can be 
detected before a morphologic change is noted on anatomical imaging. Overall, FDG-
PET was more accurate compared to CT scanning. A meta-analysis of 11 clinical reports 
with 577 patients showed an overall sensitivity of 97% and specificity of 76% for FDG-
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PET detecting recurrent colorectal cancer 63. In addition, a comprehensive review of 
the PET literature (2244 FDG-PET studies) has reported a weighted average for FDG-
PET sensitivity and specificity of 94% and 87%, respectively, compared with 79% and 
73% for CT scanning 70. Whiteford et al. 26 reported that the sensitivity of FDG-PET 
imaging for detection of mucinous adenocarcinoma (58%, n=16) was significantly lower 
than for nonmucinous adenocarcinoma (92%, n=93) (p=0.005). They proposed that this 
lower sensitivity is due to the relative hypocellularity of these tumors. Similar findings 
(sensitivity of 41%) have been reported in a subsequent series of 22 patients 71.
Staging before surgical resection of colorectal liver metastases
Liver metastases are the main cause of death in patients with colorectal cancer. 
Approximately 20% of patients already have liver metastases at the time of detection of 
the primary tumor, and another 25% will develop metastatic lesions during the following 
4 years 5,72.Without any treatment, the median survival after the detection of liver 
metastases is approximately 9 months, depending on the extent of the disease at the 
time of diagnosis 73. For patients with recurrent disease confined to the liver, resection 
of the metastases is the treatment of choice and can result in a 5-year survival of more 
than 40%, depending on the selection criteria for surgery 74-76. With the exception of lung 
metastases, the presence of extrahepatic disease, however, typically precludes surgery 
as does the involvement of major blood vessels or extensive bilobar liver disease, which 
would either preclude negative resection margins or would result in inadequate hepatic 
reserve. Therefore preoperative staging should concentrate on careful evaluation of 
extrahepatic disease and precise delineation of all liver lesions with regard to number 
and position to vital anatomic structures. This strongly supports the need for more 
effective preoperative imaging to improve staging in order to avoid futile surgery. 
Synchronous metastases, multiple metastases or bilobar disease once considered as 
absolute contra-indications for resection, currently do not preclude resections with 
curative intent per se 1. The selection of patients for surgical resection of colorectal liver 
metastases, however, still poses a significant clinical problem. A significant number of 
patients (10-25%) considered suitable for surgical resection of liver metastases appear 
to have unresectable disease identified during laparotomy 72. Moreover, 60% of patients 
will develop recurrent tumor after successful hepatic resection within 3 years, indicating 
that many of the patients must have harbored unrecognized tumor foci either in the 
liver or in extrahepatic areas at the time of liver resection 72,77,78.
Whole body survey and analysis of metabolic activity, as performed with FDG-PET has 
emerged as a pivotal diagnostic tool in patients with suspected recurrent disease in the 
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liver and has proven to be an accurate diagnostic technique for determining whether 
patients are suitable candidates for curative resection. A meta-analysis of Kinkel et al. 
documented the superiority of FDG-PET over ultrasound, CT, and MRI, and showed 
that FDG-PET might be the most sensitive imaging modality for detection of hepatic 
metastases of gastrointestinal cancer 58. A more recent meta-analysis of 61 studies 
showed a sensitivity of 95% for FDG-PET on a per-patient basis, which was significantly 
better compared to CT scanning (65%) and MRI (76%) 57. Very recently, the meta-
analysis of Wiering et al. 72 showed a pooled sensitivity and specificity of 88% and 96%, 
respectively, for hepatic disease, and 92% and 95%, respectively, for extrahepatic disease. 
For CT scanning, the pooled sensitivity and specificity were 83% and 84%, respectively, 
for hepatic lesions, and 61% and 91%, respectively, for extrahepatic lesions. 
FDG-PET as a complementary staging method has been shown to significantly alter 
and improve therapeutic management in 14 to 65% of patients with colorectal liver 
metastases, especially by detecting unsuspected extrahepatic disease in 13-36% 16,20,22,
23,28,45,52,53,59-61,78-86. A prospective study by Ruers et al. 78 demonstrated a change in clinical 
management in 20% of patients (10 out of 51 patients) being evaluated as candidates 
for resection of colorectal liver metastases, especially by detecting unsuspected 
extrahepatic disease. In a another prospective study of 102 patients with suspected or 
confirmed regional recurrence of colorectal cancer, FDG-PET influenced management 
decision in 59% of cases. The high impact on treatment planning in this study was also 
predominantly due to avoiding surgery in patients with widespread disease 27. Huebner 
et al. reported in a meta-analysis that the pooled change-in-management was calculated 
at 29% (95% confidence level, 25%-34%) 63. The pooled change in-management in the 
meta-analysis of Wiering et al. was 32% (range, 20-58%) 72. A comprehensive review 
of the PET literature has reported a weighted average change of management related 
to FDG-PET findings in 32% of 915 patients 70. The results of these numorous studies 
brought about a broad consensus that FDG-PET has a clear role in the re-staging of 
recurrent colorectal cancer. 
Although survival is not an endpoint for a diagnostic test, Strasberg et al. 87 estimated the 
survival of patients who underwent FDG-PET imaging in their preoperative evaluation 
for resection of hepatic metastases. The Kaplan-Meier estimate at three years was 77% 
for overall survival and 40% for disease-free survival. Both percentages were higher than 
those previously reported 88. Fernandez et al. showed that FDG-PET imaging prior to 
surgical resection improved the 5-year survival rate compared to historical controls 89. This 
improvement in survival is certainly mainly due to the so called Will Rogers phenomenon 
or the phenomenon of stage migration due to more careful staging of cancer 90.
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Although FDG-PET provides highly relevant information for patient management, it 
does not substitute the excellent anatomical imaging provided by spiral CT scanning. 
CT scanning provides the detailed anatomic information that is required for an optimal 
planning of hepatic resection. Resectability of liver metastases is generally determined 
by the extent of liver involvement and the specific relation of metastases to anatomic 
structures, such as the hepatic veins and the biliary tract 1. Thus, in patients with 
suspected hepatic metastases from colorectal cancer, FDG-PET may be best used in 
conjunction with anatomic imaging. Integrated PET/CT modalities, that combine the 
benefits of both anatomical (CT) and functional (PET) information and allow optimal 
coregistration of images, may lead to a significant improvement of preoperative liver 
staging and preoperative judgement on the feasibility of resection 91. A study of 45 
patients 92 reported that PET/CT imaging increases the accuracy and certainty of locating 
lesions. The frequency of equivocal and probable lesion characterization was reduced 
by 50% with PET/CT compared with PET alone, the number of definite locations was 
increased by 25%, and the overall correct staging increased from 78% to 89%.
These advances in imaging technologies bring another challenge to physicians at 
times when it is also important to provide care at an acceptable cost. Increasing cost-
effectiveness and decreasing the number of invasive procedures are currently two of 
the major trends in health care. Including FDG-PET in the evaluation of patients with 
recurrent colorectal carcinoma has been shown to be cost-effective in a study using 
clinical evaluation of effectiveness with modeling of costs and studies using decision 
tree sensitivity analysis 22,93-95. Zubeldia et al. 94 found an average expected surgical cost 
per patient of $16,278 when FDG-PET was used, compared to $21,547 for conventional 
management, a net savings of $5,269. In a prospective study involving 115 patients who 
underwent CT and FDG-PET scanning for diagnosis or staging of recurrent colorectal 
carcinoma Valk et al. 22 found per-patient savings of $3003. Their smaller cost reductions 
may be explained by the inclusion of pelvic ($12,916) and lung ($15,508) resection in 
addition to hepatic resection ($20,668). The analysis of Zubeldia considered only 
hepatic resection 94. So, integration of FDG-PET into the presurgical evaluation of 
patients with potential resectable hepatic metastases alters and improves therapeutic 
management, reduces morbidity due to futile surgery, leads to substantial cost savings 
and probably also to a better patient outcome. Randomized, controlled clinical trials 
should be performed to confirm the actual impact of FDG-PET on overall survival, in 
order to further strengthen the role of FDG-PET in the management of colorectal liver 
metastases.
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Prediction and evaluation of treatment response
The current definition of tumor response is based on the measurement of changes 
in tumor size as determined with morphological imaging methods. According to the 
RECIST (response evaluation criteria in solid tumors) criteria a tumor is classified as 
responding when the largest diameter of the tumor decreases by at least 30% 96. Despite 
the widely accepted practice of using these criteria, it is important to realize that a 30% 
decrease of tumor size is an arbitrary convention, and is not based on outcome studies. 
In fact, the correlation between morphologic tumor response and patient outcome 
is rather weak 97. Moreover, morphological imaging techniques have limitations in 
assessing the therapeutic effect, since changes in tumor size lag behind the biologic 
response to therapy, which is considered a problem in early response monitoring. 
Besides, residual non-tumoral masses may persist, despite the fact that disease activity 
may have completely resolved after successful therapy. Furthermore, the introduction 
of molecular-targeted agents such as the angiogenesis inhibitor bevacizumab, require 
new surrogate end points for monitoring therapeutic effects since they have different 
biological effects compared to classic cytotoxic chemotherapy. These new agents inhibit 
the growth of new blood vessels in cancer tissue, which does not immediately result 
in dissolution of tumor masses, and thus poses new demands on imaging modalities. 
When anticancer therapy becomes more individualized, it is increasingly important to 
identify response to therapy as early as possible. Early identification of nonresponders 
may allow physicians to spare these patients the morbidity (and costs) of systemic 
treatment. Several studies performed on tumors other than colorectal carcinoma have 
already confirmed the hypothesis that changes in tumor glucose metabolism early in 
the course of treatment predict therapy outcome and long-term prognosis 98-102. So far, 
in colorectal carcinoma only studies in small series of patients have been performed, 
and the interval between onset of antitumor therapy and FDG-PET evaluation, as well 
as the method of quantification differ per study. The optimal method for quantification 
has not yet been defined and the threshold set for response depends on multiple 
variables such as tumor type, type of therapy and interval after onset of therapy. 
Therefore, further studies are needed before definite conclusions can be drawn. This 
section reviews the currently available literature on radiotherapy and/or chemotherapy 
response monitoring in colorectal carcinoma.
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Preoperative multimodality and radiotherapy treatment response evaluation in 
primary rectal cancer
In rectal cancer, preoperative chemoradiotherapy is used in advanced T3 and T4 
tumors in the attempt to down-stage the disease, in order to reduce the risk of local 
recurrence and to allow sphincter preserving tumor resection in selected cases 103,104. 
FDG-PET may have a role in preoperative multimodality treatment response evaluation 
and in a preoperative strategy aimed at identifying patients most suitable for sphincter 
preserving surgery. Amthauer et al. 34 performed FDG-PET and endorectal ultrasound 
in 20 consecutive patients with locally advanced primary rectal cancer before and 2-
4 weeks after completion of neoadjuvant chemoradiotherapy in combination with 
regional hyperthermia. Reduction in tumor standardized uptake value (SUV) was 
significantly greater in (histopathologically confirmed) responders compared to non-
responders. Using a minimum post-therapeutic SUV reduction of 36% to define response, 
FDG-PET revealed a sensitivity of 100% and a specificity of 86%. The corresponding 
positive and negative predictive values were 93% and 100%, respectively, which was 
significantly better than for endorectal ultrasound. In a similar study performed in the 
same institute, 23 patients underwent FDG-PET, as well as CT scanning and MRI 105. 
The results suggested that FDG-PET was also superior to both CT and MRI. Guillem 
et al. 106 assessed the response in primary rectal cancer to preoperative radiation and 
5-FU-based chemotherapy in 15 patients. FDG-PET was obtained before and at 4-5 
weeks after completion of chemoradiotherapy. All patients demonstrated a pathologic 
response, which was predicted in 100% of cases by PET, compared with 78% by CT. 
They also demonstrated that estimation of rectal cancer response to preoperative 
chemoradiotherapy by FDG-PET predicts long-term clinical outcome, a finding that 
has recently been corroborated by others 107,108. It is striking that the confounding 
radiotherapy-induced effects, as discussed earlier, have less impact on the results 
of FDG-PET if it is combined with chemotherapy and/or regional hyperthermia. This 
implies that the nature of the combination of treatment modalities for neoadjuvant 
therapy is important in the timing of FDG-PET evaluation. Further studies are required 
to ascertain the exact sequence of time-dependent (radio)biological effects during 
neoadjuvant multimodality treatment.
For induction radiotherapy alone, it has not yet been sufficiently investigated whether 
FDG-PET could play a role in the preoperative radiotherapy response assessment of 
primary rectal cancer. The generally accepted interval of at least 6 months for FDG-
PET evaluation after adjuvant radiotherapy is not applicable in a neoadjuvant setting. 
Probably due to these expected confounding radiotherapy-induced effects on FDG 
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uptake only one study on this subject has been performed. This study of Schiepers et 
al. 33 investigated 9 patients with rectal cancer before and 2-3 weeks after radiotherapy. 
They observed an overall decrease of glucose utilization with a reduction in SUV 
after neoadjuvant treatment of 65% in comparison to the pretherapy value, which 
correlated to reduction of tumor burden and cell death. The authors concluded that 
they could discriminate as early as 2 weeks after radiotherapy between successfully and 
unsuccessfully treated tumors with an accuracy of 80%. These surprising results call for 
systematic investigation of the required interval for post-radiotherapy evaluation with 
FDG-PET. 
Monitoring response after local ablative therapy of liver metastases
For patients with colorectal liver metastases surgical resection offers the best chances 
for cure. In most patients with colorectal liver metastases, however, resection cannot 
be performed. When this is caused by the number and/or localization of metastases, 
local ablative techniques such as cryosurgery or radiofrequency ablation may offer 
an alternative treatment that produces localized intrahepatic tumor destruction and 
possibly results in a prolongation of survival. A prospective randomized trial on the 
impact of radiofrequency ablation versus chemotherapy (CLOCC) is on-going. 
Different morphological imaging techniques have been used to facilitate the 
intraoperative localization. However, during the process of local ablation the destruction 
process cannot easily be ascertained with intraoperative ultrasound imaging because 
of the hyperechogenicity that is induced within the treated area 109. Furthermore, 
evaluation with CT scanning or MRI of residual tumor after the ablation procedure is 
limited because post-treatment hyperemia or tissue regeneration may result in contrast 
enhancement in the periphery of the ablative necrosis 110. This can lead to either a 
delayed diagnosis of treatment failure or to confusion between incomplete local ablative 
treatment and the occurrence of new metastases in regions adjacent to the treatment 
site. Several studies described the feasibility of FDG-PET scanning in the surveillance of 
these patients 55,111-113. It appears to have great potential in identifying residual tumor soon 
after local ablative treatments. In a prospective study of 23 patients with a mean follow-
up of 16 months, Langenhoff et al. 111 showed that FDG-PET has a positive predictive 
value of 80% (4/5 lesions) and a negative predictive value for the detection of local 
treatment failure of 100% (51/51 lesions) when performed less than 3 weeks after the 
ablative procedure. There was one false-positive FDG-PET caused by abscess formation 
in a lesion treated with radiofrequency. In all patients the time point of detection of 
recurrence by FDG-PET was considerably earlier compared to the detection by CT 
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scanning. Donckier et al. 113 reported on the value of FDG-PET performed at 1 and 4 
weeks after local ablative treatment. Residual hypermetabolism in the periphery of 
ablated sites detected by FDG-PET correlated well with incomplete tumor destruction 
in 4/28 lesions. CT imaging performed at the same time failed to demonstrate residual 
hypervascularized lesions in these patients. After a median follow-up of 11 months, none 
of the 24 FDG-PET negative postablative lesions had developed a local recurrence. A 
more recent study 112 performed in 43 patients with 104 ablated lesions, CT scanning 
after treatment did not predict local treatment failure, whereas FDG-PET within 3 weeks 
after local ablative treatment predicted 6/7 local recurrences. One local recurrence was 
detected on FDG-PET 3 months after treatment. The negative predictive value of FDG-
PET at 3 months was 100%. Since FDG-PET showed one false positive result due to focal 
infection, the positive predictive value was 88%. The data presented here indicate that 
FDG-PET could play a central role in optimizing the use of local ablative treatment of 
liver metastases as it early recognizes incomplete tumor ablation, that is not detectable 
by CT scanning. FDG-PET determines the need for further investigations and guides the 
reading of the CT scan, which on its own appears difficult to interpret in the early period 
after local ablative therapy. The combined information of FDG-PET and CT scans offers 
the opportunity to re-treat tumors at an early stage.
Chemotherapy response monitoring in advanced colorectal cancer
There are four reports suggesting that FDG-PET can predict response to chemotherapy 
in patients with irresectable colorectal cancer liver metastases. Findlay et al. 114 studied 18 
patients before and at 1-2 and 4-5 weeks on 5-FU chemotherapy. Responding lesions had 
a greater reduction in FDG uptake compared to the baseline value than non responding 
lesions (-33% vs. -1%). The 4- to 5-week tumor-to-liver ratio was able to discriminate 
response from nonresponse in both a lesion-by-lesion assessment as well as in an 
overall patient response assessment with a sensitivity of 100% and specificities of 90% 
and 75%, respectively. A clear correlation was observed between the reduction of tumor 
metabolism 5 weeks after the initiation of chemotherapy and treatment outcome, which 
was not observed at 1-2 weeks on treatment. These results show the importance of a correct 
timing of FDG-PET after the onset of chemotherapy. The authors mention the so-called 
flare phenomenon that occurs 1-2 weeks after the initiation of chemotherapy, which can 
be observed as a marked increase in FDG metabolism in lesions that show a response 
later on. Bender et al. 115 studied 10 patients with irresectable liver metastases prior to and 
72 h after a single infusion of 5-FU and folinic acid. SUVs were correlated with therapy 
outcome, with a follow-up of at least 6 months. All metastases responding to therapy (n 
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= 6) exerted a statistically significant decrease of FDG uptake (-22+/-10%). Metastases 
showing a short-term effect (duration of tumor reduction <3 months, n=2) had a slightly 
diminished FDG uptake, and in progressing metastases (n = 3) an enhanced FDG uptake 
(13+/-17%) was observed. Probably the flare phenomenon does not play a role as early 
as 72 hours after initiation of chemotherapy. These preliminary data indicate that acute 
changes of glucose utilization following a single application of chemotherapy seem to 
be indicative for the final therapeutic outcome. More recently, Dimitrakopoulou-Strauss 
et al. 116 examined the ability of serial semiquantitative as well as quantitative dynamic 
FDG-PET examinations in 28 patients to predict response to second-line FOLFOX (5-FU, 
folinic acid, and oxaliplatin) at baseline and after the first and second cycle. The clinical 
response data, according to the WHO classification, served as a standard of reference. 
Even the first PET study (at baseline) was predictive with respect to therapy outcome. 
The so called fractal dimension, a parameter that can be obtained from kinetic analysis 
and may help to quantify tumor heterogeneity, showed the best results and classified 
progressive disease correctly in 90 % of cases and stable disease in 75% of cases at 
baseline. Furthermore, metastases with a baseline SUV lower than 4.6 did not respond 
to chemotherapy. The authors postulate that tumors with a low FDG uptake often 
reveal an enhanced expression of resistance genes. A low FDG uptake, particularly in 
pretreated patients, may reflect an enhanced resistance to chemotherapeutic drugs and 
is therefore associated with a poor outcome of chemotherapy. In another study with 25 
patients of similar characteristics Dimitrakopoulou-Strauss et al. 117 examined the ability 
of serial FDG-PET to predict chemotherapy response as reflected by individual survival 
times. In this study, scans were performed before initiation of therapy and after the 
first and third cycle. They showed that a combination of kinetic parameters of the first 
and the third scan provided the best results for classification into a short or long term 
survival class (defined as survival for less than 1 year or more than 1 year, respectively) 
and that even an individual prognosis of survival could be achieved. The authors feel 
that quantitative, dynamic FDG-PET should be used preferentially for chemotherapy 
response monitoring. 
Conclusions
FDG-PET plays a pivotal role in the detection of recurrent disease, the assessment 
of residual masses after treatment, the localization of recurrence in patients with an 
unexplained rise of serum CEA, and in staging patients before surgical resection of local 
recurrence and metastatic disease.
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FDG-PET is emerging as a potentially valuable technique in the prediction and evaluation 
of response of radiotherapy, systemic therapy, and combinations thereof. Correlation 
between changes in FDG uptake and overall patient survival remains a very worthwhile 
track of research to pursue. The preliminary findings call for systematic inclusion of 
FDG-PET in therapeutic trials to adequately position FDG-PET in treatment time lines 
in order to change current therapeutic concepts to individualized treatment of patients 
with advanced colorectal cancer. 
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Introduction 
Primary treatment of differentiated thyroid carcinoma consists of total thyroidectomy 
followed by ablation of thyroid tissue remnants and possible metastases by means of 
radioactive iodine (iodine-131). After complete destruction of remnants, metastases or 
recurrence can be detected by measurement of the serum thyroglobulin level as well as 
by radionuclide imaging. The present chapter discusses the relevance of the application 
of 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) in the assessment 
of thyroid nodules and the relevance of the so-called thyroid PET incidentaloma. 
Information is provided on the current and future clinical use of FDG PET for each type 
of thyroid cancer; differentiated thyroid carcinoma, Hürthle cell carcinoma, anaplastic 
thyroid carcinoma and medullary thyroid carcinoma. FDG-PET is diagnostic tool that 
currently became widely available. FDG is an analogue of glucose, reflecting cellular 
metabolic activity. The uptake of FDG in cells is related to the expression of the GLUT1 
transporter and hexokinase-I activity, both of which are upregulated.
Assessment of thyroid nodules
Solitary thyroid nodules are quite common, with a prevalence of 4% to 7% in the adult 
population of the United States. Differentiated thyroid cancer, on the other hand, is 
uncommon, with an incidence of only 40 cases per million per year. Therefore, it is a major 
diagnostic challenge to select for surgery only those patients whose nodules are most 
likely malignant. The clinical findings that should raise the suspicion of malignancy include 
rapid growth, firm or hard nodules, regional lymphadenopathy, local invasion in the neck 
and a family history of medullary thyroid carcinoma or multiple endocrine neoplasia or the 
combination of a thyroid nodule with paralysis of one or both vocal cords. Radionuclide 
scanning, using 123I, 131I or 99mTc-pertechnetate, is not routinely recommended, since thyroid 
scintigraphy does not significantly decrease the number of suspicious nodules 1, and most 
patients would also undergo a fine needle aspiration biopsy (FNAB) in such a diagnostic 
algorithm. Characteristics revealed by ultrasonography, such as hypoechogenicity, 
microcalcifications, irregular margins, increased nodular flow visualized by Doppler, and 
especially the evidence of invasion or regional lymphadenopathy, are associated with 
an increased risk of cancer; however, these features do not help to reliably distinguish 
between benign and malignant lesions 2.
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FNAB, preferably guided by ultrasonography, is the key investigation and initial 
diagnostic test in the evaluation of thyroid nodules. FNAB is safe, can be easily 
performed, without major complications, is cost-effective and has a very high negative 
predictive value of 98% 3. So, patients with nonmalignant cytology can be followed safely 
by sonography, as long as the size of the thyroid nodule remains constant. However, 
the recognized limitation of FNAB is that it shows inconclusive aspirates in up to 20% 
of cases. In patients with cytological findings suspicious for a follicular neoplasm, a 
Hürthle cell (oncocytic) neoplasm, or in case of an atypical papillary cytology or an 
repeatedly insufficient sample (“nondiagnostic”) a hemithyroidectomy is necessary 
to allow a reliable histological diagnosis. Although routine FNAB clearly increases the 
relative number of cancers at operation, still 80-85% of hemithyroidectomized patients 
eventually turn out to have benign thyroid disease.
Several studies showed that FDG-PET provides a high negative predictive value for 
thyroid malignancy, making this a potentially useful tool in the evaluation of thyroid 
nodules with inconclusive FNAB results 4,5. Aspecific tumor-seeking agents, like FDG-
PET, however, are not able to 100% differentiate benign from malignant thyroid 
nodules 4,5. Most Hürthle cell adenomas and in some cases Hashimoto’s thyroiditis, 
follicular adenomas and hyperplastic nodules also accumulate FDG (Fig. 1). The use of 
semiquatitative data (standardized uptake values) in any individual case is not helpful 
in further differentiation, due to significant overlap between benign and malignant 
lesions 4,5. Nevertheless, FDG-PET has been shown to have a significant impact on 
patient management, because it could be very helpful in the selection of patients who 
need surgery. The number of futile hemithyroidectomies in an algorithm that includes 
FDG-PET could be substantially reduced by ~ 66% 4. Figure 2 shows a typical example 
of a patient with an inconclusive FNAB and FDG uptake in two nodules. In this patient 
histology revealed two malignancies in one lobe. Cumulatative data from 8 studies 
showed that FDG-PET was able to detect 64 out of 65 malignancies. The only malignancy 
that was missed was from a study that did not use a modern dedicated PET-camera 4,5. 
Another nuclear medicine technique, dual-phase 99mTc-sestamibi, did not provide such 
high negative predictive value. Thirteen studies that reported on this issue included 210 
thyroid carcinomas in total, of which 39 were missed with 99mTc-sestamibi scintigraphy 6,7. 
Like FDG-PET, 99mTc-sestamibi scintigraphy may also be positive in follicular adenomas, 
Hürthle cell adenomas and Hashimoto’s thyroiditis, and thus would not be helpful in 
raising the specificity. Also, other nuclear medicine methods, such as 99mTc-tetrofosmin, 
201Thallium, or 201Thallium/99mTc-pertechnetate subtraction scan, have shown similar 
disappointing results.
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Figure 1. This 42 year-old woman had an inconclusive FNAB with many atypical Hürthle cells. FDG-
PET showed intensely increased FDG uptake in the right thyroid lobe. Histology demonstrated a 
2.7 cm follicular adenoma with focal Hürthle cell changes. (Reproduced with permission from de 
Geus-Oei LF, Pieters GF, Bonenkamp JJ et al. J Nucl Med. 2006;47:770-775)
Figure 2. In this 38-year-old woman, FNAB showed follicular proliferation. FDG-PET demonstrated 
two lesions in the right thyroid lobe. The final histopathological diagnosis revealed a right-sided 
pT3 follicular thyroid carcinoma and a pT1 papillary thyroid carcinoma cranial from this lesion. 
(Reproduced with permission from de Geus-Oei LF, Pieters GF, Bonenkamp JJ et al. J Nucl Med. 
2006;47:770-775)
A limitation of PET and other scintigraphic methods is the lack of anatomic information 
provided. More recently, imaging with FDG-PET has been refined further with the 
development of combined PET and computed tomography scans (PET/CT), in which 
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the PET images are fused with CT images. Integrated PET/CT combines the benefits 
of the two imaging modalities and provides the clinician with simultaneous metabolic 
and anatomic imaging information. It provides a detailed anatomic context for areas 
of increased uptake seen on PET scanning, allowing spatial localization of worrisome 
areas of increased metabolic activity, that can definitely be of help in the preoperative 
evaluation of thyroid nodules. Other concerns that may arise from the limited spatial 
resolution of PET, is that PET scanning will probably never be able to rule out microscopic 
disease. However, this is probably not a significant clinical problem, because it is 
generally supposed that thyroid carcinomas smaller than 1 cm in size are rarely of clinical 
significance. This is confirmed by large autopsy series demonstrating a high prevalence 
of incidental and unrecognized minimal (occult) thyroid carcinomas.
Therefore, in case of an inconclusive cytology, FDG-PET seems the method of choice to decide 
whether surgery or a wait and watch strategy should be recommended. It is recommend 
not to rely on standardized uptake values (SUV) in the discrimination between malignant 
and benign thyroid lesions. Patients with a suspicious thyroid nodule with inconclusive 
FNAB in combination with any visible FDG-accumulation in the thyroid nodule should be 
taken to surgery. This advice, however, is not yet implemented in official Nuclear Medicine 
Guidelines, since results from further studies with larger sample sizes are awaited in order 
to determine the true efficacy and utility of FDG-PET for this indication.
Thyroid positron emission tomography incidentaloma
A thyroid PET incidentaloma or a so-called thyroid metaboloma is defined as a newly 
identified focus of increased FDG uptake in the thyroid in a patient investigated with FDG-
PET for any other indication. Considering that the use of FDG-PET is rapidly increasing 
as an evaluating tool for various disease conditions, the incidence of thyroid FDG-PET 
incidentalomas is also increasing and clinical meaning of the thyroid PET incidentaloma 
may become more relevant in the interpretation of FDG-PET scanning. Thyroid PET 
incidentalomas occur with a frequency of 1.2% to 4.0% in the total population that is 
referred for FDG-PET 8. The risk of thyroid cancer in these incidentalomas of patients 
who underwent FDG-PET for alleged cancer or a previous history of cancer, is very high 
being 25-50% 8. This is not surprising, because it is known that a previous history of cancer 
is a major risk factor for developing another cancer elsewhere in the body, especially 
when focal thyroid FDG uptake is found during the initial staging of NSCLC 9. In patients 
with NSCLC, second primaries are more frequently found than in patients with other 
cancer types 10. Furthermore, it should be emphasized that thyroid PET incidentalomas 
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seem to harbor a higher rate of malignancy than incidentalomas found on conventional 
imaging. Patients with thyroid incidentalomas detected with ultrasonography seem to 
belong to a totally different, less cancer prone population. Therefore, the prevalence of 
thyroid ultrasound incidentalomas is much higher, ranging from 19% to 46%. The risk 
of cancer in these thyroid nodules, on the other hand, is very low ranging from 1.5% 
to 10% 11. Furthermore, focal thyroid PET incidentalomas in particular carry a high risk 
of malignancy. The majority of patients with diffuse thyroid FDG uptake have chronic 
thyroiditis. Another important clinical issue is, whether this focal uptake in the thyroid 
is due to a primary thyroid malignancy or to a metastasis from the underlying non-
thyroidal cancer. It has been shown that metastases to the thyroid are not common, 
occuring in ~ 7% of all thyroid PET incidentalomas, mainly in patients with primary lung, 
breast, renal, gastrointestinal cancers, and melanoma 12. However, the above mentioned 
percentages may differ due to the varying incidence of benign and malignant thyroid 
diseases in different populations. Considering the high risk of malignancy, thyroid PET 
incidentalomas should not be overlooked and should prompt further investigation to 
rule out cancer, of course, only when the diagnosis of thyroid cancer would influence 
patient prognosis and management. From a palpable thyroid PET incidentaloma a FNAB 
should be obtained. Those patients with suspicious cytopathology should be referred for 
thyroidectomy. If no nodule is palpable, an ultrasound is advised and when a nodule 1 cm 
or greater is imaged it should be sampled by ultrasound guided FNAB.
Differentiated thyroid carcinoma
Differentiated thyroid carcinoma is the most common endocrine malignancy, but is 
still rare (<1% of all cases of cancer). In areas not associated with nuclear fallout, the 
annual incidence ranges between 2.0-3.8 cases/100,000 in women and 1.2-2.6/100,000 
in men. Since the early 1950s, nuclear medicine has been one of the mainstays for 
management of differentiated thyroid carcinoma. Primary treatment of differentiated 
thyroid carcinoma consists of total thyroidectomy followed by ablation of thyroid tissue 
remnants and possible metastases by means of radioactive iodine (131I). After complete 
destruction of remnants, metastases or recurrence can be detected by measurement 
of the serum thyroglobulin level (Tg) as well as by radioiodine scintigraphy. Well-
differentiated thyroid cancer is recognized as being one of the most curable of all 
neoplasms. After thyroidectomy and 131I ablative therapy, in the absence of widespread 
regional or distant disease, 10 year survival rates for papillary, follicular, and Hürthle cell 
carcinomas of 93%, 85% and 76%, respectively, can be achieved 13.
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The degree of differentiation is associated with better patient survival. Furthermore, 
differentiated cancer cells do not only produce Tg (a protein that can be assayed and 
used as tumor marker), but also remain capable of accumulating iodine. Thus, post-total 
thyroidectomy remnants trap and organify iodide, and perish in the process when a 
suitable beta emitter isotope such as 131I is administered. Patients who present with 
131I-accumulating remnants or metastases receive 131I treatment, that is curative in 
most cases. This iodine avidity can not only be used for treatment but also for tumor 
localization. Whole body scintigraphy using 131I or 123I has been widely used for detection 
of residual disease or metastases of differentiated thyroid cancer. To minimize the impact 
of recurrences, early recognition and treatment is essential. Even with an estimated 
tendency of differentiated thyroid cancer to develop local or regional recurrences 
in 5-20% of cases, and distant metastases in 5-10% of cases, the combination of Tg 
measurement and radioiodine scintigraphy should alert the clinician with a sensitivity 
of 95% and specificity of close to 100%.
A considerable diagnostic dilemma occurs in ~ 15-20% of patients when dedifferentiation 
leads to a loss of the iodine concentrating ability of thyroid tumor cells 14. It is well 
known that dedifferentiation of thyroid cancer leads to the loss of the ability of thyroid 
cells to concentrate radioiodine, while the synthesis of Tg is maintained longer in the 
process of dedifferentiation 15. In these patients, the detection of the (TSH-stimulated) 
circulating tumor marker Tg reveals that thyroid cancer tissue must be present, 
however, radioiodine imaging is negative. The reason for this false-negative 131I whole 
body scan may be an insufficient TSH stimulation, iodine contamination, small tumor 
volume, or non-iodine-avid metastases. If the first and second reasons are excluded, 
and the patient truly has metastases that do not concentrate 131I, even when it is given 
in high therapeutic doses, the patient should be scheduled for FDG-PET, which is now 
the method of choice to localize these iodine negative metastases. Whereas the role of 
FDG-PET in the preoperative assessment of thyroid nodules is not yet fully evaluated, 
the use of this imaging modality in the follow-up of non-iodine-avid thyroid carcinoma 
belongs to the 1a indications for FDG-PET in oncology 16. Before the introduction of 
FDG-PET, localisation of these iodine negative thyroid cancer recurrences/metastases 
was largely based on anatomical imaging such as ultrasonography, CT, and magnetic 
resonance imaging (MRI). These methods, however, are often of limited value in the 
post-thyroidectomy patients due to the difficulties in discriminating local recurrence 
from scar tissue in cases of altered anatomy, particularly after neck dissection 17. However, 
in patients with negative 131I whole body scan but detectable Tg, FDG-PET identifies 
the source of Tg production in up to 90% of cases 18. When detected early it enables 
surgical treatment of accessible lesions, which is the only curative therapeutic option 
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in patients with non-iodine-avid thyroid tumor tissue. Therefore, exact localization of 
these malignant thyroid tumor lesions is mandatory for successful resection (Fig. 3 and 
4). The early use of FDG-PET in these patients, changes the therapeutic strategy in up 
to 50% of patients 19.
Figure 3. 54 year old female with a history of pT2N1Mx papillary thyroid carcinoma, for which 
she was twice treated with 131I. The post-therapeutic 131I scintigraphy did not show any pathologic 
uptake despite an elevated TSH-stimulated Tg (24.6 microg/L).
Figure 4. This FDG-PET/CT of the same patient demonstrated paratracheal pathologic uptake, 
according to lymphnode metastases, which were confirmed after reoperation.
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In contrast to functionally more differentiated thyroid carcinoma cells with a retained 
iodine trapping mechanism and low glucose metabolism, dedifferentiated thyroid 
carcinoma cells have lost their iodine trapping mechanism and have high glucose 
metabolism. This peculiar molecular behaviour was first described by Feine et al. 20 as 
the flip-flop phenomenon. “Flip-flop” describes the alternating uptake pattern of 131I 
and FDG by differentiated thyroid carcinomas. High glucose consumption as reflected 
by high FDG uptake represents rapid tumor growth and poor differentiation, whereas 
most of the 131I-positive metastases are FDG-negative. In some cases there might be a 
considerable overlap showing uptake of FDG as well as 131I in the same lesion. This can 
be attributed to the coexistence of different tumor clones within the same tumor site. 
This suggests that the use FDG-PET in differentiated thyoid cancer is not exclusively 
limited to I-131 negative / Tg positive patients.
The detection rate of metastases by FDG-PET varies for different organs, being highest 
in cervical lymph nodes and lowest in small pulmonary metastases 21. Futhermore, the 
sensitivity of FDG-PET increases with increasing levels of serum Tg. FDG-PET seems to 
be most promising at Tg levels of > 10 microg/L 22. In patients with elevated Tg levels, FDG-
PET has a positive predictive value of 92% 19. However, also in case of Tg < 10 microg/L 
it is justified to perform FDG-PET, because detection of recurrence or metastases in an 
early stage is crucial with respect to both prognosis and survival. In these patients curative 
treatment can only be achieved when tumor tissues are completely resected before 
widespread metastatic disease occurs. Furthermore, a negative FDG-PET has a high 
negative predictive value of 93% in patients with low Tg levels 19.
Integrated PET/CT
In some conditions, FDG-PET is not able to adequately assess the non-iodine-avid 
disease. It is known that miliary lung metastases < 6 mm remain undetected by FDG-PET 
when FDG uptake is not very high 23. Furthermore, FDG uptake can be seen in normal 
muscle due to muscle tension, in degenerative articulations, or in hypermetabolic brown 
fat in the region of the neck, mediastinum and spine, thereby decreasing the specificity 
of the scan. Additionally, intense FDG uptake by the thymus on FDG-PET does not 
necessarily indicate recurrence, and asymmetric increased FDG uptake in vocal cord 
paralysis must be interpreted with caution. Moreover, precise localization of iodine-
negative / FDG-PET-positive disease is crucial to allow complete resection and cure of 
the patient. In all these abovementioned cases, a combination of PET and CT seems to 
improve diagnostic accuracy in a therapeutically relevant way. The recent development 
of a hybrid spiral CT and PET scanner (integrated PET/CT) provides combined anatomic 
and functional imaging information, which allows tissue characterization as well as 
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assessment of the exact localization and the extent of tumor tissue in one imaging 
procedure, without repositioning the patient. Integrated PET/CT can help to avoid 
pitfalls by precisely localizing the focal FDG uptake, e.g., by correction delineation of 
hypermetabolic brown fat. Diagnostic accuracy could be increased from 78% to 93% by 
integrated PET/CT in comparison to side-by-side interpretation of PET and CT 23. PET/CT 
allows the detection of recurrent or metastatic thyroid cancer with added anatomic 
information, thereby directing surgical interventions (Fig. 4). Precise localization may 
aid the patient and surgeon by decreasing surgical time required to locate and remove 
a tumor, and also by decreasing the risk for false-negative results. Overall, the use of 
PET/CT leads to a change of therapy in ~ 48% of patients with non-iodine-avid but FDG-
avid disease 23.
Effect of thyroid-stimulating hormone levels on FDG uptake
Recently, there has been debate whether or not the sensitivity of FDG-PET could be 
further increased when scanning during elevated TSH levels. For radioiodine scanning 
of thyroid cancers an elevated TSH level is essential, because iodine-uptake in the 
thyroid is largely driven by TSH. In contrast, cellular metabolism as reflected by the 
uptake of glucose is more closely related to the growth-rate of a cell, which in the case 
of a dedifferentiated cancerous cell might be independent of TSH. The effect of TSH on 
glucose transporter activity and glucose metabolism is very complex and not yet fully 
understood. There is evidence that TSH can modulate glucose uptake and consumption 
in cultered human thyroid cells 24. TSH has been found to stimulate glucose transport and 
GLUT1 expression, while on the other hand, high concentrations of peripheral hormones 
(in particular T3) appear to increase the Glut4 transport mechanism 25. It is apparent that 
both an increase in TSH and an increase in peripheral hormone concentration do have 
stimulating effects on glucose transport and thus on FDG uptake by thyroid cancer 
cells.
Several clinical studies have shown that significantly more lesions could be identified 
after TSH stimulation than during TSH suppression (Fig. 5) 26. TSH stimulation resulted 
in either detection of new lesions or classification of the FDG uptake pattern as typical 
for malignancy. For some patients this could alter clinical management of their disease. 
Furthermore, most thyroid tumor lesions exhibited a significant increase in FDG uptake 
during TSH stimulation, associated with an increase in the tumor to background ratio 
of 63% 27. These findings suggested that there is at least partial dependency of FDG 
uptake in recurrent and metastatic thyroid carcinoma on the TSH level. However, 
other studies reported conflicting results 19. It must, however, be emphasized that it is 
recommended to perform sequential PET examinations under similar TSH conditions to 
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prevent erroneous interpretation. Several studies examined the effects of recombinant 
human TSH (rTSH) on FDG uptake 26. FDG-PET imaging after rTSH stimulation also 
revealed more lesions in a larger number of patients with a significant increase in tumor 
to background contrast compared to FDG-PET scanning in the same patients during 
TSH-suppressive T4 therapy 26.
Figure 5. Widespread metastatic papillary thyroid carcinoma in a 60-year-old male. Compared 
to the FDG-PET during thyrotropin suppression (TSH 0.4), the FDG-PET during TSH stimulation 
(TSH 160) shows many more metastatic lesions. (Reproduced with permission from van Tol KM, 
Jager PL, Piers DA et al. Thyroid 2002;12:381-387)
Prognostic value of FDG-PET
The preservation of radioiodine uptake of metastatic thyroid lesions is generally 
considered a more differentiated phenotype. Metastatic lesions that do not concentrate 
radioiodine are associated with a more aggressive biological behaviour. Prognosis in 
thyroid carcinoma is extremely variable, with 10-year overall survival rates for patients 
with papillary, follicular, Hürthle cell, and anaplastic carcinoma of 93%, 85%, 76%, and 
14%, respectively 13. Many formal prognostic systems, such as EORTC, TNM (tumor/
node/metastasis), AMES (age/metastases/extent/size), AGES (age/grade/extent/size) 
and MACIS (metastasis/age/completeness of resection/invasion/size), have recognized 
that age, gender, histological type and grade, tumor size, extrathyroidal extension, and 
 Thyroid Cancer: 18F-FDG Positron Emission Tomography 75
clinical stage at initial diagnosis are key predictors of survival 28. The presence of distant 
metastases at initial diagnosis is a negative prognostic factor in virtually all of these 
models. There are no systems, however, to update the prognosis when metachronous 
metastases develop. About 26% of these individuals who eventually die of thyroid 
cancer live for more than 10 years with recurrent active disease; FDG-PET may 
provide prognostic information in this situation. FDG uptake seems to be restricted 
to more aggressive and high-grade tumors, whereas tumors with favorable prognosis 
demonstrate no significant tracer uptake 29. A reduced survival in those patients with 
FDG-avid disease has been reported 30. When integrating the results of FDG-PET in the 
TNM classification, it appeared that survival of stages I-III FDG-PET positive patients is 
very similar to that of patients with stage IV disease 31. On the other hand, the survival 
of stage I-III FDG-PET negative patients was excellent and significantly different from 
stage I-III FDG-PET positive patients. Patients with a positive FDG-PET have more than 
7 times the risk of dying of thyroid cancer, compared to thyroid cancer survivors (with 
or without metastases) with a negative FDG-PET. Furthermore, the number and site of 
FDG-avid lesions is prognostically important. Patients with FDG-avid local recurrences 
have a much better prognosis than those with FDG-avid distant metastases 31. The 
accumulation of FDG may differ between different metastases of the same patient due 
to metabolic heterogeneity. Survival time has shown to be inversely related with the 
degree of FDG uptake in the thyroid tumor lesion with the highest metabolic activity 
(e.g., lesion with the highest maximum SUV), suggesting that prognosis is determined 
by the tumor lesion with the most rapid growth potential c.q. the most aggressive 
behavior 30. Two-year survival rates of 99% were reported in FDG-PET negative patients, 
compared to 52% in patients with the highest SUVmax. Another strong predictor of 
survival is the volume of FDG-avid disease. A study with a large number of patients 
showed that the 3-year survival probability of patients with FDG-lesion volumes of 125 
mL or less was 96% compared to 18% in patients with FDG-lesion volume greater than 125 
mL 30. Therefore, once distant metastases are diagnosed in patients with differentiated 
thyroid carcinoma, FDG-PET can identify high and low risk subsets. These findings were 
supported by an immunohistochemical study, which showed that glucose transporter 1 
(GLUT1) gene expression is related to thyroid neoplasms with an unfavorable prognosis 29. 
Microscopically, it was not possible to detect morphologic differences between the tumor 
cells expressing GLUT1 and those not expressing it. Therefore, assessment of GLUT1 
expression may be a new prognostic marker in vitro and FDG a new prognostic marker 
in vivo to identify patients requiring more aggressive treatment. New therapeutic 
strategies are urgently needed for lesions that avidly accumulate FDG, as the survival of 
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these patients is significantly reduced. When designing clinical trials for such high risk 
patients, FDG-PET could be used as quantitative outcome measures. Major improvement 
in strategies that can affect re-differentiation, accompanied with restoration of iodine-
avidity are awaited 32.
Hürthle cell carcinoma
Hürthle cell carcinoma is a histologic subtype of differentiated thyroid carcinoma 
that is clinically more aggressive. It is a rare variant with an incidence of 3%-6% of all 
thyroid malignancies and it has unique histologic and pathophysiologic features that 
differentiate this subtype from other thyroid malignancies 33. The tumor is derived from 
follicular cells and is composed mostly of oncocytic, oxyphilic follicular cells. Despite 
preserved Tg expression and high differentiation, Hürthle cell carcinomas frequently 
do not incorporate radioiodine. Therefore, 131I therapy is often not a good therapeutic 
option for treatment of recurrences and metastases, as indicated by the relatively 
low 10-year survival rate of 50%-60%. In addition, the poorer prognosis may also be 
caused by its higher biologic aggressiveness compared to other differentiated thyroid 
carcinomas. In the follow-up of patients with Hürthle cell carcinomas distant metastases 
occur in approximately 33% of cases, whereas, in papillary and follicular thyroid cancer 
only 10 and 22% of patients suffer from metastatic disease 34. Local non-radioiodine-
avid recurrence may require revision surgery and, potentially, external-beam radiation 
therapy. This makes exact localization of tumor tissue of great clinical importance.
Several functional imaging modalities have been proposed for imaging Hürthle cell 
cancer, using radiotracers such as 99mTc-sestamibi, 99mTc-dimercaptosuccinic acid, 
radiolabeled somatostatin analogs, radiolabeled anticarcinoembryonic antigen 
antibodies, and 201Tl chloride 35. Although many of these modalities showed increased 
diagnostic sensitivity compared with radioiodine scintigraphy, none of them had very 
high sensitivity or specificity in detecting residual or recurrent disease.
Indeed, several reports have shown improved sensitivity using FDG-PET. Hürthle cell 
carcinoma demonstrated intense FDG uptake and FDG-PET has been shown to be a 
powerful diagnostic technique for the detection of radioiodine-negative recurrences and 
metastases of Hürthle cell carcinoma in patients with an elevated Tg level. A sensitivity 
of 92%, a specificity of 80%, a positive predictive value of 92%, a negative predictive 
value of 80%, and an accuracy of 89% have been reported 36. FDG-PET can provide 
additional information on disease extent, leading to a change in patient management 
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in approximately 50% of patients 34. Although only few results on the value of FDG-PET 
in the follow-up of Hürthle cell tumors have been published up to now, all authors rate 
FDG-PET as a powerful method superior to other diagnostic techniques in these non-
iodine-avid recurrences. However, the usefulness of FDG-PET in patients with iodine-
avid Hürthle cell carcinoma recurrence remains controversial. It is not expected that 
FDG-PET will demonstrate additional lesions in cases with 131I-positive recurrences and 
FDG-PET can even miss these iodine-avid recurrences as is the case in papillary and 
follicular thyroid carcinoma 36. Therefore, 131I-scintigraphy should precede FDG-PET in 
all patients without iodine-negative recurrences. As in papillary and follicular thyroid 
cancer, the degree of FDG uptake in Hürthle cell tumor lesions provided significant 
prognostic information: the 5-year overall survival in patients with SUVmax<10 was 92% 
and declined to 64% in those with SUVmax > 10 
37.
Anaplastic thyroid cancer
Anaplastic thyroid carcinoma accounts for 1-5% of all thyroid cancers and is characterized 
by poor outcome and extensive local invasion at the time of initial diagnosis. The 
diagnosis of anaplastic thyroid cancer is usually not difficult. Most of the time it occurs 
in elderly patients and it is marked by rapid growth and extensive local invasion. A 
FNAB confirms the clinical impression and regardless of the therapy the outcome is 
extremely bad and survival beyond 1 year is uncommon. Thus, there is no real use for an 
elaborate staging procedure in these patients, because almost all patients are classified 
as stage IV at diagnosis. Consequently, FDG-PET in anaplastic thyroid carcinoma has not 
been studied systemically. Also, no major publications have reported the use of other 
functional radionuclide imaging techniques in anaplastic thyroid carcinoma, which may 
be due to the lack of clinically relevant results. Imaging with 131I scintigraphy and serum 
Tg measurements are not useful since these often do not adequately depict the disease 
status 12. However, in selected cases FDG-PET may be helpful in directing treatment 
and evaluating the efficacy of therapy. In some case reports and in some studies with 
limited numbers of patients this malignancy showed intense FDG uptake 18. This may be 
due to high levels of GLUT1 expression in the cytoplasm and on the cell membrane of 
anaplastic thyroid carcinoma. It has been shown that positive membranous staining was 
detected predominantly in thyroid neoplasms with an aggressive biological behavior, 
whereas low or no immunoreactivity could be seen in well-differentiated tumors or in 
normal thyroid epithelium 29. 
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Medullary thyroid cancer
Medullary thyroid cancer is a relatively uncommon tumor and accounts for 4-10% of 
all thyroid malignancies. It originates from the calcitonin-producing parafollicular 
cells (C-cells) of the thyroid, and belongs to the group of neuroendocrine tumors. 
Cells are derived from the neural crest and secrete carcinoembryonic antigen (CEA) 
and calcitonin, as well as other polypeptides such as vasoactive intestinal polypeptide 
and somatostatin 38. Medullary thyroid cancer occurs sporadically or is hereditary, with 
an autosomal dominant pattern of inheritance. Genetic and biochemical testing allow 
early preclinical identification of familial forms. These familial forms account for 25% of 
all medullary thyroid cancers and include 3 well-defined syndromes: familial medullary 
thyroid cancer and multiple endocrine neoplasia (MEN) types 2A and 2B 39. Both sporadic 
and familial medullary thyroid cancers are characterized by relatively slow tumor growth 
but early lymphatic metastatic spread. In 71-80% of all patients, pathologically proven 
cervical lymph node metastases are already present at the time of initial diagnosis. The 
corresponding value for mediastinal involvement is 36%, whereas distant metastases 
have been reported in 20% of patients 40. 
Complete surgical resection of all tumor manifestations still remains the only effective 
treatment with curative intent. The effect of external radiotherapy and chemotherapy 
remains disappointing 41. Residual or recurrent disease is a frequently encountered 
problem, particularly in patients with advanced primary tumors, even after adequately 
performed dissection. These cases are difficult to manage and are clinically the most 
relevant group. Elevated serum calcitonin and CEA levels measured 8 to 12 weeks 
postoperatively suggest persistent tumor, while a progressive increase after previous 
normalization is indicative of relapse 38. Measurement of these plasma markers is 
therefore the most frequently applied evaluation method in long-term follow-up. 
Early identification and treatment of recurrent, residual, or occult tumor is useful as 
reoperation is the only curative option which may also prevent the development of 
local symptoms or distant metastases, which is also important in patients who cannot 
be cured 42. Locoregional control may prevent airway obstruction or invasion into great 
vessels. Patients with persistent hypercalcitoninemia after apparent curative primary 
surgery may have a good prognosis with a 10-year survival of up to 86%, underlining the 
clinical relevance of exact localization of tumor tissue in curable as well as in noncurable 
patients.
However, localization of the site of disease is a major clinical problem that has not 
been completely solved yet. Selective venous catheterization, with a correct localization 
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rate of 89%, is the gold standard for identification of residual or recurrent lymph 
nodes 43. However, its invasiveness restricts general application and it is only useful 
to be performed in the case of cervical lymph node metastases 43. Efforts are ongoing 
to develop reliable noninvasive methods to localize residual and distant metastases of 
medullary thyroid cancer. Up to now there is no single sensitive diagnostic imaging 
method to reveal all residual or metastatic medullary cancer lesions. Morphologic 
imaging techniques, such as ultrasonography, CT, MRI, and different scintigraphic 
procedures, are usually performed in patients who have elevated tumor marker levels 
for localizing the responsible tumor sites. Despite high anatomical resolution, the 
morphologic imaging procedures are restricted to depiction of organ shape, tissue 
structure, and tissue size. Due to the smallness of most of the lymph node lesions 
these investigations are often insufficient. Ultrasonography has shown a lymph node 
detection rate of 28-78%, compared with 38-70% for CT and 44-74% for MRI 40. Various 
scintigraphic techniques, such as thallium chloride (201TI), 99mTc-sestamibi (MIBI) or 
99mTc-tetrofosmin, pentavalent 99mTc-dimercaptosuccinic acid (99mTc(V)- DMSA), 111In-
pentetreotide (somatostatine receptor scintigraphy), radiolabeled anti-CEA antibodies, 
and radioiodinated meta-iodobenzylguanidine (123I/131I-MIBG), have been used for 
medullary thyroid tumor imaging during follow-up 44. Furthermore, MIBG scintigraphy 
at tumor presentation is indicated when there are doubts regarding the existence 
of a concomitant pheochromocytoma (MEN syndrome) 45. However, in all of the 
aboved mentioned methods, the sensitivity is low, especially for small lesions. Due 
to variable tracer uptake and the lower spatial resolution the diagnostic performance 
of all these tracers is unsatisfactory, and none of these tracers can be considered as 
the radiopharmaceutical of choice. Therefore, in many cases several anatomical and 
functional imaging modalities have to be performed consecutively in patients with 
elevated calcitonin levels until the tumor is localized.
FDG-PET has been shown to be a useful method in staging and follow-up of medullary 
thyroid cancer. It appears that FDG-PET can identify metastatic disease more frequently 
than other functional imaging studies 46. When comparing FDG-PET and CT, it is not 
unequivocally clear which imaging method performs better in the localization of 
metastatic medullary thyroid cancer. Some studies show that CT is superior to FDG-
PET while other studies show superiority of FDG-PET 47. Nevertheless, the metabolic 
imaging findings may precede the morphologic changes evidenced by CT or MRI 
by several weeks. FDG-PET examination can be performed as early as 8 weeks after 
initial treatment when tumor markers may still be elevated and conventional imaging 
modalities are either negative or inconclusive to detect recurrent or metastatic disease 
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due to postsurgical fibrotic changes 38. In patients with medullary thyroid cancer indicated 
by elevated calcitonin levels after complete thyroidectomy, FDG-PET has a sensitivity 
and specificity of 70-80% for localizing metastatic disease 18,46. One of the reasons for 
this modest sensitivity of FDG-PET is the slow growth rate and low proliferation index 
of neuroendocrine tumors, resulting in a limited glucose consumption. This may also 
explain the inability to detect small foci of medullary thyroid cancer with FDG-PET in 
patients with only biochemical evidence of disease 48. Nevertheless, FDG-PET showed 
to be superior to all above mentioned scintigraphic imaging methods in detecting 
occult medullary throid cancer lesions. FDG-PET was more sensitive in localizing lymph 
node involvement, especially in the cervical, supraclavicular and mediastinal lymphatic 
regions 40. Interestingly, there seems to be no correlation between the calcitonin level 
and the probability of lesion detection 18,46. However, it has been suggested that more 
undifferentiated tumors that secrete less calcitonin may show higher FDG uptake, in 
analogy to the situation in differentiated thyroid cancer. To avoid misinterpretation of 
PET due to FDG accumulation in inflammatory tissue and to allow better anatomical 
localization and determination of the extent of disease, additional information by CT 
or MRI is still needed 47. Thus, a combination of CT and PET with integrated PET/CT 
seems to be the most appropriate noninvasive diagnostic approach in patients with 
medullary thyroid cancer 47. Although recent reports indicated that novel, more specific 
radiotracers, such as 6-18F-fluorodopamine or 18F-DOPA or radiolabeled minigastrin may 
be more appropriate for the detection of recurrent or metastatic medullary thyroid 
cancer 49,50, presently combined FDG-PET and CT can be recommended in case of 
postoperative elevated plasma tumor marker levels to select patients for secondary 
surgical intervention.
Summary
1. FDG-PET could play an important role in the management of patients with inconclusive 
cytological findings of a thyroid nodule, Because it has a high negative predictive 
value and is able to significantly reduce the number of futile hemithyroidectomies.
2. FDG-PET positive thyroid incidentalomas should not be overlooked and should 
prompt further investigation to rule out cancer, only when the diagnosis of thyroid 
cancer would influence patient outcome and management.
3. FDG-PET is a first-line investigation in patients with persistent or recurrent thyroid 
cancer as indicated by elevated serum thyroglobulin levels, but negative findings on 
131I whole-body scans after treatment.
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4. FDG-PET should preferentially be performed on an integrated PET/CT system, 
because fusion of metabolic and anatomic information increases diagnostic accuracy, 
improves exact localization, reduces pitfalls, and changes therapeutic strategies in a 
considerable number of thyroid cancer patients.
5. FDG uptake under high TSH levels may be advantageous in increasing the sensitivity 
of FDG-PET. If available, the use of rhTSH instead of thyroid hormone withdrawal is 
advocated, because it avoids TSH-stimulated tumor growth, deep hypothyroidism 
associated morbidity, and moreover it will result in the highest sensitivity and tumor 
to background contrast.
6. Besides localization of thyroid cancer lesions, FDG-PET provides prognostic 
information, which can be important in patients with metachronous metastases in 
particular, and can be useful as quantitative outcome measure in clinical trials.
7. FDG-PET is highly beneficial in Hürthle cell carcinoma patients with elevated Tg 
levels, but negative radioiodine scintigraphy, whereas its diagnostic impact on 
patients with radioiodine avid lesions remains limited.
8. FDG-PET in anaplastic thyroid carcinoma has not been studied systemically, because 
there is no definite clinical indication for elaborate staging procedures.
9. In medullary thyroid cancer, FDG-PET in combination with CT seems to be an 
accurate, noninvasive technique, during follow-up for detecting tumoral spread 
in patients with postoperative persistently elevated or increasing CEA and/or 
calcitoninlevels in order to identify the source of tumor marker production and to 
select patients for secondary surgical intervention.
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Abstract
Purpose: Each pathological stage of non-small cell lung cancer (NSCLC) consists 
of a heterogeneous population containing patients at much higher risk than others. 
Noninvasive functional imaging modalities, such as 18F-fluorodeoxyglucose positron 
emission tomography (FDG-PET), could play a role in further characterization of NSCLCs. 
As many factors can influence the extent of FDG uptake, the underlying mechanisms 
for FDG accumulation in tumors, are still a matter of debate. The aim of the present 
study was to investigate these possible mechanisms in the primary site of early-stage 
preoperatively untreated NSCLC.
Methods: 19 patients with early-stage NSCLC, who had undergone both preoperative 
FDG-PET imaging and curative surgery, were enrolled in this study. Standardized uptake 
values (SUVs) were used for evaluation of primary tumor FDG uptake. Final diagnosis, 
tumor type, tumor cell differentiation and size of the primary tumors were confirmed 
histopathologically in resected specimens. Histologic sections were analyzed for amount 
of inflammation and necrosis. Expression of the glucose membrane transporters (GLUT-
1 and GLUT-3); the isoforms of the glycolytic enzyme hexokinase (HK-I, HK-II and HK-III); 
and the cysteine protease caspase-3, was evaluated immunohistochemically.
Results: FDG uptake was significantly higher in squamous cell carcinomas (mean 
SUV 13.4±4.9, n=8) compared to adenocarcinomas (7.1±3.3, n=8, p=0.007), or large cell 
carcinomas (5.9±1.9, n=3, p=0.02). The degree of FDG accumulation seemed to depend 
especially on GLUT-1, GLUT-3 and tumor cell differentiation. The summed standardized 
values of these three parameters correlated significantly with the SUV (r=0.47, p=0.05). 
Conclusion: The present study supports the hypothesis that tumor cell differentiation 
in combination with overexpression of GLUT-1 and GLUT-3 determine the extent of 
FDG accumulation and that squamous cell carcinomas accumulate more FDG than 
adenocarcinomas or large cell carcinomas.
Introduction
Lung cancer is the leading cause of cancer related death in both men and women. About 
3 million new cases a year are estimated to arise worldwide, of which more than 200.000 
are in the European Union. An increase in incidence is to be expected until the first 
decades of the 21st century 1. For the average patient with a diagnosis of lung cancer 
the overall 5-year survival rates have increased from 12% in the early seventies to 15% in 
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2001 2. Five years survival ranges from 75% for patients with pT1N0 disease to virtually nil 
for patients with stage IV non-small cell lung cancer (NSCLC) 3. Surgery with curative intent 
represents the best chance for cure, but is only an option in patients with stages I, II, and 
selected cases of stage IIIA (T3N1M0) NSCLC. However, only 30% of NSCLC cases present 
at these early stages. Even if a complete curative resection can be performed, the majority 
of patients will relapse. The majority of these relapses occur at distant sites, indicating 
micrometastatic disease at presentation 4. Progress is being made due to the introduction 
of novel treatment programs, like induction chemotherapy 5, concurrent chemo-radiation 
for stage III disease 6,7, and more recently, adjuvant chemotherapy for earlier stages 8,9. It 
is of major importance to be able to predict the relapses and to prevent them with these 
active intensified treatment regimens. The tumor-node-metastasis (TNM) staging system, 
to date considered the most important tool in estimation of prognosis and guidance of 
treatment decisions 10, however, provides an incomplete biologic profile of NSCLC, does 
not always provide a satisfactory explanation for differences in relapse and survival and 
is thus far from perfect as a prognostic indicator 11,12. Each pathological stage consists of a 
heterogeneous population containing individuals at much higher risk of recurrence and 
death than others 11-13. Therefore, there is a need for noninvasive quantitative measures of 
biological aggressiveness that could play a role in further characterization of NSCLCs. A 
better understanding of biological mechanisms in lung tumor cells could be helpful and 
finally might lead to a better selection of patients who may benefit from (neo)adjuvant 
therapy. Such noninvasive quantitative measures of biological aggressiveness may be of 
particular value in stratifying patients for clinical trials.
The introduction of the combined use of fluorine-18 fluorodeoxyglucose positron 
emission tomography (FDG-PET) and computed tomography (CT) has had a great impact 
on the diagnosis and staging of lung cancer. FDG-PET provides noninvasive mediastinal 
staging and reduces the number of futile thoracotomies and mediastinoscopies 14-16. 
Furthermore, FDG-PET detects unsuspected extrathoracic metastases in 14-16.9% of 
patients otherwise deemed potentially resectable 17. The number of clinical applications 
for FDG-PET in NSCLC continues to increase. Recently, FDG-PET has also demonstrated 
its value in radiation treatment planning, detection of recurrent disease, in identifying 
tumor response to chemotherapy at an early phase of treatment and in identifying subsets 
of patients with poor outcome 18. One of the great advantages of this technique is that 
it cannot only visualize but can also quantify FDG uptake to distinguish metabolically 
highly active from less active tumor tissues and therefore offers an opportunity for 
noninvasive, in vivo tissue characterization.
The biological basis of FDG-PET is the increased glucose metabolism of malignant cells 
as compared to noncancerous tissues. After administration of the glucose analog FDG, 
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it will be transported into the tumor cell and will be phosphorylated by hexokinase. 
The intracellular FDG-6-phosphate is trapped in the malignant cells, as it will not be 
processed in the glycolytic pathway and can thus be visualized using PET. A variety of 
mechanisms have been proposed for accelerated glucose use in growing tumors and in 
transformed and malignant cells: passive diffusion, Na+-dependent glucose transport 
and via facilitative glucose transporters (GLUT). The latter is considered to be the most 
important mechanism for enhancing glucose influx into cells 19. The glucose transporters 
GLUT-1 and GLUT-3, subtypes with a relatively high affinity for glucose, belong to the 
sugar trans-porter family, which currently includes 133 individual members 20. Increased 
concentrations of the glucose phosphorylation enzyme, hexokinase, with decreased 
rates of glucose-6-phophatase are considered to accelerate glucose phosphorylation, 
which results in enhanced FDG intracellular trapping. Upregulation of hexokinase and 
glucose transporters, especially GLUT-1, and downregulation of glucose-6-phosphatase 
are frequently associated with malignant transformation. Glucose transport activity 
can be regulated by alterations in the expression of GLUT transporters and by post-
translational mechanisms, including transporter translocation to plasma membranes 21. 
Akhurst et al. recently reported that the use of chemotherapy could alter FDG uptake 
in tumors by altering the activity of hexokinase 22. Moreover, the rate of FDG uptake 
in the primary site of NSCLC has been correlated with tumor doubling time 23 and 
proliferation rates 24 which, in turn, are known to correlate with tumor aggressiveness 
25-27. Furthermore, apoptosis plays a central role in the elimination of (the precursors 
of) tumor cells. Therapy resistance can be attributed, at least in part, to a disabled 
apoptotic program 28. Sasaki et al. demonstrated that primary tumors showing high 
FDG uptake have the potential to be resistant to therapy and to metastasize 29. It was 
recently reported that strong expression of the cysteine protease caspase-3, which is a 
key enzyme in apoptotic cell death, was a significant factor to predict poor prognosis 30. 
Better understanding of a possible relationship between FDG uptake and apoptosis may 
provide insights into sensitivity or resistance of tumor cells. Furthermore, tumors that 
grow too rapidly or have a deficient vascular system are characterized by the formation 
of necrosis. Necrosis reflects cell death caused by hypoxia. Hypoxia results in enhanced 
anaerobic glycolysis and hence in increased FDG uptake 31. Finally, the presence of 
inflammatory cells, might be confounding, since inflammatory cells may have a major 
impact on FDG uptake 32.
At present it is still not fully elucidated which of these factors contribute to the variable 
levels of FDG uptake in NSCLC. Results from studies on other tumor types cannot be 
extrapolated to NSCLC, as different tumors have different glucose-regulating mechanisms 
and enzyme expression patterns in association with various oncogenic alterations 33. 
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The aim of the present study was to investigate the mechanisms that drive FDG in the 
primary site of early-stage untreated NSCLC. The relationship among FDG uptake and the 
immunohistochemical expressions of the key glucose membrane transporters, GLUT-1 
and GLUT-3; the isoforms of the glycolytic enzyme hexokinase, HK-I, HK-II and HK-III; the 
cysteine protease, caspase-3, and several histological parameters was evaluated.
Methods
Patient eligibility criteria
FDG uptake in early-stage NSCLC was measured using PET in 19 patients (18 male, 
1 female, mean age 62.4 years, range 38-76 years) who were subsequently treated with 
curative surgery. Patient characteristics are summarized in table 1. Exclusion criteria 
were poorly regulated diabetes mellitus, preoperative chemotherapy or radiotherapy 
and metachronous lung cancers treated for at least 2 years before the study period. All 
patients underwent whole body FDG-PET as part of their routine preoperative staging 
procedure. All scans were performed within 6 weeks prior to surgery. Paraffin-embedded 
material of the surgical specimens of all patients was available.
FDG-PET
A dedicated, rotating half-ring PET-scanner (ECAT-ART, Siemens/CTI, Knoxville, TN, 
USA) was used for data acquisition. Prior to FDG-injection, patients were fasted for 
at least 6 hours, inducing a low insulin-state. Immediately prior to the procedure, the 
patients were hydrated with 500 ml of water. One hour after intravenous injection of 
200-220 MBq FDG (Mallinckrodt Medical, Petten, The Netherlands), and 10 to 15 mg 
furosemide, emission and transmission images of the area between the proximal femora 
and the base of the skull were acquired (10 minutes per bed position). The images were 
corrected for attenuation and reconstructed using the ordered-subsets expectation 
maximization (OSEM) algorithm.
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Table 1.
Patient Sex Age TNM
Tumor 
histology
Differentiation 
status
Tumor  
size (cm) SUV GLUT-1 GLUT-3
1 M 57 pT1N0M0 AC moderate 1.0 3.3 6 3
2 M 61 pT1N1M0 LCC poor 2.5 3.7 9 6
3 M 38 pT3N0M0 AC poor 5.0 4.7 9 3
4 M 68 pT2N0M0 AC poor 3.5 5.7 6 6
5 M 69 pT1N0M0 AC moderate 2.6 5.9 2 3
6 M 65 pT2N1M0 AC poor 7.0 6.1 3 6
7 M 63 pT2N0M0 LCC moderate 1.8 6.5 3 3
8 M 63 pT2N0M0 SQC poor 5.6 7.0 3 0
9 F 66 pT1N1M0 LCC poor 2.4 7.4 9 9
10 M 52 pT2N0M0 AC moderate 5.5 7.5 3 3
11 M 64 pT2N1M0 SQC poor 2.5 9.6 3 6
12 M 76 pT2N0M0 AC poor 7.5 9.9 12 6
13 M 55 pT2N0M0 SQC poor 4.0 10.9 12 9
14 M 65 pT1N0M0 SQC poor 1.8 11.8 12 9
15 M 75 pT2N1M0 AC poor 3.9 13.7 6 3
16 M 52 pT3N0M0 SQC poor 2.7 13.9 6 6
17 M 65 pT2N0M0 SQC poor 4.5 14.3 12 3
18 M 67 pT3N1M0 SQC poor 5.5 16.9 12 6
19 M 63 pT3N1M0 SQC poor 5.5 22.8 6 9
SQC = squamous cell carcinoma; AC = adenocarcinoma; LCC = large cell carcinoma
FDG-PET Analysis
Two experienced nuclear medicine physicians, who had access to all clinical data, 
primarily interpreted the FDG-PET images to determine eligibility for surgery. For this 
study, all FDG-PET studies were reanalyzed in order to acquire semiquantitative data. 
For that purpose volumes of interest (VOI) were drawn around the primary site of 
the NSCLC using an automatic 50% isocontour (ECAT software tool), which enclosed 
pixels with 50% or more of the maximum radioactivity within the VOI. Standardized 
uptake values (SUVs) were calculated using the concentration of FDG in the VOI as 
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measured by PET, divided by the injected FDG dose and multiplied by body weight as a 
normalization factor. The maximum SUV (SUVmax, hereafter mentioned SUV) within the 
VOI was used for further analysis. Because no lesion was less than 1 cm in size, partial 
volume correction was not applied.
Construction of Tissue Arrays
The tissue array method 34 was chosen in order to reduce variability in the staining 
procedure for each tumor and allowed simultaneous examination of the sections. 
Hematoxylin-eosin-stained sections were examined. The areas of interest were marked. 
The corresponding paraffin blocks were slightly warmed (45°C) for 15 minutes to soften 
the wax. A 16-gauge bone marrow biopsy trephine apparatus was used to punch the 
blocks at the marked areas and a tissue cylinder of 2.0 mm in diameter was extracted. 
Using a forceps the cylinder was carefully transferred to a recipient metal paraffin block 
box. To hold the tissue cylinders, the box contained a thin layer of soft wax. After all 
tissue cylinders were aligned in the box, the box was covered with a plastic cassette 
and liquid wax was gently poured into the box. The box was then put on a hot plate to 
homogenize the wax. After 1 minute the box was removed from the hot plate and was 
cooled to room temperature slowly. Before sectioning, the tissue array paraffin block 
was chilled to -10°C. Four-micron sections were cut and mounted on silane-coated slides 
for immunohistochemical analysis.
Immunohistochemical staining procedure
The expression of GLUT-1, GLUT-3, HK-I, HK-II, HK-III and caspase-3 was studied in the 
paraffin embedded tissue arrays. The slides were dewaxed and rehydrated using xylene 
and ethanol, respectively. After immersion in 10 mmol/l citrate, pH 6.0 the slides for 
caspase-3, HK-I, HK-II and HK-III were subjected to microwave irradiation for 10 minutes 
for antigen retrieval. The slides for GLUT-1 and GLUT-3 were pretreated with pronase. 
Endogenous peroxidase activity was quenched with 40% methanol containing 0.6% 
H2O2 for 30 min. After preincubation with 5% normal human serum for 30 min, the 
slides were incubated with rabbit polyclonal antibody directed to GLUT-1 (1:200, DAKO, 
Glostrup, Denmark), rabbit polyclonal antibody directed to GLUT-3 (1:200, Lab Vision, 
CA, USA), rabbit polyclonal antibody directed to caspase-3 (1:200, BD Pharmingen, NJ, 
USA), goat polyclonal antibody directed to HK-I (1:20, Santa Cruz Biotechnology, Inc., 
CA, USA), goat polyclonal antibody against HK-II (1:70, Santa Cruz Biotechnology, Inc., 
CA, USA) goat polyclonal antibody directed to HK-III (1:20, Santa Cruz Biotechnology, 
Inc., CA, USA), for 60 min. The slides were washed with phosphate buffered saline (PBS) 
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followed by incubation with rabbit-anti-goat-biotine (1:200, DAKO, Glostrup, Denmark) 
for 30 min in case of HK-isoforms and in case of GLUT-1, GLUT-3 and caspase-3 slides 
were incubated with polyclonal goat-anti-mouse-peroxidase conjugate (GAM-HRP, 
undiluted, Immunologic, Duiven, Nederland). After washing with PBS, the slides stained 
with the hexokinase antibodies were incubated with Vectastain Elite ABC kit (Vector 
Laboratories, CA, USA) for 30 min. After washing with PBS, the bound antibodies were 
visualized using diaminobenzidine (Powervision DAB, Immunologic, Duiven, Nederland) 
as a chromogen. All slides were counterstained with hematoxylin. All antibodies 
were diluted in PBS containing 1% bovine serum albumin (BSA) and incubations were 
performed in the dark at room temperature.
Histopathologic Evaluation
Two experienced pathologists in lung cancer, who were unaware of the patient’s clinical 
data, the FDG-PET results and results of the patient’s other biomarkers, evaluated all 
of the pathologic material on a multiheaded light microscope. Disagreements were 
resolved by consensus. In the hematoxylin-eosin-stained sections tumor histology 
was determined, tumor cell differentiation was semiquantitatively scored as poor (0), 
moderate (I) or well (II), the percentage of tumor necrosis was estimated, and the 
amount of inflammation was scored as none (0), slight (I), moderate (II), or severe (III). 
The tumor size as measured in the resection specimen was recorded. All cases were 
classified according to the WHO-classification. The presence of membrane-bound GLUT-1, 
GLUT-3, caspase-3 and intracytoplasmic HK-I, -II and -III was examined for all tumor tissues. 
Red blood cells present in the tissues served as positive controls for GLUT-1. The presence 
of GLUT-1 and GLUT-3 tumor cell membrane staining and tumor cell cytoplasmic staining 
for HK isoforms I, II and III was graded by the percentage of tumor cells with positive 
staining: 0%–25% (I), 26%–50% (II), 51%–75% (III), and 76%–100% (IV). The intensity of 
staining was categorized as none (0), weak staining (I), medium staining (II), and intense 
staining (III), ignoring nonspecific nuclear staining, which was frequently noted for all 
HKs. The immunoreactive level was calculated by multiplication of the scores (intensity 
x % positive). The number of nuclear caspase-3 positive cells was semiquantitatively 
scored as none (I), occasional (II), or frequent (III).
Statistical analysis
Spearman’s rho correlations were used to estimate associations between the different 
continuous parameters (SUV, tumor size) and ordinal parameters (GLUT-1, GLUT-3, 
Hexokinase isoforms I-III, Caspase-3, amount of necrosis, inflammation and tumor cell 
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differentiation) and between the SUV and a combination of parameters. Non-parametric 
statistics (Mann-Whitney) were used to test whether FDG uptake was different based 
on the categorical parameter histological tumor type (squamous cell carcinoma, 
adenocarcinoma and large cell carcinoma). To investigate which combination of 
parameters best explained FDG uptake, regression analysis was not suitable due to the 
small number of patients and a not yet generally accepted conceptual theory about the 
relationship between the various parameters. Alternatively, to arrive at a more reliable 
overall measure and to estimate its association with FDG uptake, all parameters that 
showed a moderate association (r>0.30) with SUV and that contributed to the reliability 
(internal consistency; Cronbach’s alpha) of the overall measure were pooled. Because 
the various measures have different ranges, pooling was performed by summing 
standardized z-scores. The level of significance was set at 0.05. Statistical evaluations 
were performed using SPSS 12.0.1 statistical software (SPSS Inc, Chicago, IL).
Results
All tumors accumulated FDG and were well-visualized by PET. The mean SUV of all 
tumors was 9.6±5.0 (range 3.3-22.8). The diameter of the primary tumors as determined 
from the resected specimens, ranged from 1.0 to 7.5 cm, with a mean tumor size of 3.3 cm. 
FDG uptake was significantly higher in squamous cell carcinomas (mean SUV 13.4±4.9, 
n=8) compared to adenocarcinomas (7.1±3.3, n=8, p=0.007) or large cell carcinomas 
(5.9±1.9, n=3, p=0.02). There was no significant difference in FDG uptake between 
adenocarcinomas and large cell carcinomas (p=0.92). Immunohistochemical analysis 
indicated that GLUT-1 and GLUT-3 were mainly expressed in the membrane of cancer 
cells. A typical example of GLUT-1 and GLUT-3 immunostaining of a tumor with a SUV 
lower (fig. 1) and higher (fig.2) than the mean value (SUV 9.6) of the whole population. 
However, GLUT-1 and GLUT-3 positive granules were also observed in the cell cytoplasm 
and GLUT-3 positivity was often observed around necrotic areas or granulocytes (fig. 2). 
A very fine uniform granular pattern was observed in the cytoplasm of most HK-I, -II or 
-III-positive cancer cells (fig.3). Caspase-3 was expressed in both the nucleus and the 
cytoplasm of the cancer cells. The distribution of staining was homogenous in both 
the nucleus and the cytoplasm. No significant relationship was found between SUV 
and each of the individual parameters. In table 2, correlation coefficients between all 
parameters and corresponding p-values are shown. There was a statistically significant 
positive relationship between the GLUT-1 and GLUT-3 immunoreactive level (r=0.47, 
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p=0.04), the HK-II and HK-III immunoreactive level (r=0.56, p=0.01), GLUT-1, GLUT-3 and 
tumor cell differentiation (r=0.50, p=0.03 for both glucose transporters) and between the 
percentage of necrotic tumor compounds and the immunoreactive level of each of the 
three HK isoforms and tumor cell differentiation (r=0.49, p=0.04 for HK-I; r=0.55, p=0.02 
for HK-II; r=0.55, p=0.02 for HK-III, r=0.49, p=0.04 for tumor cell differentiation). Poorly 
differentiated tumors showed higher GLUT-1 expression than moderately differentiated 
tumors. More interestingly, the degree of FDG accumulation seemed to depend on 
GLUT-1 and GLUT-3 expression, the size of the tumor and the degree of tumor cell 
differentiation, as they showed a moderate association with the SUV (r=0.37, 0.35, 0.30 
and 0.40 respectively, table 2). The summed standardized values of the immunoreactive 
level of GLUT-1 and GLUT-3 and the differentiation grade correlated significantly with 
the SUV (r=0.47, p=0.05), which implies that these three parameters together form the 
strongest combination of variables to determine the extent of FDG accumulation.
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Figure 1 A-C. T1N0M0 moderately differentiated adenocarcinoma in a 69-year-old male (patient 
no.5). (A) Medium GLUT-1 cell membrane staining in only 10% of tumor cells. Note the staining in red 
blood cells, which served as a positive control. (B) Weak expression of GLUT-3 in 75% of tumor cells. 
(C) Coronal FDG-PET, showing FDG accumulation (SUV 5.9) in the 2.6 cm tumor in the middel lobe.
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Figure 2 A-C. T3N1M0 poorly differentiated squamous cell carcinoma in a 67-year-old male 
(patient no.18). (A) Intense GLUT-1 cell membrane staining in about 90% of tumor cells. (B) Intense 
expression of GLUT-3, which is mainly observed in or near granulocytes. (C) Coronal FDG-PET, 
showing accumulation of FDG (SUV 16.9) in the 5.5 cm tumor in the right upper lobe.
Figure 3. T3N1M0 poorly differentiated squamous cell carcinoma in a 63-year-old male (patient 
no.19). In this tumor typically high expression of hexokinase is seen in the vicinity of the necrotic 
area (located centrally in the figure). 
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Discussion
The present study shows that the degree of FDG accumulation in the primary site of 
early-stage NSCLC is mainly determined by tumor histology and the combination of the 
expression level of the glucose membrane transporters, GLUT-1 and GLUT-3 and tumor 
cell differentiation. This indicates that sufficient FDG uptake capability (reflected by 
GLUT-1 and GLUT-3) is relevant for detection of NSCLC by FDG-PET. Mamede et al. 32 
and Higashi et al. 35 found a statistically significant correlation between SUV and GLUT-1 
overexpression. Marom et al. 36, however, only observed a borderline associations between 
SUV and GLUT-1 and GLUT-3 expression. They concluded that the expression of these 
transporters alone did not affect FDG uptake in early-stage NSCLC. Chung et al. 37 and 
Brown et al. 38 did not find any statistically significant correlation. Differences in results 
between above-mentioned studies can be explained by differences in antibodies and 
detection methods used or differences in study population. More importantly, special 
attention should be paid on the method of quantification of biomarkers. In the present 
study, only membranous GLUT expression was scored because this is the location of 
biologically active GLUT-1 and -3, while some other studies also included intracellular 
GLUT-expression.
Furthermore, the present study showed a relationship between FDG uptake and 
histopathology of the tumor, as the SUV was significantly higher in squamous cell 
carcinomas compared to adenocarcinomas or large cell carcinomas. This observation is 
in line with results of several other studies 32,35,38-40. These studies also found a significant 
association between GLUT-1 expression and histological tumor type and between SUV 
and tumor differentiation. Poorly differentiated tumors showed higher FDG uptake than 
well-differentiated tumors 32,35. The only study that could not confirm these results is the 
study of Marom et al. 36. Combining these results with studies on the prognostic value of 
FDG-PET in NSCLC 29,40-46 it appears that more aggressive neoplasms or neoplasms with 
poorer prognosis, show higher levels of GLUT-1 expression on the cell membrane of 
tumor cells and thus demonstrate a higher level of FDG accumulation. This could explain 
why NSCLCs with high FDG accumulation in the primary tumor had a poorer prognosis 
than NSCLCs with low FDG uptake. The GLUT-1 membrane transporter appears to be 
a very important rate-limiting step of FDG uptake in primary lung cancer cells. Thus, 
overexpression of GLUT-1 may have an important role in the survival of cancer cells 
by promoting adequate energy supply to support their high metabolism and faster 
growth in an often less-than-ideal physiological environment, a hypothesis that is also 
supported by the study of Younes et al. 19.
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The results of the present study (table 2 and fig. 3), also suggested that the expression 
level of all three HK isoforms might be related to the extent of necrosis in the tumor. This 
positive correlation, might be explained by the findings of Yasuda et al., who reported 
that HK protein expression is localized in cancer cells near hypovascular or necrotic 
areas and that HIF-1 alpha protein expression, induced by chronic hypoxia due to poor 
vascularization, is positively correlated with HK-II expression 47. Upregulation of HK may 
allow cancer cells to maintain glucose metabolism in the hypoxic environment.
Mamede et al. 32 found a significant correlation between SUVs and the expression level 
of HK-II. Besides, they found that poorly differentiated adenocarcinomas showed higher 
HK-II expression and higher FDG uptake than well-differentiated adenocarcinomas. 
In the present study such relationship was not observed, possibly due to the limited 
number of patients in our study.
Altogether it appears that the expression of GLUT-transporters at the cell membrane 
and not expression in cytoplasmic granules may be responsible for active glucose 
transport, that FDG uptake as well as GLUT-1 expression may be higher in squamous 
cell carcinomas compared with adenocarcinomas and large cell carcinomas. GLUT-1 
expression, as well as FDG uptake, appears to be higher in poorly differentiated tumors. 
The present study, tried to unravel the complex molecular mechanisms and factors that 
regulate FDG uptake. A better understanding of the biological mechanisms that are 
involved in glucose transport, glucose metabolism and FDG accumulation could not only 
lead to better interpretation of FDG-PET as a promising noninvasive prognostic marker, 
but could also be helpful in the development of future targets for novel therapeutic 
interventions 48,49.
Conclusion
The present study supports the hypothesis that overexpression of GLUT-1 in combination 
with overexpression of GLUT-3 and tumor cell differentiation determine the extent of 
FDG accumulation and that squamous cell carcinomas accumulate more FDG than 
adenocarcinomas or large cell carcinomas.
 Biological correlates of 18F-FDG uptake in non-small-cell lung cancer 103
Acknowledgments
This study was funded with internal resources. The funding source had no involvement 
in study design and conduct, in the collection, management, analysis, and interpretation 
of data, in the writing of the report or in the decision to submit the paper for publication. 
The authors declare that none of them have a conflict of interest.
Reference List
1.  Vansteenkiste J, Fischer BM, Dooms C et al: Positron-emission tomography in prognostic and 
therapeutic assessment of lung cancer: systematic review. Lancet Oncol 5:531-540, 2004.
2.  Jemal A, Siegel R, Ward E et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006.
3.  Kopp R, Weidenhagen R, Reinmiedl J et al: Outcome following lung resections for pT1 non-small 
cell lung cancer. Eur J Surg Oncol 32:329-334, 2006.
4.  Vokes E: Seeking improved outcome in the curative treatment of non-small-cell lung cancer. Lung 
Cancer 50 Suppl 1:S20-S22, 2005.
5.  Endo S, Tsubochi H, Tetsuka K et al: Preoperative chemotherapy for cStage III-pN0 patients with 
non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 54:109-113, 2006.
6.  Rigas JR, Lara PN, Jr.: Current perspectives on treatment strategies for locally advanced, 
unresectable stage III non-small cell lung cancer. Lung Cancer 50 Suppl 2:S17-S24, 2005.
7.  Furuse K, Fukuoka M, Kawahara M et al: Phase III study of concurrent versus sequential thoracic 
radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III 
non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999.
8.  Arriagada R, Bergman B, Dunant A et al: Cisplatin-based adjuvant chemotherapy in patients with 
completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004.
9.  Winton T, Livingston R, Johnson D et al: Vinorelbine plus cisplatin vs. observation in resected non-
small-cell lung cancer. N Engl J Med 352:2589-2597, 2005.
10.  Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717, 
1997.
11.  van Rens MT, de la Riviere AB, Elbers HR et al: Prognostic assessment of 2,361 patients who 
underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117:374-
379, 2000.
12.  Watanabe Y: TNM classification for lung cancer. Ann Thorac Cardiovasc Surg 9:343-350, 2003.
13.  Jones DR, Daniel TM, Denlinger CE et al: Stage IB Nonsmall Cell Lung Cancers: Are They All the 
Same? Ann Thorac Surg 81:1958-1962, 2006.
14.  Verhagen AF, Bootsma GP, Tjan-Heijnen VC et al: FDG-PET in staging lung cancer: how does it 
change the algorithm? Lung Cancer 44:175-181, 2004.
104 Chapter 4
15.  van Tinteren H, Hoekstra OS, Smit EF et al: Effectiveness of positron emission tomography in 
the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS 
multicentre randomised trial. Lancet 359:1388-1393, 2002.
16.  Pieterman RM, van Putten JW, Meuzelaar JJ et al: Preoperative staging of non-small-cell lung 
cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000.
17.  Vesselle H, Turcotte E, Wiens L et al: Relationship between non-small cell lung cancer 
fluorodeoxyglucose uptake at positron emission tomography and surgical stage with relevance to 
patient prognosis. Clin Cancer Res 10:4709-4716, 2004.
18.  Juweid ME, Cheson BD: Positron-emission tomography and assessment of cancer therapy. N Engl 
J Med 354:496-507, 2006.
19.  Younes M, Brown RW, Stephenson M et al: Overexpression of Glut1 and Glut3 in stage I nonsmall 
cell lung carcinoma is associated with poor survival. Cancer 80:1046-1051, 1997.
20.  Kunkel M, Reichert TE, Benz P et al: Overexpression of Glut-1 and increased glucose metabolism 
in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. 
Cancer 97:1015-1024, 2003.
21.  Smith TA: FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med 
Commun 19:97-105, 1998.
22.  Akhurst T, Kates TJ, Mazumdar M et al: Recent chemotherapy reduces the sensitivity of 
[18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. 
J Clin Oncol 23:8713-8716, 2005.
23.  Duhaylongsod FG, Lowe VJ, Patz EF, Jr. et al: Lung tumor growth correlates with glucose metabolism 
measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 
60:1348-1352, 1995.
24.  Vesselle H, Schmidt RA, Pugsley JM et al: Lung cancer proliferation correlates with [F-
18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6:3837-3844, 
2000.
25.  Arai T, Kuroishi T, Saito Y et al: Tumor doubling time and prognosis in lung cancer patients: 
evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research 
Group. Jpn J Clin Oncol 24:199-204, 1994.
26.  Usuda K, Saito Y, Sagawa M et al: Tumor doubling time and prognostic assessment of patients 
with primary lung cancer. Cancer 74:2239-2244, 1994.
27.  Tirindelli-Danesi D, Teodori L, Mauro F et al: Prognostic significance of flow cytometry in lung 
cancer. A 5-year study. Cancer 60:844-851, 1987.
28.  Gallego MA, Joseph B, Hemstrom TH et al: Apoptosis-inducing factor determines the 
chemoresistance of non-small-cell lung carcinomas. Oncogene 23:6282-6291, 2004.
29.  Sasaki R, Komaki R, Macapinlac H et al: [18F]fluorodeoxyglucose uptake by positron emission 
tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23:1136-1143, 2005.
30.  Takata T, Tanaka F, Yamada T et al: Clinical significance of caspase-3 expression in pathologic-stage 
I, nonsmall-cell lung cancer. Int J Cancer 96 Suppl:54-60, 2001.
 Biological correlates of 18F-FDG uptake in non-small-cell lung cancer 105
31.  Clavo AC, Brown RS, Wahl RL: Fluorodeoxyglucose uptake in human cancer cell lines is increased 
by hypoxia. J Nucl Med 36:1625-1632, 1995.
32.  Mamede M, Higashi T, Kitaichi M et al: [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II 
expressions in cancers and inflammatory lesions of the lung. Neoplasia 7:369-379, 2005.
33.  Lee JD, Yang WI, Park YN et al: Different glucose uptake and glycolytic mechanisms between 
hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 
(18)F-FDG uptake. J Nucl Med 46:1753-1759, 2005.
34.  Pan CC, Chen PC, Chiang H: An easy method for manual construction of high-density tissue 
arrays. Appl Immunohistochem Mol Morphol 12:370-372, 2004.
35.  Higashi K, Ueda Y, Sakurai A et al: Correlation of Glut-1 glucose transporter expression with. Eur J 
Nucl Med 27:1778-1785, 2000.
36.  Marom EM, Aloia TA, Moore MB et al: Correlation of FDG-PET imaging with Glut-1 and Glut-3 
expression in early-stage non-small cell lung cancer. Lung Cancer 33:99-107, 2001.
37.  Chung JK, Lee YJ, Kim SK et al: Comparison of [18F]fluorodeoxyglucose uptake with glucose 
transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. 
Nucl Med Commun 25:11-17, 2004.
38.  Brown RS, Leung JY, Kison PV et al: Glucose transporters and FDG uptake in untreated primary 
human non-small cell lung cancer. J Nucl Med 40:556-565, 1999.
39.  Chung JH, Cho KJ, Lee SS et al: Overexpression of Glut1 in lymphoid follicles correlates with false-
positive (18)F-FDG PET results in lung cancer staging. J Nucl Med 45:999-1003, 2004.
40.  Eschmann SM, Friedel G, Paulsen F et al: Is standardised (18)F-FDG uptake value an outcome 
predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 33:263-
269, 2006.
41.  Ahuja V, Coleman RE, Herndon J et al: The prognostic significance of fluorodeoxyglucose positron 
emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83:918-924, 
1998.
42.  Downey RJ, Akhurst T, Gonen M et al: Preoperative F-18 fluorodeoxyglucose-positron emission 
tomography maximal standardized uptake value predicts survival after lung cancer resection. J 
Clin Oncol 22:3255-3260, 2004.
43.  Dhital K, Saunders CA, Seed PT et al: [(18)F]Fluorodeoxyglucose positron emission tomography 
and its prognostic value in lung cancer. Eur J Cardiothorac Surg 18:425-428, 2000.
44.  Vansteenkiste JF, Stroobants SG, Dupont PJ et al: Prognostic importance of the standardized 
uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-
cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17:3201-3206, 
1999.
45.  Jeong HJ, Min JJ, Park JM et al: Determination of the prognostic value of [(18)F]fluorodeoxyglucose 
uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl 
Med Commun 23:865-870, 2002.
46.  Higashi K, Ueda Y, Arisaka Y et al: 18F-FDG uptake as a biologic prognostic factor for recurrence 
in patients with surgically resected non-small cell lung cancer. J Nucl Med 43:39-45, 2002.
106 Chapter 4
47.  Yasuda S, Arii S, Mori A et al: Hexokinase II and VEGF expression in liver tumors: correlation with 
hypoxia-inducible factor 1 alpha and its significance. J Hepatol 40:117-123, 2004.
48.  Haberkorn U, Bellemann ME, Brix G et al: Apoptosis and changes in glucose transport early after 
treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med 28:418-425, 2001.
49.  Ishikawa N, Oguri T, Isobe T et al: SGLT gene expression in primary lung cancers and their 
metastatic lesions. Jpn J Cancer Res 92:874-879, 2001.
Radiology 237:181-188, 2005
Chapter 5
Gadopentate dimeglumine and FDG uptake 
in liver metastases of colorectal carcinoma as 
determined with MR imaging and PET
Hanneke W.M. van Laarhoven
Lioe-Fee de Geus-Oei
Bastiaan Wiering
Jasper Lok
Mark Rijpkema
Johannes H.A.M. Kaanders
Paul F.M. Krabbe
Theo Ruers
Cornelis J.A. Punt
Albert J. van der Kogel
Wim J.G. Oyen
Arend Heerschap
108 Chapter 5
 Gadopentate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma 109
Abstract 
Purpose: The purpose of this study was to examine the in vivo relationship between 
FDG uptake as measured by PET, and functional tumor vasculature as measured by 
DCE-MRI in patients with liver metastases of colorectal cancer.
Methods: All patients gave written informed consent and the study was approved by 
the institutional review board of the Radboud University Nijmegen Medical Centre, the 
Netherlands. Twenty-six patients, 12 male and 14 female patients with a mean age of 59 
years, with suspected liver metastases of histologically proven colorectal cancer who 
underwent a work-up for liver metastasectomy were included. Patients underwent whole 
body FDG-PET and tumor to non-tumor ratios of FDG uptake (T/NT) in the metastases 
were calculated. DCE-MRI was performed and the rate constant kep (s
-1) of Gadolinium-
DTPA uptake in the metastases was determined. Using the hypoxic marker pimonidazole, 
tumor hypoxia and vascular density (VD) of the metastases were determined 
immunohistochemically. To assess the relations between FDG uptake, rate constant kep of 
Gd-DTPA uptake, HF and VD the Pearson’s correlation coefficient r was calculated.
Results: A negative correlation between T/NT and kep was observed (r = -.421; p = .082). 
No correlation between tumor hypoxia and T/NT or kep was found. A positive correlation 
was observed between VD and kep (r = .458;p = .037), but not with T/NT. 
Conclusion: The negative correlation between T/NT and kep suggests that lower values 
of Gd-DTPA uptake rate imply an acutely reduced supply of oxygen which necessitates 
a higher uptake of glucose to maintain tumor energy levels. The positive correlation of 
VD with kep, but not with T/NT, emphasizes the potential of DCE-MRI to measure tumor 
vascularity in vivo and its additional value compared to ex vivo methods. 
Introduction
The current management of metastatic colorectal cancer is based on imaging methods 
which are generally anatomical in nature. An exception is positron emission tomography 
with 2-deoxy-2-18F-fluoro-D-glucose (FDG-PET). FDG-PET is based on the elevated 
glucose utilization in malignant cells compared to normal tissue.1 FDG-PET has been 
proven useful in the follow-up of patients with colorectal malignancies to differentiate 
between recurrent colorectal tumor and scar tissue.2 In a small series of patients FDG-
PET was more accurate compared to computer tomography (CT) in the determination 
of response to preoperative radiation and chemotherapy in rectal cancer.3 Furthermore, 
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FDG-PET may substantially improve the preoperative staging procedure for resection 
of liver metastases by sensitive detection of extra-hepatic disease.4,5 Previous results 
suggest that FDG-PET can predict response to chemotherapy in patients with hepatic 
metastases.6 
Although in general FDG uptake is increased in malignant tumors, the underlying 
mechanism for increased glucose uptake, and thus for the increased FDG-PET signal, 
is still a matter of debate. For glucose to be taken up and used by a cancer cell, an 
adequate vascular supply (and thus angiogenesis or vascular co-option) is necessary, 
as well as the presence of several membrane bound glucose transport proteins 
(GLUT) which facilitates transport of glucose over the cell membrane. The intracellular 
hexokinase (HK) isoforms are necessary for subsequent phosphorylation into glucose-
6-phosphate which may then be further converted via the glycolytic pathway. All these 
factors - vascularity, transmembrane transport, phosphorylation, glycolysis - are known 
to be upregulated in cancer cells7 which may be due to overexpression of the hypoxia 
inducible factor 1 (HIF-1) protein. HIF-1 can be overexpressed in tumors in response to 
tumor hypoxia resulting from an inefficient tumor vascular network and constitutively 
as a result of gene mutations.8 In fact, (constitutive) overexpression of HIF-1 induces 
VEGF expression, which may lead to an inefficient tumor vascular network, resulting in 
insufficient tumor oxygenation. Therefore, tumor hypoxia seems to play a pivotal role in 
the metabolic status of tumors. 
To improve the understanding of PET scans, several studies have focused on the 
link between FDG uptake and biomarkers like GLUT, HK and vascular density (VD). 
Some studies have reported positive correlations between these biomarkers and FDG 
uptake,9,10 but other studies have been negative.11-15 Divergent results may be explained 
by differences in tumor biology, immunohistochemical staining methods and PET 
procedures. However, one usually does not account for the fact that FDG uptake is 
measured in vivo, whereas from immunohistochemical analysis ex vivo data are obtained. 
This may be particularly important for the relationship between FDG uptake and VD, 
since it is not so much the presence of tumor vasculature, but the presence of functional 
tumor vasculature that may determine FDG uptake. 
Functionality of tumor vasculature can be monitored in vivo by dynamic contrast 
enhanced magnetic resonance imaging (DCE-MRI), using the contrast agent 
Gadolinium-DTPA (Gd-DTPA). From physiological models for the analysis of DCE-MRI 
data parameters for vascularity, for example blood flow and permeability of blood 
vessels, can be determined.16,17 DCE-MRI is currently used for tumor identification in the 
clinic. For example, in breast cancer DCE-MRI has proven to be an accurate method to 
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differentiate benign and malignant lesions.18 DCE-MRI parameters may provide a useful 
noninvasive measure for the prediction of treatment outcome and the follow-up of 
therapy19 and have been shown to have predictive value for the response to treatment 
of several primary tumors.20-25 
The purpose of this study was to examine the in vivo relationship between FDG uptake 
as measured by PET, and functional tumor vasculature as measured by DCE-MRI in 
patients with liver metastases of colorectal cancer. 
Materials and Methods
Patients
Patients with suspected liver metastases of histologically proven colorectal carcinoma 
who underwent a work-up for liver resection were eligible for this study. Patient data 
were included in the analysis of the present study when data of at least two of the 
three functional imaging modalities were available (i.e. PET and DCE-MRI, PET and 
immunohistochemistry or DCE-MRI and immunohistochemistry). All patients gave 
written informed consent and the study was approved by the institutional review board 
of the Radboud University Nijmegen Medical Centre, the Netherlands. Between May 
2001 and September 2003 data from 26 patients were available for analysis (12 male and 
14 female patients with a mean age of 60 years; range 43-74 years)
FDG-PET
Whole body FDG-PET was performed as part of the work-up for liver metastasectomy 
when clinically indicated according to the treating surgeon. Imaging was performed 
with a dedicated PET-scanner (ECAT-EXACT full ring PET-scanner, Siemens/CTI, 
Knoxville, TN, USA). Prior to FDG-injection, patients fasted for at least 6 h. Intake of 
sugar-free liquids was permitted. Immediately prior to the procedure, the patients were 
hydrated with 500 ml of water. One hour after intravenous injection of 200-220 MBq 
FDG (Mallinckrodt Medical, Petten, the Netherlands) and 12 mg furosemide, emission 
and transmission images of the area between proximal femora and the base of the skull 
were acquired (10 min per bed position). The images were corrected for attenuation and 
reconstructed using the ordered-subsets expectation maximization  algorithm. 
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FDG-PET image analysis 
Tumor metabolism was evaluated semi-quantitatively by calculation of the tumor to non-
tumor (T/NT) ratio of FDG uptake, using a semi-automated method with normal liver 
adjacent to the lesions as a reference. A volume of interest (VOI) in liver metastases 
was defined using a 50% threshold of maximum intensity. Central photopenic areas in 
the metastases, which may be regarded as areas of gross tumor necrosis, were excluded 
from the VOI. The scans were analyzed by two independent observers (W.J.G.O. seven 
years of PET experience, L.F.d.G.O. four years of PET experience) who were blinded for 
quantitative MRI and histological results. Disagreements between the two observers 
were resolved by consensus. The normal liver VOI was placed adjacent to the measured 
lesion. The boundaries of the VOIs were just within the apparent hypermetabolic zone 
of the tumor. VOIs of identical configuration were placed on normal liver tissue to serve 
as a reference for normalization. 
DCE-MRI
DCE-MRI was performed in all patients who underwent a work-up for liver 
metastasectomy as part of a wider research program to validate the use of DCE-MRI in 
patients with liver metastases. The study was approved by the institutional review board 
of the Radboud University Nijmegen Medical Centre, the Netherlands, and informed 
consent was obtained from all patients. Three researchers (H.W.M.v.L., M.R. and A.H.) 
were involved in DCE-MRI procedures and data collection (all had at least four years 
experience with liver MR). There was no randomization as to which test (MRI or PET) 
was done first; the clinical order was followed. In practice, patients had their PET scan 
before or on the same day as the MRI scan. 
Measurements were performed on a 1.5 T Siemens Vision MR system, using a body 
phased array coil. After conventional T1 and T2 weighted imaging in axial, coronal and 
saggital direction, 15 ml 0.5 M Gd-DTPA (Magnevist®, Schering, Berlin, Germany) 
was administered intravenously with an injection rate of 2.5 ml/s by a SpectrisTM MR 
injection system (Medrad, Inc., Maastricht, the Netherlands). Using a T1 weighted fast 
low-angle shot (FLASH) sequence with a time resolution of two seconds Gd-DTPA 
uptake in the tumor and the bolus passage in vessels in the spleen was monitored. 
Sequence parameters were: repetition time (TR) 50 ms, echo time 4.4 ms, flip angle 90°, 
slice thickness 7 mm, four slices, matrix 160x256, FoV 263x350 mm. DCE-MRI data were 
acquired for 90 seconds. If the four slices did not fully cover the tumor in the head-foot 
direction, slices were positioned in such a way that the largest diameter of the tumor 
(measured left to right on the coronal view) was covered. 
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Just before Gd-DTPA injection proton density weighted images were recorded with the 
same sequence parameters as the DCE-MRI except for the flip angle 8° and TR 200 
ms. Data from these images were combined with the DCE-MRI data to calculate the 
concentration of Gd-DTPA in arbitrary units, using the method described by Hittmair 
et al.26
For the analysis of the DCE-MRI data, which was blinded for the PET data analysis, a 
previously described method was used.27 In brief, a vascular normalization function (VNF) 
was obtained from pixels in the spleen using an algorithm based on the concentration 
of Gd-DTPA (high in blood vessels) and time to bolus passage (short in arteries). Using a 
physiological pharmacokinetic model17 the Gd-DTPA concentration versus time curves of 
the pixels in all MRI slices containing tumor tissue were analyzed and values of the rate 
constant kep (s
-1) of Gd-DTPA uptake were calculated according to the formula: Ct(t) = K
trans · 
e-kep · t * Cp(t), in which Ct = tissue concentration of Gd-DTPA; kep = rate constant (s
-1) between 
extra vascular extra cellular space and blood plasma; Ktrans = volume transfer constant (s-1); 
Cp = the concentration of contrast agent in plasma of a capillary; * denotes a convolution 
operation.28 In Larsson’s model,17 the Gd-DTPA uptake rate constant kep is directly related 
to tumor blood flow, the product of the permeability of perfused capillaries and the total 
surface area of perfused capillaries, according to: kep = (1 – exp(-PS/TBF)) ·
 TBF/ve, in which 
ve = volume of contrast extra vascular extra cellular space per unit volume of tissue; P = 
permeability of capillaries (cm s-1); S = total surface area of vessels (cm2); PS = permeability 
surface area product (ml s-1); TBF = tumor blood flow (ml s-1).  
The spatial distribution of the values of kep was represented in a map. On a T1 weighted 
MR image recorded directly before Gd-DTPA injection a region of interest was drawn 
which comprised the metastases. This region of interest was applied to the map of the 
rate constant kep of Gd-DTPA uptake in order to select the single values of kep for all 
tumor pixels. The mean of the rate constant kep of these pixels was calculated after log 
transformation and averaged over all slices containing tumor tissue. Log transformation 
excludes all values of kep equals zero. These tumor pixels may be regarded as necrotic 
tumor parts. Back transformation of this average log transformed value resulted in an 
average kep value for the whole tumor.
27 
In 12 patients for whom sufficient time was left before surgery was planned, the 
measurement protocol was repeated with an interval of 24 h to four days as part of 
a reproducibility study. The DCE-MRI results of ten of these 12 patients have been 
published elsewhere.27 For these patients the average kep value for the whole tumor was 
calculated from the mean of the two measurements and for further calculations this 
mean kep value was used. 
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Tumor hypoxia and vascular density
As a marker of hypoxia pimonidazole (1-((2-hydroxy-3-piperidinyl)propyl)-2-
nitroimidazole hydrochloride, Natural Pharmacia International, Belmont, Massachusets, 
USA)29-31 was injected intravenously in 20 min in a dose of 500 mg/kg, at least 12 h 
before start of surgery. Pimonidazole is a bioreductive chemical probe with an immuno-
recognizable side chain. Complete inhibition of bioreductive activation occurs at a pO2 
below 10 mmHg.31 
Immediately after surgical resection, the metastasis for which DCE-MRI data were 
available was identified in the pathology specimen using the T1 and T2 weighted MR 
images in axial, coronal and saggital direction. On the T1 weighted MRI images the 
distance in cranio-caudal direction was measured from the edge of the metastasis to 
the centre of the region where the slices for DCE-MRI were taken. In the pathology 
specimen the same distance was measured and at this level a 3 mm transversal slice 
of the liver metastasis was cut by a pathologist. In case of relatively small metastases 
(approximately 2 cm) the whole slice was taken for further analysis. In case of larger 
metastases maximally five sections of approximately 5 x 5 mm were cut from the slice 
(four sections from the rim and one from the center). The sections from the rim were 
evenly distributed, i.e. one from the dorsal part, one from the ventral part, one from 
the lateral and one from the medial part of the tumor. Sections were snap-frozen in 
isopentane (BDH, Dagenham, United Kingdom) precooled in liquid nitrogen and stored 
at -80 °C until further use. The differentiation grade and largest size of the metastases 
was recorded from the clinical pathology report.
Frozen tumor sections of 5 µm thickness were cut for immunohistochemical staining 
and analysis of hypoxia and VD. After thawing, the sections were fixed in cold (4 °C) 
acetone for 10 min, rehydrated in phosphate buffered saline (PBS) during 30 min. 
Between the consecutive steps of the staining procedure sections were rinsed three 
times for two minutes in PBS. To stain the hypoxic marker and the vasculature, sections 
were incubated with Pathologie Anatomie Leiden-Endotheel (PAL-E, mouse-antibody, 
Department of Pathology, Leiden University, Leiden, the Netherlands) diluted 1:15 and 
rabbit-anti-pimonidazole (J. A. Raleigh)30,32 diluted 1:200 in polyclonal liquid dilutant 
(PLD, Euro-DPC, Breda, the Netherlands) during 30 min at 37 °C. Sections were then 
incubated with goat-anti-mouse-Texas-red (Jackson Immuno Research Laboratories, 
West Grove, PA, USA) and donkey-anti-rabbit-Alexa488 (Molecular Probes, Leiden, the 
Netherlands), both diluted 1:200 in PLD during 30 min at 37 °C. Finally, sections were 
mounted in fluorostab (Organon, Boxtel, the Netherlands). 
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Quantitative data for hypoxia and tumor vasculature were acquired using a semi-
automatic method based on a computerized digital image analysis system, as described 
previously.33,34 In brief, a high-resolution intensified solid-state camera on a fluorescence 
microscope (Axioskop, Zeiss, Weesp, the Netherlands) with a computer-controlled 
motorized stepping stage was used to scan each tumor cross-section. Whole tumor 
sections were scanned at 100x magnification with different filters for the detection of 
the fluorescent signals. Each scan consisted of 36-144 fields of 1.2 mm2, depending on the 
size of the tumor section. From the individual microscopic fields one composite image 
was reconstructed after each scan. As a final step a contour line was drawn to delineate 
the viable tumor area, using consecutive H&E stained tumor sections to distinguish 
tumor from non-tumor tissue. The hypoxic fraction (HF) of the tumor section was 
computed as the tissue surface area stained by the hypoxic marker relative to the viable 
tumor surface area and VD was calculated as total number of vessels per mm2 of viable 
tumor area. The average HF and VD for each liver metastasis were calculated, averaging 
the scores of all tumor sections per liver metastasis.
Statistical analysis
The mean and range of T/NT, kep, HF and VD for the whole population were calculated, 
and to assess the relations between FDG uptake, rate constant kep of Gd-DTPA uptake, 
HF and VD Pearson’s correlation coefficients were calculated with SPSS (version 12.0.1). To 
calculate the 95% regression and prediction intervals for the relation between FDG T/NT 
and kep SigmaPlot (version 9) was used. Values of p < .05 were regarded as statistically 
significant, whereas values of p < .1 were interpreted as a trend.
Results
Studies performed
FDG-PET data were available for 19 of 26 patients, DCE-MRI data for 25 patients and 
immunohistochemistry data for 22 patients (table 1). In six patients (no. 4, 6, 8, 19, 21, 24) 
FDG-PET was not clinically indicated according to the attending surgeon and in 
one patient (no. 7) no liver metastases were detected by FDG-PET. In one patient (no.  
14) there was no spleen in the field of view of the MRI scan. Data of this patient were 
excluded from the analysis of Gd-DTPA uptake. In two patients no tumor material was 
available since surgery was canceled because of irresectable liver metastases (no. 11) 
or metastases outside the liver (no. 12). In one patient no tumor material was available 
116 Chapter 5
Table 1. Patient characteristics and assessment modalities. (+) indicates that data are available for 
this patient, (-) indicates that data are not available. 
number gender age PET MRI immunohisto- chemistry
TNM stage at time of  
diagnosis of primary tumor
1 female 62 + + + T3 N1 M1
2 female 51 + + + T3 N0 M1
3 male 64 + + + T1 N0 Mx
4 male 44 - + + T3 N1 Mx
5 female 69 + + + T3 N1 M1
6 female 63 - + + T3 N0 M1
7 male 67 - + + T3 N0 Mx
8 female 55 - + + T3 N2 M1
9 female 67 + + + T3 N1 Mx
10 female 55 + + + T3 N0 M0
11 male 70 + + - T3 N0 Mx
12 female 54 + + - T3 N1 Mx
13 female 58 + + + T3 N1 Mx
14 male 74 + - + T3 N1 Mx
15 male 58 + + + T3 N1 M1
16 female 52 + + + T3 N1 M1
17 male 72 + + - T3 N0 M1
18 female 57 + + + T3 N1 Mx
19 male 70 + + + T4 N0 M0
20 male 65 - + + T3 N1 M1
21 male 66 + + - T3 N1 M1
22 male 50 - + + T3 N1 M1
23 female 50 + + + T2 N0 M0
24 female 61 + + + T3 N1 M1
25 male 43 - + + T3 N1 M1
26 female 52 + + + T4 N1 Mx
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because the metastasis was treated with radiofrequent ablation (no. 21). For one of the 
patients (no. 17) no data on tumor hypoxia were available, since this patient refused 
the administration of pimonidazole. In two patients (no. 8 and 24) the liver metastases 
could not be resected,  but a biopsy was taken.  Direct comparison of FDG-PET and
DCE-MRI data could be made for 18 patients,  comparison of FDG-PET and 
immunohistochemistry data for 15 patients and comparison of DCE-MRI and 
immunohistochemistry data for 21 patients. The mean time interval between the 
performance of FDG-PET and DCE-MRI was 35 days (s.e.m. eight days), between FDG-
PET and surgery 50 days (s.e.m. ten days) and between DCE-MRI and surgery 12 days 
(s.e.m. two days). Patients did not receive anticancer therapy between FDG-PET, DCE-
MRI and surgery, except for patient no. 1 who received two cycles of 5-fluorouracil (FU) 
and leukovorin (LV) between FDG-PET and DCE-MRI and patient no. 16 who received 
one cycle of FU, LV and oxaliplatin between FDG-PET and DCE-MRI.
Comparison of T/NT and kep
From the FDG-PET images (figure 1 A) the T/NT values were calculated for all patients 
for whom FDG-PET data were available (19/26 patients). The mean T/NT of these 
patients was 2.021 (s.e.m. 0.187). On the T1 weighted MR image recorded just before Gd-
DTPA administration the metastases could easily be detected in all patients for whom 
DCE-MRI data were available (25/26 patients) (figure 1B). The mean kep of these patients 
was 0.031 (s.e.m. < 0.001). Comparison of the T/NT ratios and kep showed a trend for 
higher T/NT values at lower kep values (p = .082; figure 2). Excluding one observation 
with a relatively high T/NT ratio (upper point in figure 2) from the analysis, resulted 
in a significant correlation between T/NT and kep (p = .049). The omitted patient did 
not differ from the whole population with respect to age, co-morbidity, medication, 
differentiation grade of the metastasis or tumor diameter as measured after resection. 
Comparison of HF, VD, T/NT and kep
The mean HF for all liver metastases, computed as the tissue surface area stained by the 
hypoxic marker relative to the viable tumor surface area, was 0.134 (s.e.m. 0.013; figure 
3). No significant correlations were found between HF and FDG T/NT (p = .783), nor with 
kep (p = .442) and VD (p = .641). 
The mean VD for all liver metastases, measured as the number of vessels per mm2 
of viable tumor area, was 25.4 mm-2 (s.e.m. 1.97). A statistically significant positive 
correlation between vascular density and values of kep was found (figure 4), but there 
was no correlation between vascular density and FDG T/NT ratios (p = .944).
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Figure 1. In (A) a transversal FDG-PET image is shown for one patient. In (B) the T1 weighted MR 
image (TR 50 ms, TE 4. 4 ms, flip angle 90°, slice thickness 7 mm, matrix 160x256, FoV 263x350 
mm) shows the same liver metastasis to allow direct comparison of FDG T/NT and kep for the 
individual metastases. On this image a region of interest was drawn to delineate the metastasis, 
which was then applied to the map of the rate constant kep of Gd-DTPA uptake (C) to select the 
single values of kep for all tumor pixels.
A B
C
Figure 2. Relation between the tumor to non-tumor ratio (T/NT) of 18FDG uptake and the rate 
constant kep of Gd-DTPA uptake. The regression line (black line), 95% confidence interval (black 
curved lines) for means and the 95% prediction interval (dotted lines) for individuals are indicated. 
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Figure 3. Binary image of a complete tumor section stained for both hypoxia (green) and 
vasculature (red) in A; corresponding H&E section in (B) (100x magnification). The arrows indicate 
viable tumor tissue. 
A B
Figure 4. Relation between the rate constant kep of Gd-DTPA uptake and vascular density. The 
regression line (black line), 95% confidence interval (black curved lines) for means and the 95% 
prediction interval (dotted lines) for individuals are indicated. 
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Discussion
Relation between FDG T/NT and kep
Both FDG-PET and DCE-MRI are in vivo methods which can provide functional 
information about tumor tissue. DCE-MRI allows to obtain information on the tumor 
vascular system, which mediates the supply of glucose and oxygen. Other factors which 
may be of importance for FDG uptake, i.e. upregulation of GLUT, HK and glycolysis, 
cannot be assessed by this method and should be investigated in future studies. 
The results showed a negative correlation between T/NT ratios of FDG uptake and Gd-
DTPA uptake rate constants kep in liver metastases. When the tumor blood flow (TBF) 
is much larger than the permeability surface area product (PS), lower values of kep may 
indicate lower PS (see formula for kep in Materials and Methods). When TBF is much 
smaller than PS, lower values of kep may indicate lower TBF. A lower blood flow, lower 
permeability or smaller surface area of tumor blood vessels may all result in a reduced 
supply of nutrients like FDG and oxygen to the tumor. A reduced supply of nutrients 
could lead to lower FDG T/NT ratios in the tumor, as was shown in an experimental study 
in which substrate availability modulated glucose metabolism,35 and would result in a 
positive correlation between T/NT ratios and kep. However, the poorer vascular function, 
reflected by lower values of kep, could not only lead to a reduced supply of nutrients, but 
also to a reduced supply of oxygen. A reduced supply of oxygen would necessitate a 
higher uptake of glucose in order to maintain tumor energy levels. This would lead to 
higher FDG T/NT ratios in the tumor, thus resulting in a negative correlation between 
kep and FDG T/NT ratios. Therefore, the observed negative correlation between kep and 
FDG T/NT ratios suggests that differences in tumor oxygenation rather than differences 
in FDG delivery are a driving force for FDG uptake in colorectal liver metastases. 
Whether FDG delivery or tumor oxygenation are the driving force for FDG uptake 
may be tumor and even stage dependent. For example, a positive correlation between 
FDG uptake and the permeability surface area product as determined by DCE-MRI was 
found in patients with lung cancer36 and between the metabolic rate of FDG and blood 
flow determined by 15O-water measurements in patients with advanced breast cancer.37 
Brix et al.38 did not observe a correlation between FDG-PET and DCE-MRI parameters 
in a group of patients with suspicious breast lesions. Clearly, this group consisted of 
different stages of breast cancer, which might explain the lack of correlation between 
FDG-PET and DCE-MRI parameters. 
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Relation between HF, FDG T/NT and kep 
The hypothesis that tumor hypoxia is a driving force for FDG uptake in colorectal liver 
metastases seems to contradict the observed lack of correlation between FDG uptake 
and HF in liver metastases as measured by pimonidazole binding. In this respect the 
difference between ‘chronic’ or ‘diffusion limited’ hypoxia, according to the classical 
model of Thomlinson and Gray39 and ‘acute’ or ‘transient’ hypoxia,40 due to local and 
temporary fluctuations of tumor blood perfusion may be relevant. Experimental tumor 
cells in an acutely hypoxic environment may increase their FDG uptake more than 
twofold41,42 in order to survive the temporary decrease in oxygen supply. A decreased cell 
proliferation has been shown in chronically hypoxic regions.43 This may be interpreted 
as an energy saving method to adapt to a reduced supply of oxygen and nutrients. 
Alternatively, it may be argued that an important part of the chronically hypoxic cell 
population is becoming necrotic or apoptotic and is therefore less metabolically active. 
In these chronically hypoxic regions FDG uptake will actually decrease. Thus, depending 
on whether acute or chronic hypoxia plays a major role, hypoxic tumors can be highly 
metabolic or may have modest glucose metabolism.44 The discordance of FDG uptake 
and tumor hypoxia can be tumor type specific44 and may even be heterogeneous 
within one tumor.45 Both chronically and acutely hypoxic cell regions contribute to the 
measured hypoxic fraction as measured by pimonidazole. This may explain the lack of 
correlation between FDG uptake and hypoxia in liver metastases in this study. 
Relation between VD, FDG T/NT and kep
A positive correlation between VD and the Gd-DTPA uptake rate constant kep was observed, 
but not between VD and FDG uptake. A positive correlation between microvascular 
density and DCE-MRI vascular parameters has been reported by Hawighorst et al.25 for 
cervical carcinoma, but Su et al.46 did not observe such a correlation in breast cancer. As 
explained above, kep is defined by (the product of) permeability of perfused capillaries 
and surface area of perfused capillaries and by tumor blood flow. From this definition, 
the relation between the Gd-DTPA uptake rate constant kep and the vascular density 
is obvious. However, it should be noted that in VD, both perfused and non-perfused 
vessels are included. Since mainly the acute closure of the former seems to determine 
uptake of FDG in colorectal liver metastases, this may explain the lack of correlation 
between VD and FDG uptake and underscores the importance of functional in vivo data 
on the tumor vascular system. 
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Limitations of the study
The mean time interval between FDG-PET and DCE-MRI and FDG-PET and surgery was 
relatively long in this study. It may be suggested that the lack of correlation between FDG-
PET and immunohistochemical results was caused by this long time interval. However, 
since it seems unlikely that the correlation between FDG-PET and DCE-MRI data is 
caused by the long time interval between the two scans, the lack of correlation between 
FDG-PET and immunohistochemical results should be explained by biological factors, 
rather than the long time interval. Nevertheless, its influence cannot be excluded. Two 
patients received anticancer therapy between FDG-PET and DCE-MRI. Although this 
may have influenced the results, it only regards a small number of patients.
The mean value of kep indicates the value of this parameter over the region of interest, 
but does not reflect the heterogeneity of a tumor. Currently, statistical analyses, like a 
functional principal component analysis, are under investigation, to further characterize 
spatial heterogeneity (see for example O’Connor et al.47). Although in the present 
analysis tumor heterogeneity was not taken into account, all data are corrected for 
(gross) necrosis.
It should be noted that an exact one-to-one correlation between FDG-PET or DCE-MRI 
and immunohistochemistry was not fully possible, since tissue sections had a size of 
approximately 5 µm x 5 mm x 5 mm, whereas the PET and MRI data were obtained from 
the whole or a large part of the tumor. Also, in two patients the metastases were not 
fully removed and a biopsy was taken during surgery. It was assumed that the acquired 
material was a sufficient representation for the whole tumor. Since the sample size of 
this study was small, it should be expanded in a future follow-up.
Conclusion
For colorectal liver metastases a negative relationship was found between the rate 
constant kep of Gd-DTPA uptake as determined from DCE-MRI and FDG T/NT ratios 
as measured by PET. This suggests that in liver metastases differences in acute tumor 
hypoxia which are caused by differences in functional tumor vasculature constitute 
a driving force for FDG uptake. The observed correlation between vascular density 
and the rate constant kep of Gd-DTPA uptake, but not with T/NT ratios, emphasizes 
the potential of DCE-MRI to measure tumor vascularity in vivo and its additional value 
compared to ex vivo methods. 
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Abstract
Purpose: Tumor hyperoxygenation results in high response rates to ARCON (Accelerated 
Radiotherapy with CarbOgen and Nicotinamide). The effect of hyperoxygenation on 
tumor metabolism using [18F]fluorodeoxyglucose (FDG) positron emission tomography 
(PET) was investigated.
Methods: Within one week, FDG-PET was performed without and with hyperoxygenation 
by carbogen breathing and/or nicotinamide administration in 22 patients, eligible for 
ARCON for head-and-neck cancer. Maximum standardized uptake values (SUVmax) in 
both scans and the relative change were calculated in the primary tumor and in normal 
muscle.
Results: Alteration of the tumor oxygenation state induced profound, but variable 
metabolic changes (median ∆SUVmax -4%; range -61% to +30%). Metabolism in normal 
muscle was not affected. In three patients who did not achieve local tumor control, the 
SUVmax after hyperoxygenation differed less than 5% change as compared to baseline, 
whereas 13 of the 16 patients with local tumor control showed a larger difference (p 
<0.05).
Conclusion: Given the heterogeneous response pattern of nicotinamide and 
carbogen on FDG-uptake in head-and-neck carcinoma, the prognostic significance of 
semiquantitative FDG-PET before and after hyperoxygenation remains uncertain and 
requires confirmation in larger clinical studies before introducing the procedure as a 
predictive tool for oxygenation modifying treatments. 
Introduction
Resistance of some malignant tumors is a major problem in radiation oncology. Tumor-cell 
repopulation and hypoxia are two important mechanisms responsible for radiotherapy 
resistance 1-4. Application of Accelerated Radiotherapy with CarbOgen and Nicotinamide 
(ARCON) tries to overcome these problems 5. To counteract repopulation of clonogenic 
tumor cells during therapy, the overall treatment time is reduced by delivering the total 
radiation dose in multiple fractions per day. Tumor-cell hypoxia is counteracted with 
carbogen, a hyperoxic gas, consisting of 95%-98% oxygen and 2%-5% carbon dioxide in 
combination with the vasoactive agent nicotinamide. Oxygen mediates the biological 
effects of ionizing radiation, as the cellular damage of radiation depends strongly on 
the availability of oxygen 6. Hypoxia has a negative effect on treatment outcome not 
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only through enhanced radioresistance but also by promoting more aggressive tumor 
behavior 7,8. Hypoxia is a powerful trigger for changes in gene expression and associated 
changes in the microenvironment 9-11. Inhalation of carbogen is proposed to decrease 
diffusion-limited hypoxia and administration of nicotinamide to decrease perfusion-
limited hypoxia. Chronic or diffusion-limited hypoxia occurs in cells that are located 
relatively far away from blood vessels 12. Acute or perfusion-limited hypoxia results from 
local, temporary fluctuations in tumor blood perfusion 12.
Phase II trials indicate promising results with ARCON, especially in head-and-neck cancer 
5. However, questions about the precise mechanisms of action of hyperoxygenation of 
tumors remain to be answered. In humans, limited information on the pathophysiological 
and metabolic effects of carbogen and nicotinamide is currently available. Animal 
studies using nuclear medicine imaging techniques suggest that the metabolic activity 
is lower in hypoxic tumors compared to controls 13.
Many malignancies, including head-and-neck cancer, have increased glucose metabolism 
and accumulate the glucose analog [18F]fluorodeoxyglucose (FDG) and can thus be 
visualized using positron emission tomography (PET) 14. After internalization, FDG is 
trapped in the malignant cells, as it cannot be metabolized further 15. FDG-PET has been 
used extensively in head-and-neck cancer for staging 16,17, surveillance and detection of 
recurrence 18,19, and assessment of treatment response 20,21 with promising results. The 
advantage of FDG-PET is that it is a non-invasive, in vivo method to detect, image and 
quantify FDG-uptake which is obviously not only dependent on the metabolic activity of 
the tumor but also on the perfusion and oxygenation status of the tumor. In the current 
study, we investigate the effect of carbogen and nicotinamide on tumor metabolism 
using FDG-PET in patients with head-and-neck cancer.
Methods and materials
Patients
Twenty-two patients (18 males, 4 females) with primary stage III–IV laryngeal, 
oropharyngeal or stage II–IV hypopharyngeal squamous cell carcinomas entered this 
prospective study. The mean age was 62 years (range 47–91 years). Patient characteristics 
are summarized in Table 1. All patients were considered eligible for a phase II ARCON 
study 22. Exclusion criteria for the FDG-PET study were diabetes mellitus and pregnancy. 
The study was approved by the Institutional Review Board of the Radboud University 
Nijmegen Medical Centre. All patients gave written informed consent to participate in 
this study.
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Table 1. Tumor Characteristics
Characteristic No. of patients
Primary tumor site Larynx
Oropharynx
Hypopharynx
4
7
11
T stage T1
T2
T3
T4
2
6
10
4
N stage N0
N1
N2a
N2b
N3
6
6
1
4
5
Patient groups
All patients were scanned twice; after baseline FDG-PET, a second FDG-PET was 
performed after hyperoxygenation (median interval between the two sessions 2 days, 
range 1-7 days). Of the 22 patients, 5 patients were given nicotinamide (60 mg/kg orally) 
one hour prior to the FDG injection and 11 patients were breathing a carbogen gas 
mixture of 95% O2 and 5% CO2 for 10 minutes, which is the optimal breathing time 
to overcome hypoxia 23. During the second minute FDG was injected. The remaining 6 
patients were given the combination of nicotinamide and carbogen.
FDG-PET
A dedicated, rotating half-ring PET-scanner (ECAT-ART, Siemens/CTI, Knoxville, TN, USA) 
was used for data acquisition. Prior to FDG-injection, patients were fasting for at least 
6 h. Intake of sugar-free liquids was permitted. Immediately prior to the procedure, the 
patients were hydrated with 500 ml of water and the patients were given 5 mg diazepam 
orally for muscle relaxation. One hour after intravenous injection of 200-220 MBq FDG 
(Mallinckrodt Medical, Petten, The Netherlands), emission and transmission images of 
the head and neck area were acquired (2-3 bed positions, 10 min per bed position). The 
images were corrected for attenuation and reconstructed using the ordered-subsets 
expectation maximization (OSEM) algorithm. 
132 Chapter 6
FDG-PET analysis 
For quantification of FDG uptake, volumes of interest (VOI) were drawn around the 
primary tumor, using the 50% isocontour (enclosing pixels with 50% or more of the 
maximum radioactivity in the VOI). Maximum standardized uptake values (SUVmax) 
were calculated using the concentration of FDG in the tumor as measured by PET, 
divided by the injected dose and multiplied by body weight as a normalization factor. 
Both scans of each patient were matched in all planes using the 3D Extract Image 
software (courtesy of Dr. A.T. Willemsen, PET-centre, University Medical Centre 
Groningen, The Netherlands). The VOI of the baseline scan was copied into the second 
scan. FDG-uptake in the primary tumor after administration of nicotinamide, carbogen 
or the combination of both were quantitated and compared to baseline FDG-uptake. 
To investigate whether the change in FDG-uptake after hyperoxygenation truly reflects 
differences in tumor biology and is not based on reproducibility problems or differences 
induced by variations in body physiology, FDG-uptake in the trapezius muscle was 
measured in triplicate in every PET-scan. Nicotinamide and carbogen do not induce 
changes in glucose metabolism in resting skeletal muscle. Resting muscle tissue has 
a low metabolic rate and does not exhibit increases in NAD+ and blood flow following 
nicotinamide administration 24. The relative change (mean difference and standard 
deviation) in SUV in resting skeletal muscle was measured between the baseline PET and 
the PET after hyperoxygenation for each patient. The intrapatient interscan variability 
expressed in the repeatability coefficient was calculated 25.
Treatment
The primary tumor and bilateral neck nodes were irradiated through lateral- opposed 
photon beams (4 or 6 MV). After 30-40 Gy, an off-cord reduction of the lateral-opposed 
photon beams was made, and the posterior cervical chains were treated with lateral 
appositional electron beams. The mid and lower neck nodes were treated with an 
anterior photon field. In some cases, a posterior field was added to supplement the 
dose in the posterior midcervical chains. The boost dose was delivered through reduced 
lateral or oblique opposed portals, combined, when necessary, with an electron beam to 
boost nodal areas overlying the spinal cord or larynx. The total dose was 68 Gy for gross 
disease and 44 Gy for the electively treated areas. The dose per fraction was 2 Gy, and 
the overall treatment time was limited to 36-38 days by delivering 2 fractions daily during 
the last 1.5 weeks of treatment. The interval between fractions was at least 6 h. Dose 
specification was according to Report 29 of the International Commission on Radiation 
Units and Measurement 26. Total dose to the larynx and pharynx has been limited to 64 
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Gy, because possible sensitization of the laryngeal cartilage from normobaric carbogen 
with nicotinamide was expected 27. 
Nicotinamide (60 mg/kg) was administered orally 1-1.5h before irradiations. Carbogen 
breathing started 4 min before irradiations and continued throughout the treatment.
Follow-up
The effects of hyperoxygenation on FDG tumor uptake were correlated to clinical 
follow-up and treatment outcome. During ARCON-treatment the assessment of tumor 
response was done weekly. After treatment completion, patients were seen once every 
2 or 3 weeks until the skin and mucosa had healed. Thereafter, patients were evaluated 
once every 2 months during the first year after treatment, every 3 months in the second 
year, every 4 months in the third year, and every 6 months in the fourth and fifth 
years. Follow-up visits included indirect laryngoscopy and/or laryngoscopy by flexible 
fiberoptic scope and palpation of the neck. When a local recurrence was suspected, 
examination under anesthesia was performed and suspect abnormalities were biopsied. 
Median follow-up of the surviving patients was 21 months at the time of analysis (range 
15-56 months). No patients were lost to follow-up. 
Statistical analysis
The repeatability of the SUV was defined as twice the standard deviation of the 
differences between the duplo values of SUV measured in muscle tissue in the 
baseline scan compared to the scan after hyperoxygenation 28. This implies that for 
95% of observation pairs the absolute difference between two measurements on the 
same patient is expected to lie below this threshold. The repeatability coefficient is 
a statistical measure providing direct insight into the probability that differences 
between two measurements result from changes in tumor biology rather than from 
scan reproducibility problems. All quantitative results were analyzed using the unpaired 
t-test or Fisher’s exact test for contingency tables. The level of significance was set at 
p<0.05.
Results
The SUVmax of normal muscle was low and was not influenced by hyperoxygenation 
(mean at baseline 0.7, SD 0.2; mean after hyperoxygenation 0.7, SD 0.2). As shown 
in figure 1, the change in FDG uptake in the primary tumors, expressed as relative 
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difference between SUVmax at baseline and SUVmax after hyperoxygenation, varied 
considerably between patients (median ∆SUVmax -4%; range -61% to +30%). This 
change was not correlated with histology, tumor localization, or tumor stage.  Increases 
as well as decreases were observed with carbogen and nicotinamide and with the 
combination of both. The direction and magnitude of change in FDG uptake was thus 
fairly heterogeneous and did not correlate with the hyperoxygenation regimen used. 
Figure 2 shows an example of a patient with stage IVA oropharyngeal carcinoma, who 
was studied without and with carbogen breathing. 
The repeatability coefficient of the muscle SUV is much lower than that of the primary 
tumors (0.15 versus 1.98, respectively). Likewise, the within-patient standard deviation of 
the tumor SUV is larger than the within-patient standard deviation of the muscle SUV. 
The mean absolute difference in muscle SUV was 0.07 (SD 0.07) compared to the mean 
absolute difference in tumor SUV of 0.9 (SD 0.9). The difference in change of tumor 
SUV and muscle SUV is statistically significant (unpaired t-test, p<0.0001).
Not all 22 patients were evaluable for the estimation of the predictive value of FDG-
PET for tumor response after ARCON treatment. Three patients were excluded from the 
evaluation of local tumor control. One patient died of a rupture of the abdominal aorta 
on the 11th day of ARCON-treatment. At that time no complete response was reached yet. 
In another patient, the scheduled radiotherapy was changed to palliative chemotherapy. 
The third patient eventually opted for conventional radiation therapy. Of the remaining 
19 patients in whom ARCON treatment was evaluable, 16 patients reached local tumor 
control after a mean of 2.7 months (range 0.7-4.8 months). In all three patients in whom 
local tumor control was not achieved, the SUVmax after hyperoxygenation differed less 
than 5% change as compared to baseline, whereas 13 of the 16 patients with local tumor 
control showed a larger difference after hyperoxygenation (p <0.05). 
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Figure 1. Relative change in FDG tumor uptake in the PET-scan performed after hyperoxygenation 
with carbogen (•), nicotinamide (♦) or the combination of both (■) expressed as a percentage of 
the baseline value. Open symbols: patients not evaluable (n=3). Grey symbols: patients that failed 
to achieve local control (n=3).
Figure 2. FDG-PET images of a patient with stage IVA oropharyngeal carcinoma. The left panel 
shows two coronal slices of the baseline study of this patient. The upper coronal slice shows 
accumulation of FDG in the primary oropharyngeal tumor and the lower coronal slice shows FDG-
uptake in a left sided cervical lymph node. The right panel shows the comparable slices in the 
same patient performed after carbogen breathing. It is clearly visible that accumulation of FDG 
at baseline is higher (left panel, tumor SUVmax 7.6) than after carbogen breathing (right panel, 
tumor SUVmax 4.9). After carbogen a 35.5% reduction in FDG-uptake is measured as compared to 
the baseline value. Baseline trapezius muscle SUV was 0.9 compared to a trapezius muscle SUV 
of 0.8 after carbogen breathing.
baseline PET 
SUV 7.6
carbogen PET 
SUV 4.9
primary 
tumor
lymph 
node
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Discussion
FDG-PET is a non-invasive, in vivo method that is able to detect and quantify FDG-
uptake. FDG-uptake is dependent not only on the metabolic activity of the tumor 
but also on the perfusion and oxygenation status of the tumor 29,30. The results of this 
pilot study indicate that profound, but variable metabolic changes do occur following 
alteration of the oxygenation state of head-and-neck tumors by carbogen breathing and/
or nicotinamide administration. Both increased as well as decreased FDG-uptake was 
observed. As the measurements in reference tissue of our patients, i.e. resting skeletal 
muscle, did not show metabolic changes following hyperoxygenation, these changes in 
FDG-uptake in the primary tumor reflect differences in tumor biology and are not based 
on reproducibility problems or differences induced by variations in body physiology.
The underlying mechanisms that result in the nicotinamide and carbogen effects on 
FDG-uptake are largely unknown. An increased glucose metabolism in hypoxic tumors 
compared to normoxic tumor cells may be due to an increased anaerobic metabolism 
as a result of oxygen starvation 31. According to this theory, a decrease of FDG-uptake 
is expected following carbogen or nicotinamide administration, as the tumor switches 
from an anaerobic to an aerobic metabolism, producing more ATP from less glucose. 
Nicotinamide and/or carbogen can also induce an increase in blood perfusion of the 
tumor 32. This enhancement of perfusion may result in an increment in FDG-delivery and 
uptake. This is in line with the observations in our study that both large increases and 
decreases in FDG uptake may occur. There is an indication that nonresponsiveness of 
FDG-uptake in tumors after hyperoxygenation may be a risk factor for failure of ARCON 
treatment. However, cautious interpretation is mandatory given the small size of the 
present pilot study. Given the heterogeneous response pattern seen with all three 
hyperoxygenation regimens, it is questionable whether FDG-PET could be used as a 
reliable predictive tool.
The effect of carbogen breathing on blood flow may very well be even more complex. 
The rationale for use of gasses that include a small fraction of carbon-dioxide added 
to oxygen is an increase in respiratory drive, improved oxygen delivery from the blood 
to the tissues by a right-shift of the hemoglobin-oxygen dissociation curve, and better 
blood perfusion due to carbon-dioxide induced vasodilatation 33,34. However, when the 
tumor vasculature lacks responsive smooth muscle and is in parallel to the vasculature of 
the surrounding host tissue, carbogen can have the reverse effect on blood flow. Blood 
perfusion is then increased in the surrounding normal tissues but reduced in the tumor, 
which is known as the steal phenomenon 33,34. This could in turn result in a reduction of 
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FDG-uptake in the tumor. It remains to be established which of these effects dominate 
and what the net effect on tumor metabolism is. Very likely this differs between tumors, 
which can result in increased FDG uptake in some tumors and decreased uptake in 
others as observed in the present study.
Kelleher et al. 24 speculated on two possible ways by which nicotinamide could affect 
tumor glycolysis. The first pathway involves a direct effect of nicotinamide on tumor 
blood flow. This increase in tissue blood flow would result in an increase in O2 supply, 
which in turn would lead to radiosensitization. At the same time, the increased delivery 
of oxygen and glucose to the tissue results in a stimulation of oxidative metabolism and 
glycolysis. The conversion of nicotinamide to nicotinamide adenine dinucleotide (NAD+) 
also leads to a stimulation of oxidative metabolism and glycolysis. The second pathway 
proposed by Kelleher et al. involves no direct effect of nicotinamide on tumor blood 
flow but only via conversion to NAD+. Increased levels of NAD+ results in a stimulation 
of many metabolic processes, oxidative metabolism and glycolysis included.
A variety of invasive and noninvasive methods are available and under investigation 
for measuring the oxygenation status of tumors and tissues. Exogenous hypoxia 
markers, like 2-nitroimidazoles and intrinsic hypoxia markers, like HIF-1α and HIF-2α, 
carbonic anhydrase IX (CAIX), VEGF, and the glucose transporters GLUT1 and -3 are of 
growing interest 35-40. Another method for the analysis of tissue oxygenation estimates 
‘microvascular density’ (MVD) 37. Besides histological analysis of tissue biopsies, another 
invasive approach for estimating hypoxia is direct measurement of pO2 in human tumors 
in situ with oxygen electrodes 8,41. Obviously, this is restricted to accessible tumors. 
Furthermore, the method suffers from the contamination of non-viable, necrotic tissue 
and the number of measurements per tumor is limited. Gradient recalled echo (GRE) 
magnetic resonance imaging (MRI) is sensitive to blood oxygenation changes, and 
spin echo (SE) MRI is sensitive to perfusion/flow 42. Many other radiopharmaceuticals 
besides FDG have been used for detection and quantification of hypoxia 43. These include 
fluorinated hypoxia markers, like fluoromisonidazole ([18F]FMISO). Nitroimidazole 
compounds are reduced under hypoxic conditions and irreversibly bound to cellular 
macromolecules 44. Each diagnostic method has specific advantages and disadvantages. 
The most common disadvantage is that only static information of the tissue oxygenation 
status is provided. The main advantage of imaging techniques is that repeated 
measures are possible and that temporal changes can be assessed, allowing evaluation 
of the effectiveness of an oxygenation-modifying intervention. It is not unlikely that 
the complexity of tumor physiology requires multimodality analysis to gain a better 
understanding of the tumor micro-environment and to obtain a ‘predictive profile’ 
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which can guide the clinician in the selection of patients for ARCON therapy. This is 
clinically relevant as the increased loco-regional control rate by ARCON-treatment as 
compared to conventional regimens, is also accompanied by an increase in side effects. 
In particular the early mucosal and skin reactions were more severe than generally 
observed with conventional radiotherapy although tolerable and manageable 22,45. 
This increase in toxicity underscores the importance of developing predictive tools to 
select patients that are more likely to benefit from ARCON or other oxygen modifying 
treatments.
Conclusion 
The radiosensitizers nicotinamide and carbogen may induce large, but variable changes 
in the glucose uptake in head-and-neck carcinoma. Given this heterogeneous response 
pattern, the prognostic significance of quantitative FDG-PET before and after the 
intervention remains uncertain and requires confirmation in larger clinical studies 
before introducing the procedure as a predictive tool for oxygenation modifying 
treatments. 
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Removal of a primary colorectal tumor resulted in an increase in metabolic activity in 
its liver metastasis. Concomitantly, levels of angiostatin and endostatin in urine and 
plasma, respectively, dropped. This finding indicates that the primary tumor suppressed 
angiogenesis in its distant metastasis, and that removal of the primary lesion caused 
a flare-up in vessel neoformation and, thus, enhanced metabolic activity in its liver 
metastasis.
The dependence of solid tumors on blood supply for their ability to grow and metastasize 
is nowadays an established concept in tumor biology.1 Tumor angiogenesis, the formation 
of a neovascular bed in cancer, is the result of a complex and precise balance between 
proangiogenic and antiangiogenic factors produced by both tumor and host cells.2 
Various endogenous factors associated with angiogenesis induction have been studied, 
including vascular endothelial growth factors (VEGFs) and basic fibroblast growth 
factors (bFGFs).3 Recently, endogenous inhibitors of angiogenesis have gained more 
attention. Research in this area was initiated by the observation that in the murine 
Lewis lung carcinoma model, removal of the primary tumor was followed by a sudden 
increase of vascularization and growth of preexisting metastases. As an explanation 
for this mechanism, O’Reilly et al4 hypothesized that the primary tumor produced an 
antiangiogenic factor, which prevented vascularization and thereby hindered the growth 
of metastases. They identified the factor angiostatin, which proved to be a proteolytic 
fragment of plasminogen.4 Soon thereafter, another angiogenesis inhibitor, endostatin, 
a proteolytic fragment of collagen XVIII, was discovered.5 
Although the influence of the primary tumor on the vascularization and growth of 
distant metastases has been extensively described in mouse models, to the best of our 
knowledge this phenomenon has not been reported in patients to date. Here we report 
that a primary colorectal tumor was able to suppress the metabolic activity of its liver 
metastasis. Resection of the colorectal primary tumor reversed this effect and coincided 
with a drop in levels of angiogenesis inhibitors, suggesting a causal relationship between 
these phenomena. 
Case report
To demonstrate the possible relevance of primary tumor-derived angiogenesis 
inhibitors, we assessed the influence of (removal of) a primary colorectal carcinoma 
(moderately differentiated; T3N2M1) on a synchronous liver metastasis by fluorine-18 
fluorodeoxyglucose positron emission tomography (FDG-PET) scanning and by analysis 
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of body fluids in a 66-year-old patient admitted for palliative sigmoid resection. The 
patient’s informed consent was obtained before all experimental procedures. 
To determine the metabolic activity of the liver metastasis before and after resection of 
the primary colorectal tumor, the patient underwent FDG-PET scanning 4 days before 
and again 18 days after resection of the primary tumor. Compared to the baseline, the 
mean and maximum standardized uptake values (SUVs) increased by 65.6% and 126.3%, 
respectively, in the liver metastasis after resection of the primary tumor (Fig 1). 
To support the data from this case report, dual FDG-PET measurements have been 
performed in an additional 5 colorectal carcinoma patients with in total 12 liver 
metastases before and after removal of the primary tumor (group A). In addition, 
in 6 control patients with a total of 10 liver metastases (group B), 2 PET scans were 
performed at a time interval comparable to that in group A, but without resection of 
the primary tumor. Preliminary results demonstrate that in group A, the increase in SUV 
was 17.2% ± 17.7% and 22.9% ± 34.2% (mean ± standard deviation) for the mean and the 
maximum SUV, respectively. The increase in mean and maximum SUV was statistically 
significant, with P values of .006 and .03, respectively. In group B, changes in mean 
and maximum SUV were -10.0% ± 34.2% and -1.2% ± 32.3%, respectively, which were 
not significant. We also determined the levels of the antiangiogenic factors angiostatin 
and endostatin in body fluids (urine and serum/plasma) before and after removal of 
the primary tumor by Western blot analysis and specific enzyme-linked immunosorbent 
assay (ELISA), respectively. Urine and plasma samples were collected 4 days before and 
22 days after surgery (Fig 2). Before surgery, angiostatin was detectable in the urine 
(Fig 2, A), and the level of circulating endostatin (24.2 ng/mL) was higher than the 
mean endostatin level of 42 healthy controls plus 3 standard deviations (upper line in 
Fig 2, B). Concomitant with the observed increase in metabolic activity as measured 
by FDG-PET, the urinary angiostatin level became undetectable after surgery, and the 
circulating endostatin level dropped to 13.8 ng/mL, a value within the normal range. In 
addition, preoperative and postoperative urinary angiostatin levels were determined 
in a group of 12 colorectal carcinoma patients. Unfortunately, none of the patients in 
whom PET scans were performed could be included in this group, so we were not able 
to correlate PET scan data with angiostatin data. Preliminary results demonstrate that 
preoperative urinary angiostatin was detectable in 4 patients (33%). In all 4 of these 
patients, angiostatin disappeared from the urine after surgery. 
Endostatin levels in the same group of 12 patients did not differ significantly before 
and after surgery. It should be noted, however, that the commercial ELISA we used for 
endostatin measurements also detects other (nonantiangiogenic) fragments of collagen 
XVIII, and thus these data should be interpreted with care.
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Figure 1. Coronal FDG-PET images of a patient with synchronous colorectal liver metastasis before 
(A) and after (B) resection of the tumor. Note a marked increase of FDG accumulation at the site 
of the liver metastasis (arrow) after resection of the colorectal primary tumor (arrowhead). The * 
indicates the urinary bladder.
Figure 2. Urinary angiostatin (A) and plasma endostatin levels (B) before and after resection of 
the primary tumor. Note the disappearance of urinary angiostatin (A) and decreased levels of 
circulating endostatin (B) after resection.
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Discussion
Our data are a first indication that primary tumor-mediated suppression of metastatic 
outgrowth, as observed in animal models, may occur in humans as well. We have 
demonstrated that the increased metabolic activity in liver metastasis after removal 
of primary colorectal carcinoma as detected by FDG-PET coincided with a decrease in 
antiangiogenic factor levels.
Our results suggest that a flare-up of angiogenic activity had occurred in the metastatic 
lesion, as a result of withdrawal of the angiogenesis inhibition generated by the primary 
tumor. The expected increase in vascularity then may have caused the enhanced PET 
signal. In cancer patients, a positive correlation between SUV and microvessel density, 
an independent negative prognostic factor in many mediated types, has been described 
previously.6 Unfortunately, we could not confirm this correlation, because no liver tissue 
was available for this patient. 
Our results may suggest that to prevent accelerated vascularization and growth of 
distant (micro)metastases, the primary tumor should not be removed. However, >50% of 
patients with primary colorectal malignancies who present without metastasis are cured 
by surgery.7 Therefore, not removing the primary tumor is not an option. Furthermore, 
the risk of metastasis is proportional to the number of circulating metastatic cells 
that originate from the primary tumor.8 Obviously, resection will remove the source 
of these cells. Although no conclusion is possible on the basis of a single case, these 
results may indicate that administration of antiangiogenic compounds after the surgical 
removal of a primary tumor may be an interesting approach to inhibit outgrowth of 
distant (micro)metastases. In animal models, substantial evidence has been presented 
that vascularization and subsequent growth of distant metastases could be inhibited 
by systemic administration of the angiogenisis inhibitors angiostatin and endostatin. 
These inhibitors exert potent antitumor activity without causing toxicity or leading to 
the development of therapeutic resistance. In humans, this approach may be helpful in 
preventing the outgrowth of liver metastases, a major cause of mortality in colorectal 
carcinoma patients. A recent phase III clinical trial demonstrated that antiangiogenesis 
therapy was effective in advanced colorectal carcinoma. 
Although elevated levels of angiostatin and endostatin have been described in cancer 
patients, further delineation of the relevance of primary tumor-derived antiangiogenic 
factors for growth and metabolic activity of distant metastases in humans is needed.9 
Such studies might provide guidelines for administering adjuvant (antiangiogenic) 
therapy in cancer patients undergoing surgery for a primary tumor to prevent the 
accelerated growth of (micro)metastases after resection of the primary tumor.
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Abstract
Purpose: Fine needle aspiration biopsy (FNAB) is inconclusive in up to 20% of patients 
with solitary thyroid nodules. In these cases, hemithyroidectomy is necessary, but only 
20% of the nodules prove to be thyroid carcinoma. The aim of this study was to explore 
the potential of FDG-PET to reduce the number of unnecessary hemithyroidectomies in 
the preoperative assessment of thyroid nodules with an inconclusive FNAB. 
Methods: Forty-four consecutive patients, scheduled for hemithyroidectomy because 
of inconclusive FNAB, participated in this prospective study. FDG-PET of the thyroid 
region was performed before hemithyroidectomy and standardized uptake values (SUVs) 
were calculated. The final histopathological diagnosis served as a standard of reference. 
Results: Histopathology of the surgical specimens revealed 7 well-differentiated thyroid 
carcinomas in 6 patients, all accumulating FDG (negative predictive value 100%). FDG 
accumulated in 13 of 38 benign nodules. The pre-PET probability for cancer in this study 
population was 14% (6/44), and the post-PET probability increased to 32% (6/19). The 
number of unnecessary hemithyroidectomies in a hypothetical algorithm using FDG-
PET is only 30% (13/44) compared to 86% (38/44) without FDG-PET. FDG-PET reduces 
the number of futile hemithyroidectomies by 66% (25/38) (95% CI = 49%-80%, Fisher’s 
exact test: p=0.0038). Semiquantitative analysis using SUVs did not help to further 
reduce this number. 
Conclusion: In addition to data in the literature demonstrating accurate detection of 
thyroid cancer by FDG-PET, this study shows that FDG-PET should play an important 
role in the management of patients with inconclusive cytological diagnosis of a thyroid 
nodule. FDG-PET reduces the number of futile hemithyroidectomies by 66%. Although 
PET-scanning is a relatively costly procedure, this outweighs the costs and risks 
associated with unnecessary thyroid surgery.
Introduction
Solitary thyroid nodules are quite common, with a prevalence of 4% to 7% in the 
adult population in the United States 1. The incidence of differentiated thyroid cancer, 
however, is only 40 cases per million per year 2. The major diagnostic challenge in the 
workup of a patient with a thyroid nodule is to select only those patients with malignant 
nodules for surgery out of the large number of patients with thyroid nodules.
The clinical findings that should raise the suspicion of malignancy include rapid 
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growth, firm or hard nodules, regional lymphadenopathy and local invasion in the neck 
3. Radionuclide scanning is not routinely recommended, since thyroid scintigraphy 
does not significantly decrease the number of suspicious nodules 3, and most patients 
would also undergo FNAB in such a diagnostic algorithm 2. Characteristics revealed 
by ultrasonography, such as hypoechogenicity, microcalcifications, irregular margins, 
increased nodular flow visualized by Doppler, and, especially, the evidence of invasion or 
regional lymphadenopathy, are associated with an increased risk of cancer. Sonographic 
findings, however, cannot reliably distinguish between benign and cancerous lesions 3-5. 
Thyroid function testing may be helpful in the differential diagnosis. Nearly all patients 
with thyroid cancer are euthyroid 1.
FNAB, preferably guided by ultrasonography, has to be regarded as the key investigation 
in the initial evaluation of thyroid nodules 6. Patient management decisions and choice 
of therapy will be based mainly on the cytological diagnosis. FNAB is safe, can be 
easily performed, without major complications, and is cost-effective. Although the 
minimal tumor size detectable by ultrasound-guided FNAB is about 5 mm, it has a 
very high negative predictive value of 98% 7, so patients with nonmalignant cytology 
can be followed safely by sonography, as long as the thyroid nodule size remains 
constant. FNAB, however, does also have several recognized limitations. FNAB shows 
inconclusive aspirates in up to 20% of cases 8,9. In patients with cytological findings 
characteristic of a follicular or Hürthle cell neoplasm or Hashimoto’s thyroiditis, a 
hemithyroidectomy is necessary to allow a reliable histological diagnosis 2,10. Although 
routine FNAB clearly increases the relative number of cancers at operation, still 80-85% 
of hemithyroidectomized patients eventually turn out to have benign thyroid disease 2,10. 
A diagnostic test that decreases the number of surgical procedures for benign nodules 
could have a significant impact on patient management.
In differentiated papillary and follicular thyroid cancer, positron emission tomography 
(PET) with F-18-fluoro-deoxyglucose (FDG) has demonstrated to be very useful for 
surveillance and detection of recurrence, especially in thyroid cancer patients with a 
negative 131Iodine whole body scan but measurable thyroglobulin. In these patients, 
FDG-PET is able to detect metastatic disease in up to 90% of cases 11. In patients with 
medullary thyroid cancer with elevated calcitonin levels following thyroidectomy, 
FDG-PET has a sensitivity of 70–75% for localizing metastatic disease 11. In the current 
prospective study, the potential of FDG-PET is explored to reduce the number of 
unnecessary hemithyroidectomies performed for solitary thyroid nodules that have 
inconclusive FNAB results and ultimately prove to be benign.
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Materials and methods
Patients
Patients scheduled for hemithyroidectomy for a palpable solitary thyroid nodule with 
an inconclusive FNAB were eligible for this prospective study. The study was conducted 
in one general hospital (bed capacity: 450) and one university hospital (bed capacity: 
950) in The Netherlands. In our practice an inconclusive cytology is encountered in 20% 
of patients with a suspicious thyroid nodule. Forty-four consecutive patients with a 
mean age of 50 years (range 22 to 77 years) were enrolled from June 2001 to December 
2004 (Table 1). All patients were euthyroid. Exclusion criteria were diabetes mellitus and 
pregnancy. The study was approved by the Institutional Review Board of the Radboud 
University Nijmegen Medical Centre and written informed consent was obtained from 
each patient.
Diagnostic Workup of Thyroid Nodules
If a suspicious thyroid nodule was observed, the initial diagnostic study was FNAB. A 
suspicious nodule was defined as follows: a nodule in a patient with a family history 
of medullary thyroid carcinoma or multiple endocrine neoplasia, a nodule with rapid 
growth, a firm or hard nodule, fixation of the nodule to adjacent structures and a 
nodule detected in combination with paralysis of one or both vocal cords or regional 
lymphadenopathy. A nodule with a moderate suspicion was defined as: a nodule in a 
patient of either <20 years or >70 years, a nodule in a male patient, a history of head 
and neck irradiation, a nodule >4 cm in diameter, a partially cystic nodule, or symptoms 
of compression, including dysphagia, dysphonia, hoarseness, dyspnea, and cough. 
If cytology revealed malignancy, a total thyroidectomy was performed. In case of an 
unequivocally benign cytological diagnosis, patients remained under observation. In 
cases of an inconclusive cytological finding or if malignancy could not be excluded, 
patients proceeded to hemithyroidectomy to allow a reliable histological diagnosis. 
Cytological findings were considered inconclusive in case these findings were suspicious 
for a follicular neoplasm, a Hürthle cell (oncocytic) neoplasm, or in case of an atypical 
papillary cytology or an repeatedly insufficient sample (“nondiagnostic”).
Experimental Design
FDG-PET was performed only in those patients scheduled for hemithyroidectomy based 
on inconclusive cytology. The interval between FNAB and FDG-PET was at least 5 weeks 
to avoid FDG accumulation due to the biopsy trauma.
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Table 1. Characteristics, Cytology, Histopathology, and FDG-PET results of 44 Patients with 
Thyroid Nodules with inconclusive FNAB
Patient Sex Age Cytology Histology PET SUV
1 F 77 Follicular proliferation Nodular hyperplasia -
2 F 51 Follicular proliferation Nodular hyperplasia -
3 F 42 Follicular proliferation Nodular hyperplasia -
4 M 49 Follicular proliferation Nodular hyperplasia -
5 F 61 Follicular proliferation Nodular hyperplasia -
6 F 56 Follicular proliferation Nodular hyperplasia -
7 F 45 Follicular proliferation Nodular hyperplasia -
8 F 42 Follicular proliferation Nodular hyperplasia -
9 F 73 Follicular proliferation Nodular hyperplasia -
10 F 57 Follicular proliferation Nodular hyperplasia -
11 F 56 Follicular proliferation Nodular hyperplasia -
12 F 38 Insufficient cells (3 x FNAB) Nodular hyperplasia -
13 F 47 Atypical Hürthle+Follicular cells Nodular hyperplasia + 2.0
14 M 41 Insufficient cells (3 x FNAB) Follicular adenoma -
15 F 70 Follicular proliferation Follicular adenoma -
16 F 30 Follicular proliferation Follicular adenoma -
17 F 61 Follicular proliferation Follicular adenoma -
18 F 38 Follicular proliferation Follicular adenoma -
19 F 42 Follicular proliferation Follicular adenoma -
20 F 61 Follicular proliferation Follicular adenoma -
21 F 37 Hürthle+follicular cells Follicular adenoma -
22 F 48 Follicular proliferation Follicular adenoma -
23 F 40 Follicular proliferation Follicular adenoma -
24 F 41 Follicular proliferation Follicular adenoma + 1.1
25 F 29 Follicular proliferation Follicular adenoma + 3.6
26 F 41 Follicular proliferation Follicular adenoma + 4.3
27 F 46 Follicular proliferation Follicular adenoma + 7.8
28 F 22 Hürthle+follicular cells Follicular adenoma + 35.1
29 F 64 Follicular proliferation Hashimoto thyroiditis -
30 F 66 Follicular proliferation Hashimoto thyroiditis+Follicular adenoma -
31 F 40 Hürthle+follicular cells Hashimoto thyroiditis+Nodular hyperplasia -
32 F 24 Follicular proliferation Hashimoto thyroiditis+Follicular adenoma + 3.0
33 F 57 Follicular proliferation Hashimoto thyroiditis+Nodular hyperplasia + 4.2
34 F 50 Follicular proliferation Hashimoto thyroiditis + 6.2
35 F 70 Follicular proliferation Hashimoto thyroiditis+Nodular hyperplasia + 13.1
36 F 73 Multiple Hürthle cells Follicular adenoma/Hürthle cell adenoma + 4.2
37 F 42 Atypical Hürthle cells Follicular adenoma/Hürthle cell adenoma + 6.9
38 F 63 Atypical Hürthle cells Hürthle cell adenoma + 11.4
39 F 36 Hürthle+follicular cells pT2 Papillary carcinoma + 0.9
40 F 47 Follicular proliferation pT1 Papillary carcinoma + 2.1
41 F 25 Atypical follicular proliferation pT2 Follicular carcinoma + 2.1
42 F 54 Atypical Hürthle cells pT1 Follicular carcinoma + 5.5
43 F 38 Follicular proliferation pT3 Follicular+pT1papillary carcinoma + 8.0 / 4.2
44 M 45 Follicular proliferation pT3 Follicular carcinoma + 20.4
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A dedicated PET scanner (ECAT-EXACT, Siemens/CTI, Knoxville, TN, USA) was used 
for data acquisition. Prior to FDG-injection, patients were fasted for at least 6 hours. 
Intake of sugar-free liquids was permitted. Immediately prior to the procedure, patients 
were given diazepam 5 mg for muscle relaxation. One hour after intravenous injection 
of 200-220 MBq FDG (Mallinckrodt Medical, Petten, The Netherlands), emission and 
transmission images of the head and neck area were acquired (2 bed positions, 10 
minutes per bed position). The images were corrected for attenuation and reconstructed 
using the ordered-subsets expectation maximization (OSEM) algorithm. 
Evaluation of the Data
The images were evaluated by two independent experienced observers. These observers 
were not aware of the localization of the nodule and were also blinded to the final 
histological diagnosis. The scans were classified as negative (no FDG uptake in the 
thyroid nodule) or as positive (any FDG uptake in the thyroid nodule above background 
activity). If FDG-PET visualized the thyroid nodule, standardized uptake values (SUVs) 
were calculated for semi-quantitative analysis of FDG uptake. If the thyroid nodule 
was not visible on the FDG-PET images, no quantification was attempted. A volume of 
interest was drawn around visible nodules using an automatic 50% isocontour (ECAT 
software tool), which enclosed pixels with 50% or more of the maximum radioactivity 
in the volume of interest. Standardized uptake values were calculated using the 
concentration of FDG in the volume of interest as measured by PET, divided by the 
injected FDG dose and multiplied by body weight as a normalization factor.
After FDG-PET, all patients subsequently underwent hemithyroidectomy and the final 
histopathological diagnosis of the nodules was determined. This diagnosis was regarded 
as the standard of reference and was used for verification of the FDG-PET results.
Statistical Analysis
When designing the study, a power analysis was performed to estimate the required 
size of the patient population. Data from the literature suggest that only 15-20% of 
patients with inconclusive FNAB of palpable thyroid nodules have thyroid cancer 2,10. 
Thus, 80-85% of patients are resigned to unnecessary hemithyroidectomy to rule out 
malignancy. To detect a 30% reduction of unnecessary hemithyroidectomies as a result 
of inclusion of FDG-PET in the preoperative diagnostic workup, a sample size of 42 
patients is required (alpha 0.05, power 0.80). The results of the study were analyzed 
using Fisher’s exact test. The level of significance was set at 0.05.
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Results
FNAB
FNAB yielded cytological specimens with follicular proliferation in 33 patients, 
cytological specimens with numerous Hürthle cells in 4 patients and a combination of 
numerous Hürthle cells and follicular cells in 5 patients (Table 1). In 2 patients, three 
repetitive FNABs showed an insufficient number of cells to allow a correct cytological 
interpretation. Thyroid cancer could not be excluded in all of these patients, and they 
were thus scheduled for hemithyroidectomy.
Histopathological and FDG-PET Results
Histopathology of the surgical specimens revealed 7 well-differentiated thyroid 
carcinomas in 6 of the 44 patients: 2 papillary carcinoma, 3 follicular carcinoma, and 
one patient (patient 43, Fig. 1) had two primaries in one lobe: a palpable large follicular 
carcinoma and a small papillary carcinoma (Table 1). All malignant tumors accumulated 
FDG and were clearly visible as areas of increased FDG uptake. Therefore, there were no 
false negative results. This implies a negative predictive value of 100% (95% confidence 
interval 86-100%). The nodules of 38 of the 44 patients were histologically benign. 
Histology of these benign nodules revealed nodular hyperplasia in 13, follicular adenoma 
in 15, Hashimoto’s thyroiditis in 7 and a Hürthle cell adenoma in 3. FDG accumulated in 
13 of the 38 histologically benign tumors: 1 of 13 hyperplastic nodules, 5 of 15 follicular 
adenomas, 4 of 7 Hashimoto’s thyroiditis and in all 3 Hürthle cell adenomas (Fig. 2). 
The remaining 25 patients did not show increased tracer uptake in the thyroid. The 
number of unnecessary hemithyroidectomies in the diagnostic algorithm where FDG-
PET is implemented is 13 out of 44 (30%) compared to 38 out of 44 in an algorithm 
without FDG-PET (86%). This implies that FDG-PET can reduce the number of needless 
hemithyroidectomies by 66% (25/38) (95% CI = 49%-80%, Fisher’s exact test: p=0.0038). 
The pre-PET probability to have cancer in the patients scheduled for hemithyroidectomy 
was 14% (6/44), and the post-PET probability increased to 32% (6/19). Figure 3 shows a 
proposal for the diagnostic workup including FDG-PET.
Semiquantitative Analysis
All carcinomas were clearly visible on FDG-PET. The mean SUV of the carcinomas 
was 6.2 ± 6.7 (range 0.9 to 20.4, Table 1). The mean SUV of the benign lesions with 
increased FDG uptake was similar (7.9 ± 8.9, range 1.1 to 35.1). In Figure 2, SUV plots 
of the various histological diagnoses are shown. The SUVs of PET-negative nodules 
were set at zero. This Figure demonstrates that SUV did not help to separate malignant 
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lesions from benign lesions, as there is a distinct overlap. The mean SUV of the FDG-
PET positive nodules in the patients with follicular adenoma, Hashimoto’s thyroiditis, 
nodular hyperplasia and Hürthle cell adenoma was 10.4 ± 14.0, 6.6 ± 4.5, 2.0 and 7.5 ± 3.6, 
respectively. All patients with Hürthle cell adenoma had increased focal FDG-uptake in 
the thyroid (Fig. 4). Twelve out of 13 lesions with nodular hyperplasia, 10 out of 15 with 
follicular adenoma, and 3 out of 7 with Hashimoto’s thyroiditis showed no visual FDG-
uptake in the thyroid nodules.
Figure 1. In this 38-year-old woman, FNAB showed follicular proliferation. FDG-PET demonstrated 
two lesions in the right thyroid lobe. The final histopathological diagnosis revealed a right-sided 
pT3 follicular thyroid carcinoma and a pT1 papillary thyroid carcinoma cranial from this lesion. 
Figure 2. FDG SUV for all 44 patients plotted against final histological diagnosis. In this plot, SUV 
of invisible nodules on FDG-PET was set at zero. SUV did not help to separate malignant from 
benign lesions, as there is a distinct overlap.
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Figure 3. Diagnostic algorithm including FDG-PET In the existing diagnostic algorithm, nodules 
with an inconclusive cytological diagnosis must be removed, and a hemithyroidectomy is 
necessary to allow a reliable histological diagnosis. In the proposed diagnostic algorithm, FDG-
PET is implemented as shown.
Figure 4. This 42 year-old woman (patient 37) had an inconclusive FNAB with many atypical 
Hürthle cells. FDG-PET showed intensely increased FDG uptake in the right thyroid lobe. Histology 
demonstrated a 2.7 cm follicular adenoma with focal Hürthle cell changes.
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Discussion
The present study shows that the number of futile hemithyroidectomies in an algorithm 
that includes FDG-PET can be reduced by 66%. FDG-PET is able to increase the probability 
of cancer in case of inconclusive FNAB; the pre-PET probability to have cancer in this 
study population was 14% (6/44), and the post-PET probability increased to 32% (6/19). 
FDG-PET missed none of the seven differentiated thyroid carcinomas, which implies a 
negative predictive value of 100%. FDG-PET was not negative in all benign nodules, as 
FDG accumulated in 13 of the 38 histologically benign tumors. Nevertheless, our study 
proves that FDG-PET is very helpful in the selection of patients who need surgery. If FDG-
PET would be implemented in the preoperative workup for patients with inconclusive 
cytology, this would substantially decrease the number of futile hemithyroidectomies. 
Such strategy would not only avoid risks and morbidity associated with thyroid surgery, 
but would also lead to cost savings. The reimbursement for FDG-PET in The Netherlands 
is approximately Euro 1200 , which compares favorably to the results from a recent cost 
analysis performed in the Netherlands by Hooft et al. 12. They showed that the costs 
were mainly driven by the costs for surgery and hospitalization: mean costs per patient 
amounting to Euro 3.311 in case of benign cytology, without considering the costs of 
additional treatment, economic or indirect costs.
The high negative predictive value of the current prospective study is in line with various 
other small, retrospective studies 2,13-15 and studies with varying degrees of selection 
bias 16-18. A total of 58 thyroid carcinomas were included in these studies of which only 
one was missed with FDG-PET in a study that did not use a modern dedicated PET-
camera 16. Another nuclear medicine technique, dual-phase 99mTc-sestamibi, did not 
provide such high negative predictive value. Thirteen studies 19-24 that reported on this 
issue included 210 thyroid carcinomas altogether, of which 39 were missed with 99mTc-
sestamibi scintigraphy. Like FDG-PET, 99mTc-sestamibi scintigraphy may also be positive 
in follicular adenomas, Hürthle cell adenomas and Hashimoto’s thyroiditis and would 
thus not be helpful in raising specificity 19-24. Also, further nuclear medicine methods 
such as 99mTc-tetrofosmin, 201Thallium or 201Thallium/99mTc-pertechnetate subtraction 
scan have shown similar disappointing results 25.
Furthermore, the current study is unique, as an unselected and uniform patient population 
of consecutive patients with inconclusive FNABs was prospectively investigated with 
sufficient power to draw reliable conclusions. The study of Wolf et al. 15 retrospectively 
studied patients and the studies of Joensuu and Sasaki 16,18 selected patients with thyroid 
carcinoma and patients with benign thyroid tumors for their respective studies. Sasaki 
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studied not only new preoperative cases but also recurrent or metastatic carcinoma. 
Kresnik et al. 17 studied 43 patients with suspicious cytology indicating follicular or 
Hürthle cell proliferation but selected patients with papillary carcinoma as a positive 
control group. More importantly, the study was performed in an endemic goiter area, 
which does not represent the general population. The studies of Adler, Bloom, and 
Uematsu et al. 2,13,14 were too small to achieve sufficient power. In contrast to our findings, 
it was suggested that a higher FDG uptake in malignant tumors than in benign lesions, 
as determined by quantitative analysis (i.e., SUV), is able to differentiate successfully 
between all benign and malignant thyroid nodules 2,13,14. Kresnik and Sasaki also reported 
many overlapping cases 17,18. SUVs depend on acquisition, reconstruction, and region of 
interest parameters. The variability in SUV methodology will hamper direct comparison 
of results obtained in different studies 26. Furthermore, the partial volume effect is an 
additional source of potential error in quantifying FDG activity in tissue. When the 
size of the region of interest is smaller than approximately twice the full width at half 
maximum, FDG accumulation in the region of interest is underestimated 17,18. For all those 
reasons, we recommend not to rely on SUVs in the discrimination between malignant 
and benign thyroid lesions. Patients with a suspicious thyroid nodule with inconclusive 
FNAB in combination with any visible FDG-accumulation in the thyroid nodule should 
be taken to surgery.
Concerns may arise from the limited spatial resolution of PET. PET scanning will probably 
never be able to rule out microscopic thyroid carcinoma. However, this is probably not 
a significant clinical problem, since it is generally supposed that thyroid carcinomas 
smaller than 1 cm in size are rarely of clinical significance. This is confirmed by large 
autopsy series demonstrating a high prevalence of incidental and unrecognized minimal 
(occult) thyroid carcinomas 27-29.
Our study may also be of importance for interpretation of increased FDG uptake in the 
thyroid region in a patient investigated with FDG-PET for any other indication. Thyroid 
incidentalomas identified by FDG-PET occur with a frequency of 2.3% 30-32. In the study 
by Cohen et al. in 4525 FDG-PET examinations, it was shown that half of the PET-positive 
thyroid incidentalomas that underwent biopsy were malignant 30. Therefore, FDG-PET 
positive thyroid incidentalomas should not be overlooked and should prompt further 
investigation to rule out cancer, of course, only when the diagnosis of thyroid cancer 
would influence patient outcome and management.
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Conclusion
In addition to data in the literature demonstrating accurate detection of thyroid cancer 
by FDG-PET, this study shows that FDG-PET should play an important role in the 
management of patients with inconclusive cytological diagnosis of a thyroid nodule. 
FDG-PET reduces the number of futile hemithyroidectomies by 66%. Although PET-
scanning is a relatively costly procedure, this outweighs the costs and risks associated 
with unnecessary thyroid surgery.
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Abstract
Background: The current study focuses on the prognostic value of pretreatment 
metabolic activity in metastases as measured with [18F]fluorodeoxyglucose positron 
emission tomography (FDG-PET), as an indicator of survival in colorectal cancer.
Patients and methods: In a prospective series of 152 patients with metastatic colorectal 
cancer, of whom 67 were treated with resection of metastases and 85 with chemotherapy, 
standardized uptake values (SUV) as measured with FDG-PET, were calculated prior 
to treatment. Survival probabilities were estimated by Cox proportional regression 
analysis. For Kaplan-Meier analysis SUV was stratified by the median value. Survival 
differences were assessed using the log-rank test.
Results: SUV in metastases was a significant predictor for overall survival (hazard 
ratio 1.17, 95% confidence interval 1.06-1.30, p=0.002), independent of the subsequent 
treatment. According to the median value of the patient population a low (SUV<4.26) 
and high uptake group (SUV>4.26) was defined. The median survival and the 2- and 3-
year survival rates were 32 months, 59% and 45%, respectively, in the low-uptake group 
and 19 months, 37% and 28%, respectively, in the high-uptake group (p=0.017).
Conclusion: A significant survival benefit was observed in patients with low FDG uptake 
in metastases of colorectal cancer.
Introduction
In Europe and in the United States, each year more than 150,000 people will develop 
metastases from colorectal carcinoma 1. The prognosis has improved substantially with 
the introduction of hepatic resection for treatment of isolated liver involvement and 
of effective chemotherapeutic agents. Over the past 10 years, median survival times 
for patients with advanced colorectal carcinoma have almost doubled, ranging from 20 
months for patients with less favorable prognostic factors up to 50 months in patients 
with the most favorable prognostic factors 2-4. Several chemotherapeutic agents can 
be combined, such as fluoropyrimidines, irinotecan and oxaliplatin, chemotherapy can 
be given alone or in combination with molecular-targeted agents such as cetuximab or 
bevacizumab, and one can vary in duration and sequence of therapy 4. Furthermore, in the 
past two decades remarkable progress was made regarding the surgical techniques and 
postoperative management of major hepatic surgery 5,6. Consequently, the indications 
for hepatectomy have been extended. As individualized treatment strategies become 
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more relevant, there is a need for identification of novel biologic pretreatment factors 
that potentially predict outcome, to ensure that patients benefit from hepatic surgery, 
novel anticancer therapies and intensive treatment combinations. These pretreatment 
factors may be of particular value in stratifying patients for clinical trials. Therefore, 
there is growing interest in metabolic imaging of cancers.
Many malignancies, including colorectal carcinoma, have increased glucose metabolism. 
They accumulate the positron-emitting glucose analog [18F]fluorodeoxyglucose (FDG) 
and can thus be visualized using positron emission tomography (PET). Previous studies 
clearly indicated that FDG-PET is of value in the diagnostic work-up of patients with 
colorectal liver metastases and that FDG-PET as a complementary staging method 
improves the therapeutic management, especially by detecting unsuspected extrahepatic 
disease 7-9. A recent study reported on therapy response monitoring with FDG-PET and 
the biologic basis of the change of tumor FDG uptake in patients treated with neo-
adjuvant chemotherapy 1. Several investigators have speculated that the amount of FDG 
uptake correlated with biologic factors such as Ki-67, proliferating cell nuclear antigen, 
Glut-1, and hexokinase 1 and that FDG uptake resembles the biological behavior of the 
tumor, and might be associated with intrinsic biologic characteristics, like hypoxia 10, low 
apoptosis rate 11, cell viability 12, proliferative activity 13 and p53 overexpression 14. These 
characteristics are all potentially adverse factors in patients treated with radiotherapy 
or chemotherapy, while some of them may also impact negatively in patients treated 
surgically.
The advantage of FDG-PET is that it is a non-invasive, in vivo method that cannot only 
visualize, but can also quantify FDG uptake to distinguish metabolically active from 
less active tumor. This quantitative analysis of FDG uptake can be done before any 
treatment has been performed. In the current study, the predictive value of quantitative 
pretreatment FDG uptake for patient prognosis in metastatic colorectal carcinoma 
was investigated. If the amount of FDG uptake in metastases of colorectal carcinoma 
is of prognostic significance, this diagnostic modality could be an important adjunct 
to traditional staging and could improve appropriate selection of high-risk candidates 
for aggressive therapies and treatment combinations and could be useful as an early 
indicator of tumor chemosensitivity, which could help to refine therapeutic strategies.
 18F-FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma 175
Methods
Patients
From 2000 to 2005, a prospective series of 152 patients with histologically proven 
metastatic colorectal cancer (64 female, 88 male patients; mean age 61.6 years, range 
33-86 years) underwent FDG-PET in the diagnostic work-up before a decision was made 
between surgical resection of metastases or treatment with chemotherapy. Exclusion 
criteria were poorly regulated diabetes mellitus and pregnancy. Follow-up was closed 
on December 1, 2005.
FDG-PET
A dedicated PET scanner (ECAT-EXACT, Siemens/CTI, Knoxville, TN, USA) was used for 
data acquisition. Prior to FDG injection, patients were fasted for at least 6 hours. One 
hour after intravenous injection of 200-220 MBq FDG (Mallinckrodt Medical, Petten, 
The Netherlands), emission and transmission images were acquired. The images were 
corrected for attenuation and reconstructed using the ordered-subsets expectation 
maximization (OSEM) algorithm.
FDG-PET Analysis
All patients underwent FDG-PET within 6 weeks prior to treatment. Two experienced 
nuclear medicine physicians primarily interpreted FDG-PET images for staging on 
the basis of a visual inspection. For this study, all studies were reanalyzed to acquire 
semiquantitative data. For that purpose volumes of interest were drawn around all 
metastases using an automatic 50% isocontour (ECAT software tool), which enclosed 
pixels with 50% or more of the maximum radioactivity within the volume of interest. 
Standardized uptake values (SUV) were calculated using the concentration of FDG in 
the volume of interest as measured by PET, divided by the injected dose and multiplied 
by body weight as a normalization factor. A volume weighted mean value of each PET 
scan was derived from all lesions to give one average SUV (SUVavg, hereafter mentioned 
SUV) for each PET scan. Survival data served as a reference for the FDG-PET data.
Treatment
Surgical decision-making, as well as the decision for chemotherapy, was made by a 
multi-disciplinary team including surgeons, medical oncologists, radiation oncologists, 
pathologists, radiologists and nuclear medicine physicians for all patients. Resection of 
metastases was considered the treatment of choice in case CT and FDG-PET indicated 
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resectable liver metastases and/or less than 3 resectable lung metastases in the absence 
of other extrahepatic disease. Hepatic causes for irresectability included involvement 
of major blood vessels or extensive bilobar liver disease, which would either preclude 
negative resection margins or would result in inadequate hepatic reserve. After curative 
surgery, patients were considered to be free of disease. Curative liver resection was 
defined as any procedure (resection, radiofrequency ablation or the combination of 
both) that rendered the patient free of all hepatic disease. Patients not eligible for 
surgery were treated with 5-fluorouracil (5-FU) based chemotherapy in combination 
with leucovorin (LV), capecitabine, irinotecan or combination therapy (capecitabine 
with irinotecan or 5-FU with oxaliplatin and LV) as first line treatment. Irinotecan or 
capecitabine in combination with oxaliplatin was given as second line treatment.
Clinical Follow-Up 
Overall survival was defined as the time interval from date of FDG-PET until death 
related to malignancy or date of last follow-up. In the surgically treated patient group, 
disease-free survival was also estimated. Disease-free survival was defined as the time 
interval between FDG-PET and the first recurrence of the disease (local-regional or 
distant recurrence). Follow-up was performed according to a stringent protocol for 3 
years. Apart from clinical examinations, routine laboratory tests, and carcinoembryonic 
antigen (CEA) measurement patients underwent a CT scan of the abdomen every 3 
months and a CT scan of the chest every 6 months, and in case of inconclusive findings 
on CT, an additional FDG-PET scan, an ultrasound and/or MR scan was performed. For 
the surgically treated group the variables that form the prognostic scoring system 
according to Fong et al. 15 (node-positive primary, disease-free interval from primary 
to metastases, number of liver metastases, diameter of the largest liver lesion, and the 
preoperative CEA level) were also recorded prospectively. These five variables were 
dichotomized into a low- and a high-risk category. A patient variable was assigned to 
the high risk category if the disease-free interval was 12 months or more after resection 
of the primary tumor, if the number of liver lesions was more than 1, if the largest 
liver lesion was more than 5 cm, if the primary tumor was node-positive, and if the 
preoperative CEA level exceeded 200 ng/mL. The clinical risk score according to Fong 
et al. assigns each of the five criteria one point if it is part of the high-risk category, 
resulting in a score of zero to five.
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Statistical Analysis
The predictive value of SUV for overall and disease-free survival was determined. The 
main end-point was overall survival. Overall and disease-free survival probabilities were 
estimated by the univariate Cox regression analysis and the estimated hazard ratio and 
95% confidence interval (CI) were reported. SUV, disease-free interval from the primary 
to discovery of the liver metastases (months), number of liver metastases, diameter of 
the largest liver lesion (cm), and the preoperative CEA level (ng/mL) were analyzed as 
continuous variables. Invasiveness of the primary tumor (pT), nodal status of the primary 
(pN) and the histologic grade of the primary were analyzed as categorical variables. The 
overall survival curve with respect to SUV was generated using Kaplan-Meier estimates. 
SUVs were stratified by the median value to avoid data-driven significance for the cut-
off level. Significance of the differences between the low- and high SUV group was 
assessed using the log-rank test. Spearman’s rho correlations were used to determine 
associations between the SUV and the degree of tumor cell differentiation of the liver 
metastases and the SUV and the Fong’s score. Statistical analyses were performed using 
the SPSS 12.0.1 package. Statistical tests were based on a two-sided significance level 
and the level of significance was set at 0.05.
Results
Patients
The median follow-up was 17 months (range 2-61 months) for surviving patients. At 
the closeout date 71 of the 152 patients had died. No patients were lost to follow-up. 
Assessment of preoperative CT and FDG-PET revealed that most patients had metastatic 
involvement of the liver (n = 149). Lung metastases were found in 14 patients. The 
histological tumor type was adenocarcinoma in 134 patients, mucinous adenocarcinoma 
in 3 patients, adenocarcinoma with some mucinous components in 13 patients, adeno-
acanthoma in 1 patient and adenocarcinoma with neuroendocrine morphology in 1 
patient. In 67 patients liver surgery with curative intent was performed, using resection 
(n = 42), radiofrequency ablation (n = 9) or resection combined with radiofrequency 
ablation (n = 16). Four out of these 67 patients received chemotherapy postoperatively. 
In 85 patients, metastases were not resectable. In first-line treatment these patients 
received capecitabine, irinotecan or combinations of capecitabine and irinotecan or 
5-FU (with or without oxaliplatin) and LV (n = 72). In second-line treatment patients 
received irinotecan or capecitabine in combination with oxaliplatin (n = 13).
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Survival
In the surgically treated patients disease-free survival was estimated using the Fong-
criteria as an independent variable (table 1). During follow-up 35 out of the 67 surgically 
treated patients presented with recurrent disease and 32 remained disease-free. The 
aggregated Fong-criteria proved to be a predictor for disease-free survival (hazard 
ratio 1.75, 95% CI=1.24-2.47, p=0.002) as shown in table 1. The individual variables 
that are assessed in the prognostic scoring system of Fong were not predictive for 
recurrence or survival (table 1). There was no association between SUV and Fong’s 
score (r=-0.006, p=0.96) or between SUV and the degree of tumor cell differentiation 
of the liver metastases (r=0.04, p=0.66). Median overall survival in the whole group was 
15.5 months (range 1-61 months). Median overall survival in the surgery group was 22 
months (range 2-61 months), which was significantly longer than the median survival in 
the chemotherapy group (12 months, range 1-54 months, p<0.001).
Table 1. Results of univariate Cox proportional regression analysis for predicting overall survival 
and disease-free survival in the surgically treated group (n=67)
Variable Overall survival Disease-free survival
Hazard 
ratio 95% CI p value
Hazard 
ratio 95% CI p value
pT
pN (dichotomized N0 vs N1-3)*
CEA preoperative (ng/mL)*
Disease-free interval (month)*
Number of liver metastases*
Largest liver lesion (mm)*
Histologic grade of primary tumor
Fongcriteria
1.34
0.93
1.11
0.99
0.97
1.25
0.85
1.34
0.47-3.78
0.47-1.84
0.81-1.52
0.94-1.04
0.78-1.20
0.54-2.90
0.52-1.36
0.80-2.22
0.59
0.82
0.51
0.62
0.76
0.60
0.49
0.27
1.87
1.01
1.13
1.00
1.03
0.88
1.12
1.75
0.69-5.10
0.65-1.58
0.93-1.36
0.97-1.03
0.91-1.17
0.51-1.53
0.79-1.58
1.24-2.47
0.22
0.95
0.23
0.88
0.65
0.66
0.52
0.002
* variables that are assessed in the prognostic scoring system according to Fong et al.
FDG Uptake
For the whole study population, the mean and median of the SUV were 4.33 and 4.26, 
respectively (range 0.5-12.14). In the group of patients who underwent curative liver 
surgery (n = 67), the mean and median of the SUV were 3.65 and 3.60 (range 0.80-9.60). 
In the chemotherapy group (n = 85), the mean and median of the SUV were 4.86 and 
4.66 (range 0.50-12.14), being significantly higher than in the surgery group (p<0.03). 
The mean SUV in the group of patients, who remained free of disease after hepatic 
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resection, was not significantly different from the mean SUV in the group of patients 
with recurrent disease after hepatic resection (3.47±1.69, n = 35 vs. 3.84±1.96, n = 32, 
respectively).
Prediction of survival by FDG-PET
Although median SUV proved to be higher in the group of patients treated with 
chemotherapy as compared to patients treated by surgery, the SUV of individual patients 
proved to be highly variable and largely overlapping in both groups. Therefore, SUV of 
metastatic lesions was evaluated for the whole group. SUV of the metastases proved to 
be an independent and significant predictor for overall survival (hazard ratio 1.17, 95% 
CI 1.06-1.30, p = 0.002), irrespective of the subsequent choice of therapy (i.e. surgery 
or chemotherapy). A one-unit increase in SUV corresponded to a 17% increase in the 
risk of death. To generate Kaplan-Meier survival curves, SUV values were dichotomized 
at 4.26, being the median value of the study cohort. The Kaplan-Meier survival analysis 
further confirmed the value of SUV to predict survival, as the difference in survival was 
highly significant (p = 0.017, log-rank test, figure 1). The 2-year survival rates according to 
Kaplan-Meier were 59% in the low-uptake group (SUV < 4.26) and 37% in the high-uptake 
group (SUV > 4.26); the 3-year survival rates were 45% in the low-uptake group and 28% 
in the high-uptake group. Median survival in the low-uptake group was 32 months and 
19 months in the high-uptake group. At the closeout date, 32 of 76 patients in the low-
uptake group and 39 of 76 patients in the high-uptake group died of their disease. There 
was no difference in age or gender when comparing the low-uptake group (mean age 
62.0 years, 31 females, 45 males) with the high-uptake group (mean age 61.2 years, 33 
females, 43 males). The hazard ratio did not change significantly when analyzing the 
SUV of just one lesion per PET-scan, i.e. the SUV of the most FDG avid lesion of the 
patient (hazard ratio 1.19, 95% CI 1.08-1.31, p < 0.0001). Also the median survival and the 2- 
and 3-year survival rates were comparable, being 32 months, 59% and 45%, respectively, 
for the low-uptake group (SUV < 4.53) and 19 months, 36% and 28%, respectively for the 
high-uptake group (SUV> 4.53).
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Figure 1. Kaplan-Meier analysis of the relationship between SUV (dichotomized using median 
value of 4.26) and overall survival
Discussion
As compared to the tumors of patients with colorectal liver metastases who were taken 
to surgery, the tumors of patients who underwent chemotherapy were on average 
metabolically somewhat more active, which may reflect enhanced tumor aggressiveness. 
However, uptake of FDG in tumors proved to be highly variable within the two treatment 
groups with considerable overlap between the groups. However, when analyzing SUV 
for the whole group, the metabolic activity of the metastatic colorectal carcinoma as 
depicted by FDG uptake, proved to be a significant independent predictor for overall 
survival, regardless of whether patients subsequently underwent curative surgery or 
chemotherapy. A one-unit increase in SUV corresponded to a significant increase in 
the risk of death with 17%. When dichotomizing SUV values at the median value of the 
patient population, there was a highly significant difference in survival, as patients in 
the low-uptake group had a median survival of 32 months, as compared to 19 months in 
the high uptake group. Comparable survival rates and hazard ratio were observed when 
analyzing all metastases or only the most FDG avid (i.e. the most aggressive) lesion.
It is well established that patients with unresectable disease have a much poorer outcome 
than patients with resectable disease. The 5-year survival for hepatic metastasectomy 
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now approaches 30%-40%, with a median survival up to 50 months in patients with the 
most favorable prognostic factors. Unresectable patients who are treated with current 
state-of-the-art multidrug systemic therapy have a median survival of 18-20 months 
3. However, many of the patients treated with systemic therapy have more advanced 
disease than patients who are selected for liver metastasectomy, which may contribute 
to the difference in survival observed between these groups 4. Nevertheless, the present 
study suggests that metabolic activity of the metastases is also an important factor, 
since SUV proved to be an independent predictive factor for survival, no matter if the 
patient had resectable or irresectable, more widespread disease. Thus, our data indicate 
that intense glucose metabolism in metastases of colorectal cancer is a negative marker 
of prognosis.
To the best of our knowledge, there are no studies addressing the predictive value of 
FDG uptake for survival in metastatic colorectal carcinoma. However, our results are in 
line with the results of previous reports on the prognostic information of FDG uptake in 
patients with primary tumors such as non-small cell lung cancer (NSCLC) 16-22, head and 
neck squamous cell carcinoma (HNSCC) 23-29, breast cancer 14,30,31, glioma 32, esophageal 
carcinoma 33,34, pancreatic cancer 35-38 and hepatocellular carcinoma 39. As early as 1985, 
Patronas et al. 32 already reported a significant correlation between FDG uptake and 
survival in patients with gliomas. Several studies in patients with NSCLC treated with 
complete resection reported that SUV and pathologic tumor size, provided excellent 
independent prognostic information 16,17,19. The combination of SUV and pathologic tumor 
size identified a subgroup of patients at highest risk for death as a result of recurrent 
disease after resection. Other studies in NSCLC found that staging of tumor-node-
metastasis and SUV were independent prognostic variables 20-22. However, the SUV for 
the primary tumor was the strongest prognostic factor, whereas the prognostic ability 
of the SUV for the regional lymph nodes remained uncertain. There was an indication 
that primary tumors showing high SUVs have the potential to be resistant to therapy 
and to metastasize 22. Jeong et al found that the SUV of squamous cell carcinoma was 
higher than that of adenocarcinomas 20. Previous clinical series in HNSCC 23-29 also 
suggested that highly elevated primary tumor FDG uptake predicted worse prognosis. 
It was shown that patients with an advanced clinical stage 26 or tumors of lesser 
differentiation 25,26 display higher FDG uptake and that higher baseline SUV predicted 
inferior response to radiotherapy, local disease control, and survival 27,29. In pancreatic 
cancer SUVs were also introduced as a new metabolic predictor of prognosis 35-38. Most 
previous studies in this tumor type demonstrated that tumor-associated histologic 
characteristics are important in defining prognosis. However, most of them were 
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available only after a resection procedure has been performed 36. In another series of 
pancreatic cancer, the SUV was not able to predict survival in a subgroup of patients 
with resectable tumors 35. In the subgroup with unresectable tumors, however, SUV 
proved to be an independent prognostic indicator for overall survival. In breast tumors 
FDG uptake was also a significant predictor of prognosis 30 and some investigators 14,31 
examined the possible association between FDG uptake and several histopathological 
and immunohistochemical factors. The results of the present study also support the 
hypothesis that FDG uptake reflects biological aggressiveness 23. 
Conclusions 
Pretreatment FDG uptake in metastatic colorectal cancer predicts outcome, irrespective 
of the subsequent treatment modality, as patients with FDG avid disease show reduced 
overall survival. FDG-PET could become an important adjunct to traditional staging 
to improve appropriate selection of high-risk candidates for aggressive multimodality 
treatments and could be helpful in stratifying patients for prospective studies when 
different therapeutic options are to be compared.
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Abstract
Objectives: It has been postulated that radiopharmaceuticals can be used to predict the 
therapeutic response to (chemo)therapy, which could lead to individualized treatment 
regimens. In this study 18F-deoxyglucose, 99mTc-tetrofosmin, 125I-deoxyuridineribose and 
125I-methyltyrosine were tested for this purpose. 
Methods: The uterine sarcoma cell line MES-SA (MDR-) and its multidrug resistant 
variant, MES-SA/Dx5 (MDR+) were used. The MDR+ cells express high levels of P-
glycoprotein, which makes them relatively resistant  to various  chemotherapeutic 
agents. Cells were cultured in the presence of escalating concentrations of doxorubicin 
and the cellular uptake of the radiopharmaceuticals was determined.
Results: Decreasing 18F-deoxyglucose uptake at escalating doxorubicin concentrations 
reflected the chemosensitivity of the cells: 18F-deoxyglucose uptake in the MDR- cells 
was reduced to 40 % of the baseline level in the presence of 1 µM doxorubicin, compared 
to 74 % in the MDR+ cells. The 125I-deoxyuridineribose uptake in MDR- cells was reduced 
to 2% of the baseline level when cultured at a concentration of 1 µM doxorubicin, while 
this was 79% in the MDR+ cells. The same trend, was observed with 125I-methyltyrosine. 
The enhanced doxorubicin chemosensitivity of MDR+ cells in the presence of verapamil, 
a modulator of P-glycoprotein, was reflected by the reduced uptake of 18F-deoxyglucose, 
125I-deoxyuridineribose and 125I-methyltyrosine. Furthermore, baseline 99mTc-tetrofosmin 
uptake in MDR+ cells was more than 6-fold lower than in MDR- cells. 
Conclusion: In the presence of doxorubicin the uptake of 18F-deoxyglucose, 125I-
deoxyuridineribose and to a lesser extent 125I-methyltyrosine is more pronouncedly 
reduced in MDR- cells than in MDR+ cells. The reversal of doxorubicin-resistance of 
MDR+ cells by verapamil was also reflected by the uptake of  18F-deoxyglucose, 125I-
deoxyuridineribose and 125I-methyltyrosine. 99mTc-tetrofosmin uptake reflected P-
glycoprotein expression without exposure to doxorubicin.
Introduction
One of the major problems in the treatment of cancer with chemotherapeutics is 
the development of multidrug resistance (MDR) by tumor cells. It is of great clinical 
importance to identify those patients that will respond to particular anticancer agents 
and therefore to avoid unnecessary toxicity, (effective) therapy delay and expense in 
nonresponsive patients. Particularly in case of newer biological treatments involving 
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cytostatic (in contrast to cytolytic) drugs, an extended period of observation is often 
required before significant changes in the patient’s clinical status or in the radiographic 
evaluations are observed. Therefore there is need for a relevant measure of treatment 
response that could identify treatment “success” or “failure” much earlier than changes 
in tumor size or volume identified with CT or MR. Early assessment of treatment 
response is critical in designing appropriate and individualized treatment regimens 1. 
Various mechanisms are responsible for multidrug resistance, one of the most important 
being the overexpression of a plasma membrane phosphoglycoprotein, P-glycoprotein 
(P-gp), which is encoded by the MDR1 gene. P-gp, is the transporter protein responsible 
for actively pumping cytotoxic agents out of the cell. Besides P-gp, alternative intracellular 
mechanisms of resistance have been reported including intracellular entrapment, 
compartmentalisation or redistribution via the multidrug resistance-associated protein 
(MRP) and the lung-resistant protein (LRP), enhanced drug detoxification by glutathion-
S transferase, changes in levels or activity of nuclear targets such as topoisomerase II 
and alterations in the control of apoptosis 2. Since overexpression of P-gp is the most 
important mechanism responsible for MDR we focused on P-gp in the present study. 
The distribution of P-gp in many organs suggests that the expression of P-gp actually is 
a physiological protection mechanism of the human body. P-gp can provide protection 
by extruding toxins out of the cells into urine, bile and the intestinal lumen. It appears 
to protect critical organs such as the brain and the testes against toxic compounds. The 
MDR1 gene is expressed in several normal human tissues, associated with secretory or 
barrier functions and in some bone marrow and blood cells 3. Overexpression of P-gp 
may result in increased excretion and decreased retention of various MDR substrates 
and decreased cytotoxic efficacy of anticancer agents 4. 
Chemotherapeutic agents such as anthracyclines (daunorubicin and doxorubicin), 
vinca alkaloids (vincristine and vinblastine), epipodophyllotoxins (etoposide) and 
taxanes (paclitaxel) are all substrates for P-gp and are extruded out of the cell by P-gp. 
Besides chemotherapeutic drugs, several other drugs are substrates for P-gp, such as 
cardiovascular drugs (verapamil and digoxin), and immunosuppressives (cyclosporin A, 
PSC833). It is not clearly understood yet by what mechanism P-gp is able to recognize 
such diverse compounds and most likely more than one drug binding site is involved 
5,6.
It is of great relevance to identify patients with MDR due to overexpression of P-gp. 
Detection of protein and RNA expression for the MDR1 pump can be performed in 
human tumor samples using a variety of techniques, such as immunohistochemistry, 
quantitative autoradiography, and reverse transcriptase polymerase chain reaction 7-10. 
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However, detection of P-gp does not necessarily provide any information about the 
function of these pumps in the respective tissues. Furthermore, serial tumor biopsies 
are not generally performed. Radiotracers that can visualize the activity of cellular efflux 
pumps non-invasively are therefore of interest. In addition, various radiopharmaceuticals 
can potentially be used to predict the therapeutic response to chemotherapy. Here 
we studied four radiopharmaceuticals (18F-deoxyglucose (=FDG), 99mTc-tetrofosmin 
(=TF), 125I-methyltyrosine (=IMT) and 125I-deoxyuridineribose (=IUdR)) for their ability to 
monitor the response of cancer cells to doxorubicin treatment. 
The experiments were performed in the presence and absence of the calcium channel 
blocker verapamil, a potent modulator of P-gp. To inhibit P-gp mediated extrusion of 
chemotherapeutic agents, this modulator can be used beside other modulators such as 
the immuno-suppressive agent cyclosporin A and PSC833 11. Verapamil most likely acts 
by binding competitively to binding sites on the MDR transport proteins or by altering 
the affinities of the recognition domains in those proteins 12. Being informed about 
the effect of a modulator on both tumor tissue and normal tissues in each individual 
patient before starting chemotherapy could be clinically useful. This may help to select 
patients who will eventually benefit most from the addition of a modulator to the 
chemotherapeutic regimen 13. 
Materials and methods
Cell lines
The cell line MES-SA 1976 (ATCC, CRL-1976) and its multidrug resistant variant, MES-
SA/Dx5 1977 (ATCC, CRL-1977) were used in these experiments. The development and 
characterisation of the human uterine sarcoma cell line MES-SA and its multistep-
selected MDR variant Dx5 cells have been described elsewhere 14,15. In brief, wild-type 
MES-SA 1976 (P-gp-negative) cells were derived from a human uterine sarcoma. MES-
SA/Dx5 1977 (P-gp-positive) cells were derived from MES-SA 1976 cells grown in the 
presence of increasing doxorubicin concentrations. As a result of doxorubicin exposure 
MES-SA/Dx5 1977 cells express high levels of MDR1 RNA and P-gp (but not MRP), and 
are relatively resistant to doxorubicin as well as to various other chemotherapeutic 
agents. Doxorubicin resistance in this cell line is stable despite long periods of growth 
in drug-free medium. 
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Radiopharmaceuticals
18
Fluoro-2-deoxy-D-glucose (FDG): 
18
Fluoro-2-deoxy-D-glucose was obtained commercially 
from Tyco Health B.V. Petten, the Netherlands. 
99mTc-Tetrofosmin (TF): Tetrofosmin kits were obtained commercially (Myoview®, 
Amersham Healthcare, UK). The labeling and quality control procedures were carried 
out according to the manufacturers instructions. The radiochemical purity of TF used in 
the present study was consistently higher than 95%. 
125I-Iodo-methyl-tyrosine (IMT): Synthesis of IMT was carried out essentially as described 
by Krummeich et al. 16. 133-µl Iodogen (0.75 mg/ml) was added in a glass reaction vial 
(Iodogen tube) and the chloroform was evaporated under a stream of nitrogen. 400 µl 
0.11 M borate buffer, pH 8.0 and 90 µl of L-alpha-methyl tyrosine (Sigma-Aldrich Chemie 
b.v., Zwijndrecht, the Netherlands) dissolved in 0.22 M borate buffer pH 1.7 were added. 
Subsequently 200-250 µCi of Na-125I was added. The reaction was allowed to proceed 
for 10 min at room temperature. The reaction mixture was transfered into a 1.5 ml vial 
and 250 µl of Na2S2O5 (2 mg/ml) in 0.11 M borate buffer, pH 8.0, was added. A Sep-Pak 
C-18 cartridge (Waters Corporation, Milford, MA, WAT051910) was activated with 15 ml 
ethanol and rinsed with 15 ml 5% ethanol in 0.9% NaCl.  The reaction mixture was loaded 
onto the conditioned Sep-Pak cartridge. The Sep-Pak cartridge was eluted with 13 ml 5% 
ethanol in 0.9% NaCl, fractions of 1 ml were collected. The carrier-free IMT eluted in the 
fraction 4-6. The RCP of the IMT was analyzed using an HPLC system with C-18 column 
(Zorbax Rx-C18, 4.6 x 25 cm) equipped with a radiodetector. H2O/ethanol/acetic acid 
(92.5/5/2.5) was used as eluens with a flow of 0.5 ml/min. Rf values were: L-α-methyl 
tyrosine precursor 2.75 min (UV 280 nm), free 125I 3.1 min and 125I-IMT product 10.1 min. 
Radiochemical yield was higher than 95%, with  a specific activity of 3612 GBq/mol.
5-[125I]Iodo-2’-deoxyuridine (IUdR): Non-carrier-added sterile 5-[125I]Iodo-2’-deoxyuridine 
(IUdR) (specific activity 74 TBq/mmol) was purchased from Amersham International 
(Bucks., UK). 
Drugs
Doxorubicin hydrochloride was obtained as Adriblastina RTU (2 mg/ml for injection) 
(Pharmacia and Upjohn, Woerden, The Netherlands). It was stored at 4 °C and protected 
from light. Verapamil hydrochloride (2.5 mg/ml) was purchased from Knoll AG, BASF 
Pharma, Ludwigshafen, Germany.
 Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals 195
In vitro assay
Cells were cultured at 37 °C, 5% CO2, in RPMI-1640 (Gibco, Life technologies, 52400-25) 
with 10% foetal calf serum (FCS) and 2 mM glutamine using 162 cm2 culture flasks. Cells 
(105 cells/ml) were seeded in 24-wells plates. The aim of the first series of experiments 
was to determine the optimal doxorubicin incubation schedule. Doxorubicin (escalating 
concentrations 0-1000 µM) was added starting at 72, 48 and 24 h before addition of the 
radiopharmaceuticals as presented in Fig. 1. Subsequently the medium was removed 
from the wells and cells were washed twice with saline. To each well 106 cpm/ml (1 
ml/well) 125I-deoxyuridineribose in RPMI-1640 + 0.5% BSA (Gibco, Invitrogen. Breda, 
the Netherlands), 125I-methyltyrosine in RPMI-1640 + 0.5% BSA, 18F-deoxyglucose 
in glucose-free-DMEM + 0.5% BSA or 99mTc-tetrofosmin in RPMI-1640 + 0.5% BSA, 
respectively was added. After 1 h of incubation at 37 ºC, cells were washed, swabbed 
and counted in a well-type gamma counter. The mean cell-associated activity of each of 
the radiopharmaceuticals following incubation in the absence of doxorubicin was set 
at 100%. The uptake at the various doxorubicin concentrations was expressed as the 
percentage of this activity.
Figure 1. Schematic representation of the incubation schemes of doxorubicin (escalating 
concentrations 0-1000 µM) used in the in vitro experiments.
MTT assay
In order to investigate whether tracer uptake indeed reflected cell proliferation, the 
mitochondrial dehydrogenase activity, and hence cell survival was measured using the 
MTT assay (3-[4.5-dimethylthiazol-2-yl]-2.5-diphenyltetrazolium bromide, Thiazolyl blue, 
Sigma Chemical Co, St. Louis, Mo, USA). Dissolved MTT is converted to an insoluble 
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purple formazan by cleavage of the tetrazolium ring by mitochondrial dehydrogenases 
of viable cells, and the absorbance of the solubilized formazan solution is proportional to 
the number of viable cells. Cell surivival of both cell lines (MES-SA 1976 and MES-SA/Dx5 
1977) at doxorubicin concentrations of 0-1 µM, was expressed relative to their controls 
in the absence of any treatment. Cells were seeded into 24 well plates (in triplicate) at 
a density of approximately 3x104 cells per well in RPMI-1640 with 10% FCS and 2 mM 
glutamine for 48h. At 48h the medium was replaced by doxorubicin (concentrations 0-1 
µM) in RPMI-1640 for an exposure period of 48 h. Then cells were washed with saline 
and the MTT stock solution (5 mg/ml in RPMI-1640 without phenol red with 10% FCS 
and 2 mM glutamine) was added to each well (320 µl/well) and incubated for 5 h at 37 °C. 
At the end of the incubation period the medium was removed, cells were washed twice 
with saline and the converted dye was solubilized with 1 ml 0.01 N HCl/10% SDS during 
16 h at 37 °C. Absorbance of converted dye was measured at a wavelength of 570 nm. 
Results
MTT assay
MTT results provide evidence that 48 h exposure to doxorubicin could induce reproducible 
cell death at escalating doxorubicin concentrations (0-1 mM) to an increasing extent, 
with an obvious difference between the MDR- cells and MDR+ cells. Measurements 
of relative cell survival compared to untreated control cells showed that doxorubicin 
induced 80% cell death at 1 µM in the MDR- cells, compared to only 5 % at 1 µM in the 
MDR+ cells.  
Experiments to determine the most optimal incubation scheme
The aim of the first series of experiments was to determine the schedule to expose 
cancer cells to doxorubicin that would lead to the most pronounced effect on the 
uptake of each of the radiopharmaceuticals. Fig 2 demonstrates the results of the five 
different doxorubicin incubation schemes measured with FDG. The most pronounced 
difference in reduction of FDG uptake between the MDR+ and MDR- cell line at low 
doxorubicin dose levels (0.1-1.0 µM) was seen with the incubation schemes 2, 3 and 4. 
This also applied for IMT and IUdR. Based on these observations, scheme number 4 (48 h 
doxorubicin exposure, followed by 1 h incubation with each of the radiopharmaceuticals) 
was chosen for future experiments. In this scheme there is no delay between incubation 
with doxorubicin and addition of radiopharmaceuticals,  avoiding tumor cell recovery. 
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The FDG uptake at escalating doxorubicin doses (Fig 2) correlated with the 
chemosensitivity of the cells: FDG uptake of the MDR- cells declined at lower doxorubicin 
concentrations compared to that of MDR+ cells. To reach the same reduction of FDG 
uptake a 10-fold higher doxorubicin concentration was needed in the MDR+ cells. 
Higher doxorubicin levels (>100 µM) were cytotoxic to both cell lines, regardless of their 
chemosensitivity. 
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Figure 2. These graphs demonstrate the results of the five different doxorubicin incubation 
schemes as shown in Fig. 1 measured with FDG. 
The results from the IUdR and IMT experiments showed an even more pronounced 
effect (Fig. 3). In the chemo-sensitive cells IUdR uptake was reduced to zero at a 100-
fold lower dose than the chemo-resistant cells (1 µM compared to 100 µM). With IMT 
this was almost a 1000-fold (1 µM compared to 1000 µM).
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99mTetrofosmin (TF) differed from the other three radiotracers in some aspects. Since the 
amount of uptake of this tracer reflects the P-gp activity, there is no need to expose the 
cells to doxorubicin in the assay. In order to measure P-gp activity just the percentage 
of uptake of TF in the absence of doxorubicin are of interest. Baseline TF uptake of the 
MDR+ cells was more than 6-fold lower compared to that in MDR- cells, presumably due 
to enhanced P-gp activity of MDR+ cells.
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Figure 3. Results of doxorubicin incubation scheme 4 (see Fig. 1). Measurements with 125I-
Methyltyrosine (A) and 125IUdR (B).
Effects of verapamil 
In the second series of experiments the effect of the P-gp antagonist verapamil on 
the effect of doxorubicin on tracer uptake was investigated. In the first experiment a 
suitable verapamil concentration was determined for these experiments. Both cell lines 
were incubated with escalating verapamil concentrations (1-125 µg/ml) in the absence 
of doxorubicin (Fig. 4). At the two highest verpamil concentrations tested (25 and 125 
µg/ml) the FDG uptake of the cells was reduced and therefore 5 µg/ml verapamil was 
used in further experiments.  
Subsequently, the effect of verapamil (5 µg/ml) on cell viability at various doxorubicin 
concentrations was tested in the MTT assay (Fig. 5). Verapamil had only a limited 
effect on the number of viable cells. In the presence of verapamil the MDR+ cells were 
more susceptible to high concentrations of doxorubicin (10-100 µM). Interestingly, the 
number of MDR- cells at low doxorubicin concentrations (0.1-1 µM) was also reduced by 
verapamil. Verapamil only slightly affected cell viability when cultured in the presence 
of doxorubicin.
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Figure 4. Effect of the verapamil concentration on the FDG uptake of MDR- and MDR+ cells. 
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Figure 5. Effect of verapamil (5 µg/ml) on the cell numbers following incubation at escalating 
doxorubicin concentrations as measured in the MTT assay.
In contrast, the reversal of the drug-resistance by verapamil was clearly reflected by the 
uptake of FDG, IUdR and IMT. Fig 6A shows that FDG uptake in the MDR+ cells was 
markedly reduced due to the presence of verapamil. In fact, based on the FDG uptake 
the MDR+ cells became almost as sensitive to doxorubicin as the MDR- cells. The uptake 
of FDG was markedly reduced in the MDR+ cells when verapamil was coincubated: from 
79% to 18% at 1.0 µM doxorubicin. Although less pronounced, this effect of verapamil 
was also observed with the MDR- cells: from 48% to 3% at 1.0 µM doxorubicin. The 
same trend was observed with IUdR and IMT (Fig. 6B and 6C). The effects on TF uptake 
were less apparant (Fig. 7). In the absence of verapamil the uptake of TF was 0.13% ID 
in the MDR+ cells compared to 0.87% ID in the MDR- cells, whereas in the presence of 
verapamil these values were 0.19% ID and 1.43% ID respectively. 
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Figure 6. 18FDG-, 125IUdR- and 125I-Methyltyrosine uptake at escalating doxorubicin doses in MDR- 
and MDR+ cells in the presence and absence of verapamil.
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Figure 7. 99mTc-tetrofosmin uptake of the MDR+ cells was lower than of MDR- cells. 99mTc-
tetrofosmin uptake increased in the presence of the modulator verapamil.
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Discussion
The results of this study show that 18Fluoro-2-deoxy-D-glucose (=FDG), 5-[125I]Iodo-2’-
deoxyuridine (=IudR) and 125I-Iodo-methyl-tyrosine (=IMT) uptake is more pronouncedly 
reduced after exposure to doxorubicin in MES-SA cells that are drug sensitive as 
compared to MES-SA cells that are drug resistant. The difference between the sensitive 
and resistant cell line was displayed most pronouncedly by IUdR. The results from the 
MTT assay showed that tracer uptake reflected cell viability. Exposure to doxorubicin 
induced a reduction in cell mitochondrial dehydrogenase activity, which was more 
pronounced in the MDR- cells. In these assays  the radiopharmaceuticals FDG, IMT 
and IUdR had similar features. First, all showed a clear discrimination in uptake pattern 
between the sensitive and the resistant cell line. Second, the effect was reversed 
by addition of a P-gp-modulator. The three radiopharmaceuticals, also had various 
distinctive features, which makes each of them unique. 
Radiopharmaceuticals originally developed for diagnosis of cardiac viability could 
be used as sensitive tool for the detection of MDR. 99mTc-tetrofosmin (= TF) was the 
first radiotracer studied for this application. As compared to FDG, IMT and IUdR, TF 
potentially has the advantage that it can be used before starting chemotherapy. The 
other three radiopharmaceuticals reflect the change in cell metabolism or proliferating 
activity after exposure to doxorubicin, which is essentially different from TF-
accumulation which is based on functional imaging of P-gp. Our results show that a 
reduced intracellular accumulation of TF is seen in resistant cells as compared to their 
drug-sensitive counterpart. Unexpectedly, the reduced uptake of TF in MDR+ cells was 
only minimally enhanced when verapamil was coincubated. Possibly due to the relatively 
high P-gp expression on these cells verapamil could not effectively enhance intracellular 
TF accumulation. Interestingly, the MTT assay showed coincubation of verapamil hardly 
affected the number of viable cells. In contrast, the cellular uptake of FDG, IMT and 
IUdR was marked reduced when verapamil was added, indicating that verapamil reduced 
the metabolic functions of the cells (glycolytic acitivity, aminoacid transport and DNA 
synthesis, respecitively) rather than affecting the number of cells. 
18Fluoro-2-deoxy-D-glucose (=FDG) was chosen as an indicator for cell metabolic activity. 
FDG enters normal and malignant cells using the same transport mechanisms as glucose 
and is trapped intracellularly because of its low dephosphorylation rate. The increased 
rate of glycolysis in tumor cells enhances the uptake of FDG relative to normal cells. The 
therapeutic effectiveness of cancer treatment by radiotherapy and chemotherapy is 
usually evaluated by morphologic changes in tumor size examined by X-ray studies, CT, 
ultrasound or MRI. An advantage of FDG-PET over these anatomic-structure imaging 
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modalities, is the ability to distinguish active or recurrent disease and residual scar 
tissue after therapy. The most important advantage of FDG is that metabolic alterations 
of tumor cells, indicative of tumor response to therapy, may occur before alterations in 
tumor size. Our results show that FDG is able to differentiate between the MDR+ cells 
and MDR- cells, i.e. FDG uptake decreased more pronouncedly in the responding cells. 
Studies on small numbers of patients suggest that FDG uptake decreases in responding 
lesions, although a correlation between FDG uptake and the P-gp status of tumors has 
not yet been established 17-21. 
Another relevant target for functional tumor imaging is the uptake of amino acid 
analogs in cancer cells for which radiolabeled amino acids, like 125I-Iodo-methyl-tyrosine 
(=IMT), can be applied. It is known that IMT shows a favourable normal distribution. 
Physiological low uptake is found in the brain, liver and spleen, but intense uptake in 
the kidneys and urinary system, since it is renally excreted 22. The results of our in vitro 
experiments showed that the suppression of cell proliferation by doxorubicin can be 
measured using IMT.
The potential for obtaining functional images of DNA synthesis using PET and SPECT 
has been recognized for some time 23. Halogenated thymidine analogs such as IUdR can 
be used as cell proliferation markers for in vitro studies because these compounds are 
rapidly incorporated into newly synthesized DNA. In vivo, the use of IUdR is limited due 
to the moderate image quality and the inaccurate calculation of proliferation rates, due 
to its rapid in vivo degradation. The C–N glycosidic bond of IUdR is not stable in vivo, 
which leads to metabolites with reduced tumor affinity 24. The attractive aspect of IUdR 
is that the uptake of IUdR reflects DNA synthesis and hence the proliferative status of 
tumors and normal tissues. In our experiments IUdR displayed the most marked relative 
reduction in MES-SA cells that respond to exposure to doxorubicin, as compared to FDG 
and IMT. 
Clinically it is also important to detect and evaluate multidrug resistance transporter 
activity in tumors, since this could also be utilized as a tool in identifying patients who 
may benefit from combined therapy with P-gp or multidrug resistance-associated protein 
(MRP) modulators as well as in the evaluation of the effectiveness of such treatment in 
vivo. It might also allow selection of the proper modulator for the individual patient. A 
number of drugs have been identified (e.g., calcium channel blockers, anti-arrhythmics, 
antidepressants, and many others) which can reverse P-gp-mediated MDR. These 
drugs (e.g. verapamil, quinidine, and cyclosporin A) sensitize MDR tumor cells to co-
administered cytotoxic agents. However, many of them are of limited clinical use due to 
side effects in the relevant doses 25. Clinical trials of inhibitors have often been hampered 
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by the inability to document multidrug resistance in solid tumors of individual patients 
26. It may be valuable to assess the effect of a modulator on both tumor tissue and 
normal tissues in each individual patient prior to treatment, not only to choose the most 
effective modulator or combination of modulators in clinical trails, but also to determine 
the most effective dose combined with the least toxicity of anticancer drugs. Response 
to doxorubicin was affected by the presence or absence of verapamil. This could clearly 
be measured with FDG, IMT as well as with IUdR. However, in contrast to other studies 
27 in the present study verapamil did not dramatically increase the accumulation of TF 
in the MDR+ cells. 
Conclusion
The present study shows that FDG, IUdR and IMT uptake is more pronouncedly reduced 
in MES-SA cells that respond to exposure to doxorubicin than in cells that do not. IUdR 
displayed the most marked relative reduction. Unlike these three radiopharmaceuticals, 
TF shows these differences before exposure to doxorubicin, reflecting the expression 
of the MDR1 gene. The P-gp modulator verapamil is able to reverse the doxorubicin 
resistance which could be measured with three out of four radiopharmaceuticals. These 
findings warrant comparative studies in in vivo tumor models.
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Abstract
Purpose: There is growing interest in applying FDG-PET for chemotherapeutic response 
evaluation. To determine changes in tumor metabolism with time, accurate quantitative 
results are required. Consequently, dynamic scanning should be applied to determine a 
tumor time-activity curve and a plasma time-activity curve, for which arterial sampling 
is the commonly accepted gold standard. Arterial sampling, however, is an invasive 
procedure, and less suitable for repetitive use in patients undergoing chemotherapy. 
The aim of the present study was to validate a noninvasive image derived method to 
determine the input function from PET images. 
Methods: 136 dynamic FDG-PET scans were obtained in 76 oncological patients. Image-
derived input functions (IDIFs) were obtained using volumes of interest of the left 
ventricle, the ascending aorta and the abdominal aorta. Calculation of the metabolic rate 
of glucose (MRGlu) in tumor lesions as determined with the Patlak graphical analysis 
using these IDIFs, have been compared with measurements using the arterial plasma 
time-activity curve as the gold standard. 
Results: MRGlu values using the IDIF of the ascending aorta, the left ventricle or the 
abdominal aorta, showed a strong relationship with MRGlu based on arterial sampling. 
The comparability between the measures was also high, with the intraclass correlation 
coefficient being 0.98 (95% confidence interval: 0.97-0.99) for IDIF ascending aorta, 
0.94 (0.92-0.96) for IDIF left ventricle and 0.96 (0.93-0.98) for IDIF abdominal aorta.
Conclusion: Good correlations were observed between MRGlu values based on IDIFs 
and those based on arterial sampling. Uncorrected image-derived methods are accurate 
and simple, can be applied in oncological therapy monitoring studies and thus represent 
a clinically viable alternative to arterial blood sampling. 
Introduction
Positron emission tomography with fluorine-18 fluorodeoxyglucose (FDG-PET) is a 
highly valuable diagnostic tool for detection, staging and surveillance of a variety of 
primary and recurrent tumors 1-3. For these applications, a qualitative and/or semi-
quantitative image interpretation has been found sufficient in most cases. In recent 
years, however, there is growing interest in applying FDG-PET for chemotherapeutic 
response evaluation. Conventional imaging modalities, like computed tomography (CT) 
and magnetic resonance imaging (MRI), currently used to monitor therapeutic effects 
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in oncology, are based on morphologic changes. However, it is assumed that metabolic 
changes precede changes in lesion morphology and, therefore, techniques that image 
metabolism rather than anatomy might more accurately monitor response and overall 
treatment outcome, and could possibly assist in making early decisions regarding the 
course of therapy. In contrast to staging studies, chemotherapy response monitoring 
studies may require quantification in order to accurately determine changes in tumor 
metabolism with time. For accurate quantitative results, dynamic kinetic analyses 
require analysis of the radiopharmaceutical’s blood clearance and uptake in the target 
tissue, i.e. the tumor. Consequently, dynamic scanning should be applied, in order to 
derive time-activity curves for both the tumor and the plasma. For the latter arterial 
sampling is the commonly accepted gold standard 4-10. 
Arterial sampling, however, is an invasive procedure, and less suitable for repetitive use in 
patients undergoing chemotherapy. The radial artery is occasionally difficult to cannulate, 
and especially after multiple cannulation sessions, considerable experience and technical 
expertise is required. The procedure may be cumbersome to the patient, while being 
generally safe. However, in a small number of cases it is associated with morbidity, 
since it may cause complications such as thrombosis, hemorrhage, pseudoaneurysm 
formation, infection, nerve injury and limb ischemia 11. Moreover, it is not always 
feasible to perform arterial cannulation during the follow-up scans, since a substantial 
proportion of patients experience chemotherapy-induced thrombocytopenia, which is 
considered a contraindication for arterial cannulation. The measurement of the samples 
is quite laborious and not always feasible in a busy clinical environment where patient 
throughput is high. For all these reasons, arterial cannulation is less suitable for routine 
clinical response studies, where repetitive scans are required. An alternative method used 
for characterization of the input function is blood time-activity curves derived from the 
PET images, using volumes of interest (VOIs) on large vascular structures such as the 
left ventricle or the aorta. These image-based methods are attractive because they are 
noninvasive and, if validated, can make the quantification reliable and practical. It must 
be emphasized, however, that image-derived input functions (IDIFs) potentially suffer 
from low signal-to-noise ratios, from partial volume and spillover problems, and that the 
method is more susceptible to patient movement as a potential source of further error 
10,12,13. Therefore, it is necessary to assess the accuracy of FDG-PET measurements based 
on different input functions before FDG-PET can be applied for therapy monitoring in 
routine clinical practice. In the present study, calculation of the metabolic rate of glucose 
(MRGlu) using noninvasive IDIFs obtained from several large vascular structures have been 
compared with calculations using the arterial plasma time-activity curve as a reference. 
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Materials and methods
Patient Population
From March 2002 to August 2005, 136 dynamic FDG-PET scans were obtained in 76 
oncological patients (47 males, 29 females) with a mean age of 63 years (range 33 
to 79 years) as part of a larger protocol to monitor the effects of chemotherapy. The 
patient population comprised of 36 patients with metastatic colorectal carcinoma, 37 
patients with metastatic non-small cell lung carcinoma and 3 patients with metastatic 
breast carcinoma. For all 136 evaluated scans arterial sampling derived input functions 
were obtained. Exclusion criteria were diabetes mellitus and pregnancy. The study 
was approved by the Institutional Review Board of the Radboud University Nijmegen 
Medical Centre and written informed consent was obtained from each patient. 
A total of 367 input functions were analyzed to calculate a MRGlu, of which 136 were 
arterial sampling derived, 79 ascending aorta image-derived, 98 left ventricle image-
derived and 54 abdominal aorta image-derived. In 64 scans, both the heart and ascending 
aorta and in 32 scans both the heart and abdominal aorta could be included in the same 
field of view. In 15 scans only the ascending aorta, in 22 scans only the abdominal aorta 
and in 2 scans only the heart could be included in the same field of view as the primary 
tumor or measurable metastases. 
Patient Preparation
Prior to FDG-injection, patients were fasted for at least 6 hours. Intake of non-calorie 
beverages was permitted. Cannulas were inserted in an antecubital vein (18-gauge 
cannula) for FDG-injection and in a radial artery (20-gauge cannula) for blood sampling. 
The arterial cannula was inserted after patency of the ulnar artery had been checked 
by the Allen test and after local anesthesia with lidocaine. Blood glucose levels were 
measured (hexokinase method, Aeroset, Abbott diagnostics, Illinois, USA) before FDG 
injection. All were within the normal range in all patients.
PET Image Acquisition
All scans were acquired on an ECAT-EXACT47 PET scanner (Siemens/CTI, Knoxville, TN, 
USA) producing 47 planes over an axial field of view of 16.2 cm. Patients were positioned 
supine and a location for the dynamic acquisition was chosen that multiple inclusion 
of as many measurable tumor lesions in the field of view as possible, as determined 
on previous CT scans and whole-body FDG-PET. After a scout transmission scan to 
verify patient positioning, a 20-min transmission scan was made, using the internal 
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68Ge/68Ga sources, to correct for photon attenuation. Subsequently, approximately 
200 MBq FDG dissolved in 8 mL saline was injected intravenously over a 1-min period, 
using a constant infusion remote-controlled pump (Medrad, Indianola, PA), followed 
by a 40-mL saline flush at a rate of 8 mL/s to ensure complete delivery of FDG. The 
dynamic data acquisition, performed in septa-extended (2-dimensional) mode, was 
started simultaneously with the injection of FDG and consisted of 16 time frames with 
variable frame length (10x30 s, 3x300 s, 3x600 s) for a total time of 50 min. All images 
were decay corrected to the start time of the first frame of the dynamic series. The 
emission and transmission sinograms were corrected for randoms. Scatter correction 
based on measured scatter fractions as implemented in the ECAT 7.2.1. software for 2D 
reconstructions was used. Attenuation-corrected images were reconstructed in 128x128 
matrices using filtered backprojection with a Gaussian filter of 4 mm full width at half 
maximum (FWHM). This resulted in 47x3.375 mm slices for each frame, with a pixel size 
of 3.432-mm and spatial resolution of 6-mm FWHM in the reconstructed images.
Arterial Blood Sampling
Arterial blood samples were taken manually at set times to provide an arterial plasma 
input function. Immediately after the start of tracer injection, when blood activity 
concentrations varied mostly, seven arterial blood samples (2 mL) were drawn at 15-sec 
intervals. The next arterial blood samples were drawn at 135 sec, 165 sec, 225 sec, 285 sec, 
7.5 min, 12.5 min, 17.5 min, 25 min, 35 min and 45 min post-injection. The radioactivity in 
plasma (circa 500 µL, obtained by centrifugation) was determined using the standard 
solution method as described by Greuter et al. 14. Blood samples and standard solution 
were weighed using an AC100 balance (Mettler-Toledo, Zurich, Switzerland). A 
VDC404 dose calibrator (Veenstra Instruments BV, Joure, The Netherlands) was used 
for measuring activity in syringes and a well-type gamma counter (Wallac 1480 Wizard, 
Perkin Elmer Lifescience, Zaventem, Belgium) was used for determination of activity 
concentrations from the weighed blood samples.
Image-Derived Input Function (IDIF)
The image-based input functions were determined by measuring FDG counts in VOIs 
over the heart, ascending aorta or abdominal aorta, depending on the body location of 
the study. An early time frame (frame 3, i.e. 60-90 sec post injection) was used, in which 
the bolus of activity was best visualized, and time-activity curves were created using 
VOIs that consisted of several regions of interest drawn over the blood pool area in 
as many planes as possible. For VOI definition in the ascending- and abdominal aorta 
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a semiautomatic threshold-based region-growing program was used. All VOIs were 
confirmed visually. For VOI definition in the heart, VOIs were drawn manually on the 
left ventricular cavity. The VOIs for the left ventricle were copied to the last time frame 
to check for possible contamination from myocardium uptake. In order to minimize 
spillover and partial volume effects, these regions were placed at least two pixels (≈ 7 
mm) apart from the myocardial wall.
Tumor Time-Activity Curves
Tumor time-activity curves were obtained by placing VOIs semiautomatically over the 
tumor and metastases using a threshold of 50% of the maximum pixel value within the 
lesion. The locations of the lesions were evaluated visually on the transaxial, coronal, 
and sagittal images. For this purpose the late frames (frame 14-16) were summed, 
yielding a static image of 30 min and a scan mid-time of 35 min post injection. The tumor 
VOIs were then copied to the dynamic imaging sequence to obtain time-activity curves. 
The same tumor VOIs were used for both image-derived and arterial-blood sampling 
derived Patlak plots, to eliminate any effect of variability due to VOI size or placement 
on the comparison of the invasive and noninvasive methods. A volume weighted mean 
value of all lesions in each PET scan was derived to provide one MRGlu for each study. 
Tumors with high FDG-uptake, as well as tumors with low metabolic activity due to 
chemotherapy response, were included in the evaluation. 
Patlak Graphical Analyses  
Patlak graphical analysis 15 was used to compare the MRGlu in the tumor and/or 
metastases, calculated from both IDIF and arterial sampling. Data from the literature 16-18 
have shown that for each of the three tumor types studied (colorectal carcinoma, non-
small cell lung carcinoma (NSCLC) and breast cancer) the presence and possible effect 
of a fourth rate constant (k4) could be neglected and that this mathematical model in 
these tumor types proved to be an appropriate alternative to compartmental analysis 
4,10,19,20. Patlak graphical analysis is based on the assumption that the ratio of the tracer 
concentration in tissue to that in plasma increases linearly when plotted as a function 
of normalized time. This linear relationship follows directly from the FDG model when 
the free tissue FDG concentration is constant and unidirectional transport, i.e. trapping 
of FDG can be assumed. This assumption in practice occurs about 5 min post injection. 
The Patlak analysis was performed over the period from 5 to 50 min after injection. 
Furthermore, the MRGlu (expressed in µmol.mL-1.min-1) in tumor was calculated by 
multiplication of the slope of the Patlak-plot (K1k3.(k2+k3)
-1) and the basic blood glucose 
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level (expressed in µmol.mL-1). In this study the lumped constant used was set to 1 and 
was assumed to be constant over time, because no studies on the actual value of the 
lumped constant in tumors outside the central nervous system have been reported 
yet. The fractional blood volume in tumor was set to zero. More details of the Patlak 
graphical analyses and its assumptions can be found elsewhere 15.
Statistical Analysis
The MRGlu in the tumor/metastases, calculated from the arterial sampling derived input 
function, served as the standard of reference for the analysis. Intraclass correlation 
coefficients (ICC) were estimated as a statistic to express the comparability between 
MRGlu values obtained with IDIFs and the reference data. In addition, regression analysis 
was performed to predict the IDIF-derived MRGlu values based on the reference data 
and to estimate the slope of the function of the relationship between the measures.
To investigate the influence of myocardial uptake the same analyses have been 
performed on the IDIF of the left ventricle subdivided in a group without and a group 
with myocardial uptake.
Results
MRGlu based on the IDIF of the ascending aorta (Fig. 1A), the IDIF of the left ventricle 
(Fig. 1B) and the IDIF of the abdominal aorta (Fig. 1C) showed a strong relationship 
with MRGlu based on arterial sampling. The comparability between the measures was 
also high, ICC being 0.98 (95% confidence interval: 0.97-0.99) for IDIF ascending aorta, 
0.94 (0.92-0.96) for IDIF left ventricle and 0.96 (0.93-0.98) for IDIF abdominal aorta. The 
slopes of the three scatterplots showed a slight systematic deviation of 6-8%, intercepts 
were near zero (Fig. 1). No differences in distribution were observed between each of 
the three types of cancer (NSCLC, colon cancer, breast cancer) as indicated in figure 1.
Comparability for MRGlu based on the IDIF of the left ventricle and the ascending aorta 
was 0.95 (95% confidence interval: 0.92-0.97). For MRGlu based on IDIF left ventricle 
and abdominal aorta the ICC was also 0.95 (0.90-0.97).
Figure 2 shows the scatterplots of the MRGlu based on the IDIF of the left ventricle 
in patients without (Fig. 2A) and with myocardial FDG-uptake (Fig. 2B), versus arterial 
sampling based MRGlu. For the group without myocardial FDG-uptake (n=59) the ICC 
was 0.95 (0.92-0.97). The ICC for the group with myocardial FDG-uptake (n=39) was 0.94 
(0.89-0.97).
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Figure 1. Scatterplots of MRGlu expressed in µmol.mL-1.min-1, as calculated using IDIF ascending 
aorta (A) or IDIF left ventricle (B) or IDIF abdominal aorta (C) to that using the arterial sampling 
derived input function. 95% Prediction intervals are indicated by dotted lines. Different symbol 
colors represent different types of cancer lesions.
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Figure 2. Scatterplots of MRGlu values based on the IDIF of the left ventricle versus MRGlu values 
based on arterial sampling, for the group without (A) and with FDG-uptake in the myocardial wall (B).
Discussion
In the present study calculations of MRGlu using IDIFs derived from the ascending 
aorta, the left ventricle and the abdominal aorta have been validated against arterial 
blood sampling, which served as the reference method. Highly significant correlations 
have been observed for each of the three IDIF methods. The slopes of all three 
scatterplots (Fig. 1) were close to one, with intercepts near zero, which means that the 
distribution of the values showed no large systematic deviation. Also, the intraclass 
correlation coefficients for MRGlus estimated by the three types of IDIFs compared to 
arterial sampling derived MRGlus were excellent, indicating that the use of IDIFs is an 
accurate method for measuring glucose consumption compared to arterial sampling. 
The IDIF ascending aorta did not show any prominent outliers and showed the highest 
correlation with the gold standard. The advantage of using the ascending aorta is the 
possibility of defining larger VOIs, thus providing data with better statistical properties 
and lack of spillover from potentially high uptake tissues such as myocardium. Partial 
volume effects, however, remain possible.
Our findings are in line with findings of van der Weerdt et al. 4. They evaluated the 
accuracy of IDIF from the left ventricle, left atrium and ascending aorta in 18 cardiac 
FDG-PET studies. IDIFs are frequently used in cardiac FDG-PET studies for calculation 
of the myocardial MRGlu. Using the left atrium is standard practice in cardiology, but is 
more difficult in oncological studies due to poor FDG-uptake after a 6-h fasting period, 
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making it difficult to accurately localize the atrium. Potential spillover effects from the 
myocardium will be less than in cardiac FDG-PET and therefore results obtained from 
such cardiac studies 4,9,10,12,13,19 cannot be extrapolated directly to FDG-PET for oncological 
applications.
In therapy response monitoring studies, IDIFs from large vascular structures or the left 
ventricle are already used 21,22. However, the obtained data are rarely validated against 
the gold standard. Although the validity of using IDIFs has previously been evaluated 
in a number of studies, using other PET radiopharmaceuticals than FDG 5-7,23-26, and in 
several studies in dogs, mice, rabbits and pigs 8,23,26-29, similar work has not been carried 
out for FDG in large numbers of oncological patients. To date, the largest study which 
validates IDIFs against arterial sampling was done by van der Weerdt et al. who included 
18 patients for cardiac FDG-PET 4. Thus, there is a need to validate the use of IDIFs for 
oncological application. The present study suggests that the use of uncorrected IDIF 
methods provides accurate data, which can be translated to clinical practice. 
A number of factors could affect the accuracy of IDIFs. IDIFs potentially suffer from 
partial volume effects. Furthermore, the left ventricular curve can contain spillover 
from the myocardium, due to the limited spatial resolution of PET scanners and cardiac 
movement. This can affect the tail of the input curve and lead to substantial errors in 
MRGlu values. Time shifts between the true arterial input function and the measured 
IDIF can also result in errors. Furthermore, patient movement is an other potential 
source of error in determining IDIFs. In addition, noise could be introduced by the 
limited number of counts acquired in each time frame. Especially small VOIs suffer 
from higher noise levels. Finally, manual VOI definition of the vascular structures could 
introduce inter- and intraobserver variability. 
For accurate estimations of glucose consumption, many corrections can be applied. 
Several methods have been reported for correcting left ventricular time-activity curves 
for partial volume effects 10,12,13. Partial volume effects can be corrected by estimating 
the diameter of the vessel via activity profile analysis with non-linear regression 
techniques. The dependency of the final recovery coefficient on the filter used in the 
image reconstruction process can be determined analytically 30. The disproportional raise 
in activity in the tail of the left ventricle IDIF could be corrected by using information 
from independent venous blood samples in later time frames 9,20. The use of arterialized 
venous samples after increasing the temperature of the hand or forearm to 43° C to 
minimize arteriovenous differences, has been described 31. The blood volume in a tumor 
generally gives an unknown contribution to the tumor PET signal.  Therefore, the use of 
blood volume corrections is another parameter that can influence diagnostic accuracy 
32. Fractal dimension may help to quantify heterogeneity. Increased fractal dimension is 
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indicative of a more chaotic distribution of FDG 32. The application of factor analysis, a 
method by which it is possible to generate an input function from smaller vessels, also 
appears promising but needs further evaluation 33. 
In general, arterially sampled and uncorrected image-derived input functions will differ. 
When only the partial volume effect is of importance, the IDIF-curve will be isomorphic 
to the arterially sampled curve, as illustrated in Fig. 3A. Thus, for all time points the IDIF 
activity concentrations will be lower than the arterially sampled ones by the same factor 
f (f < 1). As can immediately be concluded from the Patlak equation this will result in an 
IDIF-derived MRGlu value that is higher by 1/f as compared to the one derived from 
arterially sampled values:
where: CT(t) = tumor activity concentration; Cp(t) = blood plasma activity concentration 
K1, k2, k3 are the rate constants as defined in the two-compartment FDG model without 
trapping.
On the other hand, for cases where trapping of FDG occurs, e.g. in the myocardium or in 
blood vessel walls, and partial volume effects are small, the IDIF and arterially sampled 
values will be equal up to the time point where the relative contribution of trapped 
FDG can be neglected. For later time points, however, the IDIF values will exceed the 
arterially sampled values (Fig. 3B). This trapping effect will lead to lower MRGlu values 
for IDIFs as compared to arterial sampling. Obviously, in clinical practice, both effects 
may be present, leading to slope values > 1 when the partial volume effect is predominant, 
and to slope values <1 when trapping is predominant (Fig.1 and 2). It is clear that for both 
aorta-derived input functions the partial volume effect dominates (slopes > 1) whereas 
for the left ventricle-derived input functions the trapping effect is stronger (Fig. 1). This 
effect is further elucidated as the MRGlu values based on the left ventricle derived 
input functions lead to a slope of 0.98 in case of absent myocardial FDG-uptake (Fig. 
2A), and to a slope of 0.88 when high myocardial uptake is present (Fig. 2B).
The use of IDIF methods is most attractive if they are not laborious and are not based 
on many assumptions. Each manipulation of raw data could introduce human error and 
makes the method prone to black box problems. Because PET scanners have undergone 
considerable technical improvement over the past decade (higher spatial resolution, 
increased field of view) corrections should be avoided whenever possible. While some 
errors are expected, due to the above mentioned problems, the benefits from having a 
clinically usable, fast and noninvasive procedure, which does not depend on calibration 
or conversion factors between PET and well counter data, in combination with the 
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presented high degree of similarity between the IDIF and arterially sampled based 
MRGlu values, suggests that this procedure is suitable for routine clinical application in 
dynamic FDG-PET chemotherapy monitoring studies.
Figure 3. Example of an IDIF left ventricle of a patient without myocardial uptake of FDG (A) and 
a patient with high FDG-uptake in the myocardial wall (B) compared to the arterially sampled 
input functions derived from the same dynamic dataset. In case A, where only the partial volume 
effect effected the IDIF, all time points are lower but the shape of the IDIF-curve stays isomorphic 
to that of the arterially sampled one. In case B, where trapping of FDG is predominant, the shape 
of the IDIF-curve stays isomorphic until the time where trapping cannot be neglected anymore 
and the IDIF-values start to exceed the arterially sampled ones.
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Conclusion
Despite a variety in potential errors when generating IDIFs, strong correlations were 
observed between MRGlu values based on IDIFs and based on arterial sampling. 
Uncorrected image-derived methods are accurate and simple, can be applied in 
oncological therapy monitoring studies and represent a clinically viable alternative to 
arterial blood sampling. 
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Abstract
Background: The aim of this prospective study was to evaluate the value of F-18-
fluorodeoxyglucose positron emission tomography (FDG-PET) for the assessment 
of chemotherapy response in patients with non-small-cell lung cancer (NSCLC). 
Furthermore, part of the objective of this study was to compare two methods to quantify 
changes in glucose metabolism.
Methods: In 51 patients dynamic FDG-PET was performed before and at 5-8 weeks into 
treatment. Simplified methods to measure glucose metabolism (SUV) and quantitative 
measures (MRGlu), derived from Patlak analysis were evaluated. The overall- and 
progression free survival with respect to MRGlu and SUV were calculated using Kaplan-
Meier estimates. Fractional changes in tumor glucose use were stratified by the median 
value and also the predefined EORTC metabolic response criteria and criteria applying 
cut-off levels similar to those of RECIST, were evaluated.
Results: When stratifying at the median value of ∆MRGlu and ∆SUV, the difference in 
overall- (p=0.017 for ∆MRGlu, p=0.018 for ∆SUV) and progression free survival (p=0.002 
for ∆MRGlu, p=0.0009 for ∆SUV) was highly significant. When applying the predefined 
criteria for metabolic response, the cut-off levels as also used for size measurement 
(RECIST) showed significant differences for ∆SUV between response categories in 
progression free- (p=0.0003) as well as overall survival (p=0.027).
Conclusion: The degree of chemotherapy-induced changes in tumor glucose metabolism 
as determined by FDG-PET is highly predictive for patient outcome, stratifying patients 
into groups with widely differing overall- and progression free survival probabilities. 
The use of FDG-PET for therapy monitoring seems clinically feasible, since simplified 
methods to measure tumor glucose use (SUV) are sufficiently reliable and can replace 
more complex, quantitative measures (MRGlu) in this patient population.
Introduction
Molecular imaging with F-18-fluorodeoxyglucose positron emission tomography (FDG-
PET) has an established role in the standard of care in presurgical staging of patients with 
non-small-cell lung cancer (NSCLC). The addition of FDG-PET to the diagnostic work-up 
has been shown to significantly reduce the number of futile mediastinoscopies and 
thoracotomies 1-3. FDG-PET has also demonstrated its potential in radiation treatment 
planning and detection of recurrent disease 4-7.
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Nowadays, there is an increasing interest in the role of FDG-PET beyond staging, 
such as the prediction of tumor response to therapy. Response assessment with 
morphological imaging techniques has limitations in reliably distinguishing necrotic 
tumor or fibrotic scar from residual tumor tissue 8. Indeed, final treatment outcome 
will be determined more by the biological aggressiveness of residual tumor than by its 
volume 9. Furthermore some new therapies may be cytostatic instead of cytoreductive, 
in which case successful treatment may not lead to a decrease in tumor size, and thus 
poses new demands on imaging modalities.
FDG-PET is ideally suited to overcome these kinds of problems. One of the advantages 
of FDG-PET is that it cannot only visualize but can also quantify FDG uptake to 
distinguish metabolically highly active from less active tumor tissues. Furthermore, 
metabolic alterations of tumor cells, indicative of tumor response to therapy, may occur 
before alterations in tumor size. Early prediction of tumor response is of particular 
interest in patients with advanced stages of NSCLC. Tumor progression during first-line 
chemotherapy occurs in approximately 30% of patients 10. Due to relatively slow tumor 
shrinkage as measured on morphological imaging modalities, a significant percentage 
of patients will continue to undergo toxic therapy for weeks without benefit.
In the present prospective study a design was used, which allowed for comparative 
analysis of different quantitative PET methods to measure tumor glucose use at various 
levels of complexity. Furthermore, prospective as well as posthoc definitions for 
metabolic response were assessed in order to evaluate the value of FDG-PET in therapy 
response monitoring of NSCLC.
Patients and methods
Patient eligibility criteria
Between March 2002 and December 2005 all patients in the Radboud University 
Nijmegen Medical Centre with any stage of NSCLC and measurable tumor lesions 
according to the Response Evaluation Criteria in Solid Tumors (RECIST), who were 
scheduled to undergo induction chemotherapy or chemotherapy in a palliative setting, 
were offered the opportunity to participate in the study. Initial staging was performed 
according to the guidelines of the American Society of Clinical Oncology 11. Exclusion 
criteria were diabetes mellitus or pregnancy. In all patients, treatment decision-
making was done by a multi-disciplinary team including cardio-thoracic surgeons, 
pulmonologists, medical oncologists, radiation oncologists, pathologists, radiologists 
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and nuclear medicine physicians. Clinicians had access to the pre-treatment staging 
static whole body PET-scan, but were blinded to the results of the dynamic FDG-PET 
scans. The study was approved by the Institutional Review Board of the Radboud 
University Nijmegen Medical Centre and written informed consent was obtained from 
each patient.
FDG-PET
Quantitative dynamic FDG-PET data acquisition and reconstruction
Dynamic FDG-PET was performed at baseline and after the second or third cycle of 
chemotherapy, depending on the chemotherapy regimen. The median interval between 
the clinical staging FDG-PET and the baseline dynamic FDG-PET was 3 days. Patients 
fasted for at least 6 h before imaging. Intake of noncaloric beverages was permitted. 
All scans were acquired on an ECAT-EXACT47 PET scanner (Siemens/CTI, Knoxville, TN, 
USA). The field of view for dynamic acquisition was based on whole-body FDG-PET and 
CT scans performed for initial staging, including as many measurable tumor lesions 
as possible. A 20-min transmission scan was made, using the internal 68Ge/68Ga 
sources, to correct for photon attenuation. Approximately 200 MBq FDG was injected 
intravenously over a 1-min period, using a constant infusion remote-controlled pump 
(Medrad, Indianola, PA). The dynamic data acquisition, performed in septa-extended (2-
dimensional) mode, was started simultaneously with the injection of FDG and consisted 
of 16 time frames with variable frame length (10x30 s, 3x300 s, 3x600 s) for a total time of 
50 min. A more detailed description of the data acquisition, reconstruction and analysis 
methods was published previously 12.
Plasma time-activity curves
To measure the blood clearance of FDG, plasma time-activity curves were derived from 
arterial blood sampling when feasible. Arterial blood samples were taken manually 
at set times to provide an arterial plasma input function as described previously 12. 
When arterial cannulation was contra-indicated or not feasible, an image-based input 
function was determined by measuring FDG counts in a volume of interest (VOI) over 
the ascending aorta, which accurately determines FDG blood levels 12.
Tumor Time-Activity Curves
Tumor time-activity curves were obtained by placing VOIs semiautomatically over the 
tumor and metastases using a threshold of 50% of the maximum pixel value within the 
lesion. Necrotic areas were excluded from the VOIs. A volume weighted mean value of 
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tumor glucose use (metabolic rate of glucose, further mentioned MRglu) of all lesions in 
each PET scan was derived to provide one value for each study. VOIs drawn on the first 
FDG-PET (before initiation of chemotherapy) were copied to the second FDG-PET (after 
2-3 cycles of chemotherapy).
Patlak Graphical Analyses
For quantitative measurement of glucose metabolism Patlak graphical analysis was used to 
calculate the MRGlu (expressed in µmol.mL
-1.min-1) in tumor tissue 13,14. A detailed description 
of the Patlak graphical analyses and its assumptions have been published elsewhere 12,13. In 
brief, the Patlak approach takes into account differences in the whole-body distribution 
of FDG at the time of scanning, which may affect the accumulation of FDG in the tumor 
tissue. Furthermore, the MRGlu in tumor was calculated by multiplication of the slope of 
the Patlak-plot and the basic blood glucose level (expressed in µmol.mL-1). Blood glucose 
level was measured (hexokinase method, Aeroset, Abbott diagnostics, Illinois, USA) before 
FDG injection. The fractional change in MRGlu between the FDG-PET at baseline and after 
2-3 cycles of chemotherapy was calculated.
Standardized Uptake Value
FDG-PET scans were also evaluated semi-quantitatively by standardized uptake value 
(SUV) analysis. SUVs normalized to injected activity and patients’ body weight were 
calculated from the mean activity concentration in the tumor VOIs between 40 and 
50 minutes post injection, which is the last time-frame of the dynamic scan. A volume 
weighted mean value of each PET scan was derived from all lesions to give one average 
SUV (SUVavg, hereafter mentioned SUV) for each PET scan. The percent change in SUV 
between the FDG-PET at baseline and after 2-3 cycles of chemotherapy was calculated.
Clinical Follow-Up
During and after treatment, patients were followed with clinical examination at regular 
intervals, chest CTs, X-rays and other imaging studies as clinically indicated. Tumor 
response was evaluated according to RECIST criteria without knowledge of the results 
of the PET studies. When recurrence was suspected or proven, patients were always 
restaged. The progression/relapse pattern and cause of death were determined in all 
cases. The date of local or distant progression was defined as the earliest date at which 
disease progression was confirmed, either clinically or by imaging or biopsy. Patients who 
were progression free at the closeout date (November 1, 2006) or who had died from 
any cause had their time to progression censored at that date. Survival was measured 
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from the date of the baseline PET scan to the date of death. Patients who were still alive 
at the closeout date had their survival censored to that date.
Statistical Analysis
Survival and progression free survival served as the standard of reference. Cox proportional 
hazards regression analysis was used to assess the predictive value of response evaluation 
with FDG-PET, as expressed in the percentage change in MRGlu and SUV between the 
FDG-PET at baseline and after 2-3 cycles of chemotherapy. The data have been adjusted 
for tumor stage at the time of the baseline PET scan. Statistical significance was assessed 
using the Wald’s chi-square test. The overall and progression free survival with respect to 
MRGlu and SUV were calculated using Kaplan-Meier estimates. The percentage change in 
measurements between the first and second scan were stratified by the median value to 
avoid data-driven significance for the cut-off level. However, stratification at the median 
value is still a post-hoc definition for metabolic response. To avoid this bias, also some 
predefined, prospective definitions of metabolic response were used. For that purpose 
the population was categorized according to the definitions for metabolic response 
of The European Organization for Research and Treatment of Cancer (EORTC), into a 
group with complete or partial response (∆<-25%), a group with stable disease (∆-25% 
to +25%) and a group with progressive disease (∆>+25%) 15. Furthermore the population 
was categorized according to the cut-off values also used for size measurement (RECIST), 
for which applies that ∆<-30% is complete or partial response, ∆-30% to +20% is stable 
disease and ∆>+20% is progressive disease 16. Groups were compared using the Breslow 
test. The Breslow test counts losses that occur early in the survival distribution more 
heavily than losses that occur late, because sample sizes are larger in early months relative 
to late months. Spearman’s rho correlations were used to determine the comparability 
between the different methods to measure glucose metabolism. Statistical tests were 
based on a two-sided significance level and the level of significance was set at 0.05.
Results
Patient characteristics
Sixty consecutive eligible NSCLC patients were included in this prospective study. 
After the first FDG-PET, 9 patients were excluded for several reasons; due to technical 
issues (n=1), refusal to undergo a second FDG-PET (n=2), death before the second 
FDG-PET (n=1) and early discontinuation of chemotherapy due to a significant decline 
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in performance status (n=5). Therefore, complete FDG-PET data sets (median interval 
between baseline and follow-up FDG-PET 49±17 days) were available in 51 patients (37 
males, 14 females; mean age 59 years, range 38-76 years) for analysis of the predictive 
value. Patient characteristics are summarized in table 1.
Table 1. Patient characteristics
Mean age 59 years (range 38-76 years)
Men 37
Women 14
Histology
Squamous cell carcinoma
Adenocarcinoma
Large cell carcinoma
Bronchoalveolar cell carcinoma
Clear cell carcinoma
21
24
4
1
1
Tumor differentiation
very poor
poor
intermediate
well
unspecified
13
6
7
1
24
Tumor stage
IB
IIA
IIIA
IIIB
IV
1
1
8
10
31
Treatment
15 patients were treated with induction chemotherapy and 36 patients were treated 
in a palliative setting. Of the latter 36 patients, 32 received chemotherapy in first line 
and 4 in second line. The chemotherapy regimens used were Carboplatin/Gemcitabine 
(n=27), Gemcitabine/Cisplatinum (n=9), Carboplatin/Etoposide (n=9), Cisplatinum/
Vinorelbine (n=2), Cisplatin/Etoposide (n=1), Triapine/Gemcitabine (n=1), Carboplatin/
Docetaxel (n=1) and Docetaxel (n=1). After induction chemotherapy (n=15), 2 patients 
underwent surgery, 10 patients were treated with radical radiotherapy and 3 patients 
were treated with radiotherapy with palliative intent because of progression during 
induction chemotherapy based on CT criteria.
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Patient Follow-Up
No patients were lost to follow-up. Median follow-up time was overall 13 months (range 
2-48 months), for surviving patients 20 months (range 9-45 months), and for deceased 
patients 9 months (2-48 months). During this time period, 38 patients had died and tumor 
progression was diagnosed in 45 out of the 51 patients. Median time to progression was 
7 months (range 0-39 months). Overall survival after baseline FDG-PET at 1 year was 
57%, at 2 years 36% and at 3 years 22%. Progression free survival after baseline FDG-PET 
at 1 year was 26%, at 2 years 17% and at 3 years 8%.
Quantitative Changes in FDG Uptake
Mean MRglu at baseline was 0.146±0.079 µmol.mL
-1.min-1 (range 0.028 to 0.356) and during 
evaluation 0.084±0.072 µmol.mL-1.min-1 (range 0.009 to 0.355). The median fractional 
change of MRglu as compared to baseline was -47%±55% (range -93% to +226%). Mean 
SUV at baseline was 5.27±2.51 (range 1.37 to 16.66) and during evaluation 3.72±2.75 
(range 0.71 to 16.64). The median fractional change of SUV as compared to baseline was 
-35%±42% (range -73% to +125%). 
Figure 1 shows a typical example of a patient with a stage IV NSCLC and tumor lesions 
who responded to chemotherapy. There is an 82% decrease in MRglu and a 65% decrease 
in SUV relative to baseline.
18FDG uptake measured with simplified methods (SUV) showed a significant correlation 
with MRglu as measured with the Patlak analysis (r=0.84, p<0.0001) at baseline, after 2-
3 cycles of chemotherapy (r=0.93, p<0.0001), as well as in terms of fractional changes 
after 2-3 cycles of chemotherapy (r=0.94, p<0.0001).
Figure 1. typical example of a patient with a stage IV NSCLC and tumor lesions who respond to 
chemotherapy. Relative to baseline [A], there is an 82% decrease in MRglu and a 65% decrease in 
SUV on FDG-PET after 2 cycles of Carboplatin/Gemcitabine [B].
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Prediction of survival by FDG-PET
To generate Kaplan-Meier survival curves, the decrease in tumor glucose metabolism 
was dichotomized at the median value, which was -47% and -35% for ∆MRGlu and ∆SUV, 
respectively. The Kaplan-Meier survival curves for overall survival are shown in figure 
2A (∆MRGlu) and figure 2B (∆SUV). The difference in survival between both strata was 
highly significant for both ∆MRGlu and ∆SUV (p=0.017 for ∆MRGlu and p=0.018 for ∆SUV, 
table 2A and Figure 2A-B). For patients with a decrease in MRGlu lower than the median 
value, median overall survival was only 8 months, whereas it was 17 months for patients 
with a more pronounced decrease in MRGlu.
Table 2. Survival Estimates
2A. Median and 1, 2 and 3-year overall survival rates (OS) for strata dichotomized using median 
values of ∆MRGlu and ∆SUV between the PET-scan at baseline and evaluation
Overall Survival
median OS  
(months)
1 year OS  
(%)
2 years OS  
(%)
3 years OS  
(%) p-value
All patients 13 57% 36% 22%
PET response
∆MRGlu < -47%
∆MRGlu > -47%
∆SUV < -35%
∆SUV > -35%
17
8
17
9
75%
38%
72%
40%
42%
26%
47%
26%
25%
20%
27%
17%
0.017
0.018
2B. Median and 1, 2 and 3-year progression free survival rates (PFS) for strata dichotomized using 
median values of ∆MRGlu and ∆SUV between the PET-scan at baseline and evaluation
Progression Free Survival
median PFS 
(months)
1 year PFS 
(%)
2 years PFS 
(%)
3 years PFS 
(%) p-value
All patients 7 26% 17% 8%
PET response
∆MRGlu < -47%
∆MRGlu > -47%
∆SUV < -35%
∆SUV > -35%
10
3
11
3
34%
15%
41%
12%
23%
8%
31%
4%
8%
4%
19%
0%
0.002
0.0009
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Figure 2. Kaplan Meier Estimates for Overall Survival. Kaplan-Meier analysis of the relationship 
between overall survival and [A] ∆MRGlu (dichotomized using median value of -47%) and [B] ∆SUV 
(dichotomized using median value of -35%). 
There was also a significant difference in progression free survival between both groups 
when dichotomized at the median value of ∆MRGlu (p=0.002) and of ∆SUV (p=0.0009) 
(table 2B). Patients with a decrease of MRGlu by more than 47% were characterized by 
a significantly longer time to progression (median, 10 versus 3 months; p=0.002). The 
results obtained for ∆SUV were also evident: median progression free survival, 11 versus 
3 months. The corresponding Kaplan-Meier curves for progression free survival are 
shown in fig. 3A (∆MRGlu) and fig. 3B (∆SUV). There was a highly significant increase 
in the rates of progression associated with worsening response as assessed by PET 
on Cox proportional regression analysis adjusting for disease stage at the time of 
commencement of treatment (p=0.018 for ∆MRGlu and p=0.028 for ∆SUV). 
Applying predefined, prospective definitions of metabolic response with cut-off levels 
according to Young et al. (EORTC) and according to the cut-off levels also used for 
size measurement (RECIST) the complete data set showed similar highly significant 
differences in progression free survival (table 3A-B). However, for prediction of overall 
survival categorization according to these predefined cut-off levels showed only 
statistically significant differences for RECIST cut-off levels applied to ∆SUV (p=0.027).
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Table 3. Progression free survival estimates for predefined metabolic response categories
3A: Median and 1, 2 and 3-year progression free survival rates (PFS) for EORTC metabolic response 
categories.
median PFS 
(months)
1 year PFS 
(%)
2 years PFS 
(%)
3 years PFS 
(%) p-value
CR/PR: ∆MRGlu < -25%
SD: ∆MRGlu -25% to +25%
PD: ∆MRGlu > +25%
CR/PR: ∆SUV < -25%
SD: ∆SUV -25% to +25%
PD: ∆SUV > +25%
8
3
1
11
3
0
33%
9%
0%
39%
13%
0%
19%
0%
0%
26%
6%
0%
9%
0%
0%
16%
0%
0%
0.007
0.0003
3B: Median and 1, 2 and 3-year progression free survival rates (PFS) for metabolic response 
categories applying cut-off levels that are used for clinical response with conventional methods 
(size measurement) according to RECIST
median PFS 
(months)
1 year PFS 
(%)
2 years PFS 
(%)
3 years PFS 
(%) p-value
CR/PR: ∆MRGlu < -30%
SD: ∆MRGlu -30% to +20%
PD: ∆MRGlu > +20%
CR/PR: ∆SUV < -30% 
SD: ∆SUV -30% to +20% 
PD: ∆SUV > +20%
10
3
1
11
3
0
36%
9%
0%
42%
11%
0%
21%
0%
0%
28%
0%
0%
10%
0%
0%
17%
0%
0%
0.006
0.0003
CR = complete response
PR = partial response
SD = stable disease
PD = progressive disease
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Figure 3. Kaplan Meier Estimates for Progression Free Survival. Kaplan-Meier analysis of the 
relationship between progression free survival and [A] ∆MRGlu (dichotomized using median value 
of -47%) and [B] ∆SUV (dichotomized using median value of -35%).
Discussion
The results of this prospective study show that fractional changes in tumor glucose 
metabolism from baseline FDG-PET to FDG-PET after 2-3 cycles of chemotherapy, 
were highly predictive for patient outcome in patients with NSCLC. When applying the 
generally used posthoc definition for metabolic response, by stratifying at the median 
value of ∆MRGlu and ∆SUV, the difference in overall survival between both strata was 
highly significant (p=0.017 for ∆MRGlu and p=0.018 for ∆SUV). Also a difference in 
progression free survival was seen (p=0.002 for ∆MRGlu and p=0.0009 for ∆SUV).
The strength of the present study is that also some predefined, prospective definitions of 
metabolic response were evaluated, comparing three strata for assessment of metabolic 
changes by FDG-PET. One of these prospective definitions was proposed by the EORTC 
15 to provide a framework for comparison between studies and to facilitate assessment 
of the technique. A >25% decrease in glucose metabolism was estimated to be a sign 
of partial metabolic response after two or more cycles of chemotherapy. According to 
this EORTC definition the present study demonstrated highly significant differences 
in progression free survival between each stratum (p=0.007 for ∆MRGlu and p=0.0003 
for ∆SUV). The same significant results were found when using the cut-off levels that 
are proposed for evaluation after one cycle of chemotherapy, for which applies that 
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a metabolic response is defined by a decrease in tumor glucose metabolism of >15%. 
However, for prediction of overall survival using these EORTC criteria, no statistical 
significance was reached, only a trend was found (p=0.0504). This is probably due to 
the limited number of patients in each stratum: more censored patients for overall 
survival compared to progression free survival in combination with smaller groups 
due to categorization into three groups (complete response (CR) / partial response 
(PR), stable disease (SD) and progressive disease (PD)) instead of two. The EORTC PET 
response criteria were developed by consensus between a range of PET experts and 
currently represent the most authoritative SUV-based recommendations. Also when 
applying the same cut-off levels that are used for size measurement in standard clinical 
response assessment with conventional methods according to RECIST 16,17, significant 
differences between the strata were found in progression free as well as overall survival 
with respect to ∆SUV.
These results imply that measurement of treatment-induced changes in tumor glucose 
metabolism with PET is quite robust. There is even more considerable evidence for this, 
since simplified FDG-PET measures (SUV) and the more complex, quantitative measures, 
derived from Patlak graphical analysis (MRGlu) show comparable highly significant 
results indicative for treatment outcome. Given the high correlation between ∆SUV 
and ∆MRGlu (r=0.94, p<0.0001) there is no obvious need to apply the more complex 
dynamic imaging protocols (necessary for MRGlu calculation) for prediction of therapy 
response in monitoring chemotherapy of NSCLC. This indicates that FDG-PET can be 
readily implemented as a routine clinical tool for response monitoring when some basic 
requirements of quality assurance are met 18. Multiple follow-up scans encourage a 
simplified approach to improve patient compliance, an important feature of successful 
clinical trials. Another advantage of the SUV is that it can be calculated from static 
whole-body FDG-PET studies. In quantitative dynamic scans only one axial field of view 
of typically 15-20 cm can be studied during the dynamic data acquisition. As metastatic 
lesions in different parts of the body may respond differently to chemotherapy, this 
represents a principal advantage of SUV.
The results of the present study are in line with other studies on the predictive value 
of FDG-PET in locally advanced NSCLC. Several studies indicated a possible role for 
PET in assessment of response during or after radiotherapy 19, induction chemotherapy 
20-22 or a combination thereof 8,23-27. The earliest study, performed in 1996 by Ichiya et al. 
19 showed a more prominent decrease in FDG uptake in patients with a radiotherapy 
response on CT compared with those with no change in tumor size on CT. In the pilot 
study of Vansteenkiste et al. 20 a reduction in FDG uptake of >50% in the primary tumor 
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or mediastinal clearance after induction chemotherapy, proved to be a better predictor 
of long-term survival compared to the standard used WHO criteria 28,29 for response 
assessment on CT. Another study that evaluated response monitoring of induction 
chemotherapy 21 showed that FDG-PET identified prognostically different strata in 
patients considered responsive according to CT. In this prospective multicenter study 
FDG-PET was performed before, after one and three cycles of induction chemotherapy. 
The residual metabolic rate of glucose after one cycle selected patients with different 
outcomes. The residual metabolic rate of glucose after completion of induction 
chemotherapy proved to be the best prognostic factor. The other six studies 8,23-27 showed 
that FDG-PET was also predictive with respect to therapy outcome of combined modality 
therapy. Metabolic response proved to be associated with pathological response 23,24,26,27. 
A study performed by Mac Manus et al. 25, showed a significantly longer median survival 
for patients with complete metabolic response than for patients with non-complete 
metabolic response (31 versus 11 months). 
The experience with FDG-PET on therapy response monitoring in advanced stages 
of NSCLC is limited. So far, a single well designed study on response assessment in 
advanced stages (stage IIIB or IV), using serial PET-scans was performed by Weber et 
al. 30. Fifty-seven patients scheduled to undergo platinum-based chemotherapy were 
studied before and after the first cycle of therapy. A decrease in SUV of 20% or more 
after one cycle of chemotherapy was associated with a longer time to progression (163 
days versus 54 days) and longer median overall survival time (252 days versus151 days). 
The 1-year survival rate was also significantly higher in metabolic responders compared 
to nonresponders (44% versus 10%). This study showed that a reduction of metabolic 
activity already after one cycle of chemotherapy is closely correlated with final outcome 
of therapy.
Conclusion
These findings in advanced stages of NSCLC in combination with the results of the 
studies in locally advanced NSCLC indicate that PET imaging may be used to predict the 
clinical outcome of chemotherapy. SUV showed to be a robust parameter to detect a 
metabolic response. As no sophisticated methods for data analysis are required, the use 
of FDG-PET for therapy monitoring seems clinically feasible.
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Abstract
Background: The aim of this prospective study was to evaluate the value of F-18-
fluorodeoxyglucose positron emission tomography (FDG-PET) for early assessment of 
chemotherapy response in patients with advanced colorectal cancer.
Methods: Dynamic FDG-PET was performed before and at 2 (n=50) and 6 months (n=19) 
after start of treatment. Quantitative Patlak analysis (MRGlu) and a simplified method to 
measure glucose metabolism (SUV) were evaluated. The predictive value of changes in 
glucose metabolism was assessed with Cox proportional regression analysis. Overall- 
and progression free survival was calculated using Kaplan-Meier estimates.
Results: There was an increase in the rates of death (p=0.049 for ∆MRGlu PET1-2; p=0.017 
for ∆SUV PET1-2; p=0.032 for ∆MRGlu PET1-3; p=0.048 for ∆SUV PET1-3) and progression 
(p=0.026 for ∆MRGlu PET1-2; p=0.035 for ∆SUV PET1-2; p=0.041 for ∆MRGlu PET1-3; p=0.081 
for ∆SUV PET1-3) associated with worse response as assessed by PET on Cox proportional 
regression analysis. The overall- and progression free survival analysis showed a 
significant predictive value at broad ranges of ∆MRGlu and ∆SUV cut-off levels.
Conclusion: The degree of chemotherapy-induced changes in tumor glucose metabolism 
is highly predictive for patient outcome. The use of FDG-PET for therapy monitoring 
seems clinically feasible, since simplified methods (SUV) are sufficiently reliable.
Introduction
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a molecular 
imaging technique that visualizes and quantifies metabolic processes in cancer cells. 
Currently, FDG-PET has an established role in staging colorectal cancer patients before 
surgical resection of metastases 1-4, in the localization of recurrence in patients with an 
unexplained rise of serum carcinoembryonic antigen (CEA) 5 and in the assessment of 
residual masses after treatment 6. FDG-PET significantly improves patient management, 
reduces futile surgery, leads to substantial cost savings and probably also to a better 
patient outcome 7,8.
There is an increasing interest in the role of FDG-PET beyond staging, for prediction 
of tumor response to therapy. Although the hallmark for evaluation of therapeutic 
effectiveness of cancer treatment, current morphological imaging techniques such as 
computed tomography (CT) have limitations in reliably distinguishing necrotic tumor 
or fibrotic scar from residual tumor tissue. FDG-PET could be helpful in solving this 
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problem. The positron emitter FDG is transported into cells analogously to glucose 
and is converted to FDG-6-phosphate. This metabolite is trapped in the cell, as it will 
not be processed in the glycolytic pathway and hence will accumulate preferentially 
in those cells with high glucose uptake, such as tumor cells 9. FDG-PET cannot only 
distinguish active disease from residual scar tissue 6, but can also quantify FDG uptake 
to distinguish metabolically highly active from less active tumor tissues. Furthermore, 
metabolic alterations in tumor cells, indicative of tumor response to therapy, may occur 
before alterations in tumor size. The experience with FDG-PET in the assessment of 
therapy response in advanced colorectal cancer, however, is still limited. In the present 
prospective study the value of FDG-PET for this indication is investigated, by measuring 
tumor glucose metabolism before and after 2 and 6 months of chemotherapeutic 
treatment.
Patients and methods
Patient eligibility criteria
Between March 2002 and December 2005 all patients in the Radboud University 
Nijmegen Medical Centre with metastatic colorectal cancer, who were scheduled to 
undergo chemotherapy in a palliative setting, were asked to participate in the study. 
Patients with diabetes mellitus were excluded. In all patients, treatment decision-making 
was done by a multi-disciplinary team including medical oncologists, surgeons, radiation 
oncologists, pathologists, radiologists and nuclear medicine physicians. Clinicians were 
blinded to the results of the dynamic FDG-PET scans. The study was approved by the 
Institutional Review Board of the Radboud University Nijmegen Medical Centre and 
written informed consent was obtained from each patient.
FDG-PET
Quantitative dynamic FDG-PET data acquisition and reconstruction
Dynamic FDG-PET was performed at baseline and after two and six months of 
treatment. Patients fasted for at least 6 h before imaging. All scans were acquired on 
an ECAT-EXACT47 PET scanner (Siemens/CTI, Knoxville, TN, USA). The field of view for 
dynamic acquisition was based on whole-body FDG-PET and CT scans performed for 
initial staging. A 20-min transmission scan was made, using the internal 68Ge/68Ga 
sources, to correct for photon attenuation. Subsequently, approximately 200 MBq FDG 
dissolved in 8 mL saline was injected intravenously over a 1-min period, using a constant 
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infusion remote-controlled pump (Medrad, Indianola, PA). The dynamic data acquisition, 
performed in septa-extended (2-dimensional) mode, was started simultaneously with 
the injection of FDG and consisted of 16 time frames with variable frame length (10x30 
s, 3x300 s, 3x600 s) for a total time of 50 min. A more detailed description of the data 
acquisition, reconstruction and analysis methods was published previously 10.
Plasma time-activity curves
To measure the blood clearance of FDG, plasma time-activity curves were derived from 
arterial blood sampling when feasible. Arterial blood samples were taken manually to 
provide an arterial plasma input function as described previously 10. The radioactivity in 
plasma was determined using the standard solution method as described by Greuter et 
al. 11.
When arterial cannulation was contra-indicated or not feasible, an image-based input 
function was determined by measuring FDG counts in a volume of interest (VOI) over 
the abdominal or ascending aorta, which accurately determines FDG blood levels 10.
Tumor Time-Activity Curves
Tumor time-activity curves were obtained by placing VOIs semiautomatically over the 
tumor metastases using a threshold of 50% of the maximum pixel value within the 
lesion. For this purpose the late frames (frame 14-16) were summed, yielding a static 
image of 30 min duration and a scan mid-time of 35 min post injection. The tumor VOIs 
were then copied to the dynamic imaging sequence to obtain time-activity curves. A 
volume weighted mean value of tumor glucose use (metabolic rate of glucose, further 
mentioned MRglu) of all lesions in each PET scan was derived to provide one value for 
each study. VOIs drawn on the first FDG-PET (before initiation of chemotherapy) were 
copied to the second and third FDG-PET (2 and 6 months after start of treatment).
Patlak Graphical Analyses
For quantitative measurement of glucose metabolism Patlak graphical analysis was 
used to calculate the MRGlu (expressed in µmol.mL
-1.min-1) in tumor tissue 12,13. A detailed 
description of the Patlak graphical analyses and its assumptions have been published 
elsewhere 10,12. In brief, the Patlak approach takes into account differences in the whole-
body distribution of FDG at the time of scanning, which may affect the accumulation 
of FDG in the tumor tissue. Therefore, the MRglu is in principle a more reliable measure 
of tumor glucose use than the standardized uptake value (SUV). The Patlak analysis was 
performed over the period from 5 to 50 min after injection. Furthermore, the MRGlu in 
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tumor was calculated by multiplication of the slope of the Patlak-plot and the basic blood 
glucose level (expressed in µmol.mL-1), measured before FDG injection (hexokinase 
method, Aeroset, Abbott diagnostics, Illinois, USA). The fractional change in MRGlu 
between the first, second and third FDG-PET was calculated.
Standardized Uptake Value
FDG-PET scans were also evaluated semi-quantitatively by standardized uptake value 
(SUV) analysis. SUVs normalized to injected activity and patients’ body weight were 
calculated from the mean activity concentration in the tumor VOIs between 40 and 
50 minutes post injection, which is the last time-frame of the dynamic scan. A volume 
weighted mean value of each PET scan was derived from all lesions to give one average 
SUV (SUVavg, hereafter mentioned SUV) for each PET scan. The fractional change in SUV 
between the first, second and third FDG-PET was calculated.
Clinical Follow-Up
Follow-up was performed according to a stringent protocol for 3 years. Apart from clinical 
examinations, routine laboratory tests, and CEA measurement patients underwent a CT 
or MRI scan of the abdomen every 3 months and a CT scan of the chest every 6 months, 
and in case of inconclusive findings, an ultrasound and/or an additional FDG-PET scan 
was performed. Tumor response was evaluated according to RECIST criteria without 
knowledge of the results of the PET studies. The date of progression was defined 
as the earliest date at which disease progression was confirmed. Patients who were 
progression free at the closeout date (March 1, 2007) had their time to progression 
censored at that date. Survival was measured from the date of the baseline PET scan to 
the date of death. Patients who were still alive at the closeout date had their survival 
censored at that date.
Statistical Analysis
Survival and progression free survival served as the standard of reference. Cox 
proportional hazards regression analysis was used to assess the predictive value of 
response evaluation with FDG-PET, as expressed in the fractional change in MRGlu and 
SUV between the FDG-PET at baseline and after 2 and 6 months of chemotherapy. 
Statistical significance was assessed using the Wald’s chi-square test. The overall- and 
progression free survival with respect to ∆MRGlu and ∆SUV were calculated using Kaplan-
Meier estimates. The fractional change in measurements between the first and second 
FDG-PET and the first and third FDG-PET were stratified by a range of cut-off values. 
 Chemotherapy response evaluation with 18F-FDG-PET in patients with colorectal cancer 247
However, to avoid the bias of data-driven significance for the cut-off level also some 
predefined, prospective definitions of metabolic response were tested. For that purpose 
the population was categorized according to the definitions for metabolic response 
of The European Organization for Research and Treatment of Cancer  (EORTC), into a 
group with complete or partial response (∆<-25%), a group with stable disease (∆-25% 
to +25%) and a group with progressive disease (∆>+25%) 14. Furthermore the population 
was categorized according to the cut-off values also used for size measurement (RECIST), 
for which applies that ∆<-30% is complete or partial response, ∆-30% to +20% is stable 
disease and ∆>+20% is progressive disease 15. Groups were compared using the Log 
Rank test (for assessment of overall survival) and the Breslow test (for assessment of 
progression free survival). Since many events of progression occurred during early time 
points the Breslow test was used to analyze progression free survival. Spearman’s rho 
correlations were used to determine the comparability between the different methods 
to measure glucose metabolism. Statistical tests were based on a two-sided significance 
level and the level of significance was set at 0.05.
Results
Patient characteristics
Sixty-one consecutive patients with advanced colorectal cancer were included in this 
prospective study. After the first FDG-PET, 11 patients were excluded due to technical 
issues (n=1), refusal to undergo a second FDG-PET (n=3), death before the second FDG-
PET (n=2) and early discontinuation of chemotherapy due to a significant decline in 
performance status (n=5). Only in patients who were still on the same treatment schedule 
after 6 months a third FDG-PET was performed. Thus, complete data sets of two PET-
scans were available in 50 patients and of three PET-scans in 19 patients. The mean 
interval between the first and the second FDG-PET was 61±18 days and between the 
first and the third FDG-PET 171±32 days. The evaluable population consisted of 37 males 
and 13 females with a mean age 61 years (range 45-79 years). Patient characteristics are 
summarized in table 1.
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Table 1. Patient characteristics
Mean age 61 years (range 45-79 years)
Men 37
Women 13
Histology
Adenocarcinoma
Mucinous adenocarcinoma
47
3
Differentiation of primary tumor
poor
intermediate
well
unspecified
8
31
2
9
Location primary tumor
colon
sigmoid
rectum
colon + rectum
11
23
9
7
Location of metastases
liver
lung
(retro)peritoneal lymph nodes
bone
43
15
4
2
Treatment
Twenty-seven patients received chemotherapy in first line, 16 in second line, 6 in third 
line and 1 in fourth line. The chemotherapy regimens used were Irinotecan (n=12), 
Capecitabine (n=12), Capecitabine/Irinotecan (n=8), 5-Fluorouracil (5-FU)/Oxaliplatin/
Leucovorin (n=8), Capecitabine/Oxaliplatin (n=6), 5-FU/Leucovorin (n=2), 5-FU/
Irinotecan/Leucovorin (n=1) and Capecitabine/Oxaliplatin/Bevacizumab/Cetuximab 
(n=1).
Patient Follow-Up
No patients were lost to follow-up. Median follow-up time was overall 18.5 months 
(range 5-45 months), for surviving patients 25 months (range 14-45 months), and for 
deceased patients 16 months (5-34 months). During this time period, 35 patients had 
died and tumor progression was diagnosed in 49 out of the 50 patients. Median time to 
progression was 6 months (range 0-28 months). The estimated cumulative proportion 
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surviving at 1 year after baseline FDG-PET was 76%, at 2 years 36% and at 3 years 18%. 
The estimated cumulative proportion progression free at 1 year after baseline FDG-PET 
was 22%, at 2 years 4% and at 3 years 0%.
Quantitative Changes in FDG Uptake
Mean MRglu at baseline was 0.121±0.059 µmol.mL
-1.min-1 (range 0.014 to 0.267), during 
first evaluation 0.076±0.063 µmol.mL-1.min-1 (range 0.007 to 0.263) and during second 
evaluation 0.087±0.074 µmol.mL-1.min-1 (range 0.001 to 0.246). The median fractional 
change at first evaluation of MRglu as compared to baseline was -52%±100% (range -90% 
to +588%) and at second evaluation -46%±57% (range -99% to +140%). Mean SUV at 
baseline was 5.16±1.84 (range 1.68 to 9.81), during first evaluation 4.09±2.11 (range 1.15 to 
11.30) and during second evaluation 4.58±2.13 (range 2.19 to 9.81). The median fractional 
change at first evaluation of SUV as compared to baseline was -28%±32% (range -64% 
to +61%) and at second evaluation -17%±54% (range -59% to +187%).
Figure 1 shows a typical example of a patient with liver metastases of colorectal 
carcinoma who responded to chemotherapy.
18FDG uptake measured with simplified methods (SUV) showed a significant correlation 
with MRglu as measured with the Patlak analysis (rho=0.82, p<0.0001) at baseline, after 
2 months of chemotherapy (rho=0.81, p<0.0001), after 6 months of chemotherapy 
(rho=0.92, p<0.0001), as well as in terms of fractional changes after 2 months of 
chemotherapy (rho=0.78, p<0.0001) and after 6 months of chemotherapy (rho=0.89, 
p<0.0001).
Figure 1. typical example of a patient with liver metastases that respond to chemotherapy. 
Relative to baseline [A], there is a 52% decrease in MRglu and a 41% decrease in SUV on FDG-PET 
after 2 months of chemotherapy [B].
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Prediction of survival by FDG-PET
There was a significant increase in death rates associated with worsening response as 
assessed by PET on Cox proportional regression analysis (p=0.049 for ∆MRGlu and p=0.017 
for ∆SUV after 2 months of chemotherapy and p=0.032 for ∆MRGlu and p=0.048 for ∆SUV 
after 6 months of chemotherapy). There was also an increase in the rates of progression 
associated with worsening response as assessed by PET on Cox proportional regression 
analysis, that was statistically significant for both ∆MRGlu (p=0.026) and ∆SUV (p=0.035) 
after 2 months of chemotherapy and for ∆MRGlu after 6 months of chemotherapy 
(p=0.041 for ∆MRGlu and p=0.081 for ∆SUV). The overall-, as well as the progression 
free Kaplan Meier survival analysis showed significant discriminative p-values at broad 
ranges of ∆MRGlu (table 2) and ∆SUV (table 3) cut-off levels. In figure 2A (∆MRGlu, cut-off 
value of -65%) and figure 2B (∆SUV, cut-off value of -20%) typical examples of Kaplan-
Meier curves for overall survival are shown. Figure 3A (∆MRGlu) and figure 3B (∆SUV) 
demonstrate the corresponding Kaplan-Meier curves for progression free survival.
Applying predefined, prospective definitions of metabolic response with cut-off levels 
according to Young et al. 14 (EORTC) and according to the cut-off levels also used for size 
measurement (RECIST) some significant differences in progression free- (p=0.002 for 
EORTC and p=0.001 for RECIST) and overall survival (p=0.064 for EORTC and p=0.023 for 
RECIST) are seen for ∆SUV between the first and second FDG-PET. For ∆MRGlu however, 
only the predefined cut-off levels according to EORTC showed statistically significant 
differences for prediction of progression free survival (p=0.036).
Table 2. Discriminative values for overall- and progression free survival of various ∆MRglu cut-off levels.
Cut-off values 
∆MRglu PET1-2
-15%
-20%
-25 %
-30%
-35%
-40%
-45%
-50%
-55%
-60%
-65%
-70%
-75%
Overall 
Survival
p-value
0.060
0.036*
0.036*
0.132
0.061
0.056
0.026*
0.038*
0.016*
0.004*
0.009*
0.025*
0.022*
Progression 
free survival
p-value
0.019*
0.012*
0.012*
0.065
0.028*
0.028*
0.043*
0.065
0.029*
0.017*
0.023*
0.042*
0.098
Cut-off values 
∆MRglu PET1-3
-15%
-20%
-25 %
-30%
-35%
-40%
-45%
-50%
-55%
-60%
-65%
-70%
-75%
Overall 
Survival
p-value
0.019*
0.019*
0.019*
0.019*
0.050*
0.041*
0.041*
0.041*
0.130
0.294
0.202
0.098
0.098
Progression 
free survival
p-value
0.160
0.160
0.160
0.160
0.087
0.011*
0.011*
0.011*
0.007*
0.057
0.031*
0.033*
0.033*
*p<0.05
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Figure 2. Kaplan Meier Estimates for Overall Survival. Kaplan-Meier analysis of the relationship 
between overall survival and [A] ∆MRGlu between the first and second FDG-PET (dichotomized 
using a cut-off value of -65%, p=0.009) and [B] ∆SUV between the first and the second FDG-PET 
(dichotomized using a cut-off value of -20%, p=0.021). 
Table 3. Discriminative values for overall- and progression free survival of various ∆SUV cut-off 
levels.
Cut-off values 
∆SUV PET1-2
20%
15%
10%
5%
0%
-5%
-10%
-15%
-20%
-25 %
-30%
-35%
-40%
Overall 
Survival
p-value
0.008*
0.008*
0.031*
0.028*
0.024*
0.068
0.040*
0.021*
0.021*
0.117
0.155
0.164
0.575
Progression 
free survival
p-value
<0.0001*
0.002*
0.003*
0.009*
0.009*
0.037*
0.006*
0.004*
0.004*
0.010*
0.040*
0.055
0.169
Cut-off values 
∆SUV PET1-3
20%
15%
10%
5%
0%
-5%
-10%
-15%
-20%
-25 %
-30%
-35%
-40%
Overall 
Survival
p-value
0.356
0.052
0.052
0.019*
0.019*
0.019*
0.002*
0.031*
0.361
0.171
0.394
0.394
0.191
Progression 
free survival
p-value
0.699
0.042*
0.042*
0.160
0.160
0.160
0.311
0.824
0.286
0.127
0.128
0.128
0.037*
*p<0.05
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Figure 3. Kaplan Meier Estimates for Progression Free Survival. Kaplan-Meier analysis of the 
relationship between progression free survival and [A] ∆MRGlu between the first and second FDG-
PET (dichotomized using a cut-off value of -65%, p=0.023) and [B] ∆SUV between the first and 
second FDG-PET (dichotomized using a cut-off value of -20%, p=0.004). 
Discussion
This prospective study shows that fractional changes in tumor glucose metabolism were 
highly predictive for outcome in patients with advanced colorectal cancer, stratifying 
patients into groups with sharply distinguished overall- and progression free survival 
probabilities. The overall survival, as well as the progression free Kaplan Meier survival 
analysis showed significant discriminative p-values at broad ranges of ∆MRGlu and ∆SUV 
cut-off levels.
The strength of the present study is that also some prospective definitions of metabolic 
response were evaluated, comparing three strata for assessment of metabolic changes 
by FDG-PET. When considering >25% decrease in glucose metabolism as proposed by 
the EORTC as a definition of partial metabolic response after two or more cycles of 
chemotherapy 14, the present study demonstrated significant differences in progression 
free survival between each stratum (p=0.036 for ∆MRGlu and p=0.002 for ∆SUV). However, 
for prediction of overall survival using these EORTC criteria, no statistical significance 
was reached. This is probably due to the limited number of patients in each stratum: 
more censored patients for overall survival compared to progression free survival in 
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combination with smaller groups due to categorization into three groups (complete 
response (CR) / partial response (PR), stable disease (SD) and progressive disease (PD)) 
instead of two. When applying the cut-off levels that are used for size measurement in 
standard clinical response assessment with conventional methods according to RECIST 
15,16, significant differences between the strata were found in progression free- as well 
as overall survival with respect to ∆SUV. These results imply that measurement of 
treatment-induced changes in tumor glucose metabolism with PET is quite robust. This 
indicates that FDG-PET can be readily implemented when some basic requirements of 
quality assurance are met without the need for complex dynamic imaging protocols 
(necessary for MRGlu calculation) 
17. Also, a noncomplex approach will facilitate broad 
introduction in clinical practice and improve patient compliance, an important feature 
of successful clinical trials. Another advantage of the SUV is that it can be calculated 
from static whole-body FDG-PET studies, which depicts all metastases. In quantitative 
dynamic scans only one axial field of view of typically 15-20 cm can be studied during 
the dynamic data acquisition. As metastatic lesions in different parts of the body may 
respond differently to chemotherapy, this represents a principal advantage of SUV over 
Patlak analysis.
Several studies indicated a possible role for FDG-PET in the prediction and evaluation of 
treatment response, such as monitoring of radiotherapy and multimodality treatment 
response in primary rectal cancer 18-24 and monitoring response after local ablative 
therapy of liver metastases 25-28. The experience with FDG-PET in the assessment of 
chemotherapy response in advanced colorectal cancer, however, is limited to four 
reports in mostly small series of patients with irresectable colorectal cancer liver 
metastases 29-32. Findlay et al. 29 studied 18 patients treated with 5-FU chemotherapy. A 
correlation was observed between the reduction of tumor metabolism 5 weeks after the 
initiation of chemotherapy and treatment outcome, which was not observed at 1-2 weeks 
on treatment. These results show the importance of a correct timing of FDG-PET after 
the onset of chemotherapy. Bender et al. 30 studied 10 patients with irresectable liver 
metastases prior to and 72 h after a single infusion of 5-FU and folinic acid. SUVs were 
correlated with therapy outcome, with a follow-up of at least 6 months. More recently, 
Dimitrakopoulou-Strauss et al. 31,32 examined the ability of serial semiquantitative as well 
as quantitative dynamic FDG-PET examinations in 28 patients to predict response to 
second-line FOLFOX (5-FU/folinic acid/oxaliplatin) at baseline and after the first and 
second cycle. The authors postulated that quantitative, dynamic FDG-PET should be 
used preferentially for chemotherapy response monitoring. However, the results of the 
present study, that included almost twice as much patients, showed that semiquantitative 
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analysis, for which no complex dynamic imaging protocols are needed, is sufficiently 
reliable.
In conclusion, FDG-PET imaging may be used to predict the clinical outcome of 
chemotherapy in patients with advanced colorectal cancer. As no sophisticated methods 
for data analysis are required, the use of FDG-PET for therapy monitoring seems 
clinically feasible. However, further studies are needed to study whether FDG-PET can 
be performed even earlier to predict the result of anticancer therapy. Nevertheless, 
the findings of the present study provide the basis for randomized clinical trials to 
evaluate if FDG-PET based decisions to change treatment prevents toxicity and costs of 
ineffective therapy without negatively affecting overall survival. If so, FDG-PET aids in 
individualized treatment of patients with advanced colorectal cancer and may provide 
early surrogate endpoints in clinical trials when evaluating the effects of systemic 
therapy, especially since the choice of agents has been considerably expanded.
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FDG-uptake: mechanisms and interactions 
The biological basis of FDG-PET in oncology is the increased glucose metabolism of 
malignant cells as compared to noncancerous tissues. After administration of the glucose 
analog FDG, it will be transported into the tumor cell and will be phosphorylated by 
hexokinase. The intracellular FDG-6-phosphate is trapped in the malignant cells, as it will 
not be processed in the glycolytic pathway and can thus be visualized using PET. A variety 
of mechanisms have been proposed for accelerated glucose use in growing tumors and 
in transformed and malignant cells: passive diffusion, Na+-dependent glucose transport 
and via facilitative glucose transporters (GLUT). The latter is considered to be the most 
important mechanism for enhancing glucose influx into cells. The glucose transporters 
GLUT-1 and GLUT-3, subtypes with a relatively high affinity for glucose, belong to the 
sugar trans-porter family, which currently includes 133 individual members. Increased 
concentrations of the glucose phosphorylation enzyme, hexokinase, with decreased 
rates of glucose-6-phophatase are considered to accelerate glucose phosphorylation, 
which results in enhanced FDG intracellular trapping. Upregulation of hexokinase and 
glucose transporters, especially GLUT-1, and downregulation of glucose-6-phosphatase 
are frequently associated with malignant transformation. Glucose transport activity 
can be regulated by alterations in the expression of GLUT transporters and by post-
translational mechanisms, including transporter translocation to plasma membranes. 
Furthermore it was reported that the use of chemotherapy could alter FDG uptake in 
tumors by altering the activity of hexokinase. Moreover, the rate of FDG uptake in a 
tumor has been correlated with tumor doubling time and proliferation rates which, in 
turn, are known to correlate with tumor aggressiveness. Furthermore, apoptosis plays a 
central role in the elimination of (the precursors of) tumor cells. Therapy resistance can 
be attributed, at least in part, to a disabled apoptotic program. It has been demonstrated 
that primary tumors showing high FDG uptake have the potential to be resistant to 
therapy and to metastasize and that strong expression of the cysteine protease 
caspase-3, which is a key enzyme in apoptotic cell death, was a significant factor to 
predict poor prognosis. Better understanding of a possible relationship between FDG 
uptake and apoptosis may provide insights into sensitivity or resistance of tumor 
cells. Furthermore, tumors that grow too rapidly or have a deficient vascular system 
are characterized by the formation of necrosis. Necrosis reflects cell death caused 
by hypoxia. Hypoxia results in enhanced anaerobic glycolysis and hence in increased 
FDG uptake. Finally, the presence of inflammatory cells might be confounding, since 
inflammatory cells may have a major impact on FDG uptake. At present it is still not 
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fully elucidated which of these factors contribute to the variable levels of FDG uptake 
in non-small-cell lung carcinoma, colorectal carcinoma and head and neck squamous 
cell carcinoma. Results from studies in other tumor types cannot just be extrapolated 
to the cancer types presented in this thesis, as different tumors have different glucose-
regulating mechanisms and enzyme expression patterns in association with various 
oncogenic alterations. The studies presented in chapter 4, 5, 6 and 7, tried to unravel 
the complex molecular mechanisms and factors that regulate and/or interfere with 
FDG uptake. A better understanding of the biological mechanisms that are involved 
in glucose transport, glucose metabolism and FDG accumulation cannot only lead to 
better interpretation of FDG-PET as a promising imaging biomarker, but could also be 
helpful in the development of future targets for novel therapeutic interventions.
From the study presented in chapter 4 it can be learned that the degree of FDG 
accumulation in the primary site of early-stage non-small-cell lung cancer (NSCLC) is 
mainly determined by the combination of the expression level of the glucose membrane 
transporters, GLUT-1 and GLUT-3 and tumor cell differentiation. This indicates that 
sufficient FDG uptake capability (reflected by GLUT-1 and GLUT-3) is relevant for 
detection of NSCLC by FDG-PET. Furthermore we learned that expression of GLUT-
transporters at the cell membrane and not expression in cytoplasmic granules may be 
responsible for active glucose transport, that FDG uptake as well as GLUT-1 expression 
may be higher in squamous cell carcinomas compared with adenocarcinomas and large 
cell carcinomas. And that GLUT-1 expression, as well as FDG uptake, appears to be 
higher in poorly differentiated tumors.
Several studies have focused on the link between FDG uptake and vascular density. 
Some studies have reported a positive association between vascular density and FDG 
uptake, but other studies have been negative. Divergent results may be explained by the 
fact that FDG uptake is measured in vivo, whereas from immunohistochemical analysis 
ex vivo data are obtained. This may be particularly important for the (lack of) relationship 
between FDG uptake and vascular density, since it is not so much the presence of tumor 
vasculature, but the presence of functional tumor vasculature that may drive FDG 
uptake. It should be noted when determining vascular density both perfused and non-
perfused vessels are included. Since mainly the latter seems to determine uptake of FDG 
in colorectal liver metastases, this may explain the lack of correlation between vascular 
density and FDG uptake and underscores the importance of functional in vivo data on 
the tumor vascular system that was investigated in chapter 5. Functionality of tumor 
vasculature was monitored in vivo by dynamic contrast enhanced magnetic resonance 
imaging (DCE-MRI), using the contrast agent Gadolinium-DTPA (Gd-DTPA) to examine 
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the in vivo relationship between FDG uptake, as measured by PET, and functional tumor 
vasculature, as measured by DCE-MRI, in patients with liver metastases of colorectal 
cancer. A negative correlation between tumor metabolism (FDG uptake) and functional 
tumor vasculature (Gd-DTPA uptake) in liver metastases was observed. A lower blood 
flow, lower permeability or smaller surface area of tumor blood vessels may all result 
in a reduced supply of nutrients like glucose. A reduced supply of nutrients could thus 
lead to lower FDG uptake in the tumor. However, poor vascular function could not only 
lead to a reduced supply of nutrients, but also to a reduced supply of oxygen. A reduced 
supply of oxygen would necessitate a higher uptake of glucose in order to maintain 
tumor energy levels. Therefore, the observed negative correlation between functional 
tumor vasculature (Gd-DTPA uptake) and tumor metabolism (FDG uptake) suggests 
that differences in tumor oxygenation rather than differences in FDG delivery are a 
driving force for FDG uptake in colorectal liver metastases. 
The hypothesis that tumor hypoxia is a driving force for FDG uptake in colorectal liver 
metastases seems to be contradicted by the observed lack of correlation between FDG 
uptake and hypoxic fraction in liver metastases as measured by pimonidazole binding 
(chapter 5). In this respect the difference between ‘chronic’ or ‘diffusion limited’ hypoxia, 
according to the classical model of Thomlinson and Gray and ‘acute’ or ‘transient’ 
hypoxia, due to local and temporary fluctuations of tumor blood perfusion may be 
relevant. Experimental tumor cells in an acutely hypoxic environment may increase 
their FDG uptake more than twofold in order to survive the temporary decrease in 
oxygen supply. A decreased cell proliferation has been shown in chronically hypoxic 
regions. This may be interpreted as an energy saving method to adapt to a reduced 
supply of oxygen and nutrients. Alternatively, it may be argued that an important part 
of the chronically hypoxic cell population are becoming necrotic or apoptotic and are 
therefore less metabolically active. In these chronically hypoxic regions FDG uptake will 
actually decrease. Thus, depending on whether acute or chronic hypoxia plays a major 
role, hypoxic tumors can be highly metabolic or may have modest glucose metabolism. 
The discordance of FDG uptake and tumor hypoxia can be tumor type specific and may 
even be heterogeneous within one tumor. Both chronically and acutely hypoxic cell 
regions contribute to the measured hypoxic fraction as measured by pimonidazole, 
which may explain the lack of correlation between FDG uptake and hypoxia in liver 
metastases. Whether other techniques to measure tumor oxygenation can accurately 
distinguish between acute and chronic hypoxia is still a matter of debate.
The results of the pilot study as presented in chapter 6 indicate that profound, but 
variable metabolic changes occur following alteration of the oxygenation state of head-
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and-neck tumors by the radiosensitizers carbogen and/or nicotinamide. Both increased 
as well as decreased FDG-uptake was observed. As the measurements in reference 
tissue of our patients, i.e. resting skeletal muscle, did not show metabolic changes 
following hyperoxygenation, these changes in FDG-uptake in the primary tumor 
reflect differences in tumor biology and are not based on reproducibility problems 
or differences induced by variations in body physiology. These observations may be 
probably due to the factors mentioned in chapter 5. Inhalation of carbogen is proposed 
to decrease chronic or diffusion-limited hypoxia and administration of nicotinamide to 
decrease acute or perfusion-limited hypoxia. Diffusion-limited hypoxia occurs in cells 
that are located relatively far away from blood vessels. Perfusion-limited hypoxia results 
from local, temporary fluctuations in tumor blood perfusion. The effect of carbogen 
breathing on blood flow may very well be even more complex. The rationale for use of 
gasses that include a small fraction of carbon dioxide added to oxygen is an increase 
in respiratory drive, improved oxygen delivery from the blood to the tissues by a right-
shift of the hemoglobin-oxygen dissociation curve, and better blood perfusion due to 
carbon dioxide induced vasodilatation. However, when the tumor vasculature lacks 
responsive smooth muscle and is in parallel to the vasculature of the surrounding host 
tissue, carbogen can have the reverse effect on blood flow. Blood perfusion is then 
increased in the surrounding normal tissues but reduced in the tumor, which is known 
as the steal phenomenon. This could in turn result in a reduction of FDG-uptake in the 
tumor. It remains to be established which of these effects dominate and what the net 
effect on tumor metabolism is. Very likely this differs between tumors, which can result 
in increased FDG uptake in some tumors and decreased uptake in others as observed 
in the present study. There are more speculations on two possible ways by which 
nicotinamide could affect tumor glycolysis. The first pathway involves a direct effect of 
nicotinamide on tumor blood flow. This increase in tissue blood flow would result in an 
increase in oxygen supply, which in turn would lead to radiosensitization. At the same 
time, the increased delivery of oxygen and glucose to the tissue results in a stimulation 
of oxidative metabolism and glycolysis. The conversion of nicotinamide to nicotinamide 
adenine dinucleotide (NAD+) also leads to a stimulation of oxidative metabolism and 
glycolysis. The second pathway involves no direct effect of nicotinamide on tumor blood 
flow but only via conversion to NAD+. Increased levels of NAD+ results in a stimulation 
of many metabolic processes, oxidative metabolism and glycolysis included. 
Beside all the hypotheses on the FDG-uptake mechanisms, the pilot study in chapter 6 
indicates that nonresponsiveness of FDG-uptake in tumors after hyperoxygenation may 
be a risk factor for failure of accelerated radiotherapy with carbogen and nicotinamide 
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treatment (ARCON). In three patients who did not achieve local tumor control, the 
SUVmax after hyperoxygenation differed less than 5% change as compared to baseline, 
whereas 13 of the 16 patients with local tumor control showed a larger difference (p 
<0.05). However, cautious interpretation of potential predictive value of FDG-PET is 
mandatory given the relatively small size of the present pilot study. Whether the absence 
of a metabolic response of tumors to hyperoxygenation proves to be a risk factor for 
failure of ARCON treatment remains to be confirmed in further clinical studies.
Many other radiopharmaceuticals besides FDG have been used for detection 
and quantification of hypoxia. These include fluorinated hypoxia markers, like 
fluoromisonidazole ([18F]FMISO). Nitroimidazole compounds are reduced under 
hypoxic conditions and irreversibly bound to cellular macromolecules. There are 
exogenous hypoxia markers, like 2-nitroimidazoles and intrinsic hypoxia markers, like 
HIF-1α and HIF-2α, carbonic anhydrase IX (CAIX), VEGF, and the glucose transporters 
GLUT1 and GLUT3 and another method for the analysis of tissue oxygenation estimates 
‘microvascular density’ (MVD). Each diagnostic method has specific advantages and 
disadvantages. The most common disadvantage of exogenous hypoxia markers is that 
only static information of the tissue oxygenation status is provided. The main advantage 
of imaging techniques is that repeated measures are possible and that temporal changes 
can be assessed, allowing evaluation of the effectiveness of an oxygenation-modifying 
intervention. It is not unlikely that the complexity of tumor physiology requires 
multimodality analysis to gain a better understanding of the tumor micro-environment 
and to obtain a ‘predictive profile’ which can guide the clinician in the selection of 
patients for ARCON therapy. This is clinically relevant as the increased loco-regional 
control rate by ARCON-treatment as compared to conventional regimens, is also 
accompanied by an increase in side effects. With ARCON, the early mucosal and skin 
reactions were more severe than generally observed with conventional radiotherapy, 
causing delayed recovery with longer healing times. This increase in toxicity underscores 
the importance of developing predictive tools to select patients that are more likely to 
benefit from ARCON or other oxygen modifying treatments.
Chapter 7 deals with the established concept in tumor biology that solid tumors 
are dependent on blood supply for their ability to grow and metastasize. Tumor 
angiogenesis, the formation of a neovascular bed in cancer, is the result of a complex 
and precise balance between proangiogenic and antiangiogenic factors produced by 
both tumor and host cells. Chapter 7 discusses the possible relevance of primary tumor-
derived angiogenesis inhibitors. To support the hypothesis that a primary tumor is able 
to suppress angiogenesis in its distant metastases, due to production of angiostatin 
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and endostatin, a case is presented in which removal of a primary colorectal tumor 
resulted in an increase in metabolic activity in its liver metastasis as measured with 
PET. Concomitantly, levels of angiostatin and endostatin in urine and plasma dropped, 
suggesting a causal relationship between these phenomena. Although no conclusion 
is possible on the basis of a single case, these results may indicate that administration 
of antiangiogenic compounds after the surgical removal of a primary tumor may be 
an interesting approach to inhibit outgrowth of distant (micro)metastases. In animal 
models, substantial evidence has been presented that vascularization and subsequent 
growth of distant metastases could be inhibited by systemic administration of the 
angiogenesis inhibitors angiostatin and endostatin. These observations call for further 
studies in humans. Further delineation of the relevance of primary tumor-derived 
antiangiogenic factors for growth and metabolic activity of distant metastases is needed. 
Such studies might provide knowledge for the rationale of administration of adjuvant 
antiangiogenic therapy to prevent the accelerated growth of (micro)metastases after 
resection of the primary tumor.
Tissue characterization
FDG-PET may also contribute to the characterization of lesions. The potential impact 
of tissue characterization with FDG-PET on patient management is illustrated by the 
diagnostic problem of thyroid nodules (chapter 8). Fine needle aspiration biopsy (FNAB) 
has to be regarded as the key investigation in the initial evaluation of thyroid nodules. 
Currently, patient management decisions and choice of therapy will be based mainly 
on the cytologic diagnosis. FNAB, however, has several recognized limitations. The 
sample is not always sufficient to allow a correct cytologic interpretation. There is a risk 
of sampling error that means that the sample is perhaps not representative of the lesion 
in question. Furthermore, follicular adenomas are particularly difficult to distinguish 
from well-differentiated follicular cancers. These patients need to undergo surgery for 
a histologic diagnosis, because the distinction is based on the presence of capsular 
invasion. Also the patients with Hürthle cells in their cytological examination should 
have surgery. Hashimoto’s thyroiditis is the third type that leads to indeterminant or 
false-positive cytologic diagnoses. However at surgery, only 20% of the nodules appear 
to be malignant, which means that futile hemithyroidectomy is performed in up to 
80% of patients. The prospective study described in chapter 8 investigated whether it 
is possible to overcome this problem when FDG-PET is implemented in the diagnostic 
 General discussion and future perspectives 267
algorithm. The results show that FDG-PET seems to be the method of choice to decide 
whether surgery or a wait and watch strategy should be recommended in case of an 
inconclusive cytology. It is recommend not relying on standardized uptake values (SUV) 
in the discrimination between malignant and benign thyroid lesions. Patients with a 
suspicious thyroid nodule with inconclusive FNAB in combination with any visible FDG-
accumulation in the thyroid nodule should be taken to surgery. 
Prognostic value
The tumor-node-metastasis (TNM) staging system is considered the most important 
tool to estimate prognosis and to date the most important guide in treatment decisions. 
However, the TNM staging system provides an incomplete biologic profile of most of 
the tumors, does not always provide a satisfactory explanation for differences in relapse 
and survival and is thus far from perfect as a prognostic indicator. The appropriate use 
of novel treatment programs requires a fundamental understanding of tumor biology 
and, ultimately, a more comprehensive approach to therapeutic planning. The results of 
the prospective study presented in chapter 9 support the hypothesis that FDG uptake 
reflects biological aggressiveness and that the quantitative measures of biological 
aggressiveness (or SUVs) could be better indicators for survival and risk of relapse. 
More specifically, the data presented in this chapter indicated that intense glucose 
metabolism in metastases of colorectal cancer was a negative marker of prognosis. These 
results were in line with the results of previous reports on the prognostic information of 
FDG uptake in patients with other primary tumors such as non-small cell lung cancer, 
head and neck squamous cell carcinoma, breast cancer, glioma, esophageal carcinoma, 
pancreatic cancer and hepatocellular carcinoma. However, there are still many questions 
and concerns. It is not yet clear whether the relationship between SUV and prognosis 
is continuous rather than based on a threshold. It seems reasonable to hypothesize 
that there is no true standardized uptake threshold value but, rather, a transition zone, 
within which the prognosis gradually worsens. Therefore, more studies are needed fully 
elucidate the prognostic significance of FDG-PET in clinical medicine to define high 
risk populations and before this technique can be used to select patients for specific 
treatment strategies, such as aggressive therapies, adjuvant treatments and treatment 
combinations an aspect that is of particular interest in the stratification of patients for 
clinical trials. A precise definition of high-risk populations requires a precise definition 
of the best cut-off levels of the semiquantitative measure (i.e. the SUV) per patient 
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category c.q. per patient tumor stage. Since the standardized uptake threshold values are 
likely to be disease and drug specific it would be desirable, in the most ideal situation, to 
study a homogeneous patient cohort in which all patients have the same tumor stage, 
the same tumor histology and are treated by the same therapeutic protocol, in order to 
assess objectively the prognostic information provided by FDG uptake. However, more 
complex issues are to be considered. There is an significant variation in PET-scanner 
hardware, scanner calibration, patient preparation, acquisition and reconstruction 
protocols, in data processing and data analysis software. There appears to be a 
strong dependency of SUVs on image resolution, noise and region of interest (ROI) 
methodology. Therefore, institutional-based technical factors can lead to variations in 
measurement of SUV and might hinder the integrated or comparative interpretation of 
the results from one centre to another. In future multi-centre trials standardization of 
acquisition, reconstruction and ROI methods is an important prerequisite for the use 
of SUV quantification for prognostic stratification and needs to be specified in EORTC 
(European Organization for Research and Treatment of Cancer) recommendations and/
or NCI (National Cancer Institute) guidelines. Application-specific phantom studies may 
reveal small persistent unavoidable differences and can be used to determine inter-
institute correction factors. Moreover, application of partial volume correction methods 
for heterogeneous tumors is still cumbersome and needs to be among the goals of 
future research. Assessment of inter-institute correction factors is less critical in trials 
focusing on assessment of treatment response. However, measurements of fractional 
changes in SUV over time are only reliable when sequential scans of the same patient 
are performed using the same scanner, under identical scanning, image reconstruction 
and data analysis conditions, what means that serial scans of one patients should be 
performed in the same institute.
Finally, future research should determine whether prognostic stratification with FDG-
PET seemingly improves survival because of stage migration or whether it truly improves 
survival because of better therapeutic decision making. It must be emphasized that 
further research in this field is of great importance, since this type of research may 
induce major changes in therapeutic concepts. Appropriate incorporation of FDG-PET 
as an imaging biomarker could dramatically alter diagnostic strategies, affect treatment 
options, and eventually improve patient outcomes. The preliminary findings presented 
in this thesis call for systematic inclusion of FDG-PET in therapeutic trials to adequately 
position FDG-PET in treatment time lines in order to change current therapeutic 
concepts to individualized treatment of patients.
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Chemotherapy response monitoring
The results of the in vitro experiments described in chapter 10 showed that FDG (reflects 
glycolytic acitivity), as well as the radiolabeled amino acid 125I-methyltyrosine (reflects 
aminoacid transport) and the halogenated thymidine analogs 125I-deoxyuridineribose 
(reflects DNA synthesis) were able to differentiate between multidrug resistant cells 
and multidrug sensitive cells. 125I-deoxyuridineribose displayed the most marked relative 
reduction in DNA synthesis and hence proliferative status, in response to exposure of 
drug-sensitive cells to doxorubicin. However, in vivo, the use of 25I-deoxyuridineribose is 
limited due to the moderate image quality and the inaccurate calculation of proliferation 
rates, due to its rapid in vivo degradation. Response to doxorubicin was affected by the 
presence or absence of the multidrug resistance-associated protein (P-gp) modulator, 
verapamil, which was clearly measured with FDG, 125I-methyltyrosine as well as with 125I-
deoxyuridineribose. The radiopharmaceutical 99mTc-tetrofosmin, originally developed 
for diagnosis of myocardial perfusion, has the advantage that it can be used before 
starting chemotherapy. The other three radiopharmaceuticals reflect the change in cell 
metabolism or proliferating activity after exposure to doxorubicin, which is essentially 
different from 99mTc-tetrofosmin that is based on functional imaging of P-gp. Our results 
show that a reduced intracellular accumulation of 99mTc-tetrofosmin is seen in resistant 
cells as compared to their drug-sensitive counterpart. Unexpectedly, the reduced uptake 
of 99mTc-tetrofosmin in resistant cells was only minimally enhanced when verapamil 
was coincubated. These findings warrant comparative studies in in vivo tumor models, 
because it may become clinically important to detect and evaluate multidrug resistance 
transporter activity in tumors. In the near future molecular imaging could hopefully be 
utilized as a tool in identifying patients who may benefit from combined therapy with 
P-gp or multidrug resistance-associated protein modulators as well as in the evaluation 
of the effectiveness of such treatment in vivo. It might also allow selection of the proper 
modulator for the individual patient. A number of drugs have been identified (e.g., 
calcium channel blockers, anti-arrhythmics, antidepressants, and many others) which 
can reverse P-gp-mediated multidrug resistancy. These drugs (e.g. verapamil, quinidine, 
and cyclosporine A) sensitize multidrug resistant tumor cells to co-administered 
cytotoxic agents. However, many of them are of limited clinical use due to side effects 
in the relevant doses. It may be valuable to assess the effect of a modulator on both 
tumor tissue and normal tissues in each individual patient prior to treatment, not only 
to choose the most effective modulator or combination of modulators in clinical trails, 
but also to determine the most effective dose combined with the least toxicity of 
anticancer drugs.
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Although the hallmark for evaluation of therapeutic effectiveness of cancer treatment, 
current morphological imaging techniques such as computed tomography (CT) have 
limitations in reliably distinguishing necrotic tumor or fibrotic scar from residual tumor 
tissue. Furthermore, CT scanning is known to be an imperfect tool to evaluate local 
response after radiotherapy, given the possibilities of fibrosis, effusions, atelectasis, and/
or radiation pneumonitis. Some lesions may persist indefinitely on CT scan, despite the 
achievement of local control. CT and MRI have significant limitations at anatomic sites 
such as the pleura. Irregular tumor shapes may be difficult to measure, also due to poor 
contrast at the interface between tumor and normal thoracic structures. Furthermore 
some new therapies may be cytostatic instead of cytoreductive, in which case successful 
treatment may not lead to a decrease in tumor size, and thus poses new demands on 
imaging modalities. FDG-PET is ideally suited to overcome these kinds of problems. The 
prospective studies described in chapter 12 and chapter 13, demonstrated that FDG-PET 
is a valuable technique in the evaluation of tumor response to chemotherapy. For non-
small-cell lung cancer patients (chapter 12) as well as colorectal cancer patients (chapter 
13) it has been shown that the degree of chemotherapy-induced changes in tumor 
glucose metabolism was highly predictive for patient outcome, stratifying patients 
into groups with widely differing overall- and progression free survival probabilities. 
In chapter 13 it was confirmed by performing FDG-PET after 6 month of treatment that 
patients with a metabolic response early in the course of therapy are likely to maintain 
the clinically meaningful response later.
Changes in FDG uptake as a response to a therapeutic intervention can be assessed 
qualitatively, but also have the potential to be quantitated. To allow reliable 
determination of changes in tumor metabolism with time, accurate quantitative 
results are required. For therapy response studies, however, a variety of techniques 
and analytical methods are currently used, which vary widely in the required scanning 
time and the complexity of data analysis. The optimal method was not yet defined, 
because it was still unclear whether more advanced kinetic techniques were superior 
to more basic methods like calculation of the SUV. For SUV calculation only the amount 
of injected radioactivity and the body weight of the patient are required. These two 
parameters are used to normalize the measured activity concentration within the tumor 
between different patients and scans. SUVs, however, do not differentiate between 
metabolized and nonmetabolized intracellular or extracellular FDG. Therefore more 
advanced kinetic techniques and analytical methods, like the Patlak analysis, take into 
account differences in the whole-body distribution of FDG that may affect tumor tissue 
uptake at the time of scanning. The measure derived from this Patlak analysis, MRGlu, 
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is therefore in principle a more reliable measure than SUV. However, a disadvantage 
is that kinetic techniques generally require dynamic data acquisition. This means that 
multiple images of the tumor region are recorded to measure the time course of FDG 
accumulation by the tumor tissue. In addition, the clearance of FDG from the blood has 
to be determined, for which arterial sampling is the commonly accepted gold standard. 
Arterial sampling, however, is an invasive procedure, and less suitable for repetitive use 
in patients undergoing chemotherapy. An alternative method used for characterization 
of the input function is blood time-activity curves derived from the PET images, 
using volumes of interest on large vascular structures such as the left ventricle or the 
aorta. These image-based methods are attractive because they are noninvasive and, if 
validated, can make the quantification reliable and practical. Because image-derived 
input functions potentially suffer from low signal-to-noise ratios, from partial volume 
and spillover problems, and from patient movement, it was necessary to assess the 
accuracy of FDG-PET measurements based on different input functions before FDG-PET 
can be applied for therapy monitoring in routine clinical practice. The study presented 
in chapter 11 compared calculation of the MRGlu using noninvasive image-derived input 
functions obtained from several large vascular structures with calculations using the 
arterial plasma time-activity curve as a reference. The results showed that uncorrected 
image-derived methods are accurate and simple, can be applied in oncological therapy 
monitoring studies and thus represent a clinically viable alternative to arterial blood 
sampling. Therefore it was justified to include for the studies described in chapter 12 and 
13 patients also when arterial cannulation was contra-indicated or not feasible. In these 
prospective studies a study design was used, which allowed for comparative analysis of 
quantitative (MRGlu) and semiquantitative (SUV) PET methods. Multiple follow-up scans 
encourage a simplified approach to improve patient compliance, an important feature 
of successful clinical trials. Calculation of the SUV is a simplified method that can be 
calculated from static whole-body FDG-PET studies. In quantitative dynamic scans only 
one axial field of view of typically 15-20 cm can be studied during the dynamic data 
acquisition. As metastatic lesions in different parts of the body may respond differently 
to chemotherapy, this represents a principal advantage of SUV. The results presented 
in chapter 12 and 13 showed that semiquantitative methods (SUV) could replace the 
more complex, quantitative (MRGlu), Patlak graphical analysis in this patient group. As no 
sophisticated methods for data analysis are required, the use of FDG-PET for therapy 
monitoring seems clinically feasible.
To facilitate implementation of FDG-PET for therapy assessment in clinical practice it 
is important to define prospective response criteria like mandatory in conventional 
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response assessment using size criteria (Response Evaluation Criteria in Solid Tumors 
or RECIST). To provide a framework for comparison between studies The European 
Organization for Research and Treatment of Cancer (EORTC) proposed criteria, already 
in 1999, for FDG-PET to assess the response to treatment, analogous to the definition 
of RECIST. A 15% to 25% decrease in SUV was estimated to be a sign of partial metabolic 
response after one cycle of chemotherapy and greater than 25% after more than one 
treatment cycle. These criteria were developed by consensus between a range of PET 
experts and currently represent the most authoritative SUV-based recommendations. 
However, objective validation of the EORTC-proposed thresholds of responsiveness 
was lacking up to now. Therefore prospective definitions of metabolic response were 
evaluated in the response monitoring studies as reported in chapter 12 and 13. The results 
demonstrated highly significant differences in (progression free) survival between each 
stratum. Also when applying the same cut-off levels that are used for size measurement 
in standard clinical response assessment with conventional methods according to 
RECIST, significant differences between the strata were found in progression free as 
well as overall survival.
Many factors may influence SUV measurements, such as patient size, plasma glucose 
and insulin levels, and the interval between FDG injection and image acquisition. 
Furthermore, a significant loss of body weight during anticancer therapy could affect 
the use of serial measurements of the SUV. Correction of SUV by body surface area 
(SUVBSM) or lean body mass (SUVLBM) reduces this dependency on body weight. Future 
comparative studies should define which simplified method is best: SUV corrected for 
body surface area, SUV corrected for lean body mass, SUV corrected for plasma glucose, 
or the SUV used in the present thesis (i.e. just corrected for body weight).
Another factor that can affect the (semi)quantitative values is the definition of the so-
called ‘region of interest’ or ROI, the tumor region to be sampled on the PET image. 
Tumors are heterogeneous, containing non-tumor elements like fibrosis, necrosis 
and cystic regions. In response assessment the distribution of viable tumor and total 
tumor volume may change over the time course of serial scanning. This becomes more 
likely as the period between the pretherapy and post-therapy scan is extended and 
ROI definition may be further compromised by alteration of the patient position, the 
location of the tumor in relation to other organs and the paucity of anatomical detail 
on PET scans. Determination of the most suitable and reliable ROI definition method 
should also be subject of future comparative studies.
Apart from technical and methodological issues and ROI definition, another important 
variable is the timing of FDG-PET for response assessment. Optimal timing of PET scans 
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at some point during the treatment schedule or soon after the completion of treatment 
depends on different chemosensitivities of tumors, tumor heterogeneity and modes of 
drug action. Assessments performed too early might overestimate FDG uptake, since 
glucose metabolism can still be present in cells that have received lethal damage, and 
due to inflammatory reactions in responding tissues. Assessments that are performed 
too late can also be less suitable, due to the risk of tumor repopulation. Especially after 
radiotherapy it has been frequently recommended to carefully select the optimal interval 
from completion of radiotherapy to FDG-PET imaging. It is recommended to perform 
post-therapy FDG-PET studies at 3-6 months after irradiation in order to completely 
exclude influences of inflammation. In the post-therapy setting, approximately 25% of 
FDG uptake can occur in macrophages, neutrophils, fibroblasts, and granulation tissue. 
On the other hand, late measurements do not accurately reflect the status of the tumor 
after therapy. Furthermore, response monitoring at an earlier and perhaps clinically 
more relevant stage of treatment is important, especially when evaluating induction 
treatments. At present, there are no systematic data available on the determination of 
the most optimal time to perform FDG-PET after radiotherapy or chemotherapy. So, 
the aspect of timing is probably the most important for future research in the field of 
response assessment with FDG-PET.
Although the present research showed that FDG-PET is of value in predicting outcome of 
anti-tumor therapy, therapy assessment with FDG-PET is still in its infancy. The methods 
of measurement of FDG uptake currently are diverse, timing with respect to anticancer 
therapy and used thresholds to define response are variable. Therefore, further study 
is required which has to deal with these major issues before it is possible to draw 
definite conclusions on FDG-PET as a tool for therapy response monitoring. Therapy 
response assessment with FDG-PET remains a very worthwhile track of research to 
pursue, since FDG-PET could be helpful in shortening the track of early clinical trials 
that assess new antineoplastic agents and could also be helpful in improving patient 
management by reducing morbidity, efforts and costs of ineffective treatment in 
nonresponders. Eventually, randomized trials comparing PET-controlled strategies with 
standard strategies need to be performed to provide definite proof for the clinical value 
of treatment monitoring with FDG-PET.
Finally, it should not be ignored that there are more radiopharmaceuticals for PET 
beyond FDG. The goal of more targeted, individualized therapies probably needs more 
specific, biologically directed imaging, a role for which PET is ideally suited. Future 
applications of PET for therapy response assessment will likely involve other tracers 
in addition to FDG, to better characterize tumor biology and more effectively measure 
response to therapy.
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Currently, there is an increasing interest in the oncological applications of FDG-PET 
beyond staging. This thesis focused on the utilization of FDG-PET as an imaging 
biomarker. Four diagnostic challenges on this topic were subject for investigation: the 
understanding of the underlying mechanisms of FDG accumulation, characterization 
of lesions, definition of high-risk populations and prediction of treatment outcome 
with FDG-PET. These topics were studied in three types of cancer: non-small-cell lung 
cancer (NSCLC), colorectal cancer and cancer of the head- and neck area. The advances 
in molecular imaging with FDG-PET in these tumor sides were discussed in the first 
three chapters.
Chapter 1 provides a systematic review of the literature on the value of FDG-PET as 
a marker for prediction (i.e. therapy response monitoring) and prognosis in NSCLC, 
addressing the predictive value of FDG-PET in locally advanced and advanced disease, 
the prognostic value of FDG-PET at diagnosis, after induction treatment and in recurrent 
disease. Furthermore, the background and recommendations for the application of 
FDG-PET for these indications were discussed.
Chapter 2 discusses the current role and potential future applications in the management 
of patients with colorectal cancer. The literature was reviewed on the established role 
of FDG-PET in distinguishing fibrosis and scar from viable tumor in residual masses 
of rectal cancer, localization of recurrence in patients with an unexplained rise of 
serum carcinoembryonic antigen, staging before surgical resection of recurrence and/
or metastases, and on its emerging role in the prediction and evaluation of treatment 
response, such as monitoring of radiotherapy and multimodality treatment response 
in primary rectal cancer, monitoring response after local ablative therapy of liver 
metastases and monitoring chemotherapy response in advanced colorectal cancer.
An overview of the applications of FDG-PET in Thyroid cancer is provided in Chapter 3. 
The role of FDG-PET in the assessment of thyroid nodules and the relevance of the so-
called thyroid PET incidentaloma, were discussed. Information is provided on the current 
and future clinical use of FDG PET for each type of thyroid cancer; differentiated thyroid 
carcinoma, Hürthle cell carcinoma, anaplastic thyroid carcinoma and medullary thyroid 
carcinoma.
FDG-uptake: mechanisms and interactions
As many factors can influence the extent of FDG uptake, the underlying mechanisms 
for FDG accumulation in tumors, are still a matter of debate. In Chapter 4 these 
possible mechanisms were investigated in the primary site of early-stage preoperatively 
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untreated NSCLC. Nineteen patients, who had undergone both preoperative FDG-PET 
imaging and curative surgery, were enrolled in this study. Standardized uptake values 
(SUVs) were used for evaluation of primary tumor FDG uptake. Final diagnosis and 
size of the primary tumors were confirmed histopathological in resected specimens 
and histologic sections were analyzed for degree of necrosis and anti tumor immune 
response. Expression of the glucose membrane transporters (GLUT-1 and GLUT-3); the 
isoforms of the rate-limiting glycolytic enzyme hexokinase (HK-I, HK-II and HK-III); 
and the cysteine protease caspase-3, was evaluated by immunohistochemistry. FDG 
uptake appeared to be significantly higher in squamous cell carcinomas compared to 
adenocarcinomas, or large cell carcinomas. Furthermore, the results showed that tumor 
cell differentiation in combination with overexpression of GLUT-1 and GLUT-3 primarily 
determine the extent of FDG accumulation in untreated early-stage NSCLC.
Chapter 5 describes an examination of the in vivo relationship between FDG uptake as 
measured with PET and functional tumor vasculature as measured by DCE-MRI in patients 
with liver metastases of colorectal cancer. Twenty-six patients with liver metastases of 
colorectal cancer who were prepared for liver metastasectomy were included. Whole 
body FDG-PET was performed and tumor to non-tumor ratios of FDG uptake (T/NT) 
in the metastases were calculated. DCE-MRI was performed and the rate constant kep 
(s-1) of Gadolinium-DTPA uptake in the metastases was determined. Tumor hypoxia and 
vascular density of the metastases were determined by immunohistochemistry with 
the use of the hypoxic marker pimonidazole. To assess any correlation between FDG 
uptake, rate constant kep of Gd-DTPA uptake, hypoxic fraction and vascular density 
the Pearson’s correlation r was calculated. A negative correlation between T/NT and 
kep was observed. No correlation between tumor hypoxia and T/NT or kep was found. A 
positive correlation was observed between vascular density and kep, but not with T/NT. 
The negative correlation between T/NT and kep suggests that lower values of Gd-DTPA 
uptake rate imply an acutely reduced supply of oxygen, which necessitates a higher 
uptake of glucose to maintain tumor energy levels. The positive correlation of vascular 
density with kep, but not with T/NT, emphasizes the potential of DCE-MRI to measure 
tumor vascularity in vivo and its additional value compared to ex vivo methods.
Oxygen mediates the biological effects of ionizing radiation, as the cellular damage 
of radiation depends strongly on the availability of oxygen. Hypoxia has a negative 
effect on treatment outcome not only through enhanced radioresistance but also 
by promoting more aggressive tumor behavior. Tumor-cell repopulation is the 
other important mechanism responsible for radiotherapy resistance. Application of 
Accelerated Radiotherapy with CarbOgen and Nicotinamide (ARCON) tries to overcome 
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these problems. To counteract repopulation of clonogenic tumor cells during therapy, 
the overall treatment time is reduced by delivering the total radiation dose in multiple 
fractions per day and tumor-cell hypoxia is counteracted with the inhalation of the 
hyperoxic gas carbogen, to decrease diffusion-limited hypoxia, and the administration 
of the vasoactive agent nicotinamide, to decrease perfusion-limited hypoxia. In Chapter 
6 the effect of hyperoxygenation on tumor metabolism as determined with FDG-PET 
was investigated in patients with head-and-neck cancer. Within one week, FDG-PET 
was performed with and without hyperoxygenation by carbogen breathing and/or 
nicotinamide administration in 22 patients, eligible for ARCON. Maximum standardized 
uptake values (SUVmax) in both scans and the fractional change were calculated in 
the primary tumor and in normal muscle. Alteration of the tumor oxygenation state 
induced profound, but variable metabolic changes. Metabolism in normal muscle, 
however, was not affected. In three patients who did not achieve local tumor control, 
the SUVmax after hyperoxygenation remained relatively constant (<5% change as 
compared to baseline), whereas 13 of the 16 patients with local tumor control showed a 
larger difference. The prognostic significance of semiquantitative FDG-PET before and 
after hyperoxygenation, however, remains uncertain and requires confirmation in larger 
clinical studies before introducing the procedure as a predictive tool for oxygenation 
modifying treatments.
Tumor angiogenesis, the formation of a neovascular bed in cancer, is the result of a 
complex and precise balance between proangiogenic and antiangiogenic factors 
produced by both tumor and host cells. Chapter 7 discusses the possible relevance of 
primary tumor-derived angiogenesis inhibitors. To support the hypothesis that a primary 
tumor is able to suppress angiogenesis in its distant metastases, due to production of 
angiostatin and endostatin, a case is presented in which removal of a primary colorectal 
tumor resulted in an increase in metabolic activity in its liver metastasis as measured 
with PET. Concomitantly, levels of angiostatin and endostatin in urine and plasma, 
respectively, dropped. This finding was also noticed in 5 comparable subjects but not 
in 6 control patients, that underwent two PET-scans without resection of the primary 
tumor, which could be an indication that removal of the primary lesion causes a flare-up 
in vessel neoformation, which probably was the cause of enhanced metabolic activity 
in its liver metastases.
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Tissue characterization
Also in the characterization of lesions, the domain of pathological evaluation, FDG-
PET may contribute in a non-invasive way. This is of major importance since it could 
reduce the need for invasive procedures and futile surgery, which ultimately results in a 
decrease of morbidity and costs. The significant impact that tissue characterization with 
FDG-PET could have on patient management is illustrated by the prospective study that 
was described in Chapter 8. The aim of that study was to explore the potential of FDG-
PET to reduce the number of unnecessary hemithyroidectomies in the preoperative 
assessment of thyroid nodules with an inconclusive fine needle aspiration biopsy 
(FNAB). The problem of FNAB is the inconclusive finding in up to 20% of patients with 
solitary thyroid nodules. In these cases, hemithyroidectomy is necessary, but only 
20% of the nodules ultimately prove to be thyroid carcinoma. Forty-four consecutive 
patients, scheduled for hemithyroidectomy because of inconclusive FNAB, participated 
in the study. FDG-PET of the thyroid region was performed before hemithyroidectomy 
and SUVs were calculated. The final histopathological diagnosis served as a standard 
of reference. Histopathology of the surgical specimens revealed 7 well-differentiated 
thyroid carcinomas in 6 patients, all accumulating FDG. This resulted in a very high 
negative predictive value. FDG accumulated in 13 of 38 benign nodules. The pre-PET 
probability for cancer in this study population was 14%, and the post-PET probability 
increased to 32%. The number of unnecessary hemithyroidectomies in a hypothetical 
algorithm using FDG-PET would only be 30% compared to 86% in an algorithm without 
FDG-PET. FDG-PET significantly reduces the number of futile hemithyroidectomies by 
66%. Semiquantitative analysis using SUVs did not help to further reduce this number. 
This study concludes that FDG-PET should play an important role in the management 
of patients with inconclusive cytological diagnosis of a thyroid nodule since it is able to 
reduce the number of futile hemithyroidectomies.
Prognostic value
As individualized treatment strategies become more relevant, there is a need for 
identification of novel biologic pretreatment factors that potentially predict outcome, 
to ensure that patients benefit from novel anticancer therapies and intensive treatment 
combinations. These pretreatment factors may be of particular value in stratifying patients 
for clinical trials. “The degree of tumor metabolism” could be such a potential biologic 
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pretreatment factor that can be non-invasively measured with PET. Several investigators 
have speculated that FDG uptake resembles the biological behavior of the tumor, and 
might be associated with intrinsic biologic characteristics, like hypoxia, low apoptosis 
rate, cell viability, proliferative activity and p53 overexpression. These characteristics are 
all potentially adverse factors in patients treated with radiotherapy or chemotherapy, 
while some of them may also impact negatively in patients treated surgically. The ability of 
FDG-PET to identify high-risk populations was studied in Chapter 9. This study focused 
on the prognostic value of pretreatment metabolic activity in metastases as measured 
with FDG-PET, as an indicator of survival in colorectal cancer. In a prospective series of 
152 patients with metastatic colorectal cancer, of whom 67 were treated with resection 
of metastases and 85 with chemotherapy, SUVs were calculated prior to treatment. 
Survival probabilities were estimated by Cox proportional regression analysis. For 
Kaplan-Meier analysis SUV was stratified by the median value and survival differences 
were assessed using the log-rank test. SUV in metastases was a significant predictor for 
overall survival, independent of the subsequent treatment. According to the median 
value of the patient population a low and high uptake group was defined. Survival rates 
significantly differed between the low and high uptake group: median survival and the 
2- and 3-year survival were 32 months, 59% and 45%, respectively, in the low-uptake 
group and 19 months, 37% and 28%, respectively, in the high-uptake group. Therefore 
it could be concluded that a significant survival benefit was observed in patients with 
low FDG uptake in metastases of colorectal cancer. Furthermore, pretreatment FDG 
uptake in metastatic colorectal cancer predicts outcome, irrespective of the subsequent 
treatment modality, as patients with FDG avid disease show reduced overall survival. 
This implies that FDG-PET is a promising imaging biomarker that in the future could 
become an important adjunct to traditional staging to improve appropriate selection 
of high-risk candidates for aggressive multimodality treatments and could be helpful in 
stratifying patients for prospective studies when different therapeutic options are to 
be compared.
Chemotherapy Response Evaluation
The last part of this thesis deals with FDG-PET for the prediction of tumor response to 
therapy. Although the hallmark for evaluation of therapeutic effectiveness of cancer 
treatment, current morphological imaging techniques such as computed tomography 
(CT) have limitations in reliably distinguishing necrotic tumor or fibrotic scar from 
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residual tumor tissue. Furthermore some new therapies may be cytostatic instead of 
cytoreductive, in which case successful treatment may not lead to a decrease in tumor 
size, and thus poses new demands on imaging modalities.
One of the major problems in the treatment of cancer with chemotherapeutics is 
the development of multidrug resistance by tumor cells. It is of clinical importance to 
identify those patients that will respond to particular anticancer agents and therefore 
to avoid unnecessary toxicity, (effective) therapy delay and expense in nonresponsive 
patients. Various mechanisms are responsible for multidrug resistance, one of the most 
important being the overexpression of a plasma membrane phosphoglycoprotein, P-
glycoprotein (P-gp). P-gp, is the transporter protein responsible for actively pumping 
cytotoxic agents out of the cell, which was focused on in the study reported in chapter 10. 
Chemotherapeutic agents such as anthracyclines, vinca alkaloids, epipodophyllotoxins, 
taxanes and several other drugs, such as cardiovascular drugs (verapamil and digoxin), 
and immunosuppressives are substrates for P-gp and are extruded out of the cell by P-
gp. It is relevant to identify patients with multidrug resistance due to overexpression of 
P-gp. Detection of protein and RNA expression for the MDR1 pump can be performed 
in human tumor samples using a variety of techniques, such as immunohistochemistry, 
quantitative autoradiography, and reverse transcriptase polymerase chain reaction. 
However, detection of P-gp does not necessarily provide any information about the 
function of these pumps in the respective tissues. Radiotracers that can visualize the 
activity of cellular efflux pumps non-invasively are therefore of interest. In Chapter 
10 four radiopharmaceuticals, 18F-deoxyglucose, 99mTc-tetrofosmin, 125I-methyltyrosine 
and 125I-deoxyuridineribose, were investigated in vitro for their ability to monitor the 
response of cancer cells to doxorubicin treatment, in the presence and absence of the 
calcium channel blocker verapamil, a potent modulator of P-gp. Being informed about 
the effect of a modulator on both tumor tissue and normal tissues in each individual 
patient before starting chemotherapy could be clinically useful. This may help to select 
patients who will benefit most from the addition of a modulator to the chemotherapeutic 
regimen. The results of this study show that 18F-deoxyglucose, 125I-deoxyuridineribose and 
125I-methyltyrosine uptake is more pronouncedly reduced after exposure to doxorubicin 
in cells that are drug sensitive as compared to cells that are drug resistant. In order to 
demonstrate that tracer uptake indeed reflected cell proliferation, the mitochondrial 
dehydrogenase activity, and hence cell survival was measured. Exposure to doxorubicin 
induced a reduction in cell mitochondrial dehydrogenase activity, which was more 
pronounced in the drug sensitive cells. The radiopharmaceuticals 18F-deoxyglucose, 125I-
deoxyuridineribose and 125I-methyltyrosine all showed a clear discrimination in uptake 
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pattern between the sensitive and the resistant cell line. Second, the effect was reversed 
by addition of the P-gp-modulator verapamil. The radiopharmaceutical 99mTc-tetrofosmin 
originally developed for diagnosis of myocardial perfusion has the advantage that it could 
be used before starting chemotherapy. The other three radiopharmaceuticals reflect the 
change in cell metabolism or proliferating activity after exposure to doxorubicin, which 
is essentially different from 99mTc-tetrofosmin, which is based on functional imaging of 
P-gp. Our results show that a reduced intracellular accumulation of 99mTc-tetrofosmin is 
seen in resistant cells as compared to their drug-sensitive counterpart. Unexpectedly, 
the reduced uptake of 99mTc-tetrofosmin in resistant cells was only minimally enhanced 
when verapamil was coincubated. Possibly due to the relatively high P-gp expression 
on these cells verapamil could not effectively enhance intracellular 99mTc-tetrofosmin 
accumulation. Interestingly, the coincubation of verapamil hardly affected the number 
of viable cells. In contrast, the cellular uptake of 18F-deoxyglucose, 125I-methyltyrosine and 
125I-deoxyuridineribose was markedly reduced when verapamil was added, indicating that 
verapamil reduced the metabolic functions of the cells (glycolytic acitivity, aminoacid 
transport and DNA synthesis) rather than affecting the number of cells. 
Chapter 11 addresses some technical and methodological issues of therapy response 
evaluation with FDG-PET. Changes in FDG uptake as a response to a therapeutic 
intervention can be assessed qualitatively, but also have the potential to be quantitated. 
To allow reliable determination of changes in tumor metabolism with time, accurate 
quantitative results are required. Consequently, dynamic scanning should be applied 
to determine a tumor time-activity curve and a plasma time-activity curve, for which 
arterial sampling is the commonly accepted gold standard. Arterial sampling, however, 
is an invasive procedure, and less suitable for repetitive use in patients undergoing 
chemotherapy. The aim of the study presented in this chapter was to validate a 
noninvasive image derived method to determine the input function from PET images. 
For this purpose 136 dynamic FDG-PET scans were obtained in 76 oncological patients. 
Image-derived input functions (IDIFs) were obtained using volumes of interest of the 
left ventricle, the ascending aorta and the abdominal aorta. Calculation of the metabolic 
rate of glucose (MRGlu) in tumor lesions as determined with the Patlak graphical analysis 
using these IDIFs, have been compared with measurements using the arterial plasma 
time-activity curve as the gold standard. Good correlations were observed between 
MRGlu values based on IDIFs and those based on arterial sampling. The study showed 
that uncorrected image-derived methods are accurate and simple, can be applied in 
oncological therapy monitoring studies and thus represent a clinically viable alternative 
to arterial blood sampling. 
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Chapter 12 presented the results of a prospective study that evaluated the value of 
FDG-PET for the assessment of chemotherapy response in patients with NSCLC. In 
51 patients dynamic FDG-PET was performed before and at 5-8 weeks into treatment. 
Simplified methods to measure glucose metabolism (SUV) and quantitative measures 
(MRGlu), derived from Patlak analysis were evaluated. The overall- and progression free 
survival with respect to MRGlu and SUV were calculated using Kaplan-Meier estimates. 
Fractional changes in tumor glucose use were stratified by the median value and also 
the predefined EORTC metabolic response criteria and criteria applying cut-off levels 
similar to those of RECIST, were evaluated. When stratifying at the median value of the 
fractional change of MRGlu (∆MRGlu) and ∆SUV, the difference in overall- and progression 
free survival was highly significant. When applying the predefined criteria for metabolic 
response, the cut-off levels as also used for size measurement (RECIST) showed 
significant differences for the fractional change of SUV between response categories 
in progression free- as well as overall survival. Therefore it could be concluded that the 
degree of chemotherapy-induced changes in tumor glucose metabolism as determined 
by FDG-PET is highly predictive for patient outcome, stratifying patients into groups 
with widely differing overall- and progression free survival probabilities. Furthermore, 
the use of FDG-PET for therapy monitoring seems clinically feasible, since simplified 
methods to measure tumor glucose use (SUV) are sufficiently reliable and can replace 
more complex, quantitative measures (MRGlu) in this patient population.
The study presented in Chapter 13 had the same aim and study design as the study 
described in Chapter 12. Here, patients with advanced colorectal cancer were prospectively 
studied. Dynamic FDG-PET was performed before and at 2 (n=50) and 6 months (n=19) 
after start of treatment. There was an increase in the rates of death and progression 
associated with worse response as assessed by PET on Cox proportional regression 
analysis. The overall- and progression free survival analysis showed a significant 
predictive value at broad ranges of ∆MRGlu and ∆SUV cut-off levels. Therefore, also for 
colorectal cancer patients with advanced disease it has been shown that the degree of 
chemotherapy-induced changes in tumor glucose metabolism is highly predictive for 
patient outcome. Also in this patient category simplified methods (SUV) can replace the 
more complex quantitative measures (MRGlu).
Chapter 14 provides a general discussion of the results presented in this thesis and 
future perspectives are indicated.
Chapter 16
Samenvatting in het Nederlands
286 Hoofdstuk 16
 Samenvatting in het Nederlands 287
Inleiding
De energievoorziening van kwaadaardige cellen berust hoofdzakelijk op anaërobe 
glycolyse. Dit is echter zeer nadelig, omdat anaërobe glycolyse in vergelijking met aërobe 
glycolyse een inefficiënt proces is, waarbij per molecuul glucose maar een beperkte 
hoeveelheid energie (ATP) vrijkomt. Hierdoor ontstaat bij kankercellen een grote 
glucosebehoefte. Van deze eigenschap maakt de techniek 18F-fluorodeoxyglucose (FDG) 
positron emissie tomografie (PET) gebruik. Het FDG is een suikermolecuul, dat gelabeld 
wordt met de positron-emitter 18F. Positronemissie houdt in dat positief geladen deeltjes 
(positronen) worden uitgezonden. Een positron versmelt met het dichtstbijzijnde 
negatief geladen elektron, waarbij de deeltjes worden omgezet in twee gammastralen, 
die onder een hoek van 180° worden uitgezonden en kunnen worden gedetecteerd 
door een PET-camera. Analoog aan glucose wordt FDG via GLUT-transporters de cel in 
getransporteerd. Daar wordt het door het enzym hexokinase omgezet in FDG-6-fosfaat. 
Het FDG-6-fosfaat verschilt zodanig van het glucose-6-fosfaat, dat het gevangen wordt in 
de cel en er geen verdere afbraak via de glycolyse plaatsvindt. Hierdoor stapelt het FDG-6-
fosfaat in cellen met een verhoogd metabolisme, zoals tumorcellen. Dit fenomeen ligt ten 
grondslag aan het klinisch succes van FDG-PET. FDG-PET kan fibrose en littekenweefsel 
als gevolg van therapie goed onderscheiden van levend tumorweefsel in restmassa’s. 
De techniek is zeer geschikt voor het lokaliseren van een recidief bij patiënten met 
een onverklaarbare stijging van de serum tumormarkers. Al enkele jaren wordt FDG-
PET routinematig toegepast bij preoperatieve stadiëring van diverse maligniteiten. 
Tegenwoordig is er echter ook grote interesse voor andere toepassingen van FDG-PET 
in de oncologie. Omdat geïndividualiseerde behandelingsstrategieën steeds actueler 
worden en de keuze aan behandelingsmogelijkheden zeer snel toeneemt, is er een 
groeiende behoefte nieuwe pretherapeutische factoren of biomarkers te identificeren 
ten behoeve van voorspelling van prognose en therapie effect. Enkele nieuwe therapieën 
zijn cytostatisch en hebben geen cytoreductieve werking. Zo’n therapie kan succesvol 
zijn zonder dat dit leidt tot een afname in tumorgrootte, wat zodoende andere eisen 
stelt aan respons evaluerende beeldvormende technieken. Zo zijn er talloze zaken die 
voordeel zullen ondervinden van een accurate techniek om laesies te karakteriseren.
De moleculaire metabole informatie die FDG-PET verschaft maakt FDG-PET een 
veelbelovende beeldvormende biomarker. Een biomarker kan gedefinieerd worden als 
indicator van normale biologische processen, pathologische processen, of als indicator 
van respons op een therapeutische interventie. Biomarkers beogen richting te geven 
aan een diagnostisch traject, een ziekte te karakteriseren, een surrogaat klinisch 
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eindpunt te verschaffen, danwel het effect van therapie of de prognose te voorspellen. 
Met betrekking tot dit onderwerp werden in dit proefschrift vier items besproken: 
mogelijke mechanismen van en interacties met FDG accumulatie, karakterisering van 
weefsels met behulp van FDG-PET, differentiatie van hoog- en laag-risico populaties en 
predictie van behandelingseffect. Deze vier onderwerpen werden onderzocht in drie 
kankersoorten: niet-kleincellig longcarcinoom, colorectaal carcinoom en carcinomen 
van de hoofd-hals regio. De eerste drie hoofdstukken van dit proefschrift verschaffen 
een overzicht van de ontwikkelingen op het gebied van FDG-PET met betrekking tot 
deze drie tumorlokalisaties.
FDG accumulatie: mechanismen en interacties
Er zijn vele factoren die van invloed kunnen zijn op de mate van FDG stapeling. Op dit 
terrein bestaan nog veel onduidelijkheden. In Hoofdstuk 4 werden de onderliggende 
mechanismen van FDG accumulatie onderzocht in primaire tumoren van vroege stadia 
van onbehandeld niet-kleincellig longcarcinoom. Preoperatief werd een FDG-PET verricht 
en de mate van FDG stapeling bepaald. In het resectiepreparaat werd de uiteindelijke 
histopathologische diagnose en de grootte van de primaire tumor vastgesteld. In de 
histologische coupes werd de mate van necrose en anti-tumor immuunrespons bepaald. 
De expressiegraad van de glucose membraan transporters, van de isovormen van het 
enzym hexokinase en het cysteine protease caspase-3, werd immunohistochemisch 
bepaald. In plaveiselcelcarcinomen bleek de FDG accumulatie significant hoger dan in 
adenocarcinomen of grootcellige carcinomen. Uit de resultaten bleek bovendien dat de 
tumorcel differentiatiegraad in combinatie met de mate van overexpressie van glucose 
membraan transporters hoofdzakelijk het niveau van FDG accumulatie bepalen.
Hoofdstuk 5 beschrijft de resultaten van een studie waarbij de relatie tussen FDG 
stapeling, gemeten met PET, en functionele tumor vasculatuur, gemeten met dynamic 
contrast material-enhanced magnetic resonance imaging (DCE-MRI), bestudeerd werd 
bij patiënten met levermetastasen van colorectaal carcinoom. Na toediening van de 
merkstof pimonidazol werden in het operatiepreparaat zuurstoftekort en vaatdichtheid 
in de metastasen met behulp van immunohistochemie bepaald. De resultaten van dit 
onderzoek suggereren dat lagere waarden van de snelheidsconstante van Gadolinium-
DTPA opname, gemeten met DCE-MRI, geassocieerd zijn met een acute reductie in 
de toelevering van zuurstof. Het hierdoor ontstane zuurstoftekort leidt tot een hogere 
opname van glucose in de metastasen om zo het energieniveau van de metastasen 
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te kunnen handhaven. De positieve correlatie tussen vaatdichtheid en de hoogte 
van de Gadolinium-DTPA snelheidsconstante, benadrukt de waarde van DCE-MRI 
voor de meting van bloedvoorziening van tumoren in vivo in vergelijking met ex vivo 
methoden.
Zuurstof is van belang voor het biologisch effect van ioniserende straling, omdat de 
door straling geïnduceerde celschade sterk afhankelijk is van zuurstof. Zuurstoftekort 
of hypoxie heeft een negatieve invloed op het behandelingseffect doordat de gevolgen 
tweeërlei zijn: hypoxie veroorzaakt ongevoeligheid voor straling en bevordert 
agressiever gedrag van de tumor. Repopulatie van tumorcellen is het andere belangrijke 
mechanisme dat verantwoordelijk is voor radiotherapie resistentie. Getracht wordt 
deze problemen te overwinnen met een bijzondere vorm van radiotherapeutische 
behandeling: Accelerated Radiotherapy with CarbOgen and Nicotinamide (ARCON). 
Om repopulatie van clonogene tumorcellen gedurende de therapie tegen te gaan, 
wordt de totale stralingsdosis in meerdere fracties per dag gegeven, waardoor de 
totale behandelingsduur verkort wordt. Het zuurstofgebrek in de tumorcellen wordt 
enerzijds tegengegaan door inhalatie van het hyperbare gas carbogeen, dat de diffusie 
gelimiteerde hypoxie vermindert, en anderzijds door de inname van de vasoactieve 
stof nicotinamide, die de perfusie gelimiteerde hypoxie terugdringt. In Hoofdstuk 6 
wordt het effect van hyperoxygenatie therapie op het tumor metabolisme met behulp 
van FDG-PET onderzocht bij patiënten met hoofd-hals carcinoom. Bij patiënten die in 
aanmerking kwamen voor ARCON therapie werden binnen één week twee FDG-PET 
scans gemaakt: één zonder en één met hyperoxygenatie met behulp van carbogen 
en/of nicotinamide. Verandering in de tumor oxygenatie status induceerde subtiele 
metabole veranderingen, zowel in positieve als in negatieve zin. Het metabolisme 
in normale spieren reageerde hier echter niet op. Bij drie patiënten die geen locale 
tumorcontrole bereikten, bleef de standardized uptake value (SUV) na hyperoxygenatie 
relatief constant, terwijl er grote fractionele veranderingen gezien werden bij de meeste 
patiënten met locale tumor controle.
In Hoofdstuk 7 wordt de relevantie besproken van angiogenese remmers die door de 
primaire tumor geproduceerd worden. Tumor angiogenese, oftewel het ontstaan van 
een nieuw vaatbed in kwaadaardige weefsels, is het resultaat van een complexe en 
precieze balans tussen angiogenese bevorderende en angiogenese remmende factoren 
die geproduceerd worden door zowel tumorcellen als door normale cellen van de patiënt. 
Om de hypothese, dat een primaire tumor in staat is om de angiogenese in metastasen 
op afstand te onderdrukken, te ondersteunen, wordt een casus gepresenteerd. Bij deze 
patiënt resulteert de chirurgische verwijdering van een primaire colorectale tumor in een 
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toename in metabole activiteit van de levermetastasen. Daarbij daalden de angiostatine 
en endostatine waarden in zowel de urine als het plasma. Deze bevinding werd ook 
waargenomen in 5 vergelijkbare casus, terwijl dat niet het geval was in 6 controle 
patiënten. Bij deze controle groep werden ook twee PET-scans verricht, echter zonder 
tussentijdse chirurgische interventie. Dit zou erop kunnen wijzen dat verwijdering van 
een primaire tumor een toename in vaatnieuwvorming kan bewerkstelligen, wat de 
middels PET gemeten verhoogde metabole activiteit in de levermetastasen zou kunnen 
verklaren.
Weefsel karakterisering
Ook bij de karakterisering van laesies, het domein van de patholoog anatoom, zou 
FDG-PET op een non-invasieve manier een bijdrage kunnen leveren. Dit is van klinisch 
belang, omdat dit het aantal invasieve procedures en chirurgische ingrepen terug zou 
kunnen dringen. Uiteindelijk kan dit leiden tot een afname in morbiditeit en kosten. 
Welke implicaties dit kan hebben voor de patiëntenzorg wordt geïllustreerd aan de 
hand van de prospectieve studie beschreven in Hoofdstuk 8. Het doel van deze studie 
was te onderzoeken of FDG-PET in staat is het aantal onnodige hemithyreoidectomieën 
terug te dringen bij patiënten met een inconclusieve uitslag van een fijne naald aspiratie 
biopsie (FNAB) uit een schildkliernodus. FNAB is de procedure van eerste keus om 
schildkliernodi te evalueren. Een nadeel is echter dat in circa 20% van de gevallen 
geen uitspraak gedaan kan worden over de aard van de afwijking. In die gevallen is 
men genoodzaakt een hemithyreoidectomie te doen om zo tot een betrouwbare 
histopathologische diagnose te komen. Uiteindelijk blijkt het in slechts 20% van deze 
gevallen om een schildkliercarcinoom te gaan. In dit onderzoek werd voorafgaand 
aan de hemithyreoidectomie een PET scan van de schildklierregio vervaardigd. De 
uiteindelijke histopathologische diagnose werd beschouwd als de gouden standaard. 
Alle schildkliercarcinomen waren FDG-positief. Dit resulteerde in een hoge negatief 
voorspellende waarde. De pre-PET kans op schildkliercarcinoom in deze populatie was 
14%, en de post-PET kans steeg naar 32%. Het aantal onnodige hemithyreoidectomieën 
in een algoritme zonder FDG-PET was 86%, terwijl dat slechts 30% was in een 
algoritme met FDG-PET. Geconcludeerd kan worden dat FDG-PET een belangrijke rol 
zou kunnen spelen in het diagnostisch traject van patiënten met een inconclusieve 
cytologische diagnose van een schildkliernodus, omdat FDG-PET het aantal onnodige 
hemithyreoidectomieën aanzienlijk kan reduceren.
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Prognostische waarde
Doordat geïndividualiseerde behandelingsstrategieën in opmars zijn ontstaat de 
behoefte aan pretherapeutische (beeldvormende) biomarkers die een inschatting 
kunnen maken van de prognose van een patiënt ter ondersteuning van de keuze 
voor een bepaalde behandelingsstrategie. De mate van het tumormetabolisme zou 
een dergelijke potentiële biologische pre-therapeutische factor kunnen zijn die op 
een niet-invasieve wijze gemeten kan worden met PET. Er wordt gespeculeerd dat 
FDG accumulatie een afspiegeling is van het biologisch gedrag van een tumor en dat 
het geassocieerd zou kunnen zijn met intrinsieke biologische eigenschappen, zoals 
hypoxie, een lage apoptose snelheid, cel viabiliteit, proliferatieve activiteit en p53 
overexpressie. Deze tumoreigenschappen zijn alle potentieel ongunstig voor patiënten 
die behandeld worden met radiotherapie of chemotherapie en sommige kunnen 
zelfs nadelig zijn voor chirurgisch te behandelen patiënten. In Hoofdstuk 9 werd bij 
patiënten met gemetastaseerd colorectaal carcinoom onderzocht of FDG-PET in staat is 
om voorafgaand aan therapie hoog-risico patiënten te identificeren. De mate van FDG 
accumulatie (SUV) in metastasen bleek een significante voorspeller voor de overleving 
van patiënten. Er bestond een significant overlevingsvoordeel bij patiënten met een 
lage SUV in de metastasen. Deze bevinding was onafhankelijk van de daaropvolgende 
behandelingsmodaliteit.
Chemotherapie Respons Evaluatie
Het laatste deel van dit proefschrift werd gewijd aan chemotherapie respons evaluatie 
met behulp van FDG-PET. Een groot probleem bij de chemotherapeutische behandeling 
van kanker is het ontstaan van “multidrug resistentie”. Hierbij raken de kankercellen 
ongevoelig voor bepaalde chemotherapeutica. Verschillende mechanismen kunnen 
verantwoordelijk zijn voor multidrug resistentie. De belangrijkste onderliggende oorzaak 
is de overexpressie van een plasma membraan fosfoglycoproteïne, P-glycoproteïne (P-
gp). P-gp is het transport proteïne dat verantwoordelijk is voor het actief uit de cel 
pompen van cytotoxische stoffen en vormt het onderwerp van de studies beschreven 
in Hoofdstuk 10. Het is belangrijk patiënten met multidrug resistentie ten gevolge van 
overexpressie van P-gp te identificeren. Detectie van proteïne en RNA expressie voor 
de MDR1 pomp in weefsel is mogelijk met behulp van diverse technieken, waaronder 
immunohistochemie, kwantitatieve autoradiografie en “reverse transcriptase 
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polymerase chain” reacties. Detectie van de aanwezigheid van P-gp geeft echter geen 
informatie over de functie of mate van activiteit van deze pompen. Dit gegeven maakt 
het onderzoek naar radiofarmaca die in staat zijn de activiteit van deze efflux pompen 
in kaart te brengen zo interessant en ook relevant. In Hoofdstuk 10 werd een in vitro 
onderzoek met vier radiofarmaca (FDG, 99mTc-tetrofosmin, 125I-methyltyrosine en 125I-
deoxyuridineribose) beschreven, waarbij de mogelijkheden voor respons monitoring 
bestudeerd werden met het chemotherapeuticum doxorubicine. Dit gebeurde in aan- 
en afwezigheid van de calcium kanaal blokker verapamil, een krachtige modulator van 
P-gp. Het zou zinvol kunnen zijn voor aanvang van chemotherapie bij iedere individuele 
patiënt geïnformeerd te zijn over het eventuele effect van een P-gp modulator op zowel 
het tumor weefsel als op de normale weefsels. Dit zou van waarde kunnen zijn bij de 
selectie van patiënten die het meeste profijt zouden kunnen hebben op toevoeging van 
een modulator aan de chemotherapeutische behandeling. Dit onderzoek toonde aan 
dat de FDG, 125I-deoxyuridineribose en 125I-methyltyrosine opname duidelijker afnam in 
gevoelige cellen ten opzichte van resistente cellen na blootstelling aan doxorubicine. 
Daarnaast was dit effect omkeerbaar na toevoeging van de P-gp-modulator verapamil. Het 
radiofarmacon 99mTc-tetrofosmin, dat oorspronkelijk ontwikkeld is voor myocardperfusie 
scintigrafie heeft als voordeel, dat het in de multidrug resistentie setting al resultaten 
kan laten zien voorafgaand aan de chemotherapie. 99mTc-tetrofosmin verschilt hierin 
essentieel, omdat deze tracer direct de functie van P-gp in beeld brengt.
Hoofdstuk 11 behandelt enkele technische en methodologische aspecten van therapie 
respons evaluatie met FDG-PET. Veranderingen in FDG opname als respons op 
een therapeutische interventie kunnen zowel kwalitatief als kwantitatief benaderd 
worden. Het verkrijgen van accurate kwantitatieve resultaten zijn een eerste vereiste 
om betrouwbare en reproduceerbare uitspraken te kunnen doen over veranderingen 
in het tumor metabolisme gedurende therapie. Om dat te bereiken zou in principe 
een dynamisch scanprotocol toegepast moeten worden ter verkrijging van een tijd-
activiteits curve over het tumorweefsel en een plasma tijd-activiteits curve, waarvoor 
het doen van arteriële sampling gezien wordt als de algemeen geldende gouden 
standaard. Arteriële sampling is echter een invasieve procedure, die minder geschikt 
of zelfs ongewenst is voor herhaaldelijke toepassing bij patiënten die chemotherapie 
ondergaan. In hoofdstuk 11 werd de betrouwbaarheid onderzocht van het gebruik van 
een niet-invasieve patiëntvriendelijke methode om de plasma tijd-activiteits curve 
te verkrijgen. Geconcludeerd kon worden dat de niet invasieve methode accuraat en 
eenvoudig toepasbaar is en daardoor uitermate geschikt voor het gebruik bij de analyse 
van oncologische therapie monitoringsstudies.
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Hoofdstuk 12 beschrijft de resultaten van een prospectief onderzoek naar de waarde 
van FDG-PET in het kader van chemotherapie respons monitoring bij patiënten met 
niet-kleincellig longcarcinoom. Er werd een dynamische FDG-PET verricht voor start 
van chemotherapie en na 5-8 weken behandeling. Evaluatie vond plaats van zowel 
vereenvoudigde methoden om het glucose metabolisme te meten (SUV) als van 
kwantitatieve parameters verkregen met de Patlak analyse (MRGlu). Geconcludeerd 
kan worden dat de mate van chemotherapie geïnduceerde veranderingen in tumor 
glucose metabolisme gemeten met PET een duidelijk voorspellende waarde heeft voor 
de uitkomst van therapie. Bovendien lijkt routinematig toepassing van FDG-PET voor 
chemotherapie monitoring in deze patiënten populatie klinisch goed uitvoerbaar, omdat 
vereenvoudigde methoden om tumor glucose verbruik te meten (SUV) voldoende 
betrouwbaar blijken en derhalve in staat zijn de meer complexe kwantitatieve methoden 
(MRGlu) te vervangen.
Het onderzoek beschreven in Hoofdstuk 13 had hetzelfde doel en dezelfde studie opzet 
als het onderzoek beschreven in hoofdstuk 12. In dit onderzoek werden patiënten met 
gevorderd colorectaal carcinoom bestudeerd. Ook bij deze patiëntenpopulatie blijkt de 
mate van chemotherapie geïnduceerde veranderingen in tumor glucose metabolisme 
predictief te zijn voor de behandelingsuitkomst.
Slotopmerkingen
Geconcludeerd kan worden dat FDG-PET door het afbeelden van moleculaire metabole 
informatie een veelbelovende beeldvormende modaliteit is voor de karakterisering 
van maligniteiten. FDG-PET kan meer inzicht verschaffen in bepaalde eigenschappen 
van tumoren en in het biologisch gedrag van tumoren als reactie op therapeutische 
interventies. De onderzoeksresultaten beschreven in dit proefschrift impliceren dat 
FDG-PET een prognostische en predictieve waarde heeft. De kracht van FDG-PET 
ligt daarin, dat op een niet-invasieve manier het gehele lichaam in kaart gebracht kan 
worden. Voorts verschaft FDG-PET de mogelijkheid tot het doen van seriële studies, 
waarbij gedurende therapeutische interventies op een patiëntvriendelijke manier 
metabole veranderingen van een tumor in de tijd gemeten kunnen worden. FDG-PET 
kan het glucose metabolisme niet alleen visualiseren, maar ook kwantificeren. De 
techniek kan voorzien in enkele accurate, reproduceerbare kwantitatieve parameters 
van het glucose metabolisme van tumoren.
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Een klein woord van dank… 
Mijn eerste dankbetuiging gaat uit naar de vele patiënten die participeerden in de 
hiervoor beschreven onderzoeken. Het was niet altijd eenvoudig om patiënten te 
motiveren om daaraan deel te nemen. Wanneer men weet dat deze patiënten vaak daags 
tevoren bekend waren met hun diagnose, kunnen wij ons daar alles bij voorstellen en 
groeit de bewondering voor deze dappere mensen. Naast de lichamelijk en geestelijk 
zware strijd die zij al te voeren hadden, vonden zij de kracht en de moed om hun bijdrage 
te leveren aan de wetenschap, zonder daar zelf profijt van te zullen ondervinden.
Prof. dr. W.J.G. Oyen, beste Wim. Je bent een man van weinig woorden, maar van des 
te meer daden. Je bedenkt de meest prachtige study-designs en kiest voor iedere 
promovendus het onderzoek dat bij hem/haar past. Je intelligentie, maar vooral ook 
je denksnelheid bewonder ik enorm. Telkenmale heb ik in no-time je feedback terug, 
en niet zelden daarbij een complete make-over van mijn aangeleverd werk. Elke vraag 
kan ik zonder context aan je mailen, doordat je van al jouw promovendi doorlopend 
paraat hebt waar diegene op dat moment mee bezig is. Regelmatig was ik somber 
gestemd, maar door die éénregelige mails met de meest briljante oplossingen voor mijn 
problemen ging steeds abrupt de zon weer schijnen. “Het is vaak niet zo moeilijk” waren 
dan jouw woorden. Daarnaast houd jij je promovendi uit de wind. Zo kwam een keer als 
reply op mijn mail een kant en klare “response-letter” van jouw hand terug. Toen ik je 
daarvoor bedankte zei je: “Fee, jij moet je op dit moment met heel andere zaken bezig 
houden”. Kortom, jouw promovendi zijn stuk voor stuk bofferds, omdat ze één ding 
gemeen hebben: ze hebben jou als promotor!
Prof. dr. F.H.M. Corstens, beste Frans. Met groot respect aanschouw ik jouw inspanningen 
voor de afdeling. Jij zorgt ervoor dat wij alles hebben wat ons “research”-hartje begeert, 
waardoor wij ons naar hartelust kunnen uitleven. Een man een man, een woord een 
woord, is jouw devies. En waarachtig: daarin heb je me nog nooit teleurgesteld! Je 
continue onvoorwaardelijke steun en vaderlijke vriendschap betekenen veel voor mij. 
Na een zwemtocht in de Maas was jij het, die aan de finish stond. En nu sta je aan 
de finish van mijn promotietraject. Ik bewonder je stijl van leidinggeven. Het zorgt 
voor een hechte band tussen je medewerkers onderling, waardoor in een prettige 
sfeer veel werk verzet kan worden. Je interesseert je niet alleen voor het wérk van je 
medewerkers, maar bent ook altijd zeer begaan met hun persoonlijk wel en wee. Zelfs 
voor minder belangrijke zaken mag je gestoord worden. Zo vertelde ik je dat ik moeite 
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had met de keuze van de paranimfen. Ook daar had je een oplossing voor: “Fee, als de 
pedel het goed vindt heb ik er geen probleem mee als jij afwijkt van het protocol en drie 
paranimfen hebt. En zo geschiede… Met mijn uitgebreide dankbetuiging wijk ik ook van 
het protocol af. Maar dat komt doordat ik het eigenlijk wat onrechtvaardig vind dat de 
promovendus geen laudatio mag houden voor de promotores.
Dr. P.F.M. Krabbe, beste Paul, statistisch geweten en rekenwonder. Wat fijn dat ik op 
ieder moment bij je binnen mocht lopen. Dat snelle “doorschakelen”, daar hou ik wel 
van. Ik hoop dat onze samenwerking tot in lengte van dagen mag voortduren.
Dr. E.P. Visser, beste Eric. Als fysisch klankbord kwam je voor mijn onderzoek juist op tijd de 
afdeling binnen. Veel dank voor je hulp en uitleg met betrekking tot technische/fysische 
kwesties. De wijze waarop jij studenten weet te begeleiden is bewonderenswaardig. 
Het heeft tot de ontwikkeling van een prachtig software programma geleid dat aan al 
mijn wensen voldoet. Als dankbetuiging aan jou en aan je IT studenten Bram Cramer, 
Erik van Zomeren, Simon Evers, Laurens de Groot en Erik Janssen, is de cover van dit 
boekje geheel aan jullie werk gewijd.
Prof. dr. O.C. Boerman, beste Otto, dank voor je coaching en feedback tijdens de wekelijkse 
researchbesprekingen. Jij hebt significant bijgedragen aan mijn wetenschappelijk 
maturatieproces. Jij weet als geen ander het wapen van de humor tijdig in te zetten 
als ik weer eens wat pessimistisch uit de hoek kom. Een schouderklopje van jou doet 
wonderen!
Dr. A.T. Willemsen, Dr. J. Pruim, Dr. P.L. Jager en Johan Wiegers. Dank voor het delen 
van jullie ervaring, jullie protocollen en software. Ik heb bij jullie op de afdeling van het 
Universitair Medisch Centrum Groningen de kunst van het “dPETten” mogen afkijken. 
Toen op 8 maart 2002 onze eerste studiepatiënt verscheen, kwam Jan naar ons toe 
om ons te ondersteunen. Bij Antoon kon ik altijd terecht voor telefonische software 
consulten. Piet gaf mij het beeldmateriaal voor hoofdstuk 3 en Johan zorgde voor 
spoedzendingen als de op maat gemaakte lijnen weer eens niet op tijd door de fabrikant 
geleverd konden worden.
Dr. E.N. Robertson, hartelijk dank dat u mij op de operatiekamer geleerd hebt arteriële 
lijnen te leggen.
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Alle verwijzers wil ik bedanken dat zij steeds weer dachten aan “mijn” PET-studies. 
Ik dank hen voor het geduld, de aandacht en de tijd die zij erin staken patiënten te 
informeren en te includeren. Ik ben me er terdege van bewust dat hierdoor meer druk 
ontstond op de reeds overvolle poli’s. Zij lieten zien, hoe essentieel een goede arts-
patiënt relatie is, waarin vertrouwen, begrip en steun de kernwoorden zijn.
Alle leden van de longtumorwerkgroep en daarbij in het bijzonder het secretariaat. Dank 
voor de prettige samenwerking en fijn dat jullie steeds weer alert waren op geschikte 
kandidaten.
Bas van Hoorn, jij hebt monnikenwerk verricht! Door jouw noeste arbeid en 
doorzettingsvermogen zijn alle dynamische PET-scans perfect uitgewerkt. Je was ook 
een kei in het “administreren” van al deze data. Dank voor je waardevolle adviezen 
omtrent de ontwikkeling van ons eigen software pakket.
Rick Hermsen, dank voor het uitspitten van de stapels statussen. Jij was de stille kracht 
achter hoofdstuk 12 en 13. Ik zal nooit vergeten dat jij mij het eerste half jaar geheel pro 
Deo geholpen hebt. Succes met het laatste deel van je co-schappen. “I predict” dat jou 
een mooie toekomst te wachten staat!
Michel de Groot, Peter Kok, Antoi Meeuwis, Rudie van de Kolk, Paul Jaegers, Tineke van 
den Heuvel, Eddy Mijnheere en Marieke Artz, dank voor jullie hulp en eindeloze geduld 
bij het doen van de dynamische PET studies. Omdat we de patiënten voor aanvang van 
het gewone PET-programma scanden kwamen jullie vaak vroeger dan de vroege dienst 
om mij te assisteren. Deze studies konden verwezenlijkt worden doordat jullie mij de 
ruimte gaven vrijelijk te schuiven in het programma. Ik besef dat ik daarmee regelmatig 
het overzicht verstoord heb, waardoor ik jullie flexibiliteit des te meer gewaardeerd heb. 
Onderling hebben wij wel eens geginnegapt dat het dankwoord de helft van mijn boekje 
zou gaan beslaan, omdat zovelen een bijdrage geleverd hebben aan de bewerkelijke 
studies. En waarachtig, het komt aardig in de richting…
Julliëtte van Eerd, Cathelijne Frielink, Annemieke Soede, Peter Laverman, Emile 
Koenders en Maichel van Riel. Dank voor het zo zorgvuldig wegen van mijn talloze 
arteriële samples en voor het bereiden en terugmeten van de spuiten. Cathelijne, jij 
deed op zeer professionele wijze de hexokinase kleuringen van hoofdstuk 4 en Julliëtte, 
het ontstaan van hoofdstuk 10 is hoofdzakelijk aan jou te danken.
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Marc Zuijdwijk, Baudewijn Hendrickx, Siert Knollema, Jeroen Manders - heren, jullie 
waren mijn eerste pupillen. Stevige leerlingen om als supervisor snel van te rijpen. 
Dank voor het nemen van de arteriële samples, waardoor ik mijn tweede zwangerschap 
stralend, doch stralingsloos heb kunnen volbrengen. Dank ook voor de gezelligheid, de 
stevige discussies en voor jullie grappen en grollen.
Huub Rennen, jij was het die ons zeven jaar geleden zeer welkom ontving en ervoor 
zorgde dat Wim en ik, komende uit het westen, ons al vlot thuis gingen voelen in het 
Nijmeegse. Vanaf mijn eerste dag op de afdeling vond ik in jou een maatje. Dank voor 
al die keren dat je me hielp met van-alles-en-nog-wat in onderzoeksland. (Ik weet dat jij 
niet van al die veren houdt, waar vele pauwen voor geslacht werden… maar toch.. ook 
jij verdient het!)
Hanneke van Laarhoven, intelligent en innemend, snel en accuraat, enthousiast en 
opbouwend. Ik waardeer je bijzonder als wetenschapper, als dokter, als predikant en 
als mens! Dank voor de fijne samenwerking aan onze gemeenschappelijke studies en 
met name ook veel dank voor het prikken van de arteriële lijnen tijdens mijn verlof en 
vakanties, waardoor alles ononderbroken door kon blijven gaan.
Manuel Koppe en Bas Wiering, mijn twee chirurgische collegae, ook wij hebben 
bijzondere (onderzoeks)momenten gedeeld. Bas, dank dat je me steeds te hulp schoot 
bij database en SPSS probleempjes. Ik heb veel van jouw Syntax-kunsten geleerd.
Riena Aliredjo, onze gezamenlijke werkuurtjes achter de microscoop duurden vaak 
langer dan wij ons eigenlijk konden permitteren, doordat wij het gewoonweg niet 
na konden laten tussendoor gezellig te klessebessen. Je was een aanwinst voor onze 
longtumorwerkgroep, jammer dat je wegging.
Prof. dr. J. H. J.M. van Krieken, beste Han, ik zal nooit vergeten dat je speciaal ’s avonds 
in huis kwam (omdat we geen ander gaatje in jouw drukke agenda konden vinden) om 
alle preparaten nauwkeurig te beoordelen.
Johan Rutten en Paul Kniest, dank voor jullie advies en hulp omtrent alle IT-zaken voor 
computer en laptop. Door jullie toedoen was de werkomgeving thuis IT-matig op orde 
waardoor ik alles tijdens mijn zwangerschapsverloven op afstand kon regelen en destijds 
alles gewoon door heeft kunnen gaan. Paul, jij was het die mij zo gastvrij een plek op je 
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kamer bood toen ik hier kwam werken. Jij was de man van het eerste uur en hebt op zeer 
inventieve wijze gezorgd voor een dPET IT-omgeving met Matlab en alles erop en eraan. 
Johan, jij was Pauls opvolger en nu al zes jaar mijn gezellige en trouwe kamergenoot.
Wim van den Broek, iedereen weet hoe zuinig jij bent. Jij verdedigt op fantastische 
wijze de financiële zijde van ons fort. Het is daarom dat ik het des te meer waardeer 
dat jij nooit één krimp gegeven hebt als ik weer “broodjes-bonnen” voor mijn nuchtere 
patiënten uitschreef en extra doses FDG bestelde.
Jacqueline van Rens, dank voor de talloze statussen die je voor mij opgespoord hebt 
en voor de gang naar de bieb, voor het zoeken, kopiëren en/of bestellen van artikelen. 
Jij zorgde voor correcte adressering op de verzendlijst van dit boekje en dacht aan alle 
organisatorische details rondom het symposium. Jouw spontaan aangeboden hulp 
maakte mij steeds weer blij. En niet alleen op het gebied van research zijn bepaalde 
zaken al gedaan voordat ik het aan je gevraagd heb. Ik vraag me werkelijk soms af of je 
gedachten kan lezen.
Sandra Dahm, door jouw contacten bij secretariaten van andere ziekenhuizen zorgde 
jouw aankondiging van mijn komst er altijd voor dat ik koninklijk ontvangen werd en de 
berg statussen en koffie reeds klaar stond.
Martin Gotthardt, jou wil ik bedanken voor je vriendschap en collegialiteit. Ik voel me 
regelmatig zeer in de watten gelegd. Als er extra klinische taken te verdelen zijn ben jij 
het die deze op je neemt, waardoor er nauwelijks iets voor mij overblijft. Laat ik over je 
grappen maar zwijgen, want daar valt een apart boek over te schrijven…
Wouter Vogel, jou heb ik zien uitgroeien van ijverige co-assistent, gedreven arts-assistent 
tot een zeer vakbekwame en collegiale medespecialist. Ik vind het heel bijzonder dit 
feest samen met jou te mogen vieren! 
Alle medewerkers van de afdeling nucleaire geneeskunde, die ik niet bij name genoemd 
heb, wil ik bedanken voor het perfect uitvoeren van het dagelijks werk. Doordat het 
klinisch werk zo gestroomlijnd loopt scheppen jullie de mogelijkheid, dat óók de 
onderzoekstaak die onze afdeling heeft, zorgeloos ten uitvoer gebracht kan worden. 
De warme en hechte band onderling zorgt voor veel arbeidsvreugde en arbeidsenergie. 
Het is een voorrecht om met jullie te mogen samenwerken.
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Chantal Bleeker-Rovers, dierbare vriendschap ontwikkelde zich, toen wij in jouw laatste 
jaar bij ons op de afdeling, als kamergenootjes eenzelfde strijd voerden. Eendracht 
maakt macht, samen sterk; juist ook omdat wij vrijelijk onze mindere momenten konden 
delen. En altijd eindigden die openhartigheden met een enorme energie om verder 
te gaan. Dank voor het helpen inkorten van mijn vaak veel te lange manuscripten. In 
januari was ik jouw paranimf, dank dat jij nu mijn paranimf wilt zijn.
Carine Bavelaar-Croon, het is bijzonder hoe parallel onze levenspaden lopen. Samen 
opgeleid, in dezelfde maand getrouwd, kinderen van dezelfde leeftijd, nu allebei 
werkzaam in Nijmegen en de komende 30 jaar zusters in het vak. Leuk dat onze gezinnen 
zo gezellig met elkaar optrekken. Zeven jaar geleden was ik jouw paranimf, dank dat jij 
nu mijn paranimf wilt zijn.
Lioe-Ting Dijkhorst-Oei, je bent mijn lieve zus, mijn grote voorbeeld, een super (pete) 
tante voor onze kinderen, maar bovenal ben je mijn allerbeste vriendin. Negen jaar 
geleden was ik jouw paranimf, dank dat jij nu mijn paranimf wilt zijn.
Lieve vrienden en (schoon)familie, dank voor het meeleven met mijn proefschrift-
perikelen. 
Lieve pa en ma, dank voor de warme en zorgeloze jeugd die jullie Lioe-Ting, Yung-Chin 
en mij gaven en voor jullie onvoorwaardelijke liefde en steun tot op de dag van vandaag. 
Jullie kennen mij als geen ander en wisten dat dit het vak zou zijn dat het beste bij mij 
past. En ja, het is recht in de roos! Pa, ik ben er trots op “de dochter van…” te mogen 
zijn.
En dan tenslotte Wim, mijn lieve echtgenoot. Mijn dank aan jou is niet in woorden te 
vatten. Jij verliet Rotterdam, jouw “stadsie” waar je zo van houdt, de plek waar je geboren 
en getogen bent, om met mij mee te gaan naar Nijmegen. Naast dit grote offer bracht 
je nog vele andere offers. Dank voor het geluk dat jij me in mijn leven geeft. Ik voel me 
gezegend met onze twee bloedjes van kinderen!
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Lioe-Fee de Geus-Oei werd op 24 november 1971 geboren te Utrecht. Zij behaalde in 
1990 het eindexamen VWO aan het Christelijk Lyceum te Zeist. In datzelfde jaar werd 
aangevangen met de studie geneeskunde aan de Erasmus Universiteit Rotterdam.
In 1993 deed zij wetenschappelijk onderzoek op de afdeling nucleaire geneeskunde in 
het militair hospitaal in Peking bij Prof. dr. J.H. Tian, waar zij het effect van acupunctuur 
op de galblaas functie bestudeerde met behulp van cholescintigrafie. Dit onderzoek 
werd gesubsidieerd door het Nederlandse ministerie van VWS en de Gerrit Jan Mulder 
Stichting van de Erasmus Universiteit, die beursen toekent aan jonge wetenschappers.
De interesse in het vakgebied nucleaire geneeskunde en het plezier in het doen van 
wetenschappelijk onderzoek groeide verder door de wetenschappelijke doctoraal 
stage die zij in 1994 deed op de afdeling nucleaire geneeskunde van het Erasmus 
Medisch Centrum Rotterdam onder de inspirerende begeleiding van haar vader Dr. 
H.Y. Oei en Prof. dr. E.P. Krenning. Zij deed een onderzoek naar de sensitiviteit van 
123I scintigrafie en thyreoglobuline bepalingen bij de detectie van recidief of metastasen 
van gedifferentieerd schildkliercarcinoom.
Het artsexamen werd behaald in september 1996, waarna zij vier maanden AGNIO was 
op de afdeling cardiologie van het Medisch Centrum Rijnmond-Zuid te Rotterdam, als 
voorbereiding op de opleiding nucleaire geneeskunde, onderdeel nucleaire cardiologie. 
In januari 1997 startte zij met de opleiding tot nucleair geneeskundige op de afdeling 
interne geneeskunde van ditzelfde ziekenhuis bij opleider Dr. A. Berghout. Vanaf januari 
1998 werd de opleiding voortgezet op de afdeling nucleaire geneeskunde van het Leidsch 
Universitair Medisch Centrum bij opleider Dr. J.W. Arndt. Vanaf augustus 2000 deed zij het 
laatste deel van haar opleiding op de afdeling nucleaire geneeskunde van het Universitair 
Medisch Centrum Nijmegen Sint Raboud bij opleider Prof. dr. F.H.M. Corstens. Na haar 
registratie als nucleair geneeskundige op 1 januari 2001 bleef zij als staflid werkzaam op 
deze afdeling en werd aangevangen met de in dit proefschrift beschreven onderzoeken 
onder leiding van Prof. dr. W.J.G. Oyen, Prof. dr. F.H.M. Corstens en Dr. P.F.M. Krabbe.
Naast haar klinisch en wetenschappelijk werk is promovenda reeds enkele jaren actief 
in de redactie van het Tijdschrift voor Nucleaire Geneeskunde. Sinds januari jl. is zij 
hoofdredacteur van dit vakblad.
Promovenda is gehuwd met Wim de Geus met wie zij twee kinderen heeft, Daphne Xiao 
Qing (2001) en Leonoor Xiao Shan (2004).
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ARCON Accelerated Radiotherapy with 
CarbOgen and Nicotinamide
ATP Adenosinetrifosfate
bFGF  fibroblast growth factor
BSA bovine serum albumin
CAIX carbonic anhydrase IX
C-cells calcitonin-producing 
parafollicular cells
CEA carcinoembryonic antigen
CI confidence interval
Cp plasma concentration 
CR  complete response
Ct tissue concentration
CT computed tomography
DCE-MRI dynamic contrast enhanced 
magnetic resonance imaging
2D mode 2-dimensional mode
DMSA dimercaptosuccinic acid
DNA deoxyribonucleic acid 
∆ fractional change
ELISA enzyme-linked immunosorbent 
assay 
EORTC European Organization for 
Research and Treatment of 
Cancer
FCS  foetal calf serum
FDG 18F-fluorodeoxyglucose
FLASH fast low-angle shot 
FMISO 18F-fluoromisonidazole
FNAB fine needle aspiration biopsy
FOLFOX  5-fluorouracil /folinic acid/
oxaliplatin 
FOV  field of view
5-FU 5-fluorouracil
FWHM  full width at half maximum
GBq Giga Becquerel
68Ge/68Ga Germanium-68/Gallium-68 
GLUT glucose transporter
H&E hematoxylin and eosin
HF hypoxic fraction
HIF-1 hypoxia-inducible factor-1
HK hexokinase
HNSCC head and neck squamous cell 
carcinoma
HPLC High-performance liquid 
chromatography
123I iodine-123
131I iodine-131
ICC  Intraclass correlation 
coefficients 
IDIF Image-derived input function
IMT  Iodine-125-methyltyrosine
IUdR  Iodine-125-deoxyuridineribose 
K1, k2, k3  rate constants as defined in 
the 2-compartment FDG model 
without trapping
kep rate constant of Gadolinium-
DTPA uptake
Ktrans volume transfer constant
LRP  lung-resistant protein 
LV leucovorin
MBq  mega bequerel
MDR multidrug resistant
MEN multiple endocrine neoplasia
MIBG meta-iodobenzylguanidine
MIBI sestamibi
mo  months
MRglu metabolic rate of glucose
∆MRglu fractional change of metabolic 
rate of glucose
MRI magnetic resonance imaging
MRP multidrug resistance-associated 
protein 
MTT assay cell viability assay using  
3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
MVD microvascular density
n number of patients
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NaCl sodium chloride
NAD+ nicotinamide adenine 
dinucleotide
NSCLC non-small-cell lung cancer
OS overall survival 
OSEM ordered-subsets expectation 
maximization algorithm
PBS phosphate buffered saline
PD  progressive disease
PET positron emission tomography
PFS progression free survival
P-gp  P-glycoprotein
pN nodal status of the primary tumor
PR  partial response
PS permeability surface area product
pT invasiveness of the primary 
tumor 
r  Pearson’s correlation coefficient r
ρ  Spearman’s rho correlation 
coefficient
RECIST response evaluation criteria in 
solid tumors
Ref. reference
Rf retardation factor
RNA Ribo Nucleic Acid
ROI region of interest
rTSH recombinant human thyroid 
stimulating hormone
SD  stable disease
SD standard deviation
SDS sodium dodecyl sulphate
Sens. sensitivity
Spec. specificity
SPECT Single Photon Emission 
Computed Tomography
SUV standardized uptake value
∆SUV fractional change of standardized 
uptake value
SUVBSM SUV corrected for body surface 
area
SUVLBM SUV corrected for lean body 
mass
SUVmax maximum value of the SUV 
within the tumor
T Tesla
T1 longitudinal spin-lattice 
relaxation time
T2 transverse spin-spin relaxation 
time
T4 thyroxine-4 
TBF tumor blood flow
TBq Tera Becquerel
99mTc Technetium-99m
TF  Technetium-99m-tetrofosmin 
Tg thyroglobulin 
201Tl Thallium-201
TNM tumor-node-metastasis staging 
system
T/NT tumor-to non-tumor ratio
TR repetition time
TSH thyroid stimulating hormone
VD vascular density
Ve extravascular extracellular space 
per unit volume of tissue
VEGF vascular endothelial growth 
factor
VNF vascular normalization function
VOI volume of interest
WHO World Health Organization 
Stellingen behorende bij het proefschrift
Characterization of malignancy with FDG-PET
1. Tumorhistologie en tumorceldifferentiatie in combinatie met overexpressie van GLUT-1 
en GLUT-3 bepalen de mate van FDG accumulatie in niet-kleincellig longcarcinoom. (dit 
proefschrift)
2. Een verandering in de oxygenatie status van een tumor kan metabole veranderingen in de 
tumor induceren. (dit proefschrift)
3. FDG-PET is in staat het aantal onnodige hemithyreoidectomieën te reduceren. (dit 
proefschrift)
4. Patiënten met een hoog metabolisme in metastasen van colorectaal carcinoom behoren tot 
de hoog-risico populatie. (dit proefschrift)
5. De radiofarmaca FDG, 125I-deoxyuridineribose, 125I-methyltyrosine en 99mTc-tetrofosmin zijn 
alle vier in staat een onderscheid te maken tussen doxorubicine gevoelige en doxorubicine 
resistente cellen. (dit proefschrift)
6. Niet-invasieve methoden om de plasma tijd-activiteitscurve te bepalen zijn accuraat en 
patiëntvriendelijk. (dit proefschrift)
7. De door chemotherapie geïnduceerde verandering in tumorglucosemetabolisme heeft een 
voorspellende waarde voor therapie respons. (dit proefschrift)
8. Een patiënt heeft twee verschillende behoeften: “the need to know and understand” en 
“the need to feel known and understood”. (Prof. dr. Jozien Benzing)
9. De beste houding om RSI tegen te gaan is de volgende houding.
10. Kinderen leven niet in klokkentijd. Ze leren je om je gebruikelijke doelgerichte gedrag 
tijdelijk aan de kant te zetten. (Sarah Napthali)
11. Wie de woorden heeft, heeft niet noodzakelijkerwijs ook het verstand. (Confucius)
12. Maar het omgekeerde geldt eveneens: wie het verstand heeft, heeft niet noodzakelijkerwijs 
ook de woorden. (Lioe-Ting Dijkhorst-Oei) 
13. Als ik had gewild dat je het zou begrijpen, dan had ik het wel beter uitgelegd. (Johan Cruijff 
– zie samenvatting in het Nederlands, dit proefschrift)
14. Alleen brave meisjes kunnen ondeugend zijn. (stelling van een bepaalde collega)
Lioe-Fee de Geus-Oei
